Original Article
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
N Engl J Med 2001; 344:699-709March 8, 2001
- Abstract
Background
Drotrecogin alfa (activated), or recombinant human activated protein C, has antithrombotic, antiinflammatory, and profibrinolytic properties. In a previous study, drotrecogin alfa activated produced dose-dependent reductions in the levels of markers of coagulation and inflammation in patients with severe sepsis. In this phase 3 trial, we assessed whether treatment with drotrecogin alfa activated reduced the rate of death from any cause among patients with severe sepsis.
Methods
We conducted a randomized, double-blind, placebo-controlled, multicenter trial. Patients with systemic inflammation and organ failure due to acute infection were enrolled and assigned to receive an intravenous infusion of either placebo or drotrecogin alfa activated (24 μg per kilogram of body weight per hour) for a total duration of 96 hours. The prospectively defined primary end point was death from any cause and was assessed 28 days after the start of the infusion. Patients were monitored for adverse events; changes in vital signs, laboratory variables, and the results of microbiologic cultures; and the development of neutralizing antibodies against activated protein C.
Results
A total of 1690 randomized patients were treated (840 in the placebo group and 850 in the drotrecogin alfa activated group). The mortality rate was 30.8 percent in the placebo group and 24.7 percent in the drotrecogin alfa activated group. On the basis of the prospectively defined primary analysis, treatment with drotrecogin alfa activated was associated with a reduction in the relative risk of death of 19.4 percent (95 percent confidence interval, 6.6 to 30.5) and an absolute reduction in the risk of death of 6.1 percent (P=0.005). The incidence of serious bleeding was higher in the drotrecogin alfa activated group than in the placebo group (3.5 percent vs. 2.0 percent, P=0.06).
Conclusions
Treatment with drotrecogin alfa activated significantly reduces mortality in patients with severe sepsis and may be associated with an increased risk of bleeding.
Media in This Article
Figure 2
Kaplan–Meier Estimates of Survival among 850 Patients with Severe Sepsis in the Drotrecogin Alfa Activated Group and 840 Patients with Severe Sepsis in the Placebo Group.Figure 1
Proposed Actions of Activated Protein C in Modulating the Systemic Inflammatory, Procoagulant, and Fibrinolytic Host Responses to Infection.Article Activity
- Article
Severe sepsis, defined as sepsis associated with acute organ dysfunction, results from a generalized inflammatory and procoagulant response to an infection.1 The rate of death from severe sepsis ranges from 30 to 50 percent despite advances in critical care.2-5 In the United States, approximately 750,000 cases of sepsis occur each year, at least 225,000 of which are fatal.6
The inflammatory and procoagulant host responses to infection are closely related.7 Inflammatory cytokines, including tumor necrosis factor α, interleukin-1β, and interleukin-6, are capable of activating coagulation and inhibiting fibrinolysis, whereas the procoagulant thrombin is capable of stimulating multiple inflammatory pathways.7-11 The end result may be diffuse endovascular injury, multiorgan dysfunction, and death. Activated protein C, an endogenous protein that promotes fibrinolysis and inhibits thrombosis and inflammation, is an important modulator of the coagulation and inflammation associated with severe sepsis (Figure 1Figure 1
Proposed Actions of Activated Protein C in Modulating the Systemic Inflammatory, Procoagulant, and Fibrinolytic Host Responses to Infection.).18 Activated protein C is converted from its inactive precursor, protein C, by thrombin coupled to thrombomodulin.18 The conversion of protein C to activated protein C may be impaired during sepsis as a result of the down-regulation of thrombomodulin by inflammatory cytokines.19 Reduced levels of protein C are found in the majority of patients with sepsis and are associated with an increased risk of death.20-23 Previous preclinical and clinical studies showed that the administration of activated protein C may improve the outcome of severe sepsis. The administration of activated protein C was protective in a baboon model of lethal Escherichia coli sepsis.24 In a placebo-controlled phase 2 trial in patients with severe sepsis, an infusion of drotrecogin alfa (activated), or recombinant human activated protein C (Eli Lilly, Indianapolis), hereafter referred to as drotrecogin alfa activated, resulted in dose-dependent reductions in the plasma levels of D-dimer and serum levels of interleukin-6, markers of coagulopathy and inflammation, respectively.25 We therefore evaluated whether the administration of drotrecogin alfa activated would reduce the rate of death from all causes at 28 days in patients with severe sepsis and have an acceptable safety profile.
Methods
Patients
From July 1998 through June 2000, eligible patients were enrolled in this randomized, double-blind, placebo-controlled trial, which was conducted at 164 centers in 11 countries. The institutional review board at each center approved the protocol, and written informed consent was obtained from all participants or their authorized representatives. The clinical coordinating center (Vanderbilt Coordinating Center, Nashville) was available 24 hours a day throughout the study to answer investigators' questions regarding patients' eligibility and safety and the reporting of serious adverse events.
Selection Criteria
The criteria for severe sepsis were a modification of those defined by Bone et al. (Appendix 1).26 Patients were eligible for the trial if they had a known or suspected infection on the basis of clinical data at the time of screening and if they met the following criteria within a 24-hour period: three or more signs of systemic inflammation and the sepsis-induced dysfunction of at least one organ or system that lasted no longer than 24 hours. Patients had to begin treatment within 24 hours after they met the inclusion criteria. Exclusion criteria are summarized in Appendix 2.
Treatment Assignments
Patients were randomly assigned in a 1:1 manner to receive drotrecogin alfa activated or placebo (0.9 percent saline with or without 0.1 percent human serum albumin) at each center. Block randomization stratified according to site was used, and all assignments were made through a central randomization center. Drotrecogin alfa activated, at a dose of 24 μg per kilogram of body weight per hour, or placebo was administered intravenously at a constant rate from foil-wrapped bags for a total duration of 96 hours. The patients, investigators, and the sponsor were unaware of the patients' treatment assignments. Drotrecogin alfa activated was produced from an established mammalian cell line into which the complementary DNA for human protein C had been inserted.27
The infusion was interrupted 1 hour before any percutaneous procedure or major surgery and was resumed 1 hour and 12 hours later, respectively, in the absence of bleeding complications. The study protocol did not call for a standardized approach to critical care (e.g., the use of antibiotics, fluids, vasopressors, or ventilatory support).
Evaluation of Patients
Patients were followed for 28 days after the start of the infusion or until death. Base-line characteristics including demographic information and information on preexisting conditions, organ function, markers of disease severity, infection, and hematologic and other laboratory tests were assessed within 24 hours before the infusion was begun. Blood samples obtained at base line, on days 1 through 7, and on days 14 and 28 were assayed for D-dimer levels (Liatest D-D1 latex agglutination test kit, Diagnostica Stago, Asnieres, France) and for interleukin-6 levels (Quantikine HS enzyme immunoassay kit, R & D Systems, Minneapolis). All measurements were performed by a central laboratory (Covance Central Lab Services, Indianapolis). Blood samples for the measurement of neutralizing antibodies against activated protein C were collected on days 14 and 28 or at the time of discharge from the hospital if it occurred before one or both of these dates. Microbiologic-culture results were assessed each day beginning 48 hours after the initiation of the infusion and continuing through day 28. Patients were defined as having a deficiency of protein C if their plasma protein C activity level was below the lower limit of normal (81 percent) within 24 hours before the initiation of the infusion and defined as having septic shock if they met the criteria for cardiovascular dysfunction at any time within 6 hours before the start of the infusion.
Statistical Analysis
The primary efficacy end point was death from any cause and was assessed 28 days after the initiation of the infusion. Our prospectively defined primary analysis included all patients who received the infusion for any length of time, with patients analyzed according to the treatment group to which they were assigned at randomization. The trial was designed to enroll 2280 patients; two planned interim analyses by an independent data and safety monitoring board occurred after 760 and 1520 patients had been enrolled. Statistical guidelines to suspend enrollment if drotrecogin alfa activated was found to be significantly more efficacious than placebo were determined a priori and used the O'Brien–Fleming spending function according to the method of Lan and DeMets.28
Data were analyzed according to a prospectively defined plan. The primary analysis was based on a Cochran–Mantel–Haenszel test in which the groups were stratified on the basis of three baseline covariates: severity of disease, as reflected by the score on the Acute Physiology and Chronic Health Evaluation II (APACHE II)29 (3 to 19, 20 to 24, 25 to 29, or 30 to 53, with higher scores indicating more severe disease); age (younger than 60 years or 60 years or older); and plasma protein C activity level (40 percent or less, 41 to 60 percent, 61 to 80 percent, 81 percent or more, or unknown). The corresponding relative risk and 95 percent confidence interval were calculated with use of the logit-adjusted method. The time from the start of the infusion to death was compared in the two groups in a similar manner with use of a stratified log-rank test. Results of both stratified and nonstratified analyses are reported. We evaluated the consistency of the effects of treatment on the risk of death in the subgroups by determining whether the relative risk and 95 percent confidence interval for each subgroup included the observed relative risk for the entire population.
Changes from base-line levels of plasma D-dimer and serum interleukin-6 were analyzed in patients who had subsequent measurements with the use of analysis of variance of ranked data. For patients with missing data, we used the last-observation-carried-forward method of imputation. The proportion of patients who had serious adverse events and new infections was compared in the two groups with the use of Pearson's chi-square tests. All reported P values are two-sided.
Results
At the time of the second interim analysis of data from 1520 patients, enrollment was suspended because the differences in the mortality rate between the two groups exceeded the a priori guideline for stopping the trial. Results presented here include data from additional patients who were enrolled before the completion of the second interim analysis.
Base-Line Characteristics of the Patients
Of 1728 patients who underwent randomization, 1690 received the study drug or placebo. Thirty-eight patients (17 in the placebo group and 21 in the drotrecogin alfa activated group) never received any study drug. In the drotrecogin alfa activated group, 14 patients met at least one exclusion criterion, 4 patients became moribund before the infusion could be started, and consent was withdrawn before the infusion in the case of 3 patients. In the placebo group, 15 patients did not meet the entry criteria for the study, and 2 patients became moribund before the infusion was begun.
All randomized patients were followed for the entire 28-day study period except for one patient in the drotrecogin alfa activated group who did not receive the study drug. This patient was classified as having died on day 28 in the mortality analysis of all randomized patients.
At base line, the demographic characteristics and severity of disease were similar in the placebo group and the drotrecogin alfa activated group (Table 1Table 1
Base-Line Characteristics of the Patients.). Approximately 75 percent of the patients had at least two dysfunctional organs or systems at the time of enrollment. The lungs and the abdomen were the most common sites of infection, occurring in 53.6 percent and 19.9 percent of the patients, respectively, in the two groups combined (Table 2Table 2
Sites and Causes of Infection in Patients with Severe Sepsis.). The incidence of gram-positive and gram-negative infections was similar within each group and between the two groups. A blinded clinical evaluation committee determined that clinically appropriate antibiotic therapy that was based on the site of infection and available culture and susceptiblitily data was started within 48 hours of the diagnosis of severe sepsis and continued for at least five days or until death in 776 patients in the drotrecogin alfa activated group (91.3 percent) and in 766 patients in the placebo group (91.2 percent). Base-line levels of indicators of coagulopathy and inflammation were also similar in the two groups (Table 3Table 3
Base-Line Levels of Indicators of Coagulation and Inflammation.). Protein C deficiency was present in 87.6 percent of the patients (1379 of 1574) for whom levels were obtained. In addition, plasma D-dimer and serum interleukin-6 levels were elevated in 99.7 and 98.5 percent of the patients, respectively. Among treated patients, 82.4 percent of those in the placebo group and 81.8 percent of those in the drotrecogin alfa activated group received at least 90 percent of the intended infusion and 8.2 percent and 6.4 percent, respectively, died during the 96-hour period of infusion.Efficacy
Twenty-eight days after the start of the infusion, 259 of 840 patients in the placebo group (30.8 percent) and 210 of 850 (24.7 percent) of the patients in the drotrecogin alfa activated group had died. This difference in the rate of death from any cause was significant (P=0.005 in the nonstratified analysis) (Table 4Table 4
Analysis of the Rates and Risks of Death from Any Cause at 28 Days.) and was associated with an absolute reduction in the risk of death of 6.1 percent. The prospectively defined primary analysis in which the groups were stratified according to the base-line APACHE II score, age, and protein C activity produced similar results (P=0.005), as did the analysis that included the 38 patients who underwent randomization but who never received the infusion (P=0.003). The results of the prospectively defined primary analysis represent a reduction in the relative risk of death of 19.4 percent (95 percent confidence interval, 6.6 to 30.5) in association with treatment with drotrecogin alfa activated, as compared with placebo. A Kaplan–Meier analysis of survival yielded similar results (P=0.006) (Figure 2Figure 2Kaplan–Meier Estimates of Survival among 850 Patients with Severe Sepsis in the Drotrecogin Alfa Activated Group and 840 Patients with Severe Sepsis in the Placebo Group.). The absolute difference in survival between the two groups was evident within days after the initiation of the infusion and continued to increase throughout the remainder of the study period.Prospectively defined subgroup analyses were performed for a number of base-line characteristics, including the APACHE II score, the number of dysfunctional organs or systems, other indicators of the severity of disease, sex, age, the site of infection, the type of infection (gram-positive, gram-negative, or mixed), and presence or absence of protein C deficiency. A consistent effect of treatment with drotrecogin alfa activated was observed among the subgroups (data not shown), including the subgroup with protein C deficiency and the subgroup with normal protein C levels.
Levels of D-Dimer and Interleukin-6
Plasma D-dimer levels were significantly lower in patients in the drotrecogin alfa activated group than in patients in the placebo group on days 1 through 7 after the start of the infusion (Figure 3Figure 3
Changes in Median Plasma D-Dimer Levels in 770 Patients with Severe Sepsis in the Drotrecogin Alfa Activated Group and 729 Patients in the Placebo Group.). Decreases in serum interleukin-6 levels were significantly greater in the patients in the drotrecogin alfa activated group than in the patients in the placebo group on day 1 (P=0.009) and on days 4, 5, 6, and 7 (P=0.025, P=0.017, P=0.016, and P=0.022, respectively).Complications
The percentage of patients who had at least one serious adverse event was similar in the two groups (Table 5Table 5
Incidence of Serious Adverse Events.). The incidence of serious bleeding was higher in the drotrecogin alfa activated group than in the placebo group (3.5 percent vs. 2.0 percent) (P=0.06). This difference in the incidence of serious bleeding was observed only during the infusion period; thereafter, the incidence was similar in the two groups. Among the patients who received drotrecogin alfa activated, the incidence of serious bleeding was similar for those who received drotrecogin alfa activated alone and those who also received heparin (3.7 percent and 3.5 percent). In both the drotrecogin alfa activated group and the placebo group, serious bleeding occurred primarily in patients with an identifiable predisposition to bleeding, such as gastrointestinal ulceration, an activated partial-thromboplastin time of more than 120 seconds, a prolonged prothrombin time (an international normalized ratio of more than 3.0), a platelet count that decreased to less than 30,000 per cubic millimeter and remained at that level despite standard therapy, traumatic injury of a blood vessel, or traumatic injury of a highly vascular organ. There was a fatal intracranial hemorrhage in two patients in the drotrecogin alfa activated group during the infusion (on day 1 and day 4) and in one patient in the placebo group six days after the end of the infusion. After adjustment for the duration of survival, blood-transfusion requirements were similar in the two groups (P=0.90).There were no other safety concerns associated with treatment with drotrecogin alfa activated on the basis of assessments of organ dysfunction, vital signs, serum chemical data, or hematologic data. The incidence of thrombotic events was similar in the two groups (Table 5). New infections occurred in 25.5 percent of the patients in the drotrecogin alfa activated group and 25.1 percent of the patients in the placebo group (P=0.85). Neutralizing antibodies against activated protein C were not detected in any patient.
Discussion
In this study, the administration of drotrecogin alfa activated reduced the rate of death from any cause at 28 days in patients with a clinical diagnosis of severe sepsis, resulting in a 19.4 percent reduction in the relative risk of death and an absolute reduction of 6.1 percent. A survival benefit was evident throughout the 28-day study period, whether or not the groups were stratified according to the severity of disease. Our results indicate that in this population, 1 additional life would be saved for every 16 patients treated with drotrecogin alfa activated.
Though the study population was heterogeneous with respect to clinical features, it was homogeneous with respect to the biochemical evidence of systemic inflammation and coagulopathy. In these patients, the benefit of drotrecogin alfa activated is most likely explained by the drug's biologic activity. Activated protein C inhibits the generation of thrombin by inactivating factor Va and factor VIIIa.30,31 As compared with the patients who received placebo, patients who received drotrecogin alfa activated had greater decreases in plasma D-dimer levels during the first seven days after the infusion was initiated, indicating a reduction in the generation of thrombin. The rise in D-dimer levels after the completion of the 96-hour infusion of drotrecogin alfa activated indicates incomplete resolution of the procoagulant state seen in patients with sepsis. An evaluation of longer periods of infusion of drotrecogin alfa activated may be warranted.
Treatment with drotrecogin alfa activated decreased inflammation, as indicated by decreases in interleukin-6 levels, a finding consistent with the known antiinflammatory activity of activated protein C. The antiinflammatory activity of drotrecogin alfa activated may be mediated indirectly through the inhibition of the generation of thrombin, which leads to decreased activation of platelets, recruitment of neutrophils, and degranulation of mast cells.8 Furthermore, preclinical studies demonstrated that activated protein C has direct antiinflammatory properties, including the inhibition of neutrophil activation, the production of cytokines by lipopolysaccharide-challenged monocytes, and E-selectin–mediated adhesion of cells to vascular endothelium.32-34
A consistent effect of treatment with drotrecogin alfa activated was seen among the subgroups examined, including those stratified according to age, APACHE II score, sex, number of dysfunctional organs or systems, type of infection (gram-positive, gram-negative, or mixed), site of infection, and presence or absence of protein C deficiency at study entry. Reductions in the relative risk of death were observed regardless of whether the patients had a deficiency of protein C at base line, suggesting that drotrecogin alfa activated has pharmacologic effects that go beyond simple physiologic replacement of activated protein C. This observation further suggests that measurements of protein C are not necessary to identify which patients would benefit from treatment with drotrecogin alfa activated. A consistent treatment effect was also observed regardless of the site of infection or the type of infection.
It was consistent with the antithrombotic activity of drotrecogin alfa activated that bleeding was the most common adverse event associated with the administration of the drug. The incidence of serious bleeding suggests that 1 additional serious bleeding event would occur for every 66 patients treated with drotrecogin alfa activated. Serious bleeding tended to occur in patients with predisposing conditions, such as gastrointestinal ulceration, traumatic injury of a blood vessel or highly vascular organ injury, or markedly abnormal values for indicators of coagulation (e.g., the platelet count, the activated partial-thromboplastin time, and the prothrombin time). The incidence of thrombotic events was not increased by treatment with drotrecogin alfa activated, and the antiinflammatory effect was not associated with an increased incidence of new infections. Treatment with drotrecogin alfa activated was not associated with the development of neutralizing antibodies against activated protein C.
In summary, the biologic activity of drotrecogin alfa activated was demonstrated by the finding of greater decreases in D-dimer and interleukin-6 levels in patients who received drotrecogin alfa activated than in those who received placebo. The higher incidence of serious bleeding during infusion in the drotrecogin alfa activated group is consistent with the antithrombotic activity of the drug and occurs predominantly in patients with a predisposition to bleeding. In patients with severe sepsis, an intravenous infusion of drotrecogin alfa activated at a dose of 24 μg per kilogram per hour for 96 hours was associated with a significant reduction in mortality and a safety profile that was acceptable within the context of this clinical trial.
Supported by Eli Lilly.
Drs. LaRosa, Helterbrand, and Fisher are employees of Eli Lilly; Drs. Helterbrand and Fisher are stockholders; and Drs. Bernard, Garber, Dhainaut, Vincent, and Laterre have served as consultants to Eli Lilly.
Source Information
From the Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville (G.R.B., E.W.E.); the Department of Intensive Care, Erasme University Hospital, Brussels, Belgium (J.-L.V.); the Department of Critical Care and Emergency Medicine, Cliniques Universitaires St. Luc, Brussels, Belgium (P.-F.L.); Lilly Research Laboratories, Eli Lilly, Indianapolis (S.P.L., J.D.H., C.J.F.); the Department of Intensive Care, Cochin–Port Royal University Hospital, Paris V University, Paris (J.-F.D.); the Unidad de Cuidados Intensivos, Servicio de Medicina Intensiva, Hospital Infanta Cristina, Badajoz, Spain (A.L.-R.); the Critical Care Division, Baystate Medical Center, Springfield, Mass., and Tufts University School of Medicine, Boston (J.S.S.); and the Division of Infectious Diseases, University of Ottawa, Ottawa Hospital, Ottawa, Ont., Canada (G.E.G.).
Address reprint requests to Dr. Bernard at the Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, T-1208 Medical Center North, Vanderbilt University School of Medicine, Nashville, TN 37232, or at gordon.bernard@mcmail.vanderbilt.edu.
Additional institutions and investigators participating in the study are listed in Appendix 3.
Appendix
Appendix 1
Summary of Inclusion Criteria..Appendix 2
Summary of Exclusion Criteria..Appendix 3
In addition to the authors, the following institutions and investigators participated in the study: Clinical Evaluation Committee: D. Heiselman, G. Kinasewitz, H. Levy, R. Light, D. Maki, P. Morris, J. Sollet; Vanderbilt Coordinating Center: B. Swindell, M. Stroud, S. Higgins, M. Burdett, J. Burger, S. Calderon, J. Gottesman, T. Thomas; Data Safety and Monitoring Board: S. Opal, E. Abraham, J. Wittes, S. Lowry; Clinical Sites: Australia: R. Bellomo, I. Baldwin, Heidelberg; R. Boots, C. Rickard, Hersten; G. Dobb, G. Morris, Perth; M. Chapman, J. Myburgh, S. Creed, D. Rea, Adelaide; S. Finfer, R. Lee, M. Madnaye, St. Leonards; P. van Heerden, B. Roberts, Nedlands; C. Joyce, T. Limpus, Woolloongabba; J. Cade, C. Boyce, Parkville; D. Breen, D. Rajbhandari, Camperdown; A. Bersten, T. Hunt, Bedford Park; A. Davies, G. Hanlon, L. Howard, Prahan; Belgium: P. Hantson, M. Reynaert, X. Wittebolle, H. Spapen, I. Hubloue, D. De Backer, P. Weyers, Brussels; F. Forêt, D. Valadi, Mons; M. Simon, Arlon; Brazil: E. Knobel, E. Silva, J. Amaral, F. Machado, São Paulo; Canada: G. Jones, D. Garber, I. Watpool, Ottawa; J. Russell, V. Dunlop, T. Lehman, Vancouver; E. Jacobsohn, D. Bell, T. Wilson, Winnipeg; D. Zuege, D. Conley, Calgary; R. Johnston, D. Kutsogiannis, S. Marcushamer, D. Matheson, W. Murtha, A. Shustack, E. Konopad, P. Nicholls, N. Whalen, Edmonton; R. Light, M. Dominique, Winnipeg; C. Doig, L. Cranshaw, Calgary; I. Mayers, C. Carbonaro, B. Litwiniwich, M. Miller, Edmonton; F. Rutledge, V. Binns, J. Kehoe, London; T. Smith, J. Fuhrmann, B. Horodyski, Toronto; D. Heyland, E. Flynn, D. Witham, Kingston; J. Fenwick, L. Grandolfo, Vancouver; S. Mehta, R. MacDonald, Toronto; R. Hall, Y. Stolworthy, Halifax; J. Marshall, M. Steinberg, Toronto; K. Williams, B. Peters, Saskatoon; France: A. Cariou, Paris; J. Sollet, G. Bleichner, Argenteuil; F. Zeni, Saint-Etienne; D. Dreyfuss, A. de Lassence, Colombes; J. Timsit, E. Vantalon, Paris; J. Vedrinne, S. Duperret, Lyons; A. Tenaillon, J. Camuset, Evry; C. Martin, J. Albanese, Marseilles; C. Arich, R. Cohendy, Nîmes; B. Vallet, P. Rodie-Talbere, Lille; M. Wolff, F. Delatour, Paris; G. Fournier, D. Jacques, Pierre-Bénite; Germany: P. Kujath, A. Stolfa, Lübeck; C. Erley, W. Shöbel, Tübingen; T. Klöss, J. Kramer, Hamburg; F. Forycki, B. Ehrecke, H. Riess, D. Barckow, Berlin; D. Schmitt, J. Garbade, Leipzig, H. Darius, M. Spiecker, Mainz; M. Wehling, Mannheim; the Netherlands: J. Bakker, J. Hofhuis, M. Disberg, Apeldoorn; C. van der Linden, Heerlen; S. van der Geest, L. Steens, B. Solberg, Maastricht; G. Ong, W. in't Veld, Rotterdam; B. Speelberg, Tilburg; H. Delwig, J. Tulleken, J. Bottema, R. Spanjersberg, Groningen; New Zealand: R. Freebairn, L. Chadwick, Hastings; S. Henderson, J. Mehrtens, Christchurch; C. McArthur, L. Newby, J. Roberts, Auckland; South Africa: J. Brown, S. Tshukutsoane, Soweto; J. Pretorius, F. van Rensburg, Pretoria; J. Kilian, M. Landman, Lynnwood Ridge; M. Beale, D. Steyn, Tygerberg; Spain: R. Bayo Poleo, J. Juliá Navarez, L. López Sánchez, Badajoz; A. Esteban de la Torre, J. Lorente Balanza, J. Colchon, P. Vadillo, Madrid; A. Artigas Raventos, F. Baigorri González, G. Goma, Barcelona; C. León Gil, J. Castillo Caballero, F. Lucena Calderón, F. Ortega Vinuesa, Seville; J. Boveda Trevino, J. Caballero López, J. Ruiz Rodriguez, Barcelona; J. Caturla Such, J. Cánovas Robles, M. Delgado Lacosta, A. Silla López, Alicante; J. Gómez Rubí, V. Bixquert Montagud, A. Sánchez Martos, J. San Martin Monzo, Murcia; United States: K. Lafleur, Springfield, Mass.; B. Margolis, C. Doombos, Oak Park, Ill.; G. Kinasewitz, C. Castle, A. Eid, Oklahoma City; H. Shanies, H. Luttinger, Elmhurst, N.Y.; H. Levy, M. Niedhart, T. Roughface, Albuquerque, N.M.; L. Anderson, E. Jones, M. Morrissey, Bay Pines, Fla.; G. Matuschak, P. Dettenmeier, St. Louis; D. Heiselman, B. Park, Akron, Ohio; J. Otoshi, L. Weber, Escondido, Calif.; J. Taylor, C. Tweten, Tacoma, Wash.; R. Wunderink, C. Jones, Memphis, Tenn.; G. Kohler, C. Reed, Lake Charles, La.; M. Harrison, J. Cwengros, S. Shore, K. Hogeterp, Grand Rapids, Mich.; D. Lusbader, N. Dengler, V. Reichert, Manhasset, N.Y.; P. Comp, C. Comp, D. Spence, Oklahoma City; J. Fraiz, C. Bunce, M. Watson, Indianapolis; T. Berne, J. Murray, L. Sarmiento, N. Solera, Los Angeles; G. Rubeiz, J. Miessen, Indianapolis; J. Kellum, M. Cohen, Pittsburgh; R. Carlson, C. Johnson, Phoenix, Ariz.; H. Simms, M. Levy, S. Lizotte, J. Houtchen, Providence, R.I.; R. Schmid, J. Bauwens, S. Weise, Sun City, Ariz.; R. Taylor, J. O'Brien, St. Louis; C. Givens, T. Thompson, Newport News, Va.; D. Ziegler, D. Burns, Fort Worth, Tex.; P. Morris, A. Howard-Carroll, Winston-Salem, N.C.; G. Gomez, D. Allen, M. Spires, Indianapolis; A. Multz, I. Balatsky, New Hyde Park, N.Y.; D. Smith, J. Josephs, T. Houlihan, Lackland AFB, Tex.; M. Polkow, T. McKiernan, Hackensack, N.J.; T. Verville, V. Zimmer, Charlotte, N.C.; P. Edelstein, A. Seiver, N. Novick, Stanford, Calif.; D. Graham, V. Molnar, Springfield, Ill.; J. Siever, Phoenix, Ariz.; F. Booth, K. Brunton, R. Kerins, Buffalo, N.Y.; E. Diamond, M. Borkgren, Elk Grove Village, Ill.; V. Bandi, G. Lingle, C. Pope, Houston; D. Green, M. Majewski, Chicago; K. Bagheri, C. Murphy, T. Peters, San Diego, Calif.; S. Berman, J. Doll, E. Johnson, Honolulu; D. Maki, V. Knasinski, A. Jones, Madison, Wis.; R. Riker, D. Schlichting, Portland, Me.; S. Weiss, J. Broughton, W. Silvers, Denver; G. Coppa, M. Temperino, Staten Island, N.Y.; R. Kearl, K. Oelschlager, Phoenix, Ariz.; J. Kennedy, Jr., J. Ryder, Birmingham, Ala.; C. Naum, T. Isaacs, Indianapolis; J. McFeely, V. Perry, Berkeley, Calif.; J. Turner, B. Welcher, Sacramento, Calif.; J. Stasek, Jr., Houston; P. Papadakos, A. Holberton, Rochester, N.Y.; J. Travaline, D. Pollard, Philadelphia; B. de Boisblanc, E. Dimitry, New Orleans; M. Siegel, C. Roberts, New Haven, Conn.; D. Shasby, T. Gross, Iowa City, Iowa; D. Gervich, D. Foshe, Des Moines, Iowa; R. Light, T. Johnson, J. Rogers, Nashville; P. Kearney, J. Carpenter-Warner, A. Rockich, Lexington, Ky.; M. Birmingham, J. Hassett, D. Serrianne, Buffalo, N.Y.; M. Astiz, P. O'Neil, New York; J. Whitney, E. Tobin, A. Sheehan, Albany, N.Y.; C. Oliphant, Casper, Wyo.; R. Miller, S. Graham, Greenville, S.C.; T. Rushton, R. Ashford, Huntington, W. Va.; C. Piquette, J. Melson, Omaha, Nebr.; R. Lodato, A. Mirza, S. Schippers, Houston, R. Corbin, Beaufort, N.C.; R. Baughman, M. Kerr, Cincinnati; J. Lamberti, Falls Church, Va.; S. Pingleton, S. Porras, Kansas City, Kans.; A. Anzueto, A. Roldan, San Antonio, Tex.; D. Resnick, K. Rodvold, D. Bearden, Chicago; J. Kruse, C. Hemmen, M. Thill, Detroit; T. Lo, M. Terry, Loma Linda, Calif.; A. Wheeler, S. Bozeman, L. Collins, Nashville; V. Lampasona, Atlanta; J. Gottleib, A. Girod, Philadelphia; M. Seneff, C. Spartan, Washington, D.C.; M. Cipolle, L. Baga, Allentown, Pa.; R. Schein, Y. Ellington, Miami; F. Luchette, E. Montgomery, Cincinnati; M. Rumbak, Tampa, Fla.; T. Albertson, E. Vlastelin, Sacramento, Calif.
- References
References
1
Bone RC ,Grodzin CJ ,Balk RA . Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 1997;112:235-243
CrossRef | Web of Science | Medline2
Angus DC ,Birmingham MC ,Balk RA , et al. E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. JAMA 2000;283:1723-1730
CrossRef | Web of Science | Medline3
Rangel-Frausto MS ,Pittet D ,Costigan M ,Hwang T ,Davis CS ,Wenzel RP . The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study. JAMA 1995;273:117-123
CrossRef | Web of Science | Medline4
Annane D ,Sebille V ,Troche G ,Raphael JC ,Gajdos P ,Bellissant E . A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000;283:1038-1045
CrossRef | Web of Science | Medline5
Increase in National Hospital Discharge Survey rates for septicemia -- United States, 1979-1987. JAMA 1990;263:937-938
CrossRef6
Linde-Zwirble WT ,Angus DC ,Carcillo J ,Lidicker J ,Clermont G ,Pinsky MR . Age-specific incidence and outcome of sepsis in the US. Crit Care Med 1999;27:Suppl 1:A33-A33 abstract.
CrossRef | Web of Science7
Esmon CT ,Taylor FB Jr ,Snow TR . Inflammation and coagulation: linked processes potentially regulated through a common pathway mediated by protein C. Thromb Haemost 1991;66:160-165
Web of Science | Medline8
Yan SB ,Grinnell BW . Recombinant human protein C, protein S, and thrombomomodulin as antithrombotics. Perspect Drug Discovery Des 1993;1:503-520
CrossRef9
Stouthard JM ,Levi M ,Hack CE , et al. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost 1996;76:738-742
Web of Science | Medline10
Conkling PR ,Greenberg CS ,Weinberg JB . Tumor necrosis factor induces tissue factor-like activity in human leukemia cell line U937 and peripheral blood monocytes. Blood 1988;72:128-133
Web of Science | Medline11
Bevilacqua MP ,Pober JS ,Majeau GR ,Fiers W ,Cotran RS ,Gimbrone MA Jr . Recombinant tumor necrosis induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci U S A 1986;12:4533-4537
CrossRef | Web of Science12
Vervloet MG ,Thijs LG ,Hack CE . Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin Thromb Hemost 1998;24:33-44
CrossRef | Web of Science | Medline13
Levi M ,ten Cate B . Disseminated intravascular coagulation. N Engl J Med 1999;341:586-592
Full Text | Web of Science | Medline14
Iba T ,Kidokoro A ,Yagi Y . The role of the endothelium in changes in procoagulant activity in sepsis. J Am Coll Surg 1998;187:321-329
CrossRef | Web of Science | Medline15
Neshelm M ,Wang W ,Boffa M ,Nagashima M ,Morser J ,Bajzar L . Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost 1997;78:386-391
Web of Science | Medline16
Esmon CT . Inflammation and thrombosis: mutual regulation by protein C. Immunologist 1998;6:84-8917
Bajzar L ,Neshelm ME ,Tracy PB . The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996;88:2093-2100
Web of Science | Medline18
Esmon CT . The protein C anticoagulant pathway. Arterioscler Thromb 1992;12:135-145
CrossRef | Medline19
Boehme MW ,Deng Y ,Raeth U , et al. Release of thrombomodulin from endothelial cells by concerted action of TNF-alpha and neutrophils: in vivo and in vitro studies. Immunology 1996;87:134-140
Web of Science | Medline20
Fourrier F ,Chopin C ,Goudemand J , et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation: compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992;101:816-823
CrossRef | Web of Science | Medline21
Lorente JA ,Garcia-Frade LJ ,Landin L , et al. Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest 1993;103:1536-1542
CrossRef | Web of Science | Medline22
Boldt J ,Papsdorf M ,Rothe A ,Kumle B ,Piper S . Changes of the hemostatic network in critically ill patients -- is there a difference between sepsis, trauma, and neurosurgery patients? Crit Care Med 2000;28:445-450
CrossRef | Web of Science | Medline23
Powars D ,Larsen R ,Johnson J , et al. Epidemic meningococcemia and purpura fulminans with induced protein C deficiency. Clin Infect Dis 1993;17:254-261
CrossRef | Web of Science | Medline24
Taylor FB Jr ,Chang A ,Esmon CT ,D'Angelo A ,Vigano-D'Angelo S ,Blick KE . Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987;79:918-925
CrossRef | Web of Science | Medline25
Hartman DL ,Bernard GR ,Helterbrand JD ,Yan SB ,Fisher CJ . Recombinant human activated protein C (rhAPC) improves coagulation abnormalities associated with severe sepsis. Intensive Care Med 1998;24:Suppl 1:S77-S77 abstract.
CrossRef | Web of Science26
Bone RC ,Balk RA ,Cerra FB , et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992;101:1644-1655
CrossRef | Web of Science | Medline27
Yan SC ,Razzano P ,Chao YB , et al. Characterization and novel purification of recombinant human protein C from three mammalian cell lines. Biotechnology (N Y) 1990;8:655-661
CrossRef | Medline28
Lan KKG ,DeMets DL . Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659-663
CrossRef | Web of Science29
Knaus WA ,Draper EA ,Wagner DP ,Zimmerman JE . APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-829
CrossRef | Web of Science | Medline30
Walker FJ ,Sexton PW ,Esmon CT . The inhibition of blood coagulation by activated protein C through the selective inactivation of activated factor V. Biochim Biophys Acta 1979;571:333-342
Web of Science | Medline31
Fulcher CA ,Gardiner JE ,Griffin JH ,Zimmerman TS . Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V. Blood 1984;63:486-489
Web of Science | Medline32
Grey ST ,Tsuchida A ,Hau H ,Orthner CL ,Salem HH ,Hancock WW . Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester. J Immunol 1994;153:3664-3672
Web of Science | Medline33
Hirose K ,Okajima K ,Taoka Y , et al. Activated protein C reduces the ischemia/reperfusion-induced spinal cord injury in rats by inhibiting neutrophil activation. Ann Surg 2000;232:272-280
CrossRef | Web of Science | Medline34
Grinnell BW ,Hermann RB ,Yan SB . Human protein C inhibits selectin-mediated cell adhesion: role of unique fucosylated oligosaccharide. Glycobiology 1994;4:221-225
CrossRef | Web of Science | Medline
- Citing Articles (1911)
Citing Articles
1
M Man, S L Close, A D Shaw, G R Bernard, I S Douglas, R J Kaner, D Payen, J-L Vincent, S Fossceco, J M Janes, A G Leishman, L O'Brien, M D Williams, J G N Garcia. (2012) Beyond single-marker analyses: mining whole genome scans for insights into treatment responses in severe sepsis. The Pharmacogenomics Journal
CrossRef2
Tomasz Skirecki, Urszula Borkowska-Zielińska, Małgorzata Złotorowicz, Grażyna Hoser. (2012) Sepsis Immunopathology: Perspectives of Monitoring and Modulation of the Immune Disturbances. Archivum Immunologiae et Therapiae Experimentalis
CrossRef3
Steven J. Schwulst, John E. Mazuski. (2012) Surgical Prophylaxis and Other Complication Avoidance Care Bundles. Surgical Clinics of North America
CrossRef4
Andrew N. Chalupka, Daniel Talmor. (2012) The Economics of Sepsis. Critical Care Clinics 28:1, 57-76
CrossRef5
Carley Riley, Derek S. Wheeler. (2012) Prevention of Sepsis in Children: A New Paradigm for Public Policy. Critical Care Research and Practice 2012, 1-8
CrossRef6
Jecko Thachil, Cheng Hok Toh, Marcel Levi, Henry G Watson. (2012) The withdrawal of Activated Protein C from the use in patients with severe sepsis and DIC [Amendment to the BCSH guideline on disseminated intravascular coagulation]. British Journal of Haematologyno-no
CrossRef7
F. Stephan, L. A. Aarden, S. Zeerleder. (2012) FSAP, a new player in inflammation?. Hämostaseologie 32:1, 51-55
CrossRef8
Mark R. Gillrie, Kristine Lee, D. Channe Gowda, Shevaun P. Davis, Marc Monestier, Liwang Cui, Tran Tinh Hien, Nicholas P.J. Day, May Ho. (2012) Plasmodium falciparum Histones Induce Endothelial Proinflammatory Response and Barrier Dysfunction. The American Journal of Pathology
CrossRef9
Narayan Prasad, Sudeendra S. Gupta. (2012) Sepsis-associated acute kidney injury. Clinical Queries: Nephrology 1:1, 42-49
CrossRef10
Javier Fernández, Thierry Gustot. (2012) Management of bacterial infections in cirrhosis. Journal of Hepatology 56, S1-S12
CrossRef11
Tara Lagu, Michael B. Rothberg, Brian H. Nathanson, Penelope S. Pekow, Jay S. Steingrub, Peter K. Lindenauer. (2012) Variation in the care of septic shock: The impact of patient and hospital characteristics. Journal of Critical Care
CrossRef12
Ryan M. Carnahan, Ronald A. Herman, Kevin G. Moores. (2012) A systematic review of validated methods for identifying transfusion-related sepsis using administrative and claims data. Pharmacoepidemiology and Drug Safety 21, 222-229
CrossRef13
Derek C Angus. (2012) Drotrecogin alfa (activated) ... a sad final fizzle to a roller-coaster party. Critical Care 16:1, 107
CrossRef14
Michelle S. Chew, Adam Linder, Stefan Santen, Anders Ersson, Heiko Herwald, Henrik Thorlacius. (2011) Increased plasma levels of heparin-binding protein in patients with shock: a prospective, cohort study. Inflammation Research
CrossRef15
Byungse Suh, Rafik Samuel. 2011. Drotrecogin Alfa Activated (Recombinant Human Activated Protein C, Xigris). .
CrossRef16
Vivek Kak. (2011) Mediators of Systemic Inflammatory Response Syndrome and the Role of Recombinant Activated Protein C in Sepsis Syndrome. Infectious Disease Clinics of North America 25:4, 835-850
CrossRef17
Antoine Kimmoun, Bruno Levy. (2011) Treatment of Myocardial Dysfunction in Sepsis. Shock 36:6, 633-634
CrossRef18
Abolfazl Zarjou, Paul W. Sanders, Ravindra L. Mehta, Anupam Agarwal. (2011) Enabling Innovative Translational Research in Acute Kidney Injury. Clinical and Translational Scienceno-no
CrossRef19
Karen M. Hook, Charles S. Abrams. (2011) The Loss of Homeostasis in Hemostasis: New Approaches in Treating and Understanding Acute Disseminated Intravascular Coagulation in Critically Ill Patients*. Clinical and Translational Scienceno-no
CrossRef20
Patrizia Della Valle, Giulia Pavani, Armando D'Angelo. (2011) The protein C pathway and sepsis. Thrombosis Research
CrossRef21
Alison Boyle, Cathrine McKenzie, Sarah Yassin, Angela McLuckie, Duncan Wyncoll. (2011) Adverse events and clinical outcome associated with drotrecogin alfa-activated: A single-center experience of 498 patients over 8 years. Journal of Critical Care
CrossRef22
Philip S. Barie. (2011) The Last Xigris ® * Survivor. Surgical Infections 12:6, 423-425
CrossRef23
Ilse M. Espina, Joseph Varon. (2011) Assessing prognosis of sepsis in the ED: do we have a magic ball?. The American Journal of Emergency Medicine
CrossRef24
Philip S. Barie, Lynn J. Hydo, Jian Shou, Soumitra R. Eachempati. (2011) Efficacy of Therapy with Recombinant Human Activated Protein C of Critically Ill Surgical Patients with Infection Complicated by Septic Shock and Multiple Organ Dysfunction Syndrome. Surgical Infections 12:6, 443-449
CrossRef25
Mitchell Jay Cohen, Mariah Call, Mary Nelson, Carolyn S. Calfee, Charles T. Esmon, Karim Brohi, Jean Francois Pittet. (2011) Critical Role of Activated Protein C in Early Coagulopathy and Later Organ Failure, Infection and Death in Trauma Patients. Annals of Surgery1
CrossRef26
Jens A. Wagner, Heiner Langenfeld, Luise Klett, Stefan Störk. (2011) Activated protein C in patients with septic shock: a consecutive case series. International Journal of Clinical Pharmacy
CrossRef27
U. J. K. Soh, J. Trejo. (2011) PNAS Plus: Activated protein C promotes protease-activated receptor-1 cytoprotective signaling through -arrestin and dishevelled-2 scaffolds. Proceedings of the National Academy of Sciences
CrossRef28
J. Knapp, G. Marx, K. Weismüller, S. Steinebach, C. Lichtenstern, E. Popp, K. Mayer, F.M. Brunkhorst, M.A. Weigand, M. Bernhard. (2011) Update: intensivmedizinische Studien. Der Anaesthesist
CrossRef29
T. C. Hall, D. K. Bilku, D. Al-Leswas, C. Horst, A. R. Dennison. (2011) The difficulties of clinical trials evaluating therapeutic agents in patients with severe sepsis. Irish Journal of Medical Science
CrossRef30
C. Bigham, S. Jaggar. (2011) Ketamine for induction and maintenance during elective on-pump coronary artery bypass grafts. British Journal of Anaesthesia 107:5, 813-813
CrossRef31
L. Engelmann. (2011) Thrombophile Zustände in der Intensivmedizin. Medizinische Klinik 106:3, 189-197
CrossRef32
Katherine Soreng, H. Roma Levy. (2011) Procalcitonin: an Emerging Biomarker of Bacterial Sepsis. Clinical Microbiology Newsletter 33:22, 171-178
CrossRef33
Ritesh Maharaj. (2011) Vasopressors and the search for the optimal trial design. Contemporary Clinical Trials 32:6, 924-930
CrossRef34
P. Roddy, R. Colebunders, B. Jeffs, P. P. Palma, M. Van Herp, M. Borchert. (2011) Filovirus Hemorrhagic Fever Outbreak Case Management: A Review of Current and Future Treatment Options. Journal of Infectious Diseases 204:suppl 3, S791-S795
CrossRef35
Thorsten Brenner, Claudia Rosenhagen, Isabelle Hornig, Karsten Schmidt, Christoph Lichtenstern, Markus Mieth, Thomas Bruckner, Eike Martin, Paul Schnitzler, Stefan Hofer, Markus A. Weigand. (2011) Viral Infections in Septic Shock (VISS-Trial)–Crosslinks Between Inflammation and Immunosuppression. Journal of Surgical Research
CrossRef36
Sarah Faubel, Charles L. Edelstein. (2011) Acute kidney injury: Severity of illness scoring systems in acute kidney injury. Nature Reviews Nephrology
CrossRef37
EILEEN SUNG, JULIE GEORGE, MICHELLE PORTER. (2011) SEPSIS IN PREGNANCY. Fetal and Maternal Medicine Review 22:04, 287-305
CrossRef38
J.M. de Miguel Yanes, J.A. Andueza Lillo, J.C. Cano Ballesteros, S. Gordo Remartínez. (2011) Infecciones sistémicas en Urgencias. Sepsis. Shock séptico. Medicine - Programa de Formación Médica Continuada Acreditado 10:90, 6078-6086
CrossRef39
Marc O. Maybauer, Dirk M. Maybauer, John F. Fraser, Martin Westphal, Csaba Szabó, Robert A. Cox, Hal K. Hawkins, Lillian D. Traber, Daniel L. Traber. (2011) Combined Recombinant Human Activated Protein C and Ceftazidime Prevent the Onset of ARDS in Severe Sepsis. Shock1
CrossRef40
Menachem Oberbaum, Ram M. Spira, Esther Lukasiewicz, Yaron Armon, Noah Samuels, Shepherd Roee Singer, Vivian Barak, Gabriel Izbicki, Sharon Einav, Moshe Hersch. (2011) Effect of Traumeel S on Cytokine Profile in a Cecal Ligation and Puncture (CLP) Sepsis Model in Rats. The Journal of Alternative and Complementary Medicine111006085508005
CrossRef41
Eimear M. Gleeson, James S. O’Donnell, Roger J. S. Preston. (2011) The endothelial cell protein C receptor: cell surface conductor of cytoprotective coagulation factor signaling. Cellular and Molecular Life Sciences
CrossRef42
Gina M. Berg, Donald G. Vasquez, LaDonna S. Hale, Sue M. Nyberg, David A. Moran. (2011) Evaluation of Process Variations in Noncompliance in the Implementation of Evidence-Based Sepsis Care. Journal for Healthcare Qualityn/a-n/a
CrossRef43
Navin K. Kapur, Ce Bian, Edward Lin, Clayton B. Deming, Jason L. Sperry, Baranda S. Hansen, Nikolaos Kakouros, Jeffrey J. Rade. (2011) Inhibition of transforming growth factor-β restores endothelial thromboresistance in vein grafts. Journal of Vascular Surgery 54:4, 1117-1123.e1
CrossRef44
Jorge I.F. Salluh, Ligia S.C.F. Rabello, Maira M. Rosolem, Márcio Soares, Fernando A. Bozza, Juan Carlos R. Verdeal, Gustavo W. Mello, Hugo C. Castro Faria Neto, José Roberto Lapa e Silva, Patrícia T. Bozza. (2011) The impact of coagulation parameters on the outcomes of patients with severe community-acquired pneumonia requiring intensive care unit admission. Journal of Critical Care 26:5, 496-501
CrossRef45
Scott B. Hu, Alexander Zider, Jane C. Deng. (2011) When host defense goes awry: modeling sepsis-induced immunosuppression. Drug Discovery Today: Disease Models
CrossRef46
H. Bryant Nguyen, Chad Van Ginkel, Michael Batech, Jim Banta, Stephen W. Corbett. (2011) Comparison of Predisposition, Insult/Infection, Response, and Organ dysfunction, Acute Physiology And Chronic Health Evaluation II, and Mortality in Emergency Department Sepsis in patients meeting criteria for early goal-directed therapy and the severe sepsis resuscitation bundle. Journal of Critical Care
CrossRef47
Alexander D. Cornet, Jorrit J. Hofstra, Alexander P. Vlaar, Floor E. van den Boogaard, Joris J. Roelofs, Tom van der Poll, Marcel Levi, A.B. Johan Groeneveld, Marcus J. Schultz. (2011) Nebulized Anticoagulants Limit Coagulopathy But Not Inflammation in Pseudomonas aeruginosa-Induced Pneumonia in Rats. Shock 36:4, 417-423
CrossRef48
Ping Qiu, Xizhong Cui, Amisha Barochia, Yan Li, Charles Natanson, Peter Q Eichacker. (2011) The evolving experience with therapeutic TNF inhibition in sepsis: considering the potential influence of risk of death. Expert Opinion on Investigational Drugs1-10
CrossRef49
Andre C. Kalil, Steven P. LaRosa, Jagadish Gogate, Melvyn Lynn, Steven M. Opal. (2011) Influence of Severity of Illness on the Effects of Eritoran Tetrasodium (E5564) and on Other Therapies for Severe Sepsis. Shock 36:4, 327-331
CrossRef50
A. Puxty, P. McConnell, S. Crawley, S. McAree, T. Quasim, S. Ramsay. (2011) Recombinant activated protein C usage in Scotland: a comparison with published guidelines and a survey of attitudes*. Anaesthesiano-no
CrossRef51
Kavin G. Shah, Rongqian Wu, Asha Jacob, Ernesto P. Molmenti, Jeffrey Nicastro, Gene F. Coppa, Ping Wang. (2011) Recombinant human milk fat globule-EGF factor 8 produces dose-dependent benefits in sepsis. Intensive Care Medicine
CrossRef52
I. Michael Leitman. (2011) Modulating the Inflammatory Response in Sepsis. Journal of Surgical Research
CrossRef53
George Cox, Christopher Tzioupis, Giorgio Maria Calori, James Green, David Seligson, Peter V. Giannoudis. (2011) Cerebral fat emboli: A trigger of post-operative delirium. Injury 42, S6-S10
CrossRef54
Emily G.Y. Koo, Linda M.L. Lai, Gordon Y.S. Choi, Matthew T.V. Chan. (2011) Systemic inflammation in the elderly. Best Practice & Research Clinical Anaesthesiology 25:3, 413-425
CrossRef55
Vicenç Falcó, Ana Sánchez, Albert Pahissa, Jordi Rello. (2011) Emerging drugs for pneumococcal pneumonia. Expert Opinion on Emerging Drugs 16:3, 459-477
CrossRef56
Marcello Di Nisio, Francesco Baudo, Benilde Cosmi, Armando D'Angelo, Andrea De Gasperi, Alessandra Malato, Mario Schiavoni, Alessandro Squizzato. (2011) Diagnosis and treatment of disseminated intravascular coagulation: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thrombosis Research
CrossRef57
David Frommhold, Julia Tschada, Natascha Braach, Kirsten Buschmann, Axel Doerner, Johanna Pflaum, Marie-Sophie Stahl, Hongjie Wang, Lutz Koch, Markus Sperandio, Angelika Bierhaus, Berend Isermann, Johannes Poeschl. (2011) Protein C Concentrate Controls Leukocyte Recruitment during Inflammation and Improves Survival during Endotoxemia after Efficient in Vivo Activation. The American Journal of Pathology
CrossRef58
Kelley I. Chuang, Briana Leung, Nancy Hsu, Hobart W. Harris. (2011) Heparin protects against septic mortality via apoE-antagonism. The American Journal of Surgery 202:3, 325-335
CrossRef59
Michael A. Puskarich, Stephen Trzeciak, Nathan I. Shapiro, Ryan C. Arnold, James M. Horton, Jonathan R. Studnek, Jeffrey A. Kline, Alan E. Jones. (2011) Association between timing of antibiotic administration and mortality from septic shock in patients treated with a quantitative resuscitation protocol*. Critical Care Medicine 39:9, 2066-2071
CrossRef60
Samuel M. Brown, Nathan C. Dean. (2011) Defining Severe Pneumonia. Clinics in Chest Medicine 32:3, 469-479
CrossRef61
Sohel M. Julovi, Meilang Xue, Suat Dervish, Philip N. Sambrook, Lyn March, Christopher John Jackson. (2011) Protease Activated Receptor-2 Mediates Activated Protein C–Induced Cutaneous Wound Healing via Inhibition of p38. The American Journal of Pathology
CrossRef62
Youcef Bouazza, Nacira Sennoun, Charlène Strub, Véronique Regnault, Sebastien Gibot, Ferhat Meziani, Patrick Lacolley, Bruno Levy. (2011) Comparative effects of recombinant human activated protein C and dexamethasone in experimental septic shock. Intensive Care Medicine
CrossRef63
R. Moreno, C. L. Sprung, D. Annane, S. Chevret, J. Briegel, D. Keh, M. Singer, Y. G. Weiss, D. Payen, B. H. Cuthbertson, J.-L. Vincent. (2011) Time course of organ failure in patients with septic shock treated with hydrocortisone: results of the Corticus study. Intensive Care Medicine
CrossRef64
J.-S. Bae, A. R. Rezaie. (2011) Activated protein C inhibits high mobility group box 1 signaling in endothelial cells. Blood
CrossRef65
A. Y. Mejaddam, G. C. Velmahos. (2011) Randomized controlled trials affecting polytrauma care. European Journal of Trauma and Emergency Surgery
CrossRef66
Katerina Oikonomopoulou, Daniel Ricklin, Peter A. Ward, John D. Lambris. (2011) Interactions between coagulation and complement—their role in inflammation. Seminars in Immunopathology
CrossRef67
Liang Ma, Anthony Dorling. (2011) The roles of thrombin and protease-activated receptors in inflammation. Seminars in Immunopathology
CrossRef68
Ridhima Gupta, Kristine M. Strickland, Heather L. Mertz. (2011) Successful Treatment of Severe Sepsis With Recombinant Activated Protein C During the Third Trimester of Pregnancy. Obstetrics & Gynecology 118:2, Part 2, 492-494
CrossRef69
Line Olrik Berthelsen, Annemarie T. Kristensen, Mikael Tranholm. (2011) Animal models of DIC and their relevance to human DIC: A systematic review. Thrombosis Research 128:2, 103-116
CrossRef70
Stanley J. Dudrick, J. Alexander Palesty. (2011) Historical Highlights of the Development of Enteral Nutrition. Surgical Clinics of North America 91:4, 945-964
CrossRef71
Kazuo Kawasugi, Hideo Wada, Tsuyoshi Hatada, Kohji Okamoto, Toshimasa Uchiyama, Shigeki Kushimoto, Yoshinobu Seki, Takashi Okamura, Tsutomu Nobori. (2011) Prospective evaluation of hemostatic abnormalities in overt DIC due to various underlying diseases. Thrombosis Research 128:2, 186-190
CrossRef72
O Hayani, A Al-Beihany, R Zarychanski, A Chou, A Kharaba, A Baxter, R Patel, D S Allan. (2011) Impact of critical care outreach on hematopoietic stem cell transplant recipients: a cohort study. Bone Marrow Transplantation 46:8, 1138-1144
CrossRef73
Christoph J. Hemmer, Micha Löbermann, Marcus Unverricht, A. Vogt, Robert Krause, Emil C. Reisinger. (2011) Activated protein C protects vascular endothelial cells from apoptosis in malaria and in sepsis. Tropical Medicine & International Health 16:8, 906-913
CrossRef74
Glenn Hernandez, Ricardo Castro, Carlos Romero, Claudio de la Hoz, Daniela Angulo, Ignacio Aranguiz, Jorge Larrondo, Andres Bujes, Alejandro Bruhn. (2011) Persistent sepsis-induced hypotension without hyperlactatemia: Is it really septic shock?. Journal of Critical Care 26:4, 435.e9-435.e14
CrossRef75
Lillian S. Kao, Debbie F. Lew, Samer N. Arab, S. Rob Todd, Samir S. Awad, Matthew M. Carrick, Michael G. Corneille, Kevin P. Lally. (2011) Local variations in the epidemiology, microbiology, and outcome of necrotizing soft-tissue infections: a multicenter study. The American Journal of Surgery 202:2, 139-145
CrossRef76
Reetta Huttunen, Janne Aittoniemi. (2011) New concepts in the pathogenesis, diagnosis and treatment of bacteremia and sepsis. Journal of Infection
CrossRef77
J. Martensson, C.-R. Martling, A. Oldner, M. Bell. (2011) Impact of sepsis on levels of plasma cystatin C in AKI and non-AKI patients. Nephrology Dialysis Transplantation
CrossRef78
D. Veljkovic. (2011) Use fresh-frozen plasma in newborns, older infants and adolescents on the outcome of bleeding. ISBT Science Series 6:1, 198-205
CrossRef79
J. WANG, L. YANG, A. R. REZAIE, J. LI. (2011) Activated protein C protects against myocardial ischemic/reperfusion injury through AMP-activated protein kinase signaling. Journal of Thrombosis and Haemostasis 9:7, 1308-1317
CrossRef80
Benjamin M. Brainard, Andrew J. Brown. (2011) Defects in Coagulation Encountered in Small Animal Critical Care. Veterinary Clinics of North America: Small Animal Practice 41:4, 783-803
CrossRef81
Sarah L. Tressel, Nicole C. Kaneider, Shogo Kasuda, Caitlin Foley, Georgios Koukos, Karyn Austin, Anika Agarwal, Lidija Covic, Steven M. Opal, Athan Kuliopulos. (2011) A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis. EMBO Molecular Medicine 3:7, 370-384
CrossRef82
Jean-Louis Vincent, Elena Carrasco Serrano, Aikaterina Dimoula. (2011) Current management of sepsis in critically ill adult patients. Expert Review of Anti-infective Therapy 9:7, 847-856
CrossRef83
Christophe Clecʼh. (2011) Prognosis of sepsis: Lessons from epidemiological studies*. Critical Care Medicine 39:7, 1833-1834
CrossRef84
T. Lisman, H.G.D. Leuvenink, R.J. Porte, R.J. Ploeg. (2011) Activation of hemostasis in brain dead organ donors: An observational study. Journal of Thrombosis and Haemostasisno-no
CrossRef85
H. SAITO, T. MATSUSHITA, T. KOJIMA. (2011) Historical perspective and future direction of coagulation research. Journal of Thrombosis and Haemostasis 9, 352-363
CrossRef86
H. SUN. (2011) Exploration of the host haemostatic system by group A streptococcus: implications in searching for novel antimicrobial therapies. Journal of Thrombosis and Haemostasis 9, 189-194
CrossRef87
E. VESTEINSDOTTIR, S. KARASON, S.E. SIGURDSSON, M. GOTTFREDSSON, G.H. SIGURDSSON. (2011) Severe sepsis and septic shock: a prospective population-based study in Icelandic intensive care units. Acta Anaesthesiologica Scandinavica 55:6, 722-731
CrossRef88
C. T. ESMON, J. XU, F. LUPU. (2011) Innate immunity and coagulation. Journal of Thrombosis and Haemostasis 9, 182-188
CrossRef89
Nazima Pathan, Joanne L. Franklin, Hariklia Eleftherohorinou, Victoria J. Wright, Cheryl A. Hemingway, Simon J. Waddell, Michael Griffiths, Jayne L. Dennis, David A. Relman, Sian E. Harding, Michael Levin. (2011) Myocardial depressant effects of interleukin 6 in meningococcal sepsis are regulated by p38 mitogen-activated protein kinase*. Critical Care Medicine 39:7, 1692-1711
CrossRef90
Andra L. Blomkalns, David W. Silver. 2011. The Obese Patient. , 204-227.
CrossRef91
Palle Toft, Else Tønnesen. (2011) Immune-modulating interventions in critically ill septic patients: pharmacological options. Expert Review of Clinical Pharmacology 4:4, 491-501
CrossRef92
Andrew D. Shaw, George M. Vail, Douglas J. Haney, Jin Xie, Mark D. Williams. (2011) Severe protein C deficiency is associated with organ dysfunction in patients with severe sepsis. Journal of Critical Care
CrossRef93
D.J. Funk, J. Palma Vargas, J. Tuttle-Newhall, E.W. Moretti. (2011) The use of recombinant human activated protein C (drotrecogin alpha) in solid organ transplant recipients: case series and review of the literature. Transplant Infectious Diseaseno-no
CrossRef94
Krishnan Raghavendran, D. Willson, R.H. Notter. (2011) Surfactant Therapy for Acute Lung Injury and Acute Respiratory Distress Syndrome. Critical Care Clinics 27:3, 525-559
CrossRef95
G. J. W. van der Windt, A. J. Hoogendijk, M. Schouten, T. J. Hommes, A. F. de Vos, S. Florquin, T. van der Poll. (2011) Osteopontin Impairs Host Defense During Pneumococcal Pneumonia. Journal of Infectious Diseases 203:12, 1850-1858
CrossRef96
M. J. Flick, A. K. Chauhan, M. Frederick, K. E. Talmage, K. W. Kombrinck, W. Miller, E. S. Mullins, J. S. Palumbo, X. Zheng, N. L. Esmon, C. T. Esmon, S. Thornton, A. Becker, L. A. Pelc, E. Di Cera, D. D. Wagner, J. L. Degen. (2011) The development of inflammatory joint disease is attenuated in mice expressing the anticoagulant prothrombin mutant W215A/E217A. Blood 117:23, 6326-6337
CrossRef97
Sebastian Nuding, Henning Ebelt, Robert S. Hoke, Annette Krummenerl, Andreas Wienke, Ursula Müller-Werdan, Karl Werdan. (2011) Reducing elevated heart rate in patients with multiple organ dysfunction syndrome by the I f (funny channel current) inhibitor ivabradine. Clinical Research in Cardiology
CrossRef98
Michael Levin, Brian Eley, Saul N. Faust. 2011. Purpura Fulminans. , 162.1-162.16.
CrossRef99
Saul N. Faust, Parviz Habibi, Robert S. Heyderman. 2011. Skin Manifestations of Meningococcal Infection. , 55.1-55.17.
CrossRef100
Hollis R. OʼNeal, Tatsuki Koyama, Elizabeth A. S. Koehler, Edward Siew, Blake R. Curtis, Richard D. Fremont, Addison K. May, Gordon R. Bernard, Lorraine B. Ware. (2011) Prehospital statin and aspirin use and the prevalence of severe sepsis and acute lung injury/acute respiratory distress syndrome*. Critical Care Medicine 39:6, 1343-1350
CrossRef101
Alireza R. Rezaie. (2011) The occupancy of endothelial protein C receptor by its ligand modulates the par-1 dependent signaling specificity of coagulation proteases. IUBMB Life 63:6, 390-396
CrossRef102
David A. Brealey, Mervyn Singer, Marius Terblanche. (2011) Potential metabolic consequences of statins in sepsis*. Critical Care Medicine 39:6, 1514-1520
CrossRef103
A. P. ANDREOU, J. T. B. CRAWLEY. (2011) Thrombomodulin analogues for the treatment of ischemic stroke. Journal of Thrombosis and Haemostasis 9:6, 1171-1173
CrossRef104
Omer Ridvan Tarhan, Berit Gokce Ceylan, Nilgun Kapucuoglu, Recep Sutcu, Kadir Kumbul. (2011) Activated Protein C and Normal Saline Infusion Might Prevent Deleterious Effects of Remote Acute Lung Injury Caused by Intestinal Ischemia-Reperfusion: An Experimental Study in the Rat Model. Journal of Surgical Research 168:1, e81-e86
CrossRef105
Christophe Guitton, Nathalie Gérard, Véronique Sébille, Cédric Bretonnière, Olivier Zambon, Daniel Villers, Béatrice Charreau. (2011) Early rise in circulating endothelial protein C receptor correlates with poor outcome in severe sepsis. Intensive Care Medicine 37:6, 950-956
CrossRef106
Gina M. Howell, Matthew R. Rosengart. (2011) Necrotizing Soft Tissue Infections. Surgical Infections 12:3, 185-190
CrossRef107
Casimir J. Fitzgerald, Thomas V. Pranikoff, Gregory A. Ross, Steven Mou, Laurence B. Givner, Avinash K. Shetty. (2011) Purpura fulminans caused by community-associated methicillin-resistant Staphylococcus aureus. The American Journal of Emergency Medicine
CrossRef108
S. M. C. VANCINE, S. K. PICOLI-QUAINO, D. S. P. COSTA, S. A. L. MONTALVAO, M. C. OZELO, J. M. ANNICHINO-BIZZACCHI, E. V. DE PAULA. (2011) Evaluation of the host response to endotoxemia of FVIII and FIX deficient mice. Haemophiliano-no
CrossRef109
Michael S. Gough, Mary Anne M. Morgan, Cynthia M. Mack, Denise C. Darling, Lauren M. Frasier, Kathleen P. Doolin, Michael J. Apostolakos, Judith C. Stewart, Brian T. Graves, Erland Arning, Teodoro Bottiglieri, Robert A. Mooney, Mark W. Frampton, Anthony P. Pietropaoli. (2011) The ratio of arginine to dimethylarginines is reduced and predicts outcomes in patients with severe sepsis*. Critical Care Medicine 39:6, 1351-1358
CrossRef110
Steven A. Keller, Cathy C. Moore, Susan L. Evans, Iain H. McKillop, Toan Huynh. (2011) Activated Protein C Alters Inflammation and Protects Renal Function in Sepsis. Journal of Surgical Research 168:1, e103-e109
CrossRef111
Lior Zeller, Victor Novack, Leonid Barski, Alan Jotkowitz, Yaniv Almog. (2011) Exertional heatstroke: clinical characteristics, diagnostic and therapeutic considerations. European Journal of Internal Medicine 22:3, 296-299
CrossRef112
Jan Willem van den Berg, Marten van der Zee, Ron W. F. de Bruin, Conny van Holten-Neelen, Jeroen Bastiaans, Nicole M. A. Nagtzaam, Jan N. M. IJzermans, Robbert Benner, Willem A. Dik. (2011) Mild versus strong anti-inflammatory therapy during early sepsis in mice: A matter of life and death*. Critical Care Medicine 39:6, 1275-1281
CrossRef113
Tom van der Poll, Johannes Daan de Boer, Marcel Levi. (2011) The effect of inflammation on coagulation and vice versa. Current Opinion in Infectious Diseases 24:3, 273-278
CrossRef114
Yujie Yuan, Jianan Ren, Xiuwen Wu, Shougen Cao, Jieshou Li. (2011) Exogenous C3 Postpones Complement Exhaustion and Confers Organ Protection in Murine Sepsis. Journal of Surgical Research 168:1, e87-e94
CrossRef115
Lisa M. Brown, Carolyn S. Calfee, Michael A. Matthay, Roy G. Brower, B. Taylor Thompson, William Checkley. (2011) A simple classification model for hospital mortality in patients with acute lung injury managed with lung protective ventilation. Critical Care Medicine1
CrossRef116
H. Wang, T. Madhusudhan, T. He, B. Hummel, S. Schmidt, I. A. Vinnikov, K. Shahzad, M. Kashif, S. Muller-Krebs, V. Schwenger, A. Bierhaus, G. Rudofsky, P. P. Nawroth, B. Isermann. (2011) Low but sustained coagulation activation ameliorates glucose-induced podocyte apoptosis: protective effect of factor V Leiden in diabetic nephropathy. Blood 117:19, 5231-5242
CrossRef117
Salvatore Aversa, Salvatore Pellegrino, Ignazio Barberi, Russel J. Reiter, Eloisa Gitto. (2011) Potential utility of melatonin as an antioxidant during pregnancy and in the perinatal period. Journal of Maternal-Fetal and Neonatal Medicine1-15
CrossRef118
Laura E. White, Rahul Chaudhary, Laura J. Moore, Frederick A. Moore, Heitham T. Hassoun. (2011) Surgical Sepsis and Organ Crosstalk: The Role of the Kidney. Journal of Surgical Research 167:2, 306-315
CrossRef119
Delphine Borgel, Antoine Vieillard-Baron. (2011) La protéine C activée. médecine/sciences 27:5, 501-507
CrossRef120
O. Penack, D. Buchheidt, M. Christopeit, M. von Lilienfeld-Toal, G. Massenkeil, M. Hentrich, H. Salwender, H.- H. Wolf, H. Ostermann. (2011) Management of sepsis in neutropenic patients: guidelines from the infectious diseases working party of the German Society of Hematology and Oncology. Annals of Oncology 22:5, 1019-1029
CrossRef121
Jean-Louis Vincent, David R. Nelson, Mark D. Williams. (2011) Is worsening multiple organ failure the cause of death in patients with severe sepsis?*. Critical Care Medicine 39:5, 1050-1055
CrossRef122
Ryan Zarychanski. (2011) From mice to men: Treating sepsis with heparin*. Critical Care Medicine 39:5, 1225-1226
CrossRef123
Bart P. Ramakers, Niels P. Riksen, Johannes G. van der Hoeven, Paul Smits, Peter Pickkers. (2011) Modulation of Innate Immunity by Adenosine Receptor Stimulation. Shock1
CrossRef124
Mark Tidswell, Steven P LaRosa. (2011) Toll-like receptor-4 antagonist eritoran tetrasodium for severe sepsis. Expert Review of Anti-infective Therapy 9:5, 507-520
CrossRef125
Geraldine A. O’Rourke, Rob Rothwell. (2011) Capnocytophaga canimorsis a cause of septicaemia following a dog bite: A case review. Australian Critical Care 24:2, 93-99
CrossRef126
Sachiko Yamazaki, Syunji Inamori, Takeshi Nakatani, Michiharu Suga. (2011) Activated protein C attenuates cardiopulmonary bypass–induced acute lung injury through the regulation of neutrophil activation. The Journal of Thoracic and Cardiovascular Surgery 141:5, 1246-1252
CrossRef127
Vincenzo Toschi, Maddalena Lettino. (2011) Inhibitors of propagation of coagulation: factors V and X. British Journal of Clinical Pharmacologyno-no
CrossRef128
Arturo J Martí-Carvajal, Ivan Solà, Dimitrios Lathyris, Andrés Felipe Cardona, Arturo J Martí-Carvajal. 2011. Human recombinant activated protein C for severe sepsis. .
CrossRef129
Sushma K. Cribbs, Greg S. Martin. (2011) Stem Cells in Sepsis and Acute Lung Injury. The American Journal of the Medical Sciences 341:4, 325-332
CrossRef130
Peter J Cowan, Simon C Robson, Anthony JF dʼApice. (2011) Controlling coagulation dysregulation in xenotransplantation. Current Opinion in Organ Transplantation 16:2, 214-221
CrossRef131
R. Daniels. (2011) Surviving the first hours in sepsis: getting the basics right (an intensivist's perspective). Journal of Antimicrobial Chemotherapy 66:Supplement 2, ii11-ii23
CrossRef132
Charles S. Craik, Michael J. Page, Edwin L. Madison. (2011) Proteases as therapeutics. Biochemical Journal 435:1, 1-16
CrossRef133
Christian Joachim, Simon Nadel. (2011) Management of meningococcal disease. Paediatrics and Child Health 21:4, 153-158
CrossRef134
Daniel R. Ricciuto, Claudia C. dos Santos, Michael Hawkes, Lisa J. Toltl, Andrea L. Conroy, Nimerta Rajwans, Erin I. Lafferty, Deborah J. Cook, Alison Fox-Robichaud, Kamyar Kahnamoui, Kevin C. Kain, Patricia C. Liaw, W. Conrad Liles. (2011) Angiopoietin-1 and angiopoietin-2 as clinically informative prognostic biomarkers of morbidity and mortality in severe sepsis*. Critical Care Medicine 39:4, 702-710
CrossRef135
K. M. Ho, J. A. Tan. (2011) Use of L'Abbe and pooled calibration plots to assess the relationship between severity of illness and effectiveness in studies of corticosteroids for severe sepsis. British Journal of Anaesthesia 106:4, 528-536
CrossRef136
Arasch Wafaisade, Rolf Lefering, Bertil Bouillon, Samir G. Sakka, Oliver C. Thamm, Thomas Paffrath, Edmund Neugebauer, Marc Maegele. (2011) Epidemiology and risk factors of sepsis after multiple trauma: An analysis of 29,829 patients from the Trauma Registry of the German Society for Trauma Surgery*. Critical Care Medicine 39:4, 621-628
CrossRef137
Zi-Qiang Zhang, Yuan-Lin Song, Zhi-Hong Chen, Yao Shen, Chun-Xue Bai. (2011) Deletion of Aquaporin 5 Aggravates Acute Lung Injury Induced by Pseudomonas aeruginosa. The Journal of Trauma: Injury, Infection, and Critical Care1
CrossRef138
Lien Dejager, Iris Pinheiro, Eline Dejonckheere, Claude Libert. (2011) Cecal ligation and puncture: the gold standard model for polymicrobial sepsis?. Trends in Microbiology 19:4, 198-208
CrossRef139
Jian-ping Gao, Man Huang, Ning Li, Peng-fei Wang, Huan-lin Chen, Qiu-ping Xu. (2011) Efficacy of a novel endotoxin adsorber polyvinylidene fluoride fiber immobilized with L-serine ligand on septic pigs. Journal of Zhejiang University SCIENCE B 12:4, 264-272
CrossRef140
Michael Adamzik, Tanja Langemeier, Ulrich H. Frey, Klaus Görlinger, Fuad Saner, Holger Eggebrecht, Jürgen Peters, Matthias Hartmann. (2011) Comparison of Thrombelastometry with Simplified Acute Physiology Score II and Sequential Organ Failure Assessment Scores for the Prediction of 30-Day Survival. Shock 35:4, 339-342
CrossRef141
Naoki Aikawa, Shuji Shimazaki, Yasuhiro Yamamoto, Hidehiko Saito, Ikuro Maruyama, Ryuzo Ohno, Akio Hirayama, Yoshikazu Aoki, Nobuo Aoki. (2011) THROMBOMODULIN ALFA IN THE TREATMENT OF INFECTIOUS PATIENTS COMPLICATED BY DISSEMINATED INTRAVASCULAR COAGULATION. Shock 35:4, 349-354
CrossRef142
Amisha Barochia, Steven Solomon, Xizhong Cui, Charles Natanson, Peter Q Eichacker. (2011) Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies. Expert Opinion on Drug Metabolism & Toxicology 7:4, 479-494
CrossRef143
C. McKenzie. (2011) Antibiotic dosing in critical illness. Journal of Antimicrobial Chemotherapy 66:Supplement 2, ii25-ii31
CrossRef144
A. Sablotzki, M. Fuchs, J. Gille, A. Weimann, E. Czeslick. (2011) Therapie der posttraumatischen abdominellen Sepsis. Intensivmedizin und Notfallmedizin 48:3, 199-206
CrossRef145
Berislav V. Zlokovic, John H. Griffin. (2011) Cytoprotective protein C pathways and implications for stroke and neurological disorders. Trends in Neurosciences 34:4, 198-209
CrossRef146
Gus J. Slotman. (2011) The Systemic Mediator-Associated Response Test Identifies Patients in Failed Sepsis Clinical Trials Among Whom Novel Drugs Reduce Mortality. The Journal of Trauma: Injury, Infection, and Critical Care1
CrossRef147
Robert Słotwiński, Sylwia Słotwińska, Sylwia Kędziora, Barbara-Joanna Bałan. (2011) Innate Immunity Signaling Pathways: Links between Immunonutrition and Responses to Sepsis. Archivum Immunologiae et Therapiae Experimentalis 59:2, 139-150
CrossRef148
L.J. Mark Cross, Michael A. Matthay. (2011) Biomarkers in Acute Lung Injury: Insights into the Pathogenesis of Acute Lung Injury. Critical Care Clinics 27:2, 355-377
CrossRef149
Ricard Ferrer, Antonio Artigas. (2011) Physiologic Parameters as Biomarkers: What Can We Learn from Physiologic Variables and Variation?. Critical Care Clinics 27:2, 229-240
CrossRef150
Marcel Levi, Marcus Schultz, Tom van der Poll. (2011) Coagulation Biomarkers in Critically Ill Patients. Critical Care Clinics 27:2, 281-297
CrossRef151
L. J. TOLTL, R. C. AUSTIN, P. C. LIAW. (2011) Activated protein C modulates inflammation, apoptosis and tissue factor procoagulant activity by regulating endoplasmic reticulum calcium depletion in blood monocytes. Journal of Thrombosis and Haemostasis 9:3, 582-592
CrossRef152
Dong-Soon Im. (2011) A promising anti-inflammatory and anti-thrombotic drug for sepsis treatment. Archives of Pharmacal Research 34:3, 339-342
CrossRef153
Ashley Wysong, Priya Venkatesan. (2011) An approach to the patient with retiform purpura. Dermatologic Therapy 24:2, 151-172
CrossRef154
Jae-Hwan Park, In-Chang Hwang, Nina Ha, Sera Lee, Jung Min Kim, Sung Sook Lee, Hosung Yu, In-Taek Lim, Jun-A You, Dal-hyun Kim. (2011) Effects of the anti-sepsis drug, (S)-1-(α-naphthylmethyl)-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (CKD-712), on mortality, inflammation, and organ injuries in rodent sepsis models. Archives of Pharmacal Research 34:3, 485-494
CrossRef155
Andre C. Kalil, Junfeng Sun. (2011) Low-dose steroids for septic shock and severe sepsis: the use of Bayesian statistics to resolve clinical trial controversies. Intensive Care Medicine 37:3, 420-429
CrossRef156
G. Prat, A. Delluc, A. Renault, K. Lacut. (2011) Prévention de la maladie veineuse thromboembolique en réanimation : Quand ? Pourquoi ? Comment ?. Réanimation 20:2, 118-123
CrossRef157
Michelle C. Roughton, Shailesh Agarwal, Lawrence J. Gottlieb. (2011) Surgical Management of Acute Infectious Purpura Fulminans. Journal of Burn Care & Research 32:2, 231-236
CrossRef158
Payam Yazdan-Ashoori, Patricia Liaw, Lisa Toltl, Brian Webb, Greg Kilmer, David E. Carter, Douglas D. Fraser. (2011) Elevated plasma matrix metalloproteinases and their tissue inhibitors in patients with severe sepsis. Journal of Critical Care
CrossRef159
Deborah J. Stearns-Kurosawa, Marcin F. Osuchowski, Catherine Valentine, Shinichiro Kurosawa, Daniel G. Remick. (2011) The Pathogenesis of Sepsis. Annual Review of Pathology: Mechanisms of Disease 6:1, 19-48
CrossRef160
Peter A. Ubel, Robert Silbergleit. (2011) Behavioral Equipoise: A Way to Resolve Ethical Stalemates in Clinical Research. The American Journal of Bioethics 11:2, 1-8
CrossRef161
Jon Cohen, Stephen Drage. (2011) How I manage haematology patients with septic shock. British Journal of Haematology 152:4, 380-391
CrossRef162
John L. Moran, Patricia J. Solomon, . (2011) Conventional and advanced time series estimation: application to the Australian and New Zealand Intensive Care Society (ANZICS) adult patient database, 1993-2006. Journal of Evaluation in Clinical Practice 17:1, 45-60
CrossRef163
Steven P LaRosa, Steven M Opal. (2011) Strategies to treat sepsis: old and new. Clinical Investigation 1:2, 195-210
CrossRef164
Blair Henry, Yulia Lin, Jeannie Callum. (2011) ‘Tweaking’ potential research participants to meet clinical trial eligibility criteria: ethical concerns and scientific implications. Clinical Investigation 1:2, 181-185
CrossRef165
Khalid M. Alkharfy, Nasser M. Al-Daghri, Omar S. Al-Attas, Majed S. Alokail. (2011) The protective effect of thymoquinone against sepsis syndrome morbidity and mortality in mice. International Immunopharmacology 11:2, 250-254
CrossRef166
Brian Casserly, Michael Baram, Patricia Walsh, Andrew Sucov, Nicholas S. Ward, Mitchell M. Levy. (2011) Implementing a Collaborative Protocol in a Sepsis Intervention Program: Lessons Learned. Lung 189:1, 11-19
CrossRef167
Garrett E. Schramm, Rahul Kashyap, John J. Mullon, Ognjen Gajic, Bekele Afessa. (2011) Septic shock: A multidisciplinary response team and weekly feedback to clinicians improve the process of care and mortality*. Critical Care Medicine 39:2, 252-258
CrossRef168
Simerpreet Bal, Pawan Ojha, Michael D. Hill. (2011) Stroke Prevention Treatment of Patients with Atrial Fibrillation: Old and New. Current Neurology and Neuroscience Reports 11:1, 15-27
CrossRef169
S. Hagel, F. Brunkhorst. (2011) Sepsis. Intensivmedizin und Notfallmedizin 48:1, 57-73
CrossRef170
Elisabeth Perzborn, Susanne Roehrig, Alexander Straub, Dagmar Kubitza, Frank Misselwitz. (2011) The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nature Reviews Drug Discovery 10:1, 61-75
CrossRef171
Marion Durand, Anne Godier, Véronique Notet, Marie Hacquard, Olivier Collignon, Gilles Corbonnois, François Plénat, Jean-Pierre Carteaux, Thomas Lecompte. (2011) Recombinant activated factor VII attenuates major arterial bleeding in noncoagulopathic rabbits. European Journal of Anaesthesiology 28:1, 51-56
CrossRef172
Farid Sadaka, Jacklyn O'Brien, Matthew Migneron, Julie Stortz, Alexander Vanston, Robert W Taylor. (2011) Activated protein C in septic shock: a propensity-matched analysis. Critical Care 15:2, R89
CrossRef173
Sachin Sud, Brian H. Cuthbertson. (2011) Understanding health economic analysis in critical care : insights from recent randomized controlled trials. Current Opinion in Critical Care 17:5, 504
CrossRef174
A. Puxty, P. McConnell, S. Crawley, S. McAree, T. Quasim, S. Ramsay. (2011) Recombinant activated protein C usage in Scotland: a comparison with published guidelines and a survey of attitudes* : Recombinant activated protein C usage in Scotland. Anaesthesiano
CrossRef175
P Klein Klouwenberg, OL Cremer. (2011) Defining sepsis in the ICU: a sensitivity analysis. Critical Care 15:Suppl 1, P209
CrossRef176
F. Fourrier. (2011) Le point sur la coagulation-Troubles de l’hémostase au cours du sepsis. Réanimation 20:S2, 595-602
CrossRef177
Margarita Perez-Casal, Victoria Thompson, Colin Downey, Ingeborg Welters, Duncan Wyncoll, Jecko Thachil, Cheng Hock Toh. (2011) The clinical and functional relevance of microparticles induced by activated protein C treatment in sepsis. Critical Care 15:4, R195
CrossRef178
Erica L. Martin, V. Marco Ranieri. (2011) Phosphorylation mechanisms in intensive care medicine. Intensive Care Medicine 37:1, 7-18
CrossRef179
S. Lipinski, L. Bremer, T. Lammers, F. Thieme, S. Schreiber, P. Rosenstiel. (2011) Coagulation and inflammation. Hämostaseologie 31:2, 94-104
CrossRef180
C. Charron, A. Vieillard-Baron. (2011) Sepsi e shock settico nell
adulto. EMC - AKOS - Trattato di Medicina 13:1, 1-6
CrossRef181
Barry Dixon, Kenneth Opeskin, Georgia Stamaratis, Ian Nixon, Michael Yi, Andrew E. Newcomb, Alexander Rosalion, Yuan Zhang, John D. Santamaria, Duncan J. Campbell. (2011) Pre-operative heparin reduces pulmonary microvascular fibrin deposition following cardiac surgery. Thrombosis Research 127:1, e27-e30
CrossRef182
M Zia Sadique, Richard Grieve, David A Harrison, Brian H Cuthbertson, Kathryn M Rowan. (2011) Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?. Critical Care 15:5, R228
CrossRef183
Anastasia Antonopoulou, Evangelos J Giamarellos-Bourboulis. (2011) Immunomodulation in sepsis: state of the art and future perspective. Immunotherapy 3:1, 117-128
CrossRef184
Jens Altrichter, Martin Sauer, Katharina Kaftan, Thomas Birken, Doris Gloger, Martin Gloger, Jörg Henschel, Heiko Hickstein, Ernst Klar, Sebastian Koball, Annette Pertschy, Gabriele Nöldge-Schomburg, Dierk A Vagts, Steffen R Mitzner. (2011) Extracorporeal cell therapy of septic shock patients with donor granulocytes: a pilot study. Critical Care 15:2, R82
CrossRef185
M. Frass, M. Linkesch, S. Banyai, G. Resch, C. Dielacher, T. Löbl, C. Endler, M. Haidvogl, I. Muchitsch, E. Schuster. (2011) Adjunctive homeopathic treatment in patients with severe sepsis: a randomized, double-blind, placebo-controlled trial in an intensive care unit. Homeopathy 100:1-2, 95-100
CrossRef186
C. Nafría, I. Fernández-Cadenas, M. Mendioroz, S. Domingues-Montanari, M. Hernández-Guillamón, J. Fernández-Morales, A. del Río-Espínola, D. Giralt, L. Deu, P. Delgado, A. Rosell, J. Montaner. (2011) Update on the Serum Biomarkers and Genetic Factors Associated with Safety and Efficacy of rt-PA Treatment in Acute Stroke Patients. Stroke Research and Treatment 2011, 1-10
CrossRef187
A. T. Nurden. (2011) Platelets, inflammation and tissue regeneration. Thrombosis and Haemostasis 105:Suppl. 1, S13-S33
CrossRef188
Gordon P Otto, Maik Sossdorf, Ralf A Claus, Jürgen Rödel, Katja Menge, Konrad Reinhart, Michael Bauer, Niels C Riedemann. (2011) The late phase of sepsis is characterized by an increased microbiological burden and death rate. Critical Care 15:4, R183
CrossRef189
CrossRef190
Elizabeth A Sweetman, Gordon S Doig. (2011) Failure to report protocol violations in clinical trials: A threat to internal validity?. Trials 12:1, 214
CrossRef191
Mark T. Keegan, Ognjen Gajic, Bekele Afessa. (2011) Severity of illness scoring systems in the intensive care unit. Critical Care Medicine 39:1, 163-169
CrossRef192
(2011) Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis. Intensive Care Medicine 37:1, 86-96
CrossRef193
Michael Andrades, Arian Morina, Snežana Spasić, Ivan Spasojević. (2011) Bench-to-bedside review: Sepsis - from the redox point of view. Critical Care 15:5, 230
CrossRef194
Paolo Simioni, Massimo Boldrin, Sabrina Gavasso, Michela Seveso, Claudia Radu, Cristiana Bulato, Fiorella Calabrese, Laura Cavicchioli, Diana Bertini, Giulia M. De Benedictis, Federica Besenzon, Nicola Baldan, Luca Spiezia, Mario Plebani, Ermanno Ancona, Emanuele Cozzi. (2011) Effects of Long-Term Administration of Recombinant Human Protein C in Xenografted Primates. Transplantation 91:2, 161-168
CrossRef195
W. Joost Wiersinga. (2011) Current insights in sepsis : from pathogenesis to new treatment targets. Current Opinion in Critical Care 17:5, 480
CrossRef196
Jari Petäjä. (2011) Inflammation and coagulation. An overview. Thrombosis Research 127, S34-S37
CrossRef197
H. Weiler. (2011) Multiple receptor-mediated functions of activated protein C. Hämostaseologie 31:3, 185-195
CrossRef198
Kazutaka Takagi, Toshiki Tasaki, Takahiro Yamauchi, Hiromichi Iwasaki, Takanori Ueda. (2011) Successful Administration of Recombinant Human Soluble Thrombomodulin α (Recomodulin) for Disseminated Intravascular Coagulation during Induction Chemotherapy in an Elderly Patient with Acute Monoblastic Leukemia Involving the t(9;11)(p22;q23) MLL/AF9 Translocation. Case Reports in Hematology 2011, 1-5
CrossRef199
Kazuma Yamakawa, Satoshi Fujimi, Tomoyoshi Mohri, Hiroki Matsuda, Yasushi Nakamori, Tomoya Hirose, Osamu Tasaki, Hiroshi Ogura, Yasuyuki Kuwagata, Toshimitsu Hamasaki, Takeshi Shimazu. (2011) Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study. Critical Care 15:3, R123
CrossRef200
Brian Michael Varisco. (2011) The Pharmacology of Acute Lung Injury in Sepsis. Advances in Pharmacological Sciences 2011, 1-7
CrossRef201
T. Burnouf. (2011) Recombinant plasma proteins. Vox Sanguinis 100:1, 68-83
CrossRef202
M. Schouten, C. van ’t Veer, J. J. T. H. Roelofs, B. Gerlitz, B. W. Grinnell, M. Levi, T. van der Poll. (2011) Recombinant activated protein C attenuates coagulopathy and inflammation when administered early in murine pneumococcal pneumonia. Thrombosis and Haemostasis 106:5,
CrossRef203
G. C. K. W. Koh, J. C. M. Meijers, R. R. Maude, D. Limmathurotsakul, N. P. J. Day, S. J. Peacock, T. van der Poll, W. J. Wiersinga. (2011) Diabetes does not influence activation of coagulation, fibrinolysis or anticoagulant pathways in Gram-negative sepsis (melioidosis). Thrombosis and Haemostasis 106:6,
CrossRef204
K. C. A. A. Wildhagen, E. Lutgens, S. T. G. B. Loubele, H. ten Cate, G. A. F. Nicolaes. (2011) The structure-function relationship of activated protein C. Thrombosis and Haemostasis 106:6,
CrossRef205
Jack Hawiger, James M Musser. (2011) How to approach genome wars in sepsis?. Critical Care 15:6, 1007
CrossRef206
Etienne de Montmollin, Djillali Annane. (2011) Year in review 2010: Critical Care - multiple organ dysfunction and sepsis. Critical Care 15:6, 236
CrossRef207
Outi K. Lindström, Eija M. Tukiainen, Marja-Leena Kylänpää, Panu J. Mentula, Pauli A. Puolakkainen, Ulla M.K. Wartiovaara-Kautto, Heikki Repo, Jari M. Petäjä. (2011) Thrombin Generation in vitro and in vivo, and Disturbed Tissue Factor Regulation in Patients with Acute Pancreatitis. Pancreatology 11:6, 557-566
CrossRef208
Hector R. Wong, Jeffrey E. Nowak, Stephen W. Standage, Cláudio Flauzino de Oliveira. 2011. Sepsis. , 1413-1429.
CrossRef209
Lincoln S. Smith, Lynn J. Hernan. 2011. Shock States. , 364-378.
CrossRef210
DJ Perry, C Grove. 2011. Acquired bleeding disorders. , 565-582.
CrossRef211
Jennifer A. Frontera. (2010) Intensive Versus Conventional Insulin Therapy in Critically Ill Neurologic Patients: Still Searching for the Sweet Spot. Neurocritical Care 13:3, 295-298
CrossRef212
Murillo Assunção, Nelson Akamine, Guttemberg S. Cardoso, Patricia V.C. Mello, José Mário M. Teles, André Luis B. Nunes, Marcelo Oliveira Maia, Álvaro Rea-Neto, Flavia Ribeiro Machado. (2010) Survey on physicians' knowledge of sepsis: Do they recognize it promptly?
. Journal of Critical Care 25:4, 545-552
CrossRef213
B. Levy, S. Collin, N. Sennoun, N. Ducrocq, A. Kimmoun, P. Asfar, P. Perez, F. Meziani. (2010) Vascular hyporesponsiveness to vasopressors in septic shock: from bench to bedside. Intensive Care Medicine 36:12, 2019-2029
CrossRef214
Sushma K. Cribbs, Michael A. Matthay, Greg S. Martin. (2010) Stem cells in sepsis and acute lung injury. Critical Care Medicine 38:12, 2379-2385
CrossRef215
James M. O'Brien, Scott K. Aberegg, Naeem A. Ali, Gregory B. Diette, Stanley Lemeshow. (2010) Results from the National Sepsis Practice Survey: Use of drotrecogin α (activated) and other therapeutic decisions. Journal of Critical Care 25:4, 658.e7-658.e15
CrossRef216
Ewa Trejnowska, Marc J. Popovich. (2010) Management of Sepsis in the ICU. International Anesthesiology Clinics 47:1, 55-66
CrossRef217
Jay S. Steingrub, Michael L. Cheatham, Brad Woodward, H. Tiffany Wang, Mark B. Effron. (2010) A prospective, observational study of Xigris Use in the United States (XEUS)
CrossRef218
Joerg C. Schefold, Jeffrey Bierbrauer, Steffen Weber-Carstens. (2010) Intensive care unit—acquired weakness (ICUAW) and muscle wasting in critically ill patients with severe sepsis and septic shock. Journal of Cachexia, Sarcopenia and Muscle 1:2, 147-157
CrossRef219
Caroline Guignant, Fabienne Venet, Nicolas Voirin, Françoise Poitevin, Christophe Malcus, Julien Bohé, Alain Lepape, Guillaume Monneret. (2010) Proatrial natriuretic peptide is a better predictor of 28-day mortality in septic shock patients than proendothelin-1. Clinical Chemistry and Laboratory Medicine 48:12, 1813-1820
CrossRef220
Fuhong Su, Hongchuan Huang, Xinrong He, David Simuen, Jingwei Xie, Aric Orbach, Orit Cohen-Barak, Michael Piagnerelli, Jean-Louis Vincent. (2010) Effects of a Novel Anticoagulant Compound (TV7130) in an Ovine Model of Septic Shock. Shock 34:6, 622-627
CrossRef221
Svetolik Djurkovic, Juan C. Baracaldo, Jose A. Guerra, Jennifer Sartorius, Marilyn T. Haupt. (2010) A survey of clinicians addressing the approach to the management of severe sepsis and septic shock in the United States. Journal of Critical Care 25:4, 658.e1-658.e6
CrossRef222
Nazli Hossain, Michael J. Paidas. 2010. Disseminated Intravascular Coagulation. , 182-194.
CrossRef223
Daniele Vallisa, Carlo F. Moroni. (2010) Le urgenze ematologiche. Italian Journal of Medicine
CrossRef224
M. Chew, M. Rahman, L. Ihrman, A. Erson, S. Zhang, H. Thorlacius. (2010) Soluble CD40L (CD154) is increased in patients with shock. Inflammation Research 59:11, 979-982
CrossRef225
Peter Fraunberger, Barbara Siegele, Autar K. Walli. (2010) Spielen Statine eine Rolle als adjuvante Therapie bei Entzündung? / Do statins play a role as an adjuvant therapy in inflammation?. LaboratoriumsMedizin 34:6, 325-335
CrossRef226
Mohamed Salah Eldin, Mohamed Abdel Kader. (2010) The author replies:. Pediatric Critical Care Medicine 11:6, 768-769
CrossRef227
Mariuxi C. Manukyan, Brent R. Weil, Yue Wang, Aaron M. Abarbanell, Jeremy L. Herrmann, Jeffrey A. Poynter, Daniel R. Meldrum. (2010) The Phosphoinositide-3 Kinase Survival Signaling Mechanism in Sepsis. Shock 34:5, 442-449
CrossRef228
, B. Taylor Thompson, V. Marco Ranieri, Simon Finfer, Philip S. Barie, Jean-Francois Dhainaut, Ivor S. Douglas, Bengt Gårdlund, John C. Marshall, Andrew Rhodes. (2010) Statistical analysis plan of PROWESS SHOCK study. Intensive Care Medicine 36:11, 1972-1973
CrossRef229
Peter Fraunberger, Barbara Siegele, Autar K. Walli. (2010) Do statins play a role as an adjuvant therapy in inflammation? 1. LaboratoriumsMedizin 34:6, ---
CrossRef230
Huei Hsin Shieh, Eliane Roseli Barreira, Patricia Freitas Góes, Albert Bousso, Gabriel Alberto Ventura Brazilian, Ana Maria Melo, Silvia Maria Ibidi. (2010) Comparison of main trials of recombinant human activated protein C in sepsis—Are we encouraging more bleeding in neonates?. Pediatric Critical Care Medicine 11:6, 767-768
CrossRef231
Atul B Mehta, A Victor Hoffbrand. 2010. Haematological Aspects of Systemic Disease. , 940-955.
CrossRef232
Jean-Louis Vincent. (2010) We should abandon randomized controlled trials in the intensive care unit. Critical Care Medicine 38, S534-S538
CrossRef233
N. Soni. (2010) ARDS, acronyms and the Pinocchio effect. Anaesthesia 65:10, 976-979
CrossRef234
Lidia Decembrino, Armando D'Angelo, Franco Manzato, Agostina Solinas, Francesco Tumminelli, Annalisa De Silvestri, Sandro De Lazzari, Ezio Padovani, Mariella Magarotto, Lino Chiandetti, Sergio O. Saia, Mauro Stronati. (2010) PROTEIN C CONCENTRATE AS ADJUVANT TREATMENT IN NEONATES WITH SEPSIS-INDUCED COAGULOPATHY. Shock 34:4, 341-345
CrossRef235
Jean-Louis Vincent, Mervyn Singer. (2010) Critical care: advances and future perspectives. The Lancet 376:9749, 1354-1361
CrossRef236
Jong-Sup Bae, In-San Kim, Alireza R. Rezaie. (2010) Thrombin down-regulates the TGF-β-mediated synthesis of collagen and fibronectin by human proximal tubule epithelial cells through the EPCR-dependent activation of PAR-1. Journal of Cellular Physiology 225:1, 233-239
CrossRef237
Anne Claire Lukaszewicz, Didier Payen. (2010) The future is predetermined in severe sepsis, so what are the implications?. Critical Care Medicine 38, S512-S517
CrossRef238
Rui Moreno, Andrew Rhodes. (2010) Evidence should not be viewed in isolation. Critical Care Medicine 38, S528-S533
CrossRef239
Andre C. Kalil, Junfeng Sun, Diana F. Florescu. (2010) The importance of detecting cytomegalovirus infections in studies evaluating new therapies for severe sepsis. Critical Care Medicine 38, S663-S667
CrossRef240
Susanna Walker, Stephen Brett. (2010) Oiling the wheels of intensive care to reduce “machine friction”: The best way to improve outcomes?. Critical Care Medicine 38, S642-S648
CrossRef241
P.J. Kiel, N. Dickmeyer, J.E. Schwartz. (2010) Trimethoprim-sulfamethoxazole-induced rhabdomyolysis in an allogeneic stem cell transplant patient. Transplant Infectious Disease 12:5, 451-454
CrossRef242
Benoy Idicula Babu, Ajith K. Siriwardena. (2010) Functional Protein C Levels During the Early Phase of Clinical Acute Pancreatitis. Pancreas 39:7, 1077-1081
CrossRef243
Charles J. Medico, Patrick Walsh. (2010) Pharmacotherapy in the Critically Ill Obese Patient. Critical Care Clinics 26:4, 679-688
CrossRef244
F. J. Castellino, D. L. Donahue, R. M. Navari, V. A. Ploplis, M. Walsh. (2010) An accompanying genetic severe deficiency of tissue factor protects mice with a protein C deficiency from lethal endotoxemia. Blood
CrossRef245
Nazli Hossain, Michael J. Paidas. 2010. Disseminated Intravascular Coagulopathy. , 400-406.
CrossRef246
Errol R. Norwitz, Hee Joong Lee. 2010. Septic Shock. , 571-595.
CrossRef247
O. BRATTSTRÖM, F. GRANATH, P. ROSSI, A. OLDNER. (2010) Early predictors of morbidity and mortality in trauma patients treated in the intensive care unit. Acta Anaesthesiologica Scandinavica 54:8, 1007-1017
CrossRef248
Lee M. Demertzis, Marin H. Kollef. (2010) The Resuscitation Package in Sepsis. Current Infectious Disease Reports 12:5, 368-373
CrossRef249
Hideo Wada, Tsuyoshi Hatada, Kohji Okamoto, Toshimasa Uchiyama, Kazuo Kawasugi, Toshihiko Mayumi, Satoshi Gando, Shigeki Kushimoto, Yoshinobu Seki, Seiji Madoiwa, Takashi Okamura, Cheng Hock Toh. (2010) Modified non-overt DIC diagnostic criteria predict the early phase of overt-DIC. American Journal of Hematology 85:9, 691-694
CrossRef250
Ricardo G. Branco, Robert C. Tasker. (2010) Meningococcal Meningitis. Current Treatment Options in Neurology 12:5, 464-474
CrossRef251
Eliézer Silva, Luiz Francisco Poli de Figueiredo, Fernando Colombari. (2010) PROWESS-SHOCK TRIAL. Shock 34:Suppl 1, 48-53
CrossRef252
Djillali Annane. (2010) Adjunct Therapy for Sepsis: How Early?. Current Infectious Disease Reports 12:5, 361-367
CrossRef253
Joshua Landy, Dennis Djogovic, Wendy Sligl. (2010) Gonococcal septic shock, acute respiratory distress syndrome, and multisystem organ failure: a case report. International Journal of Infectious Diseases 14, e239-e241
CrossRef254
KULTAR SINGH, LING XIU ZHANG, KRESO BENDELJA, RYAN HEATH, SHAUN MURPHY, SURENDRA SHARMA, JAMES F. PADBURY, YOW-PIN LIM. (2010) Inter-Alpha Inhibitor Protein Administration Improves Survival From Neonatal Sepsis in Mice. Pediatric Research 68:3, 242-247
CrossRef255
Todd W. Rice, Arthur P. Wheeler, Gordon R. Bernard, Jean-Louis Vincent, Derek C. Angus, Naoki Aikawa, Ignace Demeyer, Stephen Sainati, Nicholas Amlot, Charlie Cao, Masayuki Ii, Hideyasu Matsuda, Kouji Mouri, Jon Cohen. (2010) A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis*. Critical Care Medicine 38:8, 1685-1694
CrossRef256
H. Ait-Oufella, E. Maury, S. Lehoux, B. Guidet, G. Offenstadt. (2010) The endothelium: physiological functions and role in microcirculatory failure during severe sepsis. Intensive Care Medicine 36:8, 1286-1298
CrossRef257
James D. Chalmers, Philip M. Short, Pallavi Mandal, Ahsan R. Akram, Adam T. Hill. (2010) Statins in community acquired pneumonia: Evidence from experimental and clinical studies. Respiratory Medicine 104:8, 1081-1091
CrossRef258
Ali A. El-Solh, Philippe Abou Jaoude, Jahan Porhomayon. (2010) Bicarbonate therapy in the treatment of septic shock: a second look. Internal and Emergency Medicine 5:4, 341-347
CrossRef259
Toan Huynh, Nhat Nguyen, Steven Keller, Cathy Moore, Min C. Shin, Iain H. McKillop. (2010) Reducing Leukocyte Trafficking Preserves Hepatic Function After Sepsis. The Journal of Trauma: Injury, Infection, and Critical Care 69:2, 360-367
CrossRef260
Elizabeth Chipp, Christopher S. Milner, Adam V. Blackburn. (2010) Sepsis in Burns. Annals of Plastic Surgery 65:2, 228-236
CrossRef261
Johan Mårtensson, Max Bell, Anders Oldner, Shengyuan Xu, Per Venge, Claes-Roland Martling. (2010) Neutrophil gelatinase-associated lipocalin in adult septic patients with and without acute kidney injury. Intensive Care Medicine 36:8, 1333-1340
CrossRef262
Dimitris Tousoulis, Ioannis Ph. Paroutoglou, Nikolaos Papageorgiou, Marietta Charakida, Christodoulos Stefanadis. (2010) Recent therapeutic approaches to platelet activation in coronary artery disease. Pharmacology & Therapeutics 127:2, 108-120
CrossRef263
Marius Terblanche, Nicole Assmann. 2010. Shock. , 1-21.
CrossRef264
Jean-Louis Vincent. 2010. Haemodynamic Management of Severe Sepsis. , 218-233.
CrossRef265
R. S. Parker, G. Clermont. (2010) Systems engineering medicine: engineering the inflammation response to infectious and traumatic challenges. Journal of The Royal Society Interface 7:48, 989-1013
CrossRef266
L. E. Sander, S. D. Sackett, U. Dierssen, N. Beraza, R. P. Linke, M. Muller, J. M. Blander, F. Tacke, C. Trautwein. (2010) Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. Journal of Experimental Medicine 207:7, 1453-1464
CrossRef267
Kohji Okamoto, Hideo Wada, Tsuyoshi Hatada, Toshimasa Uchiyama, Kazuo Kawasugi, Toshihiko Mayumi, Satoshi Gando, Shigeki Kushimoto, Yoshinobu Seki, Seiji Madoiwa. (2010) Frequency and hemostatic abnormalities in pre-DIC patients. Thrombosis Research 126:1, 74-78
CrossRef268
Matthew J. Martin, Kelly S. Blair, Thomas K. Curry, Niten Singh. (2010) Vena Cava Filters: Current Concepts and Controversies for the Surgeon. Current Problems in Surgery 47:7, 524-618
CrossRef269
D. Oh, M.J. Jang, S.J. Lee, S.Y. Chong, M.S. Kang, H. Wada. (2010) Evaluation of modified non-overt DIC criteria on the prediction of poor outcome in patients with sepsis. Thrombosis Research 126:1, 18-23
CrossRef270
Christopher M. Fischer, Kiichiro Yano, William C. Aird, Nathan I. Shapiro. (2010) Abnormal coagulation tests obtained in the emergency department are associated with mortality in patients with suspected infection. The Journal of Emergency Medicine
CrossRef271
Jeremy D. Scheff, Steve E. Calvano, Stephen F. Lowry, Ioannis P. Androulakis. (2010) Modeling the influence of circadian rhythms on the acute inflammatory response. Journal of Theoretical Biology 264:3, 1068-1076
CrossRef272
Jijo John, D. Bradley Woodward, Yanping Wang, S. Betty Yan, Diana Fisher, Gary T. Kinasewitz, Darell Heiselman. (2010) Troponin-I as a prognosticator of mortality in severe sepsis patients
. Journal of Critical Care 25:2, 270-275
CrossRef273
Chen Ping, Zhang Yongping, Qiao Minmin, Yao Weiyan, Yuan Yaozong. (2010) Activated Protein C Improves the Severity of Severe Acute Pancreatitis via Up-Regulating the Expressions of Endothelial Cell Protein C Receptor and Thrombomodulin. Digestive Diseases and Sciences 55:6, 1599-1609
CrossRef274
William Tarnow-Mordi, David Isaacs, Sourabh Dutta. (2010) Adjunctive Immunologic Interventions in Neonatal Sepsis. Clinics in Perinatology 37:2, 481-499
CrossRef275
Gunnar Nilsson, Sören Höjgård, Erik Berntorp. (2010) Treatment of the critically ill patient with protein C: Is it worth the cost?. Thrombosis Research 125:6, 494-500
CrossRef276
Rong Jin, Guojun Yang, Guohong Li. (2010) Molecular insights and therapeutic targets for blood–brain barrier disruption in ischemic stroke: Critical role of matrix metalloproteinases and tissue-type plasminogen activator. Neurobiology of Disease 38:3, 376-385
CrossRef277
Baltasar Sanchez, Enrique Piacentini, Vittorio Pradella, Mariano Mignini, Juan Nava. (2010) Hemodynamic effects of recombinant human activated protein C in patients with septic shock
CrossRef278
Jeffrey F. Barletta, Brad Cooper, Martin J. Ohlinger. (2010) Adverse drug events associated with disorders of coagulation. Critical Care Medicine 38, S198-S218
CrossRef279
Chunzhang Cao, Yamei Gao, Yang Li, Toni M. Antalis, Francis J. Castellino, Li Zhang. (2010) The efficacy of activated protein C in murine endotoxemia is dependent on integrin CD11b. Journal of Clinical Investigation 120:6, 1971-1980
CrossRef280
Ishaq Lat, David R. Foster, Brian Erstad. (2010) Drug-induced acute liver failure and gastrointestinal complications. Critical Care Medicine 38, S175-S187
CrossRef281
Ulrich Kunzendorf, Michael Haase, Lars Rölver, Anja Haase-Fielitz. (2010) Novel Aspects of Pharmacological Therapies for Acute Renal Failure. Drugs 70:9, 1099-1114
CrossRef282
John C. Marshall, R. Phillip Dellinger, Mitchell Levy. (2010) The Surviving Sepsis Campaign: A History and a Perspective. Surgical Infections 11:3, 275-281
CrossRef283
Beverley J. Hunt. 2010. Intensive and Critical Care. , 271-286.
CrossRef284
Raj S. Kasthuri, Nigel S. Key. 2010. Disseminated Intravascular Coagulation and other Microangiopathies. , 123-134.
CrossRef285
Stephen M. Black. (2010) New insights into acute lung injury. Vascular Pharmacology 52:5-6, 171-174
CrossRef286
Sébastien Gibot. (2010) Procalcitonin in intensive care units: the PRORATA trial. The Lancet 375:9726, 1605-1606
CrossRef287
T. Ahne, S. Ahne, R. Berner, M. Krüger. (2010) Schwere Sepsis im Kindesalter am Beispiel des Waterhouse-Friderichsen-Syndroms. Notfall + Rettungsmedizin 13:3, 251-259
CrossRef288
Didier Lebrec, Dominique Thabut, Frederic Oberti, Jean–Marc Perarnau, Bertrand Condat, Helene Barraud, Faouzi Saliba, Nicolas Carbonell, Philippe Renard, Marie–Jose Ramond, Richard Moreau, Thierry Poynard. (2010) Pentoxifylline Does Not Decrease Short-term Mortality but Does Reduce Complications in Patients With Advanced Cirrhosis. Gastroenterology 138:5, 1755-1762.e2
CrossRef289
John D. Catravas, Connie Snead, Christiana Dimitropoulou, Albert S.Y. Chang, Rudolf Lucas, Alexander D. Verin, Stephen M. Black. (2010) Harvesting, identification and barrier function of human lung microvascular endothelial cells. Vascular Pharmacology 52:5-6, 175-181
CrossRef290
Mustafa Nisanci, Muhitdin Eski, Ismail Sahin, Seyfettin Ilgan, Selcuk Isik. (2010) Saving the zone of stasis in burns with activated protein C: An experimental study in rats. Burns 36:3, 397-402
CrossRef291
Brian T. Bateman, Ulrich Schmidt, Mitchell F. Berman, Edward A. Bittner. (2010) Temporal Trends in the Epidemiology of Severe Postoperative Sepsis after Elective Surgery. Anesthesiology 112:4, 917-925
CrossRef292
Seth W. Glickman, Charles B. Cairns, Ronny M. Otero, Christopher W. Woods, Ephraim L. Tsalik, Raymond J. Langley, Jennifer C. van Velkinburgh, Lawrence P. Park, Lawrence T. Glickman, Vance G. Fowler, Stephen F. Kingsmore, Emanuel P. Rivers. (2010) Disease Progression in Hemodynamically Stable Patients Presenting to the Emergency Department With Sepsis. Academic Emergency Medicine 17:4, 383-390
CrossRef293
Stephen Trzeciak, Alan E. Jones, Nathan I. Shapiro, Anthony E. Pusateri, Ryan C. Arnold, Michael Rizzuto, Tanisha Arora, Joseph E. Parrillo, R. Phillip Dellinger. (2010) A prospective multicenter cohort study of the association between global tissue hypoxia and coagulation abnormalities during early sepsis resuscitation. Critical Care Medicine 38:4, 1092-1100
CrossRef294
K. Reinhart, F.M. Brunkhorst, H.-G. Bone, J. Bardutzky, C.-E. Dempfle, H. Forst, P. Gastmeier, H. Gerlach, M. Gründling, S. John, W. Kern, G. Kreymann, W. Krüger, P. Kujath, G. Marggraf, J. Martin, K. Mayer, A. Meier-Hellmann, M. Oppert, C. Putensen, M. Quintel, M. Ragaller, R. Rossaint, H. Seifert, C. Spies, F. Stüber, N. Weiler, A. Weimann, K. Werdan, T. Welte. (2010) Prävention, Diagnose, Therapie und Nachsorge der Sepsis. Intensivmedizin und Notfallmedizin 47:3, 185-207
CrossRef295
Jorrit J. Hofstra, Alexander P. Vlaar, Alexander D. Cornet, Barry Dixon, Joris J. Roelofs, Goda Choi, Tom van der Poll, Marcel Levi, Marcus J. Schultz. (2010) Nebulized Anticoagulants Limit Pulmonary Coagulopathy, But Not Inflammation, in a Model of Experimental Lung Injury. Journal of Aerosol Medicine and Pulmonary Drug Delivery 23:2, 105-111
CrossRef296
Peter K. Lindenauer, Michael B. Rothberg, Brian H. Nathanson, Penelope S. Pekow, Jay S. Steingrub. (2010) Activated protein C and hospital mortality in septic shock: A propensity-matched analysis*. Critical Care Medicine 38:4, 1101-1107
CrossRef297
Álvaro Castellanos-Ortega, Borja Suberviola, Luis A. García-Astudillo, María S. Holanda, Fernando Ortiz, Javier Llorca, Miguel Delgado-Rodríguez. (2010) Impact of the Surviving Sepsis Campaign protocols on hospital length of stay and mortality in septic shock patients: Results of a three-year follow-up quasi-experimental study*. Critical Care Medicine 38:4, 1036-1043
CrossRef298
Samuel M Brown, Nathan C Dean. (2010) Defining and predicting severe community-acquired pneumonia. Current Opinion in Infectious Diseases 23:2, 158-164
CrossRef299
Linda Peelen, Nicolette F. de Keizer, Evert de Jonge, Robert-Jan Bosman, Ameen Abu-Hanna, Niels Peek. (2010) Using hierarchical dynamic Bayesian networks to investigate dynamics of organ failure in patients in the Intensive Care Unit. Journal of Biomedical Informatics 43:2, 273-286
CrossRef300
Mary Anne M. Morgan, Lauren M. Frasier, Judith C. Stewart, Cynthia M. Mack, Michael S. Gough, Brian T. Graves, Michael J. Apostolakos, Kathleen P. Doolin, Denise C. Darling, Mark W. Frampton, Anthony P. Pietropaoli. (2010) Artery-to-vein differences in nitric oxide metabolites are diminished in sepsis*. Critical Care Medicine 38:4, 1069-1077
CrossRef301
Gourang P. Patel, Jaime Simon Grahe, Mathew Sperry, Sunit Singla, Ellen Elpern, Omar Lateef, Robert A. Balk. (2010) EFFICACY AND SAFETY OF DOPAMINE VERSUS NOREPINEPHRINE IN THE MANAGEMENT OF SEPTIC SHOCK. Shock 33:4, 375-380
CrossRef302
Alexander Geppert. (2010) Gleiche Therapien bei kardiogenem und septischem Schock?. Wiener klinisches Magazin 13:2, 24-29
CrossRef303
K. Reinhart, F.M. Brunkhorst, H.-G. Bone, J. Bardutzky, C.-E. Dempfle, H. Forst, P. Gastmeier, H. Gerlach, M. Gründling, S. John, W. Kern, G. Kreymann, W. Krüger, P. Kujath, G. Marggraf, J. Martin, K. Mayer, A. Meier-Hellmann, M. Oppert, C. Putensen, M. Quintel, M. Ragaller, R. Rossaint, H. Seifert, C. Spies, F. Stüber, N. Weiler, A. Weimann, K. Werdan, T. Welte. (2010) Prävention, Diagnose, Therapie und Nachsorge der Sepsis. Der Anaesthesist 59:4, 347-370
CrossRef304
Geerte L. van Sluis, Harry R. Büller, C. Arnold Spek. (2010) The role of activated protein C in cancer progression. Thrombosis Research 125, S138-S142
CrossRef305
Andre C. Kalil. (2010) Does recombinant activated protein C work in patients with severe sepsis?*. Critical Care Medicine 38:4, 1217-1220
CrossRef306
(2010) Activated Protein C for Sepsis. New England Journal of Medicine 362:12, 1150-1151
Full Text307
Joaquín Borrás-Blasco, Andrés Navarro-Ruiz, Consuelo Borrás. 2010. Emergency Clinical Trials. .
CrossRef308
John G. Raynes. 2010. The Acute Phase Response. .
CrossRef309
Peter C. Minneci, Katherine J. Deans, Michael Haley, Xizhong Cui, Charles Natanson, Peter Q. Eichacker. 2010. Factors Influencing the Efficacy of Mediator-Specific Anti-Inflammatory, Glucocorticoid, and Anticoagulant Therapies for Sepsis. .
CrossRef310
Daniela N. Männel. 2010. Shock/Sepsis. .
CrossRef311
Fangming Zhang, Rongqian Wu, Xiaoling Qiang, Mian Zhou, Ping Wang. (2010) Antagonism of α2A-adrenoceptor: a novel approach to inhibit inflammatory responses in sepsis. Journal of Molecular Medicine 88:3, 289-296
CrossRef312
Michael Joannidis, Wilfred Druml, Lui G. Forni, A. B. Johan Groeneveld, Patrick Honore, Heleen M. Oudemans-van Straaten, Claudio Ronco, Marie R. C. Schetz, Arend Jan Woittiez. (2010) Prevention of acute kidney injury and protection of renal function in the intensive care unit. Intensive Care Medicine 36:3, 392-411
CrossRef313
Wolfgang Miehsler. (2010) Mortality, morbidity and special issues of obese ICU patients. Wiener Medizinische Wochenschrift 160:5-6, 124-128
CrossRef314
Pranita P. Sarangi, Hyun-wook Lee, Minsoo Kim. (2010) Activated protein C action in inflammation. British Journal of Haematology 148:6, 817-833
CrossRef315
Roberto Romero, Nicholas Kadar, Edi Vaisbuch, Sonia S. Hassan. (2010) Maternal Death Following Cardiopulmonary Collapse After Delivery: Amniotic Fluid Embolism or Septic Shock Due to Intrauterine Infection?. American Journal of Reproductive Immunology
CrossRef316
Jin-Nong Zhang, Bo Peng, Jamile Woods, Wei Peng. (2010) Review of recent guidelines for the management of severe sepsis and septic shock. Frontiers of Medicine in China 4:1, 54-58
CrossRef317
Sylvia Knapp. (2010) Update on the role of Toll-like receptors during bacterial infections and sepsis. Wiener Medizinische Wochenschrift 160:5-6, 107-111
CrossRef318
Raghavan Murugan, Vijay Karajala-Subramanyam, Minjae Lee, Sachin Yende, Lan Kong, Melinda Carter, Derek C Angus, John A Kellum. (2010) Acute kidney injury in non-severe pneumonia is associated with an increased immune response and lower survival. Kidney International 77:6, 527-535
CrossRef319
Paul Knoebl. (2010) Blood coagulation disorders in septic patients. Wiener Medizinische Wochenschrift 160:5-6, 129-138
CrossRef320
S. Danese, S. Vetrano, L. Zhang, V. A. Poplis, F. J. Castellino. (2010) The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications. Blood 115:6, 1121-1130
CrossRef321
Mark W. Gramling, Lea M. Beaulieu, Frank C. Church. (2010) Activated protein C enhances cell motility of endothelial cells and MDA-MB-231 breast cancer cells by intracellular signal transduction. Experimental Cell Research 316:3, 314-328
CrossRef322
Sonja Oehmcke, Heiko Herwald. (2010) Contact system activation in severe infectious diseases. Journal of Molecular Medicine 88:2, 121-126
CrossRef323
Amisha V. Barochia, Xizhong Cui, David Vitberg, Anthony F. Suffredini, Naomi P. OʼGrady, Steven M. Banks, Peter Minneci, Steven J. Kern, Robert L. Danner, Charles Natanson, Peter Q. Eichacker. (2010) Bundled care for septic shock: An analysis of clinical trials*. Critical Care Medicine 38:2, 668-678
CrossRef324
Pengfei Wang, Guanwen Gong, Yousheng Li, Jieshou Li. (2010) Hydroxyethyl starch 130/0.4 augments healing of colonic anastomosis in a rat model of peritonitis. The American Journal of Surgery 199:2, 232-239
CrossRef325
Michiel E. Stegenga, Jean-Louis Vincent, George M. Vail, Jin Xie, Douglas J. Haney, Mark D. Williams, Gordon R. Bernard, Tom van der Poll. (2010) Diabetes does not alter mortality or hemostatic and inflammatory responses in patients with severe sepsis*. Critical Care Medicine 38:2, 539-545
CrossRef326
Massimo Franchini, Giuseppe Lippi. (2010) Factor V Leiden and hemophilia. Thrombosis Research 125:2, 119-123
CrossRef327
Mitchell M. Levy, R. Phillip Dellinger, Sean R. Townsend, Walter T. Linde-Zwirble, John C. Marshall, Julian Bion, Christa Schorr, Antonio Artigas, Graham Ramsay, Richard Beale, Margaret M. Parker, Herwig Gerlach, Konrad Reinhart, Eliezer Silva, Maurene Harvey, Susan Regan, Derek C. Angus. (2010) The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Medicine 36:2, 222-231
CrossRef328
Marcel Levi, Tom van der Poll. (2010) Inflammation and coagulation. Critical Care Medicine 38, S26-S34
CrossRef329
Mitchell M. Levy, R Phillip Dellinger, Sean R. Townsend, Walter T. Linde-Zwirble, John C. Marshall, Julian Bion, Christa Schorr, Antonio Artigas, Graham Ramsay, Richard Beale, Margaret M. Parker, Herwig Gerlach, Konrad Reinhart, Eliezer Silva, Maurene Harvey, Susan Regan, Derek C. Angus. (2010) The Surviving Sepsis Campaign: Results of an international guideline-based performance improvement program targeting severe sepsis*. Critical Care Medicine 38:2, 367-374
CrossRef330
Angela J Frank, B Taylor Thompson. (2010) Pharmacological treatments for acute respiratory distress syndrome. Current Opinion in Critical Care 16:1, 62-68
CrossRef331
Robert I. Parker. (2010) Thrombosis in the intensive care unit: Protein C and a whole lot more!. Critical Care Medicine 38, S1-S2
CrossRef332
M Byrne, J V Reynolds, J S O'Donnell, M Keogan, B White, M Byrne, S Murphy, S G Maher, G P Pidgeon. (2010) Long-term activation of the pro-coagulant response after neoadjuvant chemoradiation and major cancer surgery. British Journal of Cancer 102:1, 73-79
CrossRef333
Yuko Miwa, Koji Yamamoto, Akira Onishi, Masaki Iwamoto, Satoko Yazaki, Masataka Haneda, Kenta Iwasaki, DaGe Liu, Haruko Ogawa, Takaharu Nagasaka, Kazuharu Uchida, Akimasa Nakao, Kenji Kadomatsu, Takaaki Kobayashi. (2010) Potential value of human thrombomodulin and DAF expression for coagulation control in pig-to-human xenotransplantation. Xenotransplantation 17:1, 26-37
CrossRef334
John C. Marshall. (2010) From the bedside back to the bench: The role of preclinical studies in understanding clinical therapies*. Critical Care Medicine 38:1, 329-330
CrossRef335
Gary W. Procop. (2010) Molecular Diagnostics for Invasive Fungal Infections. The Journal of Molecular Diagnostics 12:1, 17-19
CrossRef336
Jean-Louis Vincent, Steven M. Opal, John C. Marshall. (2010) Ten reasons why we should NOT use severity scores as entry criteria for clinical trials or in our treatment decisions*. Critical Care Medicine 38:1, 283-287
CrossRef337
Raghukumar Thirumala, Madhusudanan Ramaswamy, Sanjay Chawla. (2010) Diagnosis and Management of Infectious Complications in Critically Ill Patients with Cancer. Critical Care Clinics 26:1, 59-91
CrossRef338
Yong-Keun Lee, Yung Ahn, Dae-Ho Leem, Jin-A Baek, Seung-O Ko, Hyo-Keun Shin. (2010) The effect of heat shock protein 70 on inducible nitric oxide synthase during sepsis in rats. Journal of the Korean Association of Oral and Maxillofacial Surgeons 36:5, 346
CrossRef339
Hideo Wada, Hidesaku Asakura, Kohji Okamoto, Toshiaki Iba, Toshimasa Uchiyama, Kazuo Kawasugi, Shin Koga, Toshihiko Mayumi, Kaoru Koike, Satoshi Gando, Shigeki Kushimoto, Yoshinobu Seki, Seiji Madoiwa, Ikuro Maruyama, Akira Yoshioka. (2010) Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thrombosis Research 125:1, 6-11
CrossRef340
Dominique D. Benoit, Eric A. Hoste. (2010) Acute Kidney Injury in Critically Ill Patients with Cancer. Critical Care Clinics 26:1, 151-179
CrossRef341
Bekele Afessa, Elie Azoulay. (2010) Critical Care of the Hematopoietic Stem Cell Transplant Recipient. Critical Care Clinics 26:1, 133-150
CrossRef342
C. T. ESMON. (2010) The discovery of the endothelial cell protein C receptor. Journal of Thrombosis and Haemostasis 8:1, 2-5
CrossRef343
Mark Tidswell, William Tillis, Steven P. LaRosa, Melvyn Lynn, Alec E. Wittek, Richard Kao, Janice Wheeler, Jagadish Gogate, Steven M. Opal. (2010) Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis*. Critical Care Medicine 38:1, 72-83
CrossRef344
Federica Chiappori, Ivan Merelli, Luciano Milanesi, Ermanna Rovida. (2010) Exploring the role of the phospholipid ligand in endothelial protein C receptor: A molecular dynamics study. Proteins: Structure, Function, and Bioinformaticsn/a-n/a
CrossRef345
Jong-Sup Bae, Alireza R. Rezaie. (2010) Thrombin and activated protein C inhibit the expression of secretory group IIA phospholipase A2 in the TNF-α-activated endothelial cells by EPCR and PAR-1 dependent mechanisms. Thrombosis Research 125:1, e9-e15
CrossRef346
Marcel Levi. (2010) Japanese consensus for disseminated intravascular coagulation (DIC): Is it a small world after all?. Thrombosis Research 125:1, 4-5
CrossRef347
Wendy L. Wahl, Saman Arbabi, Christy Zalewski, Stewart C. Wang, Mark R. Hemmila. (2010) Intensive Care Unit Core Measures Improve Infectious Complications in Burn Patients. Journal of Burn Care & Research 31:1, 190-195
CrossRef348
Kevin W. McConnell, Jonathan E. McDunn, Andrew T. Clark, W Michael Dunne, David J. Dixon, Isaiah R. Turnbull, Peter J. DiPasco, William F. Osberghaus, Benjamin Sherman, James R. Martin, Michael J. Walter, J Perren Cobb, Timothy G. Buchman, Richard S. Hotchkiss, Craig M. Coopersmith. (2010) Streptococcus pneumoniae and Pseudomonas aeruginosa pneumonia induce distinct host responses. Critical Care Medicine 38:1, 223-241
CrossRef349
John J. Hong, Younsuck Koh, Jung-Sun Park, Hyun-Don Jung, Sang-Hee B. Kim, Tae-Suk Lee, Michael M. Badellino. (2010) Enteral Administration of a Synthetic Monoacetyldiglyceride Improves Survival in a Murine Model of Abdominal Sepsis. The Journal of Trauma: Injury, Infection, and Critical Care 68:1, 62-68
CrossRef350
Fernando Nussenbaum, Ira M. Herman. (2010) Tumor Angiogenesis: Insights and Innovations. Journal of Oncology 2010, 1-24
CrossRef351
Amisha V. Barochia, Xizhong Cui, Charles Natanson, Peter Q. Eichacker. (2010) Risk of death and the efficacy of eritoran tetrasodium (E5564): Design considerations for clinical trials of anti-inflammatory agents in sepsis*. Critical Care Medicine 38:1, 306-308
CrossRef352
Evangelos Messaris, Alex P. Betrosian, Nikolaos Memos, Emmy Chatzigianni, Maria Boutsikou, Venetia Economou, Ismene Dontas, George Theodossiades, Manousos M. Konstadoulakis, Emmanuel E. Douzinas. (2010) Administration of human protein C improves survival in an experimental model of sepsis*. Critical Care Medicine 38:1, 209-216
CrossRef353
Nicolas Lerolle, Ludovic Trinquart, Caroline Bornstain, Jean-Marc Tadié, Audrey Imbert, Jean-Luc Diehl, Jean-Yves Fagon, Emmanuel Guérot. (2010) Increased intensity of treatment and decreased mortality in elderly patients in an intensive care unit over a decade*. Critical Care Medicine 38:1, 59-64
CrossRef354
Ji-Young Yoon, Jae-Young Kwon. (2010) Inflammation and Sepsis. The Korean Journal of Critical Care Medicine 25:1, 1
CrossRef355
Naohisa Kuriyama, Shuji Isaji, Takashi Hamada, Masashi Kishiwada, Ichiro Ohsawa, Masanobu Usui, Hiroyuki Sakurai, Masami Tabata, Tatsuya Hayashi, Koji Suzuki. (2010) The cytoprotective effects of addition of activated protein C into preservation solution on small-for-size grafts in rats. Liver Transplantation 16:1, 1-11
CrossRef356
Randall J. Olsen, James M. Musser. (2010) Molecular Pathogenesis of Necrotizing Fasciitis. Annual Review of Pathology: Mechanisms of Disease 5:1, 1-31
CrossRef357
Neal H. Cohen. (2010) The real reasons not to rely on severity scores*. Critical Care Medicine 38:1, 334-335
CrossRef358
P. Montravers, P. Augustin, G. Dufour, M. Desmard. 2010. Prise en charge des péritonites en réanimation. , 277-289.
CrossRef359
Toussaint, Susanne, Gerlach, Herwig, . (2009) Activated Protein C for Sepsis. New England Journal of Medicine 361:27, 2646-2652
Full Text360
P.T. Foteinou, E. Yang, I.P. Androulakis. (2009) Networks, biology and systems engineering: A case study in inflammation. Computers & Chemical Engineering 33:12, 2028-2041
CrossRef361
Mitchell J. Cohen, Natasha Bir, Pamela Rahn, Rachel Dotson, Karim Brohi, Brian B. Chesebro, Robert Mackersie, Michel Carles, Jeanine Wiener-Kronish, Jean-François Pittet. (2009) Protein C Depletion Early After Trauma Increases the Risk of Ventilator-Associated Pneumonia. The Journal of Trauma: Injury, Infection, and Critical Care 67:6, 1176-1181
CrossRef362
Brad Woodward, Martina Cartwright. (2009) Safety of drotrecogin alfa (activated) in severe sepsis: Data from adult clinical trials and observational studies. Journal of Critical Care 24:4, 595-602
CrossRef363
Jana Hudcova, Todd Sarge, Alan Lisbon, Sugantha Sundar, Daniel Talmor. (2009) Treatment With Activated Protein C Immediately After Cardiac Surgery. Journal of Cardiothoracic and Vascular Anesthesia 23:6, 858-859
CrossRef364
M. J. SCHULTZ, B. DIXON. (2009) A breathtaking and bloodcurdling story of coagulation and inflammation in acute lung injury. Journal of Thrombosis and Haemostasis 7:12, 2050-2052
CrossRef365
Rinaldo Bellomo, Stephen J. Warrillow, Michael C. Reade. (2009) Why we should be wary of single-center trials. Critical Care Medicine 37:12, 3114-3119
CrossRef366
Thierry Gustot, François Durand, Didier Lebrec, Jean-Louis Vincent, Richard Moreau. (2009) Severe sepsis in cirrhosis. Hepatology 50:6, 2022-2033
CrossRef367
Senaka Rajapakse, Anoja Rajapakse. (2009) Age bias in clinical trials in sepsis: How relevant are guidelines to older people?. Journal of Critical Care 24:4, 609-613
CrossRef368
David Ahishakiye, Sophie Lorent, Daniel De Backer, Philippe Gottignies, Jean-Louis Vincent. (2009) Drotrecogin alfa (activated) for severe sepsis: Could we consider a shorter treatment period in patients with a favorable course?. Journal of Critical Care 24:4, 590-594
CrossRef369
David Pestaña, Raquel Ramos. (2009) Early suspension of activated protein C treatment in septic patients after shock reversal. European Journal of Anaesthesiology 26:12, 1072-1075
CrossRef370
Thierry Boulain, Isabelle Runge, Nicolas Bercault, Dalila Benzekri-Lefevre, Manuel Wolf, Christian Fleury. (2009) Dopamine therapy in septic shock: Detrimental effect on survival?. Journal of Critical Care 24:4, 575-582
CrossRef371
Matthieu Le Dorze, Matthieu Legrand, Didier Payen, Can Ince. (2009) The role of the microcirculation in acute kidney injury. Current Opinion in Critical Care 15:6, 503-508
CrossRef372
H.-P. Hartung, L. Mouthon, R. Ahmed, S. Jordan, K. B. Laupland, S. Jolles. (2009) Clinical applications of intravenous immunoglobulins (IVIg) - beyond immunodeficiencies and neurology. Clinical & Experimental Immunology 158, 23-33
CrossRef373
Josh Levitsky, Alison Freifeld, Elizabeth Lyden, Julie Stoner, Diana Florescu, Alan Langnas, R. Brian Stevens, Penny Hardiman, Lisa Hill, Andre C. Kalil. (2009) Evaluation of the coagulation and inflammatory responses in solid organ transplant recipients and donors. Clinical Transplantation 23:6, 943-950
CrossRef374
David K. Meyerholz, Travis L. Piester, Andrew R. McNamara, Julio C. Sokolich, Amin D. Jaskille, Kristine C. Orion, K D. Zamba, Timothy D. Light. (2009) Pharmacologic Modification to Resuscitation Fluid After Thermal Injury—Is Drotrecogin Alfa the Answer to Arrest Burn Depth Progression?. The Journal of Trauma: Injury, Infection, and Critical Care 67:5, 996-1003
CrossRef375
Martina Crivellari, Patrizia Della Valle, Giovanni Landoni, Federico Pappalardo, Chiara Gerli, Elena Bignami, Giovanni Marino, Alberto Zangrillo, Armando D’Angelo. (2009) Human protein C zymogen concentrate in patients with severe sepsis and multiple organ failure after adult cardiac surgery. Intensive Care Medicine 35:11, 1959-1963
CrossRef376
R Phillip Dellinger, John F. Tomayko, Derek C. Angus, Steven Opal, Michael A. Cupo, Sharon McDermott, Annie Ducher, Thierry Calandra, Jonathan Cohen. (2009) Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: Results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial. Critical Care Medicine 37:11, 2929-2938
CrossRef377
Shin Hirayama, Marcelo Cypel, Masaaki Sato, Masaki Anraku, Patricia C. Liaw, Mingyao Liu, Thomas K. Waddell, Shaf Keshavjee. (2009) Activated Protein C in Ischemia-Reperfusion Injury After Experimental Lung Transplantation. The Journal of Heart and Lung Transplantation 28:11, 1180-1184
CrossRef378
Li Li, Joseph L. Messina. (2009) Acute insulin resistance following injury. Trends in Endocrinology & Metabolism 20:9, 429-435
CrossRef379
S. B. YAN, J. T. BRANDT, N. L. CORRELL, S. L. UM, J. S. BOURDAGE. (2009) Evaluation of anti-activated protein C antibody development in patients with severe sepsis from four clinical studies with drotrecogin alfa (activated). Journal of Thrombosis and Haemostasis 7:11, 1787-1794
CrossRef380
Jeffrey R. Jacobson, Konstantin G. Birukov. (2009) Activation of NFkB and coagulation in lung injury by hyperoxia and excessive mechanical ventilation: one more reason “low and slow” is the way to go?. Translational Research 154:5, 219-221
CrossRef381
Jun Xu, Xiaomei Zhang, Rosana Pelayo, Marc Monestier, Concetta T Ammollo, Fabrizio Semeraro, Fletcher B Taylor, Naomi L Esmon, Florea Lupu, Charles T Esmon. (2009) Extracellular histones are major mediators of death in sepsis. Nature Medicine 15:11, 1318-1321
CrossRef382
Matthew R. DiStasi, Klaus Ley. (2009) Opening the flood-gates: how neutrophil-endothelial interactions regulate permeability. Trends in Immunology 30:11, 547-556
CrossRef383
Véronique Lapointe, Drago Jocov, André Denault. (2009) Hemodynamic instability in septic shock. Canadian Journal of Anesthesia/Journal canadien d'anesthésie 56:11, 864-867
CrossRef384
Suzanne Heemskerk, Rosalinde Masereeuw, Frans G. M. Russel, Peter Pickkers. (2009) Selective iNOS inhibition for the treatment of sepsis-induced acute kidney injury. Nature Reviews Nephrology 5:11, 629-640
CrossRef385
Michael J. Krisinger, Li Jun Guo, Gian Luca Salvagno, Gian Cesare Guidi, Giuseppe Lippi, Björn Dahlbäck. (2009) Mouse recombinant protein C variants with enhanced membrane affinity and hyper-anticoagulant activity in mouse plasma. FEBS Journal 276:22, 6586-6602
CrossRef386
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Rosenberg, Eric S., Cort, Alice M., Ebeling, Sally H.Peters, Christine C., de Moya, Marc A., del Carmen, Marcela G., Allain, Rae M., Hirschberg, Ronald E., Shepard, Jo-Anne O., Kradin, Richard L., . (2009) Case 33-2009. New England Journal of Medicine 361:17, 1689-1697
Full Text387
Zhihui Zhong, Hristelina Ilieva, Lee Hallagan, Robert Bell, Itender Singh, Nicole Paquette, Meenakshisundaram Thiyagarajan, Rashid Deane, Jose A. Fernandez, Steven Lane, Anna B. Zlokovic, Todd Liu, John H. Griffin, Nienwen Chow, Francis J. Castellino, Konstantin Stojanovic, Don W. Cleveland, Berislav V. Zlokovic. (2009) Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. Journal of Clinical Investigation
CrossRef388
Charles T. Esmon, Jonathan D. Glass. (2009) The APCs of neuroprotection. Journal of Clinical Investigation
CrossRef389
Thomas H. Yun, James H. Morrissey. (2009) Polyphosphate and omptins: novel bacterial procoagulant agents. Journal of Cellular and Molecular Medicine 13:10, 4146-4153
CrossRef390
Andrea Nencioni, Stephen Trzeciak, Nathan I. Shapiro. (2009) The microcirculation as a diagnostic and therapeutic target in sepsis. Internal and Emergency Medicine 4:5, 413-418
CrossRef391
Fabio Silvio Taccone, Patrick Stordeur, Daniel De Backer, Jacques Creteur, Jean-Louis Vincent. (2009) γ-GLOBULIN LEVELS IN PATIENTS WITH COMMUNITY-ACQUIRED SEPTIC SHOCK. Shock 32:4, 379-385
CrossRef392
Stephen F. Lowry. (2009) The Evolution of an Inflammatory Response. Surgical Infections 10:5, 419-425
CrossRef393
Philip S. Barie, Lynn J. Hydo, Fredric M. Pieracci, Jian Shou, Soumitra R. Eachempati. (2009) Multiple Organ Dysfunction Syndrome in Critical Surgical Illness. Surgical Infections 10:5, 369-377
CrossRef394
Greet Hermans, Ilse Vanhorebeek, Sarah Derde, Greet Van den Berghe. (2009) Metabolic aspects of critical illness polyneuromyopathy. Critical Care Medicine 37, S391-S397
CrossRef395
Anne-Claire Lukaszewicz, Marion Grienay, Matthieu Resche-Rigon, Romain Pirracchio, Valérie Faivre, Bernadette Boval, Didier Payen. (2009) Monocytic HLA-DR expression in intensive care patients: Interest for prognosis and secondary infection prediction*. Critical Care Medicine 37:10, 2746-2752
CrossRef396
A.D. Niederbichler, K. Ipaktchi, A. Jokuszies, T. Hirsch, M.A. Altintas, A.E. Handschin, K.H. Busch, M. Gellert, H.-U. Steinau, P.M. Vogt, L. Steinsträsser. (2009) Chirurgische Intensivmedizin. Der Chirurg 80:10, 934-946
CrossRef397
Daniela Fischerova. (2009) Urgent care in gynaecology: Resuscitation and management of sepsis and acute blood loss. Best Practice & Research Clinical Obstetrics & Gynaecology 23:5, 679-690
CrossRef398
Sang Won Park, Sean W C Chen, Mihwa Kim, Vivette D D'Agati, H Thomas Lee. (2009) Human activated protein C attenuates both hepatic and renal injury caused by hepatic ischemia and reperfusion injury in mice. Kidney International 76:7, 739-750
CrossRef399
Jean-Louis Vincent, Eva Ocampos Martinez, Eliezer Silva. (2009) Evolving Concepts in Sepsis Definitions. Critical Care Clinics 25:4, 665-675
CrossRef400
Sergio L. Zanotti-Cavazzoni, Roy D. Goldfarb. (2009) Animal Models of Sepsis. Critical Care Clinics 25:4, 703-719
CrossRef401
Arne P Neyrinck, Kathleen D Liu, James P Howard, Michael A Matthay. (2009) Protective mechanisms of activated protein C in severe inflammatory disorders. British Journal of Pharmacology 158:4, 1034-1047
CrossRef402
D. Song, X. Ye, H. Xu, S. F. Liu. (2009) Activation of endothelial intrinsic NF- B pathway impairs protein C anticoagulation mechanism and promotes coagulation in endotoxemic mice. Blood 114:12, 2521-2529
CrossRef403
Perenlei Enkhbaatar, Matthias Lange, Yoshimitsu Nakano, Atsumori Hamahata, Collette Jonkam, Jianpu Wang, Stefan Jaroch, Lillian Traber, David Herndon, Daniel Traber. (2009) ROLE OF NEURONAL NITRIC OXIDE SYNTHASE IN OVINE SEPSIS MODEL. Shock 32:3, 253-257
CrossRef404
Scott D. Halpern, Adrienne G. Randolph, Derek C. Angus. (2009) No child left behind: Enrolling children and adults simultaneously in critical care randomized trials*. Critical Care Medicine 37:9, 2638-2641
CrossRef405
Anita J Reddy, Steven R Kleeberger. (2009) Genetic polymorphisms associated with acute lung injury. Pharmacogenomics 10:9, 1527-1539
CrossRef406
Deborah J Cook, James Douketis, Donald Arnold, Mark A Crowther. (2009) Bleeding and venous thromboembolism in the critically ill with emphasis on patients with renal insufficiency. Current Opinion in Pulmonary Medicine 15:5, 455-462
CrossRef407
Matthew R. Morrell, Scott T. Micek, Marin H. Kollef. (2009) The Management of Severe Sepsis and Septic Shock. Infectious Disease Clinics of North America 23:3, 485-501
CrossRef408
Doris Fischer, Rolf L Schloesser, Claudia A Nold-Petry, Marcel F Nold, Alex Veldman. (2009) Protein C concentrate in preterm neonates with sepsis. Acta Paediatrica 98:9, 1526-1529
CrossRef409
Mirka Sivula, Ville Pettilä, Tomi T Niemi, Marjut Varpula, Anne H Kuitunen. (2009) Thromboelastometry in patients with severe sepsis and disseminated intravascular coagulation. Blood Coagulation & Fibrinolysis 20:6, 419-426
CrossRef410
Lutz Koch, Stefan Hofer, Markus A. Weigand, David Frommhold, Johannes Poeschl. (2009) Lipopolysaccharide-induced activation of coagulation in neonatal cord and adult blood monitored by thrombelastography. Thrombosis Research 124:4, 463-467
CrossRef411
Brian M. Fuller, R. Phillip Dellinger. (2009) Hemodynamic resuscitation in septic shock: Cardiovascular support and adjunctive therapy. Current Infectious Disease Reports 11:5, 357-364
CrossRef412
Soichiro Uehara, Hiroshi Handa, Katuhiro Gotoh, Hiroshi Tomita, Mitiko Sennshuu. (2009) Plasma concentrations of growth arrest-specific protein 6 and protein S in patients with acute pancreatitis. Journal of Gastroenterology and Hepatology 24:9, 1567-1573
CrossRef413
Peter K. Linden. (2009) Approach to the Immunocompromised Host with Infection in the Intensive Care Unit. Infectious Disease Clinics of North America 23:3, 535-556
CrossRef414
Marcos I. Restrepo, Antonio Anzueto. (2009) Severe Community-Acquired Pneumonia. Infectious Disease Clinics of North America 23:3, 503-520
CrossRef415
Shyoko Honiden, John R. McArdle. (2009) Obesity in the Intensive Care Unit. Clinics in Chest Medicine 30:3, 581-599
CrossRef416
S. M. Bagshaw, S. Uchino, D. Cruz, R. Bellomo, H. Morimatsu, S. Morgera, M. Schetz, I. Tan, C. Bouman, E. Macedo, N. Gibney, A. Tolwani, H. M. Oudemans-van Straaten, C. Ronco, J. A. Kellum, . (2009) A comparison of observed versus estimated baseline creatinine for determination of RIFLE class in patients with acute kidney injury. Nephrology Dialysis Transplantation 24:9, 2739-2744
CrossRef417
G. L. Van Sluis, T. M.H. Niers, C. T. Esmon, W. Tigchelaar, D. J. Richel, H. R. Buller, C. J.F. Van Noorden, C. A. Spek. (2009) Endogenous activated protein C limits cancer cell extravasation through sphingosine-1-phosphate receptor 1-mediated vascular endothelial barrier enhancement. Blood 114:9, 1968-1973
CrossRef418
Jorrit J. Hofstra, Marcel Levi, Marcus J. Schultz. (2009) HETRASE study—Did heparin treatment benefit patients with ALI/ARDS?. Critical Care Medicine 37:8, 2490
CrossRef419
Kiho Cho, Sophia Chiu, Young-Kwan Lee, David Greenhalgh, Jean Nemzek. (2009) EXPERIMENTAL POLYMICROBIAL PERITONITIS-ASSOCIATED TRANSCRIPTIONAL REGULATION OF MURINE ENDOGENOUS RETROVIRUSES. Shock 32:2, 147-158
CrossRef420
Duane Funk, Frank Sebat, Anand Kumar. (2009) A systems approach to the early recognition and rapid administration of best practice therapy in sepsis and septic shock. Current Opinion in Critical Care 15:4, 301-307
CrossRef421
Barry A. Mizock. (2009) The Multiple Organ Dysfunction Syndrome. Disease-a-Month 55:8, 476-526
CrossRef422
Oddeke van Ruler, Marcus J. Schultz, Johannes B. Reitsma, Dirk J. Gouma, Marja A. Boermeester. (2009) Has Mortality from Sepsis Improved and What to Expect from New Treatment Modalities: Review of Current Insights. Surgical Infections 10:4, 339-348
CrossRef423
G. M. Vail, Y. J. Xie, D. J. Haney, C. J. Barnes. (2009) Biomarkers of Thrombosis, Fibrinolysis, and Inflammation in Patients with Severe Sepsis due to Community-Acquired Pneumonia with and without Streptococcus pneumoniae. Infection 37:4, 358-364
CrossRef424
Peter Teschendorf, Stephan A. Padosch, Daniela del Valle y Fuentes, Christoph Peter, André Fuchs, Erik Popp, Fabian Spöhr, Bernd W. Böttiger, Andreas Walther. (2009) Effects of activated protein C on postcardiac arrest microcirculation: An in vivo microscopy study. Resuscitation 80:8, 940-945
CrossRef425
Andre C. Kalil, Diana F. Florescu. (2009) Prevalence and mortality associated with cytomegalovirus infection in nonimmunosuppressed patients in the intensive care unit*. Critical Care Medicine 37:8, 2350-2358
CrossRef426
M.O. Maybauer, S. Rehberg, D.L. Traber, D.N. Herndon, D.M. Maybauer. (2009) Pathophysiologie des akuten Lungenversagens bei Schwerbrandverletzten mit Inhalationstrauma. Der Anaesthesist 58:8, 805-812
CrossRef427
Christopher Alan Moxon, Robert Simon Heyderman, Samuel Crocodile Wassmer. (2009) Dysregulation of coagulation in cerebral malaria. Molecular and Biochemical Parasitology 166:2, 99-108
CrossRef428
Delvaeye, Mieke, Noris, Marina, De Vriese, Astrid, Esmon, Charles T., Esmon, Naomi L., Ferrell, Gary, Del-Favero, Jurgen, Plaisance, Stephane, Claes, Bart, Lambrechts, Diether, Zoja, Carla, Remuzzi, Giuseppe, Conway, Edward M., . (2009) Thrombomodulin Mutations in Atypical Hemolytic–Uremic Syndrome. New England Journal of Medicine 361:4, 345-357
Full Text429
F.M. Brunkhorst, K. Reinhart. (2009) Supportive und adjunktive Therapie der Sepsis. Der Internist 50:7, 817-827
CrossRef430
Matthias Hartmann, Semih Özlügedik, Juergen Peters. (2009) Thiopental Inhibits Lipopolysaccharide-Induced Tissue Factor Expression. Anesthesia & Analgesia 109:1, 109-113
CrossRef431
S. Akima, W. J. Hawthorne, E. Favaloro, A. Patel, K. Blyth, Y. Mudaliar, J. R. Chapman, P. J. O’Connell. (2009) Tirofiban and Activated Protein C Synergistically Inhibit the Instant Blood Mediated Inflammatory Reaction (IBMIR) from Allogeneic Islet Cells Exposure to Human Blood. American Journal of Transplantation 9:7, 1533-1540
CrossRef432
Jan Beyer, Kai Halbritter, Matthias Weise, Sebastian Schellong. (2009) Influence of antithrombin and argatroban on disseminated intravascular coagulation parameters in a patient with septic shock. Thrombosis Research 124:3, 383-386
CrossRef433
Brent R. Weil, Troy A. Markel, Jeremy L. Herrmann, Aaron M. Abarbanell, Megan L. Kelly, Daniel R. Meldrum. (2009) Stem Cells in Sepsis. Annals of Surgery 250:1, 19-27
CrossRef434
Mitchell Levy, Marcel Levi, Mark D. Williams, Massimo Antonelli, Dazhe Wang, Mariano Alejandro Mignini. (2009) Comprehensive safety analysis of concomitant drotrecogin alfa (activated) and prophylactic heparin use in patients with severe sepsis. Intensive Care Medicine 35:7, 1196-1203
CrossRef435
N. R. Webster, H. F. Galley. (2009) Immunomodulation in the critically ill. British Journal of Anaesthesia 103:1, 70-81
CrossRef436
Jean-Francois Dhainaut, Massimo Antonelli, Patrick Wright, Arnaud Desachy, Jean Reignier, Sylvain Lavoue, Julien Charpentier, Mark Belger, Michael Cobas-Meyer, Cornelia Maier, Mariano A. Mignini, Jonathan Janes. (2009) Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shock. Intensive Care Medicine 35:7, 1187-1195
CrossRef437
Victor Novack, Miruna Eisinger, Amit Frenkel, Marius Terblanche, Neill K. J. Adhikari, Amos Douvdevani, Doron Amichay, Yaniv Almog. (2009) The effects of statin therapy on inflammatory cytokines in patients with bacterial infections: a randomized double-blind placebo controlled clinical trial. Intensive Care Medicine 35:7, 1255-1260
CrossRef438
Yoan Lamarche, Anson Cheung, Keith R. Walley, Peter Dodek. (2009) Combined use of extracorporeal membrane oxygenation and activated protein C for severe acute respiratory distress syndrome and septic shock. The Journal of Thoracic and Cardiovascular Surgery 138:1, 246-247
CrossRef439
Michael Darmon, Elie Azoulay. (2009) Critical care management of cancer patients: cause for optimism and need for objectivity. Current Opinion in Oncology 21:4, 318-326
CrossRef440
H. WEILER, E. KERSCHEN. (2009) Modulation of sepsis outcome with variants of activated protein C. Journal of Thrombosis and Haemostasis 7, 127-131
CrossRef441
O. Moerer, M. Quintel. (2009) Definition, Epidemiologie und ökonomische Aspekte der Sepsis bei Erwachsenen. Der Internist 50:7, 788-798
CrossRef442
A. Vieillard-Baron, V. Caille, C. Charron, G. Belliard, P. Aegerter, B. Page, F. Jardin. (2009) Reversal of refractory septic shock with drotrecogin alpha (activated). Intensive Care Medicine 35:7, 1204-1209
CrossRef443
L. O. Mosnier, A. Zampolli, E. J. Kerschen, R. A. Schuepbach, Y. Banerjee, J. A. Fernandez, X. V. Yang, M. Riewald, H. Weiler, Z. M. Ruggeri, J. H. Griffin. (2009) Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant. Blood 113:23, 5970-5978
CrossRef444
Laurens Nieuwenhuizen, Philip G. de Groot, Jan C. Grutters, Douwe H. Biesma. (2009) A review of pulmonary coagulopathy in acute lung injury, acute respiratory distress syndrome and pneumonia. European Journal of Haematology 82:6, 413-425
CrossRef445
Peter G. Brindley, William F. Dunn. (2009) Simulation for clinical research trials: A theoretical outline. Journal of Critical Care 24:2, 164-167
CrossRef446
J.B. Sadashivaiah, B. Carr. (2009) Severe community-acquired pneumonia. Continuing Education in Anaesthesia, Critical Care & Pain 9:3, 87-91
CrossRef447
Edward Abraham. (2009) Anticoagulants for acute lung injury: Barking up the wrong tree*. Critical Care Medicine 37:6, 2100-2101
CrossRef448
Quan-hui Yang, Da-wei Liu, Yun Long, Hong-zhong Liu, Wen-zhao Chai, Xiao-Ting Wang. (2009) Acute renal failure during sepsis: Potential role of cell cycle regulation. Journal of Infection 58:6, 459-464
CrossRef449
Nahid Qushmaq, Jeffrey I. Weitz. 2009. Overview of New Anticoagulant Drugs. , 133-154.
CrossRef450
Masataka Ishimura, Mitsumasa Saito, Shouichi Ohga, Takayuki Hoshina, Haruhisa Baba, Michiyo Urata, Ryutaro Kira, Hidetoshi Takada, Koichi Kusuhara, Dongchon Kang, Toshiro Hara. (2009) Fulminant sepsis/meningitis due to Haemophilus influenzae in a protein C-deficient heterozygote treated with activated protein C therapy. European Journal of Pediatrics 168:6, 673-677
CrossRef451
Zoe Rooney, Simon Nadel. (2009) Optimizing intensive care management in paediatric sepsis. Current Opinion in Infectious Diseases 22:3, 264-271
CrossRef452
Paola Giordano, Valerio Cecinati, Giovanni Carlo Vecchio, Giampaolo Arcamone, Francesco De Leonardis, Massimo Grassi, Letizia Pomponia Brescia, Nicola Santoro, Domenico De Mattia. (2009) Successful treatment with Protein C of febrile neutropenia in pediatric patients during cancer therapy. Immunopharmacology and Immunotoxicology 31:2, 293-298
CrossRef453
Jeremy M. Kahn, Thomas R. Ten Have, Theodore J. Iwashyna. (2009) The Relationship between Hospital Volume and Mortality in Mechanical Ventilation: An Instrumental Variable Analysis. Health Services Research 44:3, 862-879
CrossRef454
Jean-Louis Vincent, Antonio Artigas, Lars C. Petersen, Christian Meyer. (2009) A multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial assessing safety and efficacy of active site inactivated recombinant factor VIIa in subjects with acute lung injury or acute respiratory distress syndrome*. Critical Care Medicine 37:6, 1874-1880
CrossRef455
Paul P Dobesh, Donald G Klepser, Timothy R McGuire, Craig W Morgan, Keith M Olsen. (2009) Reduction in Mortality Associated with Statin Therapy in Patients with Severe Sepsis. Pharmacotherapy 29:6, 621-630
CrossRef456
Claudio Contaldo, Ahmed Elsherbiny, Nicole Lindenblatt, Jan A. Plock, Otmar Trentz, Pietro Giovanoli, Michael D. Menger, Guido A. Wanner. (2009) ERYTHROPOIETIN ENHANCES OXYGENATION IN CRITICALLY PERFUSED TISSUE THROUGH MODULATION OF NITRIC OXIDE SYNTHASE. Shock 31:6, 600-607
CrossRef457
Kenichi A. Tanaka, Nigel S. Key, Jerrold H. Levy. (2009) Blood Coagulation: Hemostasis and Thrombin Regulation. Anesthesia & Analgesia 108:5, 1433-1446
CrossRef458
Kathleen D. Liu. (2009) Critical Care Nephrology: Core Curriculum 2009. American Journal of Kidney Diseases 53:5, 898-910
CrossRef459
J. XU, Y. JI, X. ZHANG, M. DRAKE, C. T. ESMON. (2009) Endogenous activated protein C signaling is critical to protection of mice from lipopolysaccaride-induced septic shock. Journal of Thrombosis and Haemostasis 7:5, 851-856
CrossRef460
Kevin R. Novak, Paul Nardelli, Tim C. Cope, Gregory Filatov, Jonathan D. Glass, Jaffar Khan, Mark M. Rich. (2009) Inactivation of sodium channels underlies reversible neuropathy during critical illness in rats. Journal of Clinical Investigation 119:5, 1150-1158
CrossRef461
Sara E. Erickson, Greg S. Martin, J Lucian Davis, Michael A. Matthay, Mark D. Eisner. (2009) Recent trends in acute lung injury mortality: 1996–2005*. Critical Care Medicine 37:5, 1574-1579
CrossRef462
E. W. Kang, H. J. Na, S. M. Hong, S. K. Shin, S.-W. Kang, K. H. Choi, H. Y. Lee, D.-S. Han, S. H. Han. (2009) Prognostic value of elevated cardiac troponin I in ESRD patients with sepsis. Nephrology Dialysis Transplantation 24:5, 1568-1573
CrossRef463
Claudia P. Pereira, Esther B. Bachli, Gabriele Schoedon. (2009) The Wnt pathway: A macrophage effector molecule that triggers inflammation. Current Atherosclerosis Reports 11:3, 236-242
CrossRef464
, R. Beale, K. Reinhart, F. M. Brunkhorst, G. Dobb, M. Levy, G. Martin, C. Martin, G. Ramsey, E. Silva, B. Vallet, J.-L. Vincent, J. M. Janes, S. Sarwat, M. D. Williams. (2009) Promoting Global Research Excellence in Severe Sepsis (PROGRESS): Lessons from an International Sepsis Registry. Infection
CrossRef465
G. F. Elphick, P. P. Sarangi, Y.-M. Hyun, J. A. Hollenbaugh, A. Ayala, W. L. Biffl, H.-L. Chung, A. R. Rezaie, J. L. McGrath, D. J. Topham, J. S. Reichner, M. Kim. (2009) Recombinant human activated protein C inhibits integrin-mediated neutrophil migration. Blood 113:17, 4078-4085
CrossRef466
A. Russo, U. J. K. Soh, M. M. Paing, P. Arora, J. Trejo. (2009) Caveolae are required for protease-selective signaling by protease-activated receptor-1. Proceedings of the National Academy of Sciences 106:15, 6393-6397
CrossRef467
M. Bezuhly, R. Cullen, C. T. Esmon, S. F. Morris, K. A. West, B. Johnston, R. S. Liwski. (2009) Role of activated protein C and its receptor in inhibition of tumor metastasis. Blood 113:14, 3371-3374
CrossRef468
Stacy H. James. (2009) Hematology Pharmacology. AACN Advanced Critical Care 20:2, 177-192
CrossRef469
Huang Guo, Yaoming Wang, Itender Singh, Dong Liu, José A. Fernández, John H. Griffin, Nienwen Chow, Berislav V. Zlokovic. (2009) Species-dependent neuroprotection by activated protein C mutants with reduced anticoagulant activity. Journal of Neurochemistry 109:1, 116-124
CrossRef470
Michael Cohen-Wolkowiez, Daniel K Benjamin, Edmund Capparelli. (2009) Immunotherapy in neonatal sepsis: advances in treatment and prophylaxis. Current Opinion in Pediatrics 21:2, 177-181
CrossRef471
J. Cohen. (2009) Non-antibiotic strategies for sepsis. Clinical Microbiology and Infection 15:4, 302-307
CrossRef472
Fabiano Pinheiro da Silva, Victor Nizet. (2009) Cell death during sepsis: integration of disintegration in the inflammatory response to overwhelming infection. Apoptosis 14:4, 509-521
CrossRef473
M Levi, C. H. Toh, J Thachil, H. G. Watson. (2009) Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Journal of Haematology 145:1, 24-33
CrossRef474
P. Kopterides, M. E. Falagas. (2009) Statins for sepsis: a critical and updated review. Clinical Microbiology and Infection 15:4, 325-334
CrossRef475
G. Houston, B. H. Cuthbertson. (2009) Activated protein C for the treatment of severe sepsis. Clinical Microbiology and Infection 15:4, 319-324
CrossRef476
Jens Müller, Berend Isermann, Christina Dücker, Mohammad Salehi, Moritz Meyer, Max Friedrich, Thati Madhusudhan, Johannes Oldenburg, Günter Mayer, Bernd Pötzsch. (2009) An Exosite-Specific ssDNA Aptamer Inhibits the Anticoagulant Functions of Activated Protein C and Enhances Inhibition by Protein C Inhibitor. Chemistry & Biology 16:4, 442-451
CrossRef477
Daniel De Backer, Katia Donadello, Raphaël Favory. (2009) Link between coagulation abnormalities and microcirculatory dysfunction in critically ill patients. Current Opinion in Anaesthesiology 22:2, 150-154
CrossRef478
Jonathan M. Siner, Vineet Bhandari, Kathryn M. Engle, Jack A. Elias, Mark D. Siegel. (2009) ELEVATED SERUM ANGIOPOIETIN 2 LEVELS ARE ASSOCIATED WITH INCREASED MORTALITY IN SEPSIS. Shock 31:4, 348-353
CrossRef479
Francesca Rubulotta, John C. Marshall, Graham Ramsay, David Nelson, Mitchell Levy, Mark Williams. (2009) Predisposition, insult/infection, response, and organ dysfunction: A new model for staging severe sepsis. Critical Care Medicine 37:4, 1329-1335
CrossRef480
Jorrit Jan Hofstra, Goda Choi, Marcus J. Schultz. (2009) Early intravenous unfractioned heparin—also beneficial in acute lung injury?. Critical Care Medicine 37:4, 1533-1534
CrossRef481
Amisha V. Barochia, Yan Li, Xizhong Cui, Daniel A. Sweeney, Charles Natanson, Peter Q. Eichacker. (2009) Antithrombosis Trials: Should we test therapeutic heparin adjusted based on activated partial thromboplastin time in septic shock?*. Critical Care Medicine 37:4, 1486-1487
CrossRef482
Fabián Jaimes, Gisela De La Rosa, Carlos Morales, Fernando Fortich, Clara Arango, Daniel Aguirre, Álvaro Muñoz. (2009) Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study)*. Critical Care Medicine 37:4, 1185-1196
CrossRef483
Sari Karlsson, Esko Ruokonen, Tero Varpula, Tero I. Ala-Kokko, Ville Pettilä. (2009) Long-term outcome and quality-adjusted life years after severe sepsis*. Critical Care Medicine 37:4, 1268-1274
CrossRef484
Matthew C. Byrnes, Greg J. Beilman. (2009) Adjunctive Measures for Treating Surgical Infections and Sepsis. Surgical Clinics of North America 89:2, 349-363
CrossRef485
David Marsolais, Hugh Rosen. (2009) Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules. Nature Reviews Drug Discovery 8:4, 297-307
CrossRef486
Willem J Wiersinga, Tom van der Poll. (2009) Immunity to Burkholderia pseudomallei. Current Opinion in Infectious Diseases 22:2, 102-108
CrossRef487
S. Al-Rawi, L.J. Woodward, J. Knight. (2009) Puerperal streptococcal toxic shock syndrome treated with recombinant human activated protein C and intravenous immunoglobulin. International Journal of Obstetric Anesthesia 18:2, 169-172
CrossRef488
Alejandro Rodriguez, Thiago Lisboa, Stijn Blot, Ignacio Martin-Loeches, Jorge Solé-Violan, Diego Mendoza, Jordi Rello, . (2009) Mortality in ICU patients with bacterial community-acquired pneumonia: when antibiotics are not enough. Intensive Care Medicine 35:3, 430-438
CrossRef489
Eloisa Gitto, Salvatore Pellegrino, Placido Gitto, Ignazio Barberi, Russel J. Reiter. (2009) Oxidative stress of the newborn in the pre- and postnatal period and the clinical utility of melatonin. Journal of Pineal Research 46:2, 128-139
CrossRef490
Huang Guo, Itender Singh, Yaoming Wang, Rashid Deane, Theresa Barrett, José A. Fernández, Nienwen Chow, John H. Griffin, Berislav V. Zlokovic. (2009) Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity. European Journal of Neuroscience 29:6, 1119-1130
CrossRef491
Eytan Stein, Brandon McMahon, Hau Kwaan, Jessica K. Altman, Olga Frankfurt, Martin S. Tallman. (2009) The coagulopathy of acute promyelocytic leukaemia revisited. Best Practice & Research Clinical Haematology 22:1, 153-163
CrossRef492
Jason B. Martin, Arthur P. Wheeler. (2009) Approach to the Patient with Sepsis. Clinics in Chest Medicine 30:1, 1-16
CrossRef493
Steven W. Thiel, Muhammad F. Asghar, Scott T. Micek, Richard M. Reichley, Joshua A. Doherty, Marin H. Kollef. (2009) Hospital-wide impact of a standardized order set for the management of bacteremic severe sepsis*. Critical Care Medicine 37:3, 819-824
CrossRef494
John R. McArdle. (2009) Critical Care Outcomes in the Hematologic Transplant Recipient. Clinics in Chest Medicine 30:1, 155-167
CrossRef495
Michael W. Donnino, Michael N. Cocchi, Michael Howell, Peter Clardy, Daniel Talmor, Lauren Cataldo, Maureen Chase, Adel Al-Marshad, Long Ngo, Nathan I. Shapiro. (2009) Statin Therapy Is Associated with Decreased Mortality in Patients with Infection. Academic Emergency Medicine 16:3, 230-234
CrossRef496
Marcel Levi. (2009) Disseminated intravascular coagulation in cancer patients. Best Practice & Research Clinical Haematology 22:1, 129-136
CrossRef497
E Holler, H J Kolb, H Greinix, D Perrotin, F Campilho, F Aversa, L Gil, J Cornelissen, L Varanese, A Schacht, A Friese, J Rustige. (2009) Bleeding events and mortality in SCT patients: a retrospective study of hematopoietic SCT patients with organ dysfunctions due to severe sepsis or GVHD. Bone Marrow Transplantation 43:6, 491-497
CrossRef498
Petros Kopterides, Ilias I. Siempos, Apostolos Armaganidis. (2009) Prone positioning in hypoxemic respiratory failure: Meta-analysis of randomized controlled trials. Journal of Critical Care 24:1, 89-100
CrossRef499
Vinod K. Puri. (2009) Solutions for care of patients with severe sepsis: Where and how?*. Critical Care Medicine 37:3, 1128-1129
CrossRef500
Ashita J. Tolwani, Keith M. Wille. (2009) Anticoagulation for Continuous Renal Replacement Therapy. Seminars in Dialysis 22:2, 141-145
CrossRef501
Monica Savioli, Massimo Cugno, Federico Polli, Paolo Taccone, Giacomo Bellani, Paolo Spanu, Antonio Pesenti, Gaetano Iapichino, Luciano Gattinoni. (2009) Tight glycemic control may favor fibrinolysis in patients with sepsis*. Critical Care Medicine 37:2, 424-431
CrossRef502
Mitchell M Levy, Andrew Rhodes. (2009) The ongoing enigma of tight glucose control. The Lancet 373:9663, 520-521
CrossRef503
Anita Tsen, Linda A. Kirschenbaum, Catherine LaRow, Raymond Khan, Susannah Kurtz, Sandeep Bansal, Mark E. Astiz. (2009) THE EFFECT OF ANTICOAGULANTS AND THE ROLE OF THROMBIN ON NEUTROPHIL-ENDOTHELIAL CELL INTERACTIONS IN SEPTIC SHOCK. Shock 31:2, 120-124
CrossRef504
Daniel J Niven, Kevin B Laupland. (2009) Severe community-acquired pneumonia in adults: current antimicrobial chemotherapy. Expert Review of Anti-infective Therapy 7:1, 69-81
CrossRef505
M. Angstwurm, J. Hoffmann, H. Ostermann, L. Frey, M. Spannagl. (2009) Schwere Sepsis und disseminierte intravasale Gerinnung. Der Anaesthesist 58:2, 171-179
CrossRef506
Christa Claes, Ralf René Reinert, Johann-Matthias Graf Schulenburg. (2009) Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects. The European Journal of Health Economics 10:1, 25-38
CrossRef507
Michael Bezuhly, Steven F. Morris, Ridas Juskevicius, R William Currie, Kenneth A. West, Robert S. Liwski. (2009) Activated Protein C Improves Ischemic Flap Survival and Modulates Proangiogenic and Antiinflammatory Gene Expression. Plastic and Reconstructive Surgery 123:2, 502-515
CrossRef508
Willem Joost Wiersinga, Cornelis van’t Veer, Petra S. van den Pangaart, Arjen M. Dondorp, Nicholas P. Day, Sharon J. Peacock, Tom van der Poll. (2009) Immunosuppression associated with interleukin-1R-associated-kinase-M upregulation predicts mortality in Gram-negative sepsis (melioidosis). Critical Care Medicine 37:2, 569-576
CrossRef509
Matthew A. Saxonhouse, Marilyn J. Manco-Johnson. (2009) The Evaluation and Management of Neonatal Coagulation Disorders. Seminars in Perinatology 33:1, 52-65
CrossRef510
P.T. Foteinou, S.E. Calvano, S.F. Lowry, I.P. Androulakis. (2009) Translational Potential of Systems-Based Models of Inflammation. Clinical and Translational Science 2:1, 85-89
CrossRef511
Samuel M. Galvagno, William Camann. (2009) Sepsis and Acute Renal Failure in Pregnancy. Anesthesia & Analgesia 108:2, 572-575
CrossRef512
Carolyn S. Calfee, Mark D. Eisner, Polly E. Parsons, B. Taylor Thompson, Edward R. Conner, Michael A. Matthay, Lorraine B. Ware, . (2009) Soluble intercellular adhesion molecule-1 and clinical outcomes in patients with acute lung injury. Intensive Care Medicine 35:2, 248-257
CrossRef513
Lars Heslet. (2009) Look on the “air side” in pneumonia*. Critical Care Medicine 37:2, 774-775
CrossRef514
X. V. Yang, Y. Banerjee, J. A. Fernandez, H. Deguchi, X. Xu, L. O. Mosnier, Rolf. T. Urbanus, P. G. de Groot, T. C. White-Adams, O. J. T. McCarty, J. H. Griffin. (2009) Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cells. Proceedings of the National Academy of Sciences 106:1, 274-279
CrossRef515
Sennoun Nacira, Ferhat Meziani, Olivier Dessebe, Valérie Cattan, Solène Collin, Chantal Montemont, Sebastien Gibot, Pierre Asfar, Andriantsitohaina Ramaroson, Veronique Regnault, Michel Slama, Thomas Lecompte, Patrick Lacolley, Bruno Levy. (2009) Activated protein C improves lipopolysaccharide-induced cardiovascular dysfunction by decreasing tissular inflammation and oxidative stress*. Critical Care Medicine 37:1, 246-255
CrossRef516
Suk-Kyung Hong, Sang-Bum Hong, Chae-Man Lim, Younsuck Koh. (2009) The Characteristics and Prognostic Factors of Severe Sepsis in Patients Who Were Admitted to a Medical Intensive Care Unit of a Tertiary Hospital. The Korean Journal of Critical Care Medicine 24:1, 28
CrossRef517
Honglei Xu, Xiaobing Ye, Harry Steinberg, Shu Fang Liu. (2009) Selective blockade of endothelial NF-κB pathway differentially affects systemic inflammation and multiple organ dysfunction and injury in septic mice. The Journal of Pathologyn/a-n/a
CrossRef518
Daniel A. Sweeney, Charles Natanson, Peter Q. Eichacker. (2009) Recombinant human activated protein C, package labeling, and hemorrhage risks*. Critical Care Medicine 37:1, 327-329
CrossRef519
Roland Andersson, Anna Swärd, Bobby Tingstedt, Daniel Åkerberg. (2009) Treatment of Acute Pancreatitis. Drugs 69:5, 505-514
CrossRef520
Carlos Mas-Moruno, Laura Cascales, Puig Mora, Luis J. Cruz, Enrique P
CrossRef521
Claudio M. Martin, Fran Priestap, Harold Fisher, Robert A. Fowler, Daren K. Heyland, Sean P. Keenan, Christopher J. Longo, Teresa Morrison, Diane Bentley, Neil Antman. (2009) A prospective, observational registry of patients with severe sepsis: The Canadian Sepsis Treatment and Response Registry*. Critical Care Medicine 37:1, 81-88
CrossRef522
Sang Hyun Kwak. (2009) The Role of the Coagulation and Fibrinolytic Pathway in Acute Lung Injury. The Korean Journal of Critical Care Medicine 24:2, 53
CrossRef523
Ephraim L. Tsalik, Christopher W. Woods. (2009) Sepsis redefined: the search for surrogate markers. International Journal of Antimicrobial Agents 34, S16-S20
CrossRef524
Edward Abraham. (2009) Better infrastructure: Industry–academia partnerships—A marriage of convenience?. Critical Care Medicine 37:Supplement, S159-S164
CrossRef525
Ricard Ferrer, Mélanie Adda, Ana Navas, Maddalena Pasini, Antoni Artigas. (2009) Blood coagulation and inflammation in acute lung injury. Journal of Organ Dysfunction 5:2, 101-109
CrossRef526
Daniele Poole, Guido Bertolini, Silvio Garattini. (2009) Errors in the approval process and post-marketing evaluation of drotrecogin alfa (activated) for the treatment of severe sepsis. The Lancet Infectious Diseases 9:1, 67-72
CrossRef527
Lorenzo Del Sorbo, B Taylor Thompson, V Marco Ranieri. (2009) Postregistration trials: Should we? How do we?. Critical Care Medicine 37:Supplement, S154-S158
CrossRef528
François Proulx, Jean Sébastien Joyal, M Michele Mariscalco, Stéphane Leteurtre, Francis Leclerc, Jacques Lacroix. (2009) The pediatric multiple organ dysfunction syndrome. Pediatric Critical Care Medicine 10:1, 12-22
CrossRef529
Nathan I. Shapiro, Stephen Trzeciak, Judd E. Hollander, Robert Birkhahn, Ronny Otero, Tiffany M. Osborn, Eugene Moretti, H Bryant Nguyen, Kyle J. Gunnerson, David Milzman, David F. Gaieski, Munish Goyal, Charles B. Cairns, Long Ngo, Emanuel P. Rivers. (2009) A prospective, multicenter derivation of a biomarker panel to assess risk of organ dysfunction, shock, and death in emergency department patients with suspected sepsis. Critical Care Medicine 37:1, 96-104
CrossRef530
Jose J. Diaz, Patrick R. Norris, Bryan R. Collier, Marschall B. Berkes, Asli Ozdas, Addison K. May, Richard S. Miller, John A. Morris. (2009) Morbid Obesity is Not a Risk Factor for Mortality in Critically Ill Trauma Patients. The Journal of Trauma: Injury, Infection, and Critical Care 66:1, 226-231
CrossRef531
James H. Finigan. (2009) The coagulation system and pulmonary endothelial function in acute lung injury. Microvascular Research 77:1, 35-38
CrossRef532
Jukka Takala. (2009) Better conduct of clinical trials: The control group in critical care trials. Critical Care Medicine 37:Supplement, S80-S90
CrossRef533
Y.-E. Claessens, S. André, C. Vinsonneau, J.-L. Pourriat. (2009) Shock settico. EMC - Anestesia-Rianimazione 14:1, 1-16
CrossRef534
Jeremy M. Kahn. (2009) Disseminating clinical trial results in critical care. Critical Care Medicine 37:Supplement, S147-S153
CrossRef535
Michael C. Reade, Derek C. Angus. (2009) The clinical research enterprise in critical care: What’s right, what’s wrong, and what’s ahead?. Critical Care Medicine 37:Supplement, S1-S9
CrossRef536
Djillali Annane. (2009) Improving clinical trials in the critically ill: Unique challenge—Sepsis. Critical Care Medicine 37:Supplement, S117-S128
CrossRef537
Melanie van der Heijden, Geerten P van Nieuw Amerongen, Sunita Chedamni, Victor WM van Hinsbergh, AB Johan Groeneveld. (2009) The angiopoietin-Tie2 system as a therapeutic target in sepsis and acute lung injury. Expert Opinion on Therapeutic Targets 13:1, 39-53
CrossRef538
Chris A. Gentry, Kristin Busse Gross, Bhanu Sud, Douglas A. Drevets. (2009) Adverse outcomes associated with the use of drotrecogin alfa (activated) in patients with severe sepsis and baseline bleeding precautions*. Critical Care Medicine 37:1, 19-25
CrossRef539
Sushma K. Cribbs, Greg S. Martin. (2009) Going global with sepsis: The need for national registries*. Critical Care Medicine 37:1, 338-340
CrossRef540
Madhumita Mahalanabis, Hussam Al-Muayad, M. Dominika Kulinski, Dave Altman, Catherine M. Klapperich. (2009) Cell lysis and DNA extraction of gram-positive and gram-negative bacteria from whole blood in a disposable microfluidic chip. Lab on a Chip 9:19, 2811
CrossRef541
Micha Tobias Maeder, Patrick Hunziker. (2009) Sepsis-associated myocardial dysfunction: from bedside to bench. Journal of Organ Dysfunction 5:2, 79-90
CrossRef542
Marcel Levi. (2009) Disseminated intravascular coagulation (DIC) in pregnancy and the peri-partum period. Thrombosis Research 123, S63-S64
CrossRef543
Steven M. Opal, Eleni Patrozou. (2009) Translational research in the development of novel sepsis therapeutics: Logical deductive reasoning or mission impossible?. Critical Care Medicine 37:Supplement, S10-S15
CrossRef544
Duane J. Funk, Joseph E. Parrillo, Anand Kumar. (2009) Sepsis and Septic Shock: A History. Critical Care Clinics 25:1, 83-101
CrossRef545
Todd W. Rice, Gordon R. Bernard. 2009. Acute Illnesses, Critical Care, Emergency and Surgical Patients. , 443-460.
CrossRef546
M BRIONES. 2009. Protein C Concentrates. , 747-749.
CrossRef547
C. Richard, X. Monnet, N. Anguel, J.-L. Teboul. 2009. Évaluation de l'intérêt d'un outil de monitoring. , 297-311.
CrossRef548
D. De Backer, J. Creteur, J.-L. Vincent. 2009. Choc septique. , 589-604.
CrossRef549
(2008) Compound K Rich Fractions Regulate NF-κ B -dependent Inflammatory Responses and Protect Mice from Endotoxin-induced Lethal Shock. Journal of Ginseng Research 32:4, 315-323
CrossRef550
M BEHNES, M BRUECKMANN, V LIEBE, C LIEBETRAU, S LANG, C PUTENSEN, M BORGGREFE, U HOFFMANN. (2008) Levels of oxidized low-density lipoproteins are increased in patients with severe sepsis
CrossRef551
Seth R. Bauer, Simon W. Lam, Stephen S. Cha, Lance J. Oyen. (2008) Effect of corticosteroids on arginine vasopressin–containing vasopressor therapy for septic shock: a case control study. Journal of Critical Care 23:4, 500-506
CrossRef552
Corey E. Ventetuolo, Mitchell M. Levy. (2008) Biomarkers: Diagnosis and Risk Assessment in Sepsis. Clinics in Chest Medicine 29:4, 591-603
CrossRef553
Patricia Moubarak, Susanne Zilker, Hilde Wolf, Benjamin Hofner, Thomas Kneib, Helmut Küchenhoff, Karl-Walter Jauch, Wolfgang H. Hartl. (2008) ACTIVITY-GUIDED ANTITHROMBIN III THERAPY IN SEVERE SURGICAL SEPSIS. Shock 30:6, 634-641
CrossRef554
Daniel P. Schauer, Anthony C. Leonard, Richard W. Hornung, Joseph A. Johnston, Mark H. Eckman. (2008) Patient-specific decision modeling to guide the use of drotrecogin α (activated) in patients with severe sepsis. Journal of Critical Care 23:4, 484-492
CrossRef555
R. Phillip Dellinger, Jean-Louis Vincent, John Marshall, Konrad Reinhart. (2008) Important issues in the design and reporting of clinical trials in severe sepsis and acute lung injury. Journal of Critical Care 23:4, 493-499
CrossRef556
Fabrice Vallée, Benoit Vallet, Olivier Mathe, Jacqueline Parraguette, Arnaud Mari, Stein Silva, Kamran Samii, Olivier Fourcade, Michèle Genestal. (2008) Central venous-to-arterial carbon dioxide difference: an additional target for goal-directed therapy in septic shock?. Intensive Care Medicine 34:12, 2218-2225
CrossRef557
Philip S. Barie, Lynn J. Hydo, Jian Shou, Soumitra R. Eachempati. (2008) Decreasing Magnitude of Multiple Organ Dysfunction Syndrome Despite Increasingly Severe Critical Surgical Illness: A 17-Year Longitudinal Study. The Journal of Trauma: Injury, Infection, and Critical Care 65:6, 1227-1235
CrossRef558
Mohan P Venkatesh, Joseph A Garcia-Prats. (2008) Management of neonatal sepsis by Gram-negative pathogens. Expert Review of Anti-infective Therapy 6:6, 929-938
CrossRef559
Marcel Levi. (2008) The Coagulant Response in Sepsis. Clinics in Chest Medicine 29:4, 627-642
CrossRef560
Gwenhaël Colin, Djillali Annane. (2008) Corticosteroids and Human Recombinant Activated Protein C for Septic Shock. Clinics in Chest Medicine 29:4, 705-712
CrossRef561
Lionel Riou França, Stéphanie Payet, Katell Le Lay, Robert Launois. (2008) Drotrecogin Alfa's Impact on Intensive Care Workload in Real Life Practice: A Propensity Score Approach. Value in Health 11:7, 1051-1060
CrossRef562
Muge Aydogdu, Gul Gursel. (2008) Predictive Factors for Septic Shock in Patients with Ventilator-Associated Pneumonia. Southern Medical Journal 101:12, 1222-1226
CrossRef563
Jianfeng Fu, Hongwei Cao, Ning Wang, Xinchun Zheng, Yongling Lu, Xin Liu, Dong Yang, Bin Li, Jiang Zheng, Hong Zhou. (2008) An anti-sepsis monomer, 2′,5,6′,7-tetrahydroxyflavanonol (THF), identified from Scutellaria baicalensis Georgi neutralizes lipopolysaccharide in vitro and in vivo. International Immunopharmacology 8:12, 1652-1657
CrossRef564
Emanuel P. Rivers, Victor Coba, Alvaro Visbal, Melissa Whitmill, David Amponsah. (2008) Management of Sepsis: Early Resuscitation. Clinics in Chest Medicine 29:4, 689-704
CrossRef565
Scott JR Chapman, Jonathan R Iredell. (2008) Gram-negative sepsis in the intensive care unit: avoiding therapeutic failure. Current Opinion in Infectious Diseases 21:6, 604-609
CrossRef566
Carlos Mas-Moruno, Laura Cascales, Luis J. Cruz, Puig Mora, Enrique Pérez-Payá, Fernando Albericio. (2008) Nanostructure Formation Enhances the Activity of LPS-Neutralizing Peptides. ChemMedChem 3:11, 1748-1755
CrossRef567
Tarek A. Dernaika, Gary T. Kinasewitz. (2008) Heparin in the treatment of severe sepsis: A new look at an old therapy*. Critical Care Medicine 36:11, 3098-3099
CrossRef568
Z TEKE, M SACAR, C YENISEY, A ATALAY, T BICAKCI, E ERDEM. (2008) Activated protein C prevents deleterious effects of remote reperfusion injury caused by intestinal ischemia on wound healing in the left colonic anastomoses: an experimental study in the murine model. The American Journal of Surgery 196:5, 774-787
CrossRef569
Jordi Mancebo, Massimo Antonelli. (2008) Editors’ comments on a new trial of activated protein C for persistent septic shock. Intensive Care Medicine 34:11, 1948-1949
CrossRef570
Jorge IF Salluh, Pedro Póvoa, Fernando A Bozza, Marcio Soares, Patrícia T Bozza. (2008) Current perspectives for the use of corticosteroids in sepsis: patient selection is the key. Therapy 5:6, 797-800
CrossRef571
Dominique M. Vandijck, Stijn I. Blot, Johan M. Decruyenaere. (2008) Update on the Management of Infection in Patients With Severe Sepsis. Dimensions of Critical Care Nursing 27:6, 244-248
CrossRef572
X. Wittebole, C. Collienne, D. Castanares-Zapatero, P.F. Laterre. (2008) Adjunctive therapies for severe sepsis. International Journal of Antimicrobial Agents 32, S34-S38
CrossRef573
Simon Finfer, V. Marco Ranieri, B. Taylor Thompson, Philip S. Barie, Jean-François Dhainaut, Ivor S. Douglas, Bengt Gårdlund, John C. Marshall, Andrew Rhodes. (2008) Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock. Intensive Care Medicine 34:11, 1935-1947
CrossRef574
Ryan Zarychanski, Steven Doucette, Dean Fergusson, Daniel Roberts, Donald S. Houston, Satendra Sharma, Harlena Gulati, Anand Kumar. (2008) Early intravenous unfractionated heparin and mortality in septic shock*. Critical Care Medicine 36:11, 2973-2979
CrossRef575
Jean-Louis Vincent. (2008) Clinical sepsis and septic shock—definition, diagnosis and management principles. Langenbeck's Archives of Surgery 393:6, 817-824
CrossRef576
Zafer Teke, Suzan Sacar, Cigdem Yenisey, A. Ozgur Atalay, Tulay Kavak, Ergun Erdem. (2008) Role of Activated Protein C on Wound Healing Process in Left Colonic Anastomoses in the Presence of Intra-abdominal Sepsis Induced by Cecal Ligation and Puncture: An Experimental Study in the Rat. World Journal of Surgery 32:11, 2434-2443
CrossRef577
Nobutaka Chiba, Ken Nagao, Takeo Mukoyama, Yoshiteru Tominaga, Katsuhisa Tanjoh. (2008) Decreased activated protein C levels as a clinical predictor in patients with ST-elevation myocardial infarction. American Heart Journal 156:5, 931-938
CrossRef578
Haichao Wang, Shu Zhu, Rongrong Zhou, Wei Li, Andrew E. Sama. (2008) Therapeutic potential of HMGB1-targeting agents in sepsis. Expert Reviews in Molecular Medicine 10,
CrossRef579
Thomas E. Stewart. (2008) Implementing the best evidence; do not forget to be a good clinician*. Critical Care Medicine 36:11, 3106-3107
CrossRef580
Evangelos J. Giamarellos-Bourboulis. (2008) Immunomodulatory therapies for sepsis: unexpected effects with macrolides. International Journal of Antimicrobial Agents 32, S39-S43
CrossRef581
Laura Rinaldi, Marco Marietta, Mariano Alejandro Mignini, Lara Donno, Stefano Busani, Mauro Codeluppi, Michele Masetti, Massimo Girardis. (2008) Use of activated protein c in liver transplantation patients with septic shock. Liver Transplantation 14:11, 1598-1602
CrossRef582
Alain Eid, Christian J. Wiedermann, Gary T. Kinasewitz. (2008) Early Administration of High-Dose Antithrombin in Severe Sepsis: Single Center Results from the KyberSept-Trial. Anesthesia & Analgesia 107:5, 1633-1638
CrossRef583
William R. Parrish, Margot Gallowitsch-Puerta, Christopher J. Czura, Kevin J. Tracey. (2008) Experimental Therapeutic Strategies for Severe Sepsis. Annals of the New York Academy of Sciences 1144:1, 210-236
CrossRef584
Daniel A. Sweeney, Robert L. Danner, Peter Q. Eichacker, Charles Natanson. (2008) Once is not enough: clinical trials in sepsis. Intensive Care Medicine 34:11, 1955-1960
CrossRef585
Peter Teschendorf, Markus Albertsmeier, Peter Vogel, Stephan A. Padosch, Fabian Spöhr, Michael Kirschfink, Markus Schwaninger, Bernd W. Böttiger, Erik Popp. (2008) Neurological outcome and inflammation after cardiac arrest—Effects of protein C in rats. Resuscitation 79:2, 316-324
CrossRef586
Peter M. Suter, Jukka Takala. (2008) Science, medicine and industry: are we getting out of the black hole in sepsis research?. Intensive Care Medicine 34:11, 1950-1954
CrossRef587
Edward G. Seferian, Bekele Afessa, Ognjen Gajic, Mark T. Keegan, Rolf D. Hubmayr. (2008) Comparison of community and referral intensive care unit patients in a tertiary medical center: Evidence for referral bias in the critically ill*. Critical Care Medicine 36:10, 2779-2786
CrossRef588
K. J. VAN DOORN, H. SPAPEN, C. GEERS, M. DILTOER, W. SHABANA. (2008) Sepsis-related acute kidney injury: a protective effect of drotrecogin alfa (activated) treatment?. Acta Anaesthesiologica Scandinavica 52:9, 1259-1264
CrossRef589
Mark D. Siegel. (2008) Sepsis (mis) management: The hazards of a faith-based approach*. Critical Care Medicine 36:10, 2929-2930
CrossRef590
Fathima Paruk. (2008) Infection in obstetric critical care. Best Practice & Research Clinical Obstetrics & Gynaecology 22:5, 865-883
CrossRef591
Kei-ichi Sugiyama, Masashi Muroi, Ken-ichi Tanamoto. (2008) A novel TLR4-binding peptide that inhibits LPS-induced activation of NF-κB and in vivo toxicity. European Journal of Pharmacology 594:1-3, 152-156
CrossRef592
Frank M. Brunkhorst, Christoph Engel, Max Ragaller, Tobias Welte, Rolf Rossaint, Herwig Gerlach, Konstantin Mayer, Stefan John, Frank Stuber, Norbert Weiler, Michael Oppert, Onnen Moerer, Holger Bogatsch, Konrad Reinhart, Markus Loeffler, Christiane Hartog. (2008) Practice and perception—A nationwide survey of therapy habits in sepsis*. Critical Care Medicine 36:10, 2719-2725
CrossRef593
Mitchell P Fink. (2008) Animal models of sepsis and its complications. Kidney International 74:8, 991-993
CrossRef594
Damon C. Scales, Jeremy M. Kahn. (2008) Tracheostomy timing, enrollment and power in ICU clinical trials. Intensive Care Medicine 34:10, 1743-1745
CrossRef595
A TABUCHI, W KUEBLER. (2008) Endothelium–platelet interactions in inflammatory lung disease. Vascular Pharmacology 49:4-6, 141-150
CrossRef596
Zafer Teke, Mustafa Sacar, Cigdem Yenisey, A. Ozgur Atalay, Tulay Kavak, Ergun Erdem. (2008) Activated Protein C Attenuates Intestinal Mucosal Injury After Mesenteric Ischemia/Reperfusion. Journal of Surgical Research 149:2, 219-230
CrossRef597
Flavia R. Machado, Flávio G.R. Freitas. (2008) CONTROVERSIES OF SURVIVING SEPSIS CAMPAIGN BUNDLES. Shock 30:Suppl 1, 34-40
CrossRef598
N MANIATIS, A KOTANIDOU, J CATRAVAS, S ORFANOS. (2008) Endothelial pathomechanisms in acute lung injury. Vascular Pharmacology 49:4-6, 119-133
CrossRef599
Lawrence L.K. Leung, Timothy Myles, Toshihiko Nishimura, Jason J. Song, William H. Robinson. (2008) Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI). Molecular Immunology 45:16, 4080-4083
CrossRef600
Andre C. Kalil, Junfeng Sun. (2008) How many patients with severe sepsis are needed to confirm the efficacy of drotrecogin alfa activated? A Bayesian design. Intensive Care Medicine 34:10, 1804-1811
CrossRef601
Luciano Cesar Pontes Azevedo, Marcelo Park, Guilherme Paula Pinto Schettino. (2008) NOVEL POTENTIAL THERAPIES FOR SEPTIC SHOCK. Shock 30:Suppl 1, 60-66
CrossRef602
Daniel Rittirsch, Michael A. Flierl, Peter A. Ward. (2008) Harmful molecular mechanisms in sepsis. Nature Reviews Immunology 8:10, 776-787
CrossRef603
Laura Claire Price, Andrew Slack, Catherine Nelson-Piercy. (2008) Aims of obstetric critical care management. Best Practice & Research Clinical Obstetrics & Gynaecology 22:5, 775-799
CrossRef604
Alan E. Jones, Michael D. Brown, Stephen Trzeciak, Nathan I. Shapiro, John S. Garrett, Alan C. Heffner, Jeffrey A. Kline. (2008) The effect of a quantitative resuscitation strategy on mortality in patients with sepsis: A meta-analysis*. Critical Care Medicine 36:10, 2734-2739
CrossRef605
Donn Spight, Bruce Trapnell, Bin Zhao, Pierre Berclaz, Thomas P. Shanley. (2008) GRANULOCYTE-MACROPHAGE-COLONY-STIMULATING FACTOR-DEPENDENT PERITONEAL MACROPHAGE RESPONSES DETERMINE SURVIVAL IN EXPERIMENTALLY INDUCED PERITONITIS AND SEPSIS IN MICE. Shock 30:4, 434-442
CrossRef606
Marin H. Kollef, Lena M. Napolitano, Joseph S. Solomkin, Richard G. Wunderink, In‐Gyu Bae, Vance G. Fowler, Robert A. Balk, Dennis L. Stevens, James J. Rahal, Andrew F. Shorr, Peter K. Linden, Scott T. Micek. (2008) Health Care–Associated Infection (HAI): A Critical Appraisal of the Emerging Threat—Proceedings of the HAI Summit. Clinical Infectious Diseases 47:s2, S55-S99
CrossRef607
David J. Kramer, Juan M. Canabal, Lisa C. Arasi. (2008) Application of intensive care medicine principles in the management of the acute liver failure patient. Liver Transplantation 14:S2, S85-S89
CrossRef608
Jorge I.F. Salluh, Patrícia T. Bozza, Fernando A. Bozza. (2008) SURVIVING SEPSIS CAMPAIGN. Shock 30:Suppl 1, 70-72
CrossRef609
C. U. NILSSON, P. D. HELLKVIST, M. ENGSTRÖM. (2008) Effects of recombinant human activated protein C on the coagulation system: a study with rotational thromboelastometry. Acta Anaesthesiologica Scandinavica 52:9, 1246-1249
CrossRef610
Manu L. N. G. Malbrain, Inneke laet. (2008) AIDS is coming to your ICU: be prepared for acute bowel injury and acute intestinal distress syndrome…. Intensive Care Medicine 34:9, 1565-1569
CrossRef611
R MORENO, P METNITZ, B METNITZ, P BAUER, S AFONSODECARVALHO, A HOECHTL. (2008) Modeling in-hospital patient survival during the first 28 days after intensive care unit admission
CrossRef612
Fawaz Mzayek, Joni Ylöstalo, Donald J. Krogstad. (2008) Apoptosis of endothelial cells in bacterial sepsis and severe Plasmodium falciparum malaria: Do we know enough to consider clinical trials?*. Critical Care Medicine 36:9, 2690-2692
CrossRef613
Robert F. Tamburro, Neal J. Thomas, Steven Pon, Brian R. Jacobs, Joseph V. DiCarlo, Barry P. Markovitz, Larry S. Jefferson, Douglas F. Willson. (2008) Post hoc analysis of calfactant use in immunocompromised children with acute lung injury: Impact and feasibility of further clinical trials*. Pediatric Critical Care Medicine 9:5, 459-464
CrossRef614
(2008) 21st ESICM Annual Congress. Intensive Care Medicine 34:S1, 93-180
CrossRef615
Marcel Levi. (2008) Activated protein C in sepsis: a critical review. Current Opinion in Hematology 15:5, 481-486
CrossRef616
Jean-Louis Vincent. (2008) Clinical trials report. Current Infectious Disease Reports 10:5, 351-353
CrossRef617
Charles T. Esmon. (2008) Reprint of Crosstalk between inflammation and thrombosis. Maturitas 61:1-2, 122-131
CrossRef618
Hartmut Weiler, Wolfram Ruf. (2008) Activated protein C in sepsis: the promise of nonanticoagulant activated protein C. Current Opinion in Hematology 15:5, 487-493
CrossRef619
Mark L. Kahn. (2008) Counteracting clotting in sepsis. Nature Medicine 14:9, 918-919
CrossRef620
Dieter Mesotten, Ilse Vanhorebeek, Greet Van den Berghe. (2008) The altered adrenal axis and treatment with glucocorticoids during critical illness. Nature Clinical Practice Endocrinology & Metabolism 4:9, 496-505
CrossRef621
(2008) 21st ESICM Annual Congress. Intensive Care Medicine 34:S1, 5-92
CrossRef622
Celeste Latto. (2008) An Overview of Sepsis. Dimensions of Critical Care Nursing 27:5, 195-200
CrossRef623
Shabir H. Qureshi, Likui Yang, Chandrashekhara Manithody, Jong-Sup Bae, Alireza R. Rezaie. (2008) Functional properties and active-site topographies of factor X Gla- and prothrombin Gla-domain chimeras of activated protein C. Biochimica et Biophysica Acta (BBA) - General Subjects 1780:9, 1080-1086
CrossRef624
Joel M. Dulhunty, Jeffrey Lipman, Simon Finfer, . (2008) Does severe non-infectious SIRS differ from severe sepsis?. Intensive Care Medicine 34:9, 1654-1661
CrossRef625
Philip S. Barie. (2008) Current role of activated protein C therapy for severe sepsis and septic shock. Current Infectious Disease Reports 10:5, 368-376
CrossRef626
Michael Ellis. (2008) Febrile Neutropenia. Annals of the New York Academy of Sciences 1138:1, 329-350
CrossRef627
Vincenzo Cantaluppi, Barbara Assenzio, Daniela Pasero, Giuseppe Mauriello Romanazzi, Alfonso Pacitti, Giacomo Lanfranco, Valeria Puntorieri, Erica L. Martin, Luciana Mascia, Gianpaola Monti, Giampaolo Casella, Giuseppe Paolo Segoloni, Giovanni Camussi, V. Marco Ranieri. (2008) Polymyxin-B hemoperfusion inactivates circulating proapoptotic factors. Intensive Care Medicine 34:9, 1638-1645
CrossRef628
Armand R.J. Girbes, Albert Beishuizen, Rob J.M. Strack van Schijndel. (2008) Pharmacological treatment of sepsis. Fundamental & Clinical Pharmacology 22:4, 355-361
CrossRef629
Michael H. Catenacci, Kaira King. (2008) Severe Sepsis and Septic Shock: Improving Outcomes in the Emergency Department. Emergency Medicine Clinics of North America 26:3, 603-623
CrossRef630
Didier Payen, Anne-Claire Lukaszewicz, Ioulia Belikova, Valérie Faivre, Catherine Gelin, Stefan Russwurm, Jean-Marie Launay, Nicolas Sevenet. (2008) Gene profiling in human blood leucocytes during recovery from septic shock. Intensive Care Medicine 34:8, 1371-1376
CrossRef631
Chris Jackson, Kaley Whitmont, Sara Tritton, Lyn March, Philip Sambrook, Meilang Xue. (2008) New therapeutic applications for the anticoagulant, activated protein C. Expert Opinion on Biological Therapy 8:8, 1109-1122
CrossRef632
Tommaso Mauri, Andrea Coppadoro, Giacomo Bellani, Michela Bombino, Nicolo’ Patroniti, Giuseppe Peri, Alberto Mantovani, Antonio Pesenti. (2008) Pentraxin 3 in acute respiratory distress syndrome: An early marker of severity*. Critical Care Medicine 36:8, 2302-2308
CrossRef633
Enrico Di Cera. (2008) Thrombin. Molecular Aspects of Medicine 29:4, 203-254
CrossRef634
Diana Wouters, Ineke Wagenaar-Bos, Marieke van Ham, Sacha Zeerleder. (2008) C1 inhibitor: just a serine protease inhibitor? New and old considerations on therapeutic applications of C1 inhibitor. Expert Opinion on Biological Therapy 8:8, 1225-1240
CrossRef635
Lena M. Napolitano, Timothy C. Fabian, Kathleen M. Kelly, Jeffrey A. Bailey, Ernest F. Block, Wayne Langholff, Christopher Enny, Howard L. Corwin. (2008) Improved Survival of Critically Ill Trauma Patients Treated With Recombinant Human Erythropoietin. The Journal of Trauma: Injury, Infection, and Critical Care 65:2, 285-299
CrossRef636
Arash Afshari, Jørn Wetterslev, Jesper Brok, Ann Merete Møller, Arash Afshari. 2008. Antithrombin III for critically ill patients. .
CrossRef637
R. Kumar, V. Gupta. (2008) Disseminated Intravascular Coagulation: Current Concepts. The Indian Journal of Pediatrics 75:7, 733-738
CrossRef638
George C. Velmahos, Hasan B. Alam. (2008) Advances in Surgical Critical Care. Current Problems in Surgery 45:7, 453-516
CrossRef639
Gabby Elbaz, Ohad Etzion, Jorge Delgado, Avi Porath, Daniel Talmor, Victor Novack. (2008) Hypothermia in a desert climate: severity score and mortality prediction. The American Journal of Emergency Medicine 26:6, 683-688
CrossRef640
Shunji TAJIMA, Manabu SODA, Masashi BANDO, Munehiro ENOMOTO, Hideaki YAMASAWA, Shoji OHNO, Toshinori TAKADA, Eiichi SUZUKI, Fumitake GEJYO, Yukihiko SUGIYAMA. (2008) Preventive effects of edaravone, a free radical scavenger, on lipopolysaccharide-induced lung injury in mice. Respirology 13:5, 646-653
CrossRef641
Emanuel P. Rivers, Tom Ahrens. (2008) Improving Outcomes for Severe Sepsis and Septic Shock: Tools for Early Identification of At-Risk Patients and Treatment Protocol Implementation. Critical Care Clinics 24:3, 1-47
CrossRef642
Alyssa D. Chapital, Mihae Yu, Hao Chih Ho, John Wang, Wega Koss, Danny M. Takanishi. (2008) Using Transcutaneous Oxygen Pressure Measurements as Selection Criteria for Activated Protein C Use. The Journal of Trauma: Injury, Infection, and Critical Care 65:1, 30-33
CrossRef643
H. Bryant Nguyen, Jim E. Banta, Thomas W. Cho, Chad Van Ginkel, Kristy Burroughs, William A. Wittlake, Stephen W. Corbett. (2008) MORTALITY PREDICTIONS USING CURRENT PHYSIOLOGIC SCORING SYSTEMS IN PATIENTS MEETING CRITERIA FOR EARLY GOAL-DIRECTED THERAPY AND THE SEVERE SEPSIS RESUSCITATION BUNDLE. Shock 30:1, 23-28
CrossRef644
Melissa E. Brunsvold, Saman Arbabi, Mary Dimo, Wendy Wahl. (2008) Drotrecogin Alfa in Patients With Burns and Soft Tissue Injury. Journal of Burn Care & Research 29:4, 676-678
CrossRef645
Fu-Tsai Chung, Shu-Min Lin, Shinn-Yn Lin, Horng-Chyuan Lin. (2008) Impact of extravascular lung water index on outcomes of severe sepsis patients in a medical intensive care unit. Respiratory Medicine 102:7, 956-961
CrossRef646
Mark Lust, Marisa Vulcano, Silvio Danese. (2008) The protein C pathway in inflammatory bowel disease: the missing link between inflammation and coagulation. Trends in Molecular Medicine 14:6, 237-244
CrossRef647
J.-S. BAE, L. YANG, A. R. REZAIE. (2008) Lipid raft localization regulates the cleavage specificity of protease activated receptor 1 in endothelial cells. Journal of Thrombosis and Haemostasis 6:6, 954-961
CrossRef648
Z TEKE, M SACAR, C YENISEY, A ATALAY, T BICAKCI, E ERDEM. (2008) Activated protein C attenuates intestinal reperfusion–induced acute lung injury: an experimental study in a rat model. The American Journal of Surgery 195:6, 861-873
CrossRef649
Krisztina Szabó. (2008) Az uroszepszis és kezelése. Orvosi Hetilap 149:23, 1095-1099
CrossRef650
Chung-Ming Chen, Hsiu-Chu Chou, Leng-Fang Wang, Yaw-Dong Lang. (2008) Captopril decreases plasminogen activator inhibitor-1 in rats with ventilator-induced lung injury. Critical Care Medicine 36:6, 1880-1885
CrossRef651
Herbert Spapen. (2008) Liver Perfusion in Sepsis, Septic Shock, and Multiorgan Failure. The Anatomical Record: Advances in Integrative Anatomy and Evolutionary Biology 291:6, 714-720
CrossRef652
A. Tuttolomondo, A. Pinto, D. Raimondo, P. Fernandez, G. Licata. (2008) Plasma derived protein C in severe sepsis: report of two cases. Internal and Emergency Medicine 3:2, 179-182
CrossRef653
Sushma K Cribbs, Greg S Martin, Mauricio Rojas. (2008) Monitoring of endothelial dysfunction in critically ill patients: the role of endothelial progenitor cells. Current Opinion in Critical Care 14:3, 354-360
CrossRef654
Michael Adamzik, Ulrich H. Frey, Kathrin Riemann, Stephan Sixt, Nils Lehmann, Winfried Siffert, Jürgen Peters. (2008) Factor V Leiden mutation is associated with improved 30-day survival in patients with acute respiratory distress syndrome. Critical Care Medicine 36:6, 1776-1779
CrossRef655
Sari Karlsson, Ville Pettilä, Jyrki Tenhunen, Raili Laru-Sompa, Marja Hynninen, Esko Ruokonen. (2008) HMGB1 as a predictor of organ dysfunction and outcome in patients with severe sepsis. Intensive Care Medicine 34:6, 1046-1053
CrossRef656
L. R. Gorbacheva, T. P. Storozhevykh, V. G. Pinelis, O. N. Davydova, S. Ishiwata, S. M. Strukova. (2008) Activated protein C via PAR1 receptor regulates survival of neurons under conditions of glutamate excitotoxicity. Biochemistry (Moscow) 73:6, 717-724
CrossRef657
Manu L. N. G. Malbrain, Inneke De Laet. (2008) Epidemiology on intra-abdominal hypertension: An urgent call for multicenter trials*. Critical Care Medicine 36:6, 1972-1974
CrossRef658
Brant Ullery, Fredric M. Pieracci, Lynn J. Hydo, Soumitra R. Eachempati, Philip S. Barie. (2008) Treatment of Severe Sepsis Secondary to Mycobacterium Avium-Intracellulare with Recombinant Human Activated Protein C. Surgical Infections 9:3, 389-394
CrossRef659
S FUJISHIMA, H MORISAKI, A ISHIZAKA, Y KOTAKE, M MIYAKI, K YOH, K SEKINE, J SASAKI, S TASAKA, N HASEGAWA. (2008) Neutrophil elastase and systemic inflammatory response syndrome in the initiation and development of acute lung injury among critically ill patients. Biomedicine & Pharmacotherapy 62:5, 333-338
CrossRef660
Andreas H. Kramer, Thomas P. Bleck. (2008) Neurocritical care of patients with central nervous system infections. Current Treatment Options in Neurology 10:3, 201-211
CrossRef661
Mitchell P. Fink. (2008) Neuropeptide Modulators of High Mobility Group Box 1 Secretion as Potential Therapeutic Agents for Severe Sepsis. The American Journal of Pathology 172:5, 1171-1173
CrossRef662
J CATERINO. (2008) Evaluation and Management of Geriatric Infections in the Emergency Department. Emergency Medicine Clinics of North America 26:2, 319-343
CrossRef663
Naeem A. Ali. (2008) Moving toward preventive therapy in acute lung injury*. Critical Care Medicine 36:5, 1666-1667
CrossRef664
Samir Benchekroune, Peter C. J. Karpati, Christine Berton, Cédric Nathan, Joaquim Mateo, Mansour Chaara, Florence Riché, Marie-Josèphe Laisné, Didier Payen, Alexandre Mebazaa. (2008) Diastolic Arterial Blood Pressure: A Reliable Early Predictor of Survival in Human Septic Shock. The Journal of Trauma: Injury, Infection, and Critical Care 64:5, 1188-1195
CrossRef665
Simon W Lam, Seth R Bauer, Stephen S Cha, Lance J Oyen. (2008) Lack of an Effect of Body Mass on the Hemodynamic Response to Arginine Vasopressin During Septic Shock. Pharmacotherapy 28:5, 591-599
CrossRef666
Derek S Wheeler, Hector R Wong. (2008) Genetic approach to pediatric septic shock. Personalized Medicine 5:3, 249-263
CrossRef667
F.F. van Doormaal, H.R. Büller, S. Middeldorp. (2008) Development in anticoagulant therapy. Critical Reviews in Oncology/Hematology 66:2, 145-154
CrossRef668
K. Kofoed, J. Eugen-Olsen, J. Petersen, K. Larsen, O. Andersen. (2008) Predicting mortality in patients with systemic inflammatory response syndrome: an evaluation of two prognostic models, two soluble receptors, and a macrophage migration inhibitory factor. European Journal of Clinical Microbiology & Infectious Diseases 27:5, 375-383
CrossRef669
Christian J. Wiedermann, Moritoki Egi. (2008) Scoring für disseminierte intravaskuläre Gerinnung (DIC) in der Intensivmedizin. Intensivmedizin und Notfallmedizin 45:4, 205-211
CrossRef670
Laurent Muller, Samir Jaber, Alice Raillard, Jean Yves Lefrant. (2008) Use of recombinant human activated protein C in patients with severe sepsis: a French retrospective multicentre study. Intensive Care Medicine 34:5, 977-979
CrossRef671
Gilbert, Richard E., Marsden, Philip A., . (2008) Activated Protein C and Diabetic Nephropathy. New England Journal of Medicine 358:15, 1628-1630
Full Text672
Li Wan, Sean M. Bagshaw, Christoph Langenberg, Takao Saotome, Clive May, Rinaldo Bellomo. (2008) Pathophysiology of septic acute kidney injury: What do we really know?. Critical Care Medicine 36:Suppl, S198-S203
CrossRef673
Takero Mazaki, Kiyoko Ebisawa. (2008) Enteral versus Parenteral Nutrition after Gastrointestinal Surgery: A Systematic Review and Meta-Analysis of Randomized Controlled Trials in the English Literature. Journal of Gastrointestinal Surgery 12:4, 739-755
CrossRef674
Emanuel P Rivers, Victor Coba, Melissa Whitmill. (2008) Early goal-directed therapy in severe sepsis and septic shock: a contemporary review of the literature. Current Opinion in Anaesthesiology 21:2, 128-140
CrossRef675
Sheik Humarr Khan, Augustine Goba, May Chu, Cathy Roth, Tim Healing, Arthur Marx, Joseph Fair, Mary C. Guttieri, Philip Ferro, Tiffany Imes, Corina Monagin, Robert F. Garry, Daniel G. Bausch. (2008) New opportunities for field research on the pathogenesis and treatment of Lassa fever. Antiviral Research 78:1, 103-115
CrossRef676
Jean-François Dhainaut. (2008) International integrated database for the evaluation of severe sepsis (INDEPTH): clinical evaluation committee report on the safety of drotrecogin alfa (activated) therapy*. Current Medical Research and Opinion 24:4, 1187-1197
CrossRef677
R. G. Masterton, A. Galloway, G. French, M. Street, J. Armstrong, E. Brown, J. Cleverley, P. Dilworth, C. Fry, A. D. Gascoigne, A. Knox, D. Nathwani, R. Spencer, M. Wilcox. (2008) Guidelines for the management of hospital-acquired pneumonia in the UK: Report of the Working Party on Hospital-Acquired Pneumonia of the British Society for Antimicrobial Chemotherapy. Journal of Antimicrobial Chemotherapy 62:1, 5-34
CrossRef678
H. Fischer, J. Gille, M. Fuchs, K. Rockmann, H. Ostermann, A. Sablotzki. (2008) Der Einsatz von Drotrecogin alfa (activated) bei 5 schwerbrandverletzten Patienten im septischen Schock. Intensivmedizin und Notfallmedizin 45:3, 154-160
CrossRef679
F.M. Brunkhorst, K. Reinhart. (2008) Sepsistherapie. Der Chirurg 79:4, 306-314
CrossRef680
Paolo Malacarne, Martin Langer, Ennio Nascimben, Maria Luisa Moro, Daniela Giudici, Laura Lampati, Guido Bertolini. (2008) Building a continuous multicenter infection surveillance system in the intensive care unit: Findings from the initial data set of 9,493 patients from 71 Italian intensive care units. Critical Care Medicine 36:4, 1105-1113
CrossRef681
Nathan I. Shapiro, Kiichiro Yano, Hitomi Okada, Christopher Fischer, Michael Howell, Katherine C. Spokes, Long Ngo, Derek C. Angus, William C. Aird. (2008) A PROSPECTIVE, OBSERVATIONAL STUDY OF SOLUBLE FLT-1 AND VASCULAR ENDOTHELIAL GROWTH FACTOR IN SEPSIS. Shock 29:4, 452-457
CrossRef682
Juan M Canabal, David J Kramer. (2008) Management of sepsis in patients with liver failure. Current Opinion in Critical Care 14:2, 189-197
CrossRef683
Gustavo A. Ospina-Tascón, Gustavo Luiz Büchele, Jean-Louis Vincent. (2008) Multicenter, randomized, controlled trials evaluating mortality in intensive care: Doomed to fail?. Critical Care Medicine 36:4, 1311-1322
CrossRef684
T. Nakashima, A. Yokoyama, H. Ohnishi, H. Hamada, N. Ishikawa, Y. Haruta, N. Hattori, K. Tanigawa, N. Kohno. (2008) Circulating KL-6/MUC1 as an independent predictor for disseminated intravascular coagulation in acute respiratory distress syndrome. Journal of Internal Medicine 263:4, 432-439
CrossRef685
Daniel G. Bausch, A.G. Sprecher, Benjamin Jeffs, Paul Boumandouki. (2008) Treatment of Marburg and Ebola hemorrhagic fevers: A strategy for testing new drugs and vaccines under outbreak conditions. Antiviral Research 78:1, 150-161
CrossRef686
Daniel Talmor, Dan Greenberg, Michael D. Howell, Alan Lisbon, Victor Novack, Nathan Shapiro. (2008) The costs and cost-effectiveness of an integrated sepsis treatment protocol. Critical Care Medicine 36:4, 1168-1174
CrossRef687
M. DUBNIKS, P.-O. GRÄNDE. (2008) The effects of activated protein C and prostacyclin on arterial oxygenation and protein leakage in the lung and the gut under endotoxaemia in the rat. Acta Anaesthesiologica Scandinavica 52:3, 381-387
CrossRef688
S. Ridley, A. Lwin, D. Wyncoll, S. Lippett, D. Watson, K. Gunning, D. Higgins. (2008) Drotrecogin alfa (activated). European Journal of Anaesthesiology 25:3, 211-216
CrossRef689
A Martí-Carvajal, G Salanti, AF Cardona. (2008) Cochrane review: Human recombinant activated protein C for severe sepsis. Evidence-Based Child Health: A Cochrane Review Journal 3:1, 86-138
CrossRef690
Tina Dutt, Cheng Hock Toh. (2008) The Yin–Yang of thrombin and activated protein C. British Journal of Haematology 140:5, 505-515
CrossRef691
Yan Li, Xizhong Cui, Xuemei Li, Steven B. Solomon, Robert L. Danner, Steven M. Banks, Yvonne Fitz, Djillali Annane, Charles Natanson, Peter Q. Eichacker. (2008) Risk of death does not alter the efficacy of hydrocortisone therapy in a mouse E. coli pneumonia model. Intensive Care Medicine 34:3, 568-577
CrossRef692
Nelson Nicolasora, Daniel R. Kaul. (2008) Infectious Disease Emergencies. Medical Clinics of North America 92:2, 427-441
CrossRef693
David A. Talan, Gregory J. Moran, Fredrick M. Abrahamian. (2008) Severe Sepsis and Septic Shock in the Emergency Department. Infectious Disease Clinics of North America 22:1, 1-31
CrossRef694
Derek J. Linderman, William J. Janssen. (2008) Critical Care Medicine for the Hospitalist. Medical Clinics of North America 92:2, 467-479
CrossRef695
Shu-Min Lin, Yu-Min Wang, Horng-Chyuan Lin, Kang-Yun Lee, Chien-Da Huang, Chien-Ying Liu, Chun-Hua Wang, Han-Pin Kuo. (2008) Serum thrombomodulin level relates to the clinical course of disseminated intravascular coagulation, multiorgan dysfunction syndrome, and mortality in patients with sepsis*. Critical Care Medicine 36:3, 683-689
CrossRef696
Jean Carlet, Jonathan Cohen, Thierry Calandra, Steven M. Opal, Henry Masur. (2008) Sepsis: Time to reconsider the concept. Critical Care Medicine 36:3, 964-966
CrossRef697
Miklós Lipcsey, Ewa Söderberg, Samar Basu, Anders Larsson, Jan Sjölin, Mikael Åström, Mats B. Eriksson. (2008) F2-isoprostane, inflammation, cardiac function and oxygenation in the endotoxaemic pig. Prostaglandins, Leukotrienes and Essential Fatty Acids 78:3, 209-217
CrossRef698
Frédéric Pène, Stéphanie Percheron, Virginie Lemiale, Vivian Viallon, Yann-Erick Claessens, Sophie Marqué, Julien Charpentier, Derek C. Angus, Alain Cariou, Jean-Daniel Chiche, Jean-Paul Mira. (2008) Temporal changes in management and outcome of septic shock in patients with malignancies in the intensive care unit*. Critical Care Medicine 36:3, 690-696
CrossRef699
Christian Lehmann, Ricardo Scheibe, Michael Schade, Konrad Meissner, Matthias Gründling, Taras Usichenko, Michael Wendt, Orlando Hung, Sara Whynot, Michael Murphy, Dragan Pavlovic. (2008) Effects of activated protein C on the mesenteric microcirculation and cytokine release during experimental endotoxemia. Canadian Journal of Anesthesia/Journal canadien d'anesthésie 55:3, 155-162
CrossRef700
R. A. Schuepbach, C. Feistritzer, L. F. Brass, M. Riewald. (2008) Activated protein C-cleaved protease activated receptor-1 is retained on the endothelial cell surface even in the presence of thrombin. Blood 111:5, 2667-2673
CrossRef701
H DUPONT. (2008) Prospective evaluation of virulence factors of enterococci isolated from patients with peritonitis: impact on outcome. Diagnostic Microbiology and Infectious Disease 60:3, 247-253
CrossRef702
Ari R. Joffe, Jonathan P. Duff. (2008) Commentary on ‘Human recombinant activated protein C for severe sepsis’. Evidence-Based Child Health: A Cochrane Review Journal 3:1, 141-143
CrossRef703
May H. Han, Sun-Il Hwang, Dolly B. Roy, Deborah H. Lundgren, Jordan V. Price, Shalina S. Ousman, Guy Haskin Fernald, Bruce Gerlitz, William H. Robinson, Sergio E. Baranzini, Brian W. Grinnell, Cedric S. Raine, Raymond A. Sobel, David K. Han, Lawrence Steinman. (2008) Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 451:7182, 1076-1081
CrossRef704
Hongmei Gao, Susannah K. Leaver, Anne Burke-Gaffney, Simon J. Finney. (2008) Severe sepsis and Toll-like receptors. Seminars in Immunopathology 30:1, 29-40
CrossRef705
M. Shimaoka, E. J. Park. (2008) Advances in understanding sepsis. European Journal of Anaesthesiology 25:Supplement 42, 146-153
CrossRef706
Jeffrey D. Sankoff, Munish Goyal, David F. Gaieski, Kenneth Deitch, Christopher B. Davis, Allison L. Sabel, Jason S. Haukoos. (2008) Validation of the Mortality in Emergency Department Sepsis (MEDS) score in patients with the systemic inflammatory response syndrome (SIRS)*. Critical Care Medicine 36:2, 421-426
CrossRef707
Dianne P. Stephens, Jane H. Thomas, Alisa Higgins, Michael Bailey, Nicholas M. Anstey, Bart J. Currie, Allen C. Cheng. (2008) Randomized, double-blind, placebo-controlled trial of granulocyte colony-stimulating factor in patients with septic shock. Critical Care Medicine 36:2, 448-454
CrossRef708
Steven J. Schwulst, Jared T. Muenzer, Katherine C. Chang, Tejal S. Brahmbhatt, Craig M. Coopersmith, Richard S. Hotchkiss. (2008) Lymphocyte Phenotyping to Distinguish Septic from Nonseptic Critical Illness. Journal of the American College of Surgeons 206:2, 335-342
CrossRef709
Ali A. El Solh, Morohunfolu E. Akinnusi, Leith N. Alsawalha, Lilibeth A. Pineda. (2008) Outcome of Septic Shock in Older Adults After Implementation of the Sepsis âBundleâ. Journal of the American Geriatrics Society 56:2, 272-278
CrossRef710
G. Marx, K. Reinhart. (2008) Urosepsis: from the intensive care viewpoint. International Journal of Antimicrobial Agents 31, 79-84
CrossRef711
H. Knotzer, W. Hasibeder. (2008) Mikrozirkulation beim Intensivpatienten. Der Anaesthesist 57:2, 151-164
CrossRef712
Wolf Ramackers, Lars Friedrich, Andreas Tiede, Sabine Bergmann, Wolfgang Schuettler, Tobias Schuerholz, Michael Mengel, Lili Goudeva, Arnold Ganser, Jürgen Klempnauer, Siegfried Piepenbrock, Michael Winkler. (2008) Effects of pharmacological intervention on coagulopathy and organ function in xenoperfused kidneys. Xenotransplantation 15:1, 46-55
CrossRef713
B. S. Harhangi, E. J. O. Kompanje, F. W. G. Leebeek, A. I. R. Maas. (2008) Coagulation disorders after traumatic brain injury. Acta Neurochirurgica 150:2, 165-175
CrossRef714
Arturo J Martí-Carvajal, Georgia Salanti, Andrés F. Cardona-Zorrilla, Arturo J Martí-Carvajal. 2008. Human recombinant activated protein C for severe sepsis. .
CrossRef715
2008. Sepsis. , 97-118.
CrossRef716
M. Tjwa, L. Bellido-Martin, Y. Lin, E. Lutgens, S. Plaisance, F. Bono, N. Delesque-Touchard, C. Herve, R. Moura, A. D. Billiau, C. Aparicio, M. Levi, M. Daemen, M. Dewerchin, F. Lupu, J. Arnout, J.-M. Herbert, M. Waer, P. Garcia de Frutos, B. Dahlback, P. Carmeliet, M. F. Hoylaerts, L. Moons. (2008) Gas6 promotes inflammation by enhancing interactions between endothelial cells, platelets, and leukocytes. Blood 111:8, 4096-4105
CrossRef717
Su Wol Chung, Xiaoli Liu, Alvaro A. Macias, Rebecca M. Baron, Mark A. Perrella. (2008) Heme oxygenase-1–derived carbon monoxide enhances the host defense response to microbial sepsis in mice. Journal of Clinical Investigation 118:1, 239-247
CrossRef718
Benjamin Leader, Quentin J. Baca, David E. Golan. (2008) Protein therapeutics: a summary and pharmacological classification. Nature Reviews Drug Discovery 7:1, 21-39
CrossRef719
Félix Gutiérrez, Mar Masiá. (2008) Improving Outcomes of Elderly Patients with Community-Acquired Pneumonia. Drugs & Aging 25:7, 585-610
CrossRef720
Goda Choi, Jorrit-Jan H. Hofstra, Joris J. T. H. Roelofs, Anita W. Rijneveld, Paul Bresser, Jaring S. van der Zee, Sandrine Florquin, Tom van der Poll, Marcel Levi, Marcus J. Schultz. (2008) Antithrombin inhibits bronchoalveolar activation of coagulation and limits lung injury during Streptococcus pneumoniae pneumonia in rats*. Critical Care Medicine 36:1, 204-210
CrossRef721
Richard J. Beale, Tony Sherry, Katie Lei, Laura Campbell-Stephen, Julie McCook, John Smith, Werner Venetz, Birgit Alteheld, Peter Stehle, Heinz Schneider. (2008) Early enteral supplementation with key pharmaconutrients improves Sequential Organ Failure Assessment score in critically ill patients with sepsis: Outcome of a randomized, controlled, double-blind trial*. Critical Care Medicine 36:1, 131-144
CrossRef722
Andrew A. House, Claudio Ronco. (2008) Extracorporeal Blood Purification in Sepsis and Sepsis-Related Acute Kidney Injury. Blood Purification 26:1, 30-35
CrossRef723
Guido Bertolini. (2008) From national to global outcome research in the intensive care unit: A challenge to win*. Critical Care Medicine 36:1, 336-337
CrossRef724
Patricia Murphy. (2008) Complex Coagulation Abnormalities. ASA Refresher Courses in Anesthesiology 36:1, 109-117
CrossRef725
Andrey A. Komissarov, Peter A. Andreasen, Paul J. Declerck, Yuichi Kamikubo, Aiwu Zhou, András Gruber. (2008) Redirection of the reaction between activated protein C and a serpin to the substrate pathway. Thrombosis Research 122:3, 397-404
CrossRef726
Heike Weighardt, Bernhard Holzmann. (2008) Role of Toll-like receptor responses for sepsis pathogenesis. Immunobiology 212:9-10, 715-722
CrossRef727
Benno U. Ihle. (2008) Clinical Practice Guidelines for Improving Outcomes in Sepsis. Heart, Lung and Circulation 17, S26-S31
CrossRef728
John L. Moran, Peter Bristow, Patricia J. Solomon, Carol George, Graeme K. Hart. (2008) Mortality and length-of-stay outcomes, 1993–2003, in the binational Australian and New Zealand intensive care adult patient database*. Critical Care Medicine 36:1, 46-61
CrossRef729
Hideo Wada, Tsuyoshi Hatada. (2008) Pathophysiology and diagnostic criteria for disseminated intravascular coagulation associated with sepsis*. Critical Care Medicine 36:1, 348-349
CrossRef730
Sat Sharma, Gregg Eschun. (2008) Hypotension and multiple organ dysfunction syndrome. Journal of Organ Dysfunction 4:3, 130-144
CrossRef731
Jose M. Rodriguez-Paz, Todd Dorman. (2008) Patient Safety in the Intensive Care Unit. Clinical Pulmonary Medicine 15:1, 24-34
CrossRef732
Arthur Wheeler, Jay Steingrub, Gregory A. Schmidt, Philip Sanchez, Judith Jacobi, Walter Linde-Zwirble, Becky Bates, Rebecca L. Qualy, Brad Woodward, Michael Zeckel. (2008) A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: Comparison with a controlled clinical trial*. Critical Care Medicine 36:1, 14-23
CrossRef733
R. Phillip Dellinger, Mitchell M. Levy, Jean M. Carlet, Julian Bion, Margaret M. Parker, Roman Jaeschke, Konrad Reinhart, Derek C. Angus, Christian Brun-Buisson, Richard Beale, Thierry Calandra, Jean-Francois Dhainaut, Herwig Gerlach, Maurene Harvey, John J. Marini, John Marshall, Marco Ranieri, Graham Ramsay, Jonathan Sevransky, B. Taylor Thompson, Sean Townsend, Jeffrey S. Vender, Janice L. Zimmerman, Jean-Louis Vincent. (2008) Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Medicine 34:1, 17-60
CrossRef734
Steven E. Weinberger, Barbara A. Cockrill, Jess Mandel. 2008. Acute Respiratory Distress Syndrome. , 344-355.
CrossRef735
H. Bartels, J.R. Siewert. (2008) Therapie der Mediastinitis am Beispiel des Ösophaguskarzinoms. Der Chirurg 79:1, 30-37
CrossRef736
Jung-Hyun Choi. (2008) Recent Evidences of Sepsis Treatment. Infection and Chemotherapy 40:2, 67
CrossRef737
Gordon Doig. (2008) Effectiveness of drotrecogin alfa (activated) in clinical practice: A stitch in time*. Critical Care Medicine 36:1, 332-333
CrossRef738
R Phillip Dellinger, Mitchell M. Levy, Jean M. Carlet, Julian Bion, Margaret M. Parker, Roman Jaeschke, Konrad Reinhart, Derek C. Angus, Christian Brun-Buisson, Richard Beale, Thierry Calandra, Jean-Francois Dhainaut, Herwig Gerlach, Maurene Harvey, John J. Marini, John Marshall, Marco Ranieri, Graham Ramsay, Jonathan Sevransky, B Taylor Thompson, Sean Townsend, Jeffrey S. Vender, Janice L. Zimmerman, Jean-Louis Vincent. (2008) Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Critical Care Medicine 36:1, 296-327
CrossRef739
Jonathan M. Siner, Margaret A. Pisani. (2007) Mechanical Ventilation and Acute Respiratory Distress Syndrome in Older Patients. Clinics in Chest Medicine 28:4, 783-791
CrossRef740
W. Joost Wiersinga, Cees van ‘t Veer, Catharina W. Wieland, Sebastien Gibot, Berend Hooibrink, Nicholas P. Day, Sharon J. Peacock, and Tom van der Poll. (2007) Expression Profile and Function of Triggering Receptor Expressed on Myeloid Cells–1 during Melioidosis. The Journal of Infectious Diseases 196:11, 1707-1716
CrossRef741
Cynthia M. Otto. (2007) Clinical trials in spontaneous disease in dogs: a new paradigm for investigations of sepsis. Journal of Veterinary Emergency and Critical Care 17:4, 359-367
CrossRef742
Cynthia M. Otto. (2007) Sepsis in veterinary patients: what do we know and where can we go?. Journal of Veterinary Emergency and Critical Care 17:4, 329-332
CrossRef743
W FISSELL, A FLEISCHMAN, H HUMES, S ROY. (2007) Development of continuous implantable renal replacement: past and future. Translational Research 150:6, 327-336
CrossRef744
Karim Brohi, Mitchell J Cohen, Ross A Davenport. (2007) Acute coagulopathy of trauma: mechanism, identification and effect. Current Opinion in Critical Care 13:6, 680-685
CrossRef745
Nicole C Kaneider, Andrew J Leger, Anika Agarwal, Nga Nguyen, George Perides, Claudia Derian, Lidija Covic, Athan Kuliopulos. (2007) 'Role reversal' for the receptor PAR1 in sepsis-induced vascular damage. Nature Immunology 8:12, 1303-1312
CrossRef746
P. Dahlem, W.M.C. van Aalderen, A.P. Bos. (2007) Pediatric acute lung injury. Paediatric Respiratory Reviews 8:4, 348-362
CrossRef747
Kevin B. Laupland, Andrew W. Kirkpatrick, Anthony Delaney. (2007) Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: A systematic review and meta-analysis*. Critical Care Medicine 35:12, 2686-2692
CrossRef748
Y. Hassan, A. Awaisu, N. A. Aziz, N. H. K. A. Aziz, O. Ismail. (2007) Heparin-induced thrombocytopenia and recent advances in its therapy. Journal of Clinical Pharmacy and Therapeutics 32:6, 535-544
CrossRef749
S. Landers, A. Beck, J. Maurer, M. Hürtgen, M. Silomon. (2007) Tracheobronchiale Nekrose. Der Anaesthesist 56:12, 1237-1241
CrossRef750
Jean I Keddissi, Brianna C Bright, Tarek A Dernaika. (2007) Use of pressors in the management of septic shock. The Lancet 370:9602, 1827
CrossRef751
James M. Hollands, Scott T. Micek, Peggy S. McKinnon, Marin H. Kollef. 2007. Early Appropriate Empiric Therapy and Antimicrobial De-Escalation. , 231-250.
CrossRef752
J.-S. Bae, L. Yang, C. Manithody, A. R. Rezaie. (2007) The ligand occupancy of endothelial protein C receptor switches the protease-activated receptor 1-dependent signaling specificity of thrombin from a permeability-enhancing to a barrier-protective response in endothelial cells. Blood 110:12, 3909-3916
CrossRef753
Jeremy M Kahn, Barry D Fuchs. (2007) Identifying and implementing quality improvement measures in the intensive care unit. Current Opinion in Critical Care 13:6, 709-713
CrossRef754
Eric M Mortensen, Marcos I Restrepo, Laurel A Copeland, Jacqueline A Pugh, Antonio Anzueto, John E Cornell, Mary Jo V Pugh. (2007) Impact of Previous Statin and Angiotensin II Receptor Blocker Use on Mortality in Patients Hospitalized with Sepsis. Pharmacotherapy 27:12, 1619-1626
CrossRef755
Dominique Thabut, Julien Massard, Alice Gangloff, Nicolas Carbonell, Claire Francoz, Eric Nguyen-Khac, Christian Duhamel, Didier Lebrec, Thierry Poynard, Richard Moreau. (2007) Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure. Hepatology 46:6, 1872-1882
CrossRef756
K. Matsumoto, Y. Yano, E. C. Gabazza, R. Araki, N. E. Bruno, M. Suematsu, H. Akatsuka, A. Katsuki, O. Taguchi, Y. Adachi, Y. Sumida. (2007) Inverse correlation between activated protein C generation and carotid atherosclerosis in Type 2 diabetic patients. Diabetic Medicine 24:12, 1322-1328
CrossRef757
Corinna Velik-Salchner, Volker Wenzel, Dirk M. Maybauer, Marc O. Maybauer. (2007) Recombinant human activated protein C in experimental models of acute lung injury: the timing is critical!. Intensive Care Medicine 33:12, 2048-2050
CrossRef758
Lisa E. Hensley, Edward L. Stevens, S. Betty Yan, Joan B. Geisbert, William L. Macias, Tom Larsen, Kathleen M. Daddario‐DiCaprio, Gail H. Cassell, Peter B. Jahrling, Thomas W. Geisbert. (2007) Recombinant Human Activated Protein C for the Postexposure Treatment of Ebola Hemorrhagic Fever. The Journal of Infectious Diseases 196:s2, S390-S399
CrossRef759
Daniel G. Bausch, Heinz Feldmann, Thomas W. Geisbert, Mike Bray, A. G. Sprecher, Paul Boumandouki, Pierre E. Rollin, Cathy Roth, . (2007) Outbreaks of Filovirus Hemorrhagic Fever: Time to Refocus on the Patient. The Journal of Infectious Diseases 196:s2, S136-S141
CrossRef760
Steven G. Coca, Aldo J. Peixoto, Amit X. Garg, Harlan M. Krumholz, Chirag R. Parikh. (2007) The Prognostic Importance of a Small Acute Decrement in Kidney Function in Hospitalized Patients: A Systematic Review and Meta-Analysis. American Journal of Kidney Diseases 50:5, 712-720
CrossRef761
Jean-Louis Vincent. (2007) Drotrecogin alfa (activated): the treatment for severe sepsis?. Expert Opinion on Biological Therapy 7:11, 1763-1777
CrossRef762
Evelina Tacconelli, Maria A. Cataldo, Giulia De Angelis, Roberto Cauda. (2007) Risk scoring and bloodstream infections. International Journal of Antimicrobial Agents 30, 88-92
CrossRef763
Akihiko Tanaka, Kenji Minoguchi, Xiaoyang Chen, Naruhito Oda, Takuya Yokoe, Yoshitaka Yamamoto, Mayumi Yamamoto, Yoshio Watanabe, Shin Ohta, Xun Xu, Mitsuru Adachi. (2007) ACTIVATED PROTEIN C ATTENUATES LEUKOCYTE ELASTASE-INDUCED LUNG INJURY IN MICE. Shock1
CrossRef764
Sushma K. Cribbs, Greg S. Martin. (2007) Expanding the global epidemiology of sepsis*. Critical Care Medicine 35:11, 2646-2648
CrossRef765
Zhen Wang, Fuhong Su, Peter Rogiers, Jean-Louis Vincent. (2007) Beneficial effects of recombinant human activated protein C in a ewe model of septic shock*. Critical Care Medicine 35:11, 2594-2600
CrossRef766
Soumitra R. Eachempati, John C. L. Wang, Lynn J. Hydo, Jian Shou, Philip S. Barie. (2007) Acute Renal Failure in Critically Ill Surgical Patients: Persistent Lethality Despite New Modes of Renal Replacement Therapy. The Journal of Trauma: Injury, Infection, and Critical Care 63:5, 987-993
CrossRef767
Alexander D. Cornet, Albertus Beishuizen, A B. Johan Groeneveld. (2007) Activated protein C in sepsis: Tightening pulmonary endothelial cells?*. Critical Care Medicine 35:11, 2656-2658
CrossRef768
Frank Sebat, Amjad A. Musthafa, David Johnson, Andrew A. Kramer, Debbie Shoffner, Mark Eliason, Kristen Henry, Bruce Spurlock. (2007) Effect of a rapid response system for patients in shock on time to treatment and mortality during 5 years*. Critical Care Medicine 35:11, 2568-2575
CrossRef769
Philip S. Barie. (2007) “All In” For a Huge Pot: The PROWESS-SHOCK Trial for Refractory Septic Shock. Surgical Infections 8:5, 491-494
CrossRef770
A. BINDER, G. ENDLER, M. MÜLLER, C. MANNHALTER, W. ZENZ, . (2007) 4G4G genotype of the plasminogen activator inhibitor-1 promoter polymorphism associates with disseminated intravascular coagulation in children with systemic meningococcemia. Journal of Thrombosis and Haemostasis 5:10, 2049-2054
CrossRef771
Kenneth Martin, Delphine Borgel, Nicolas Lerolle, Hendrik B. Feys, Ludovic Trinquart, Karen Vanhoorelbeke, Hans Deckmyn, Paulette Legendre, Jean-Luc Diehl, Dominique Baruch. (2007) Decreased ADAMTS-13 (A disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure*. Critical Care Medicine 35:10, 2375-2382
CrossRef772
David Pestaña, Elena Casanova, María J. Villagrán, Carolina Tormo, Hanna Pérez-Chrzanowska, Javier Redondo, María V. Caldera, Concepción Royo. (2007) Continuous Hemofiltration in Hyperthermic Septic Shock Patients. The Journal of Trauma: Injury, Infection, and Critical Care 63:4, 751-756
CrossRef773
Akanksha Gupta, David T. Berg, Bruce Gerlitz, Mark A. Richardson, Elizabeth Galbreath, Samreen Syed, Avadhesh C. Sharma, Stephen F. Lowry, Brian W. Grinnell. (2007) ACTIVATED PROTEIN C SUPPRESSES ADRENOMEDULLIN AND AMELIORATES LIPOPOLYSACCHARIDE-INDUCED HYPOTENSION. Shock 28:4, 468-476
CrossRef774
Jeremy M Kahn, Derek C Angus. (2007) Health policy and future planning for survivors of critical illness. Current Opinion in Critical Care 13:5, 514-518
CrossRef775
M. Bruijn, K. Fijnvandraat, M. Peters, A. P. Bos. (2007) De effectiviteit van de behandeling van diffuse intravasale stolling bij kinderen; een systematische review. Tijdschrift voor kindergeneeskunde 75:5, 225-230
CrossRef776
Catherine L Hough, Dale M Needham. (2007) The role of future longitudinal studies in ICU survivors: understanding determinants and pathophysiology of weakness and neuromuscular dysfunction. Current Opinion in Critical Care 13:5, 489-496
CrossRef777
Jesús Villar, Lina Pérez-Méndez, Carlos Flores, Nicole Maca-Meyer, Elena Espinosa, Arturo Muriel, Rubén Sangüesa, Jesús Blanco, Mercedes Muros, Robert M. Kacmarek. (2007) A CXCL2 polymorphism is associated with better outcomes in patients with severe sepsis*. Critical Care Medicine 35:10, 2292-2297
CrossRef778
Mark R. Looney, Michael A. Matthay. (2007) The role of protein C in sepsis. Current Infectious Disease Reports 3:5, 413-418
CrossRef779
Z. Xiang, R. M. Minter, X. Bi, P. J. Woolf, Y. He. (2007) miniTUBA: medical inference by network integration of temporal data using Bayesian analysis. Bioinformatics 23:18, 2423-2432
CrossRef780
M. A. Kowalska, S. A. Mahmud, M. P. Lambert, M. Poncz, A. Slungaard. (2007) Endogenous platelet factor 4 stimulates activated protein C generation in vivo and improves survival after thrombin or lipopolysaccharide challenge. Blood 110:6, 1903-1905
CrossRef781
Lisa Hall Zimmerman. (2007) Causes and Consequences of Critical Bleeding and Mechanisms of Blood Coagulation. Pharmacotherapy 27:9 Part 2, 45S-56S
CrossRef782
Haitao Wen, Cory M. Hogaboam, Nicholas W. Lukacs, Donald N. Cook, Sergio A. Lira, Steven L. Kunkel. (2007) The chemokine receptor CCR6 is an important component of the innate immune response. European Journal of Immunology 37:9, 2487-2498
CrossRef783
Xavier Marechal, Raphael Favory, Olivier Joulin, David Montaigne, Sidi Hassoun, Brigitte Decoster, Farid Zerimech, Remi Neviere. (2007) ENDOTHELIAL GLYCOCALYX DAMAGE DURING ENDOTOXEMIA COINCIDES WITH MICROCIRCULATORY DYSFUNCTION AND VASCULAR OXIDATIVE STRESS. Shock1
CrossRef784
S. Al-Sabah, P. Goldberg, S.T. Qureshi. (2007) Pasteurella multocida septic shock following liver transplantation treated with drotrecogin alfa (activated). Transplant Infectious Disease 9:3, 233-236
CrossRef785
Stephanie Mayer, Julia Langgartner. (2007) Hämostaseologische Diagnostik und Therapie in der Intensivmedizin. Intensivmedizin und Notfallmedizin 44:6, 332-348
CrossRef786
Jean-Louis Vincent. (2007) Clinical trials report. Current Infectious Disease Reports 9:5, 355-357
CrossRef787
Kyros Ipaktchi, Aladdein Mattar, Andreas D. Niederbichler, Jiyoun Kim, Laszlo M. Hoesel, Mark R. Hemmila, Grace L. Su, Daniel G. Remick, Stewart C. Wang, Saman Arbabi. (2007) Attenuating burn wound inflammation improves pulmonary function and survival in a burn-pneumonia model. Critical Care Medicine 35:9, 2139-2144
CrossRef788
François Philippart, Jean-Marc Cavaillon. (2007) Sepsis mediators. Current Infectious Disease Reports 9:5, 358-365
CrossRef789
Marcel Levi. (2007) Disseminated intravascular coagulation. Critical Care Medicine 35:9, 2191-2195
CrossRef790
Kyle A Weant, Aaron M Cook. (2007) Potential Roles for Statins in Critically Ill Patients. Pharmacotherapy 27:9, 1279-1296
CrossRef791
William B. Norbury, Marc G. Jeschke, David N. Herndon. (2007) Metabolism modulators in sepsis: Propranolol. Critical Care Medicine 35:Suppl, S616-S620
CrossRef792
Emanuel P. Rivers, James A. Kruse, Gordon Jacobsen, Kant Shah, Manisha Loomba, Ronny Otero, Ed W. Childs. (2007) The influence of early hemodynamic optimization on biomarker patterns of severe sepsis and septic shock*. Critical Care Medicine 35:9, 2016-2024
CrossRef793
Willem Joost Wiersinga, Tom Poll. (2007) Is the septic response good or bad?. Current Infectious Disease Reports 9:5, 366-373
CrossRef794
Yang Song, George Y. H. Chi. (2007) A method for testing a prespecified subgroup in clinical trials. Statistics in Medicine 26:19, 3535-3549
CrossRef795
Alexander Binder, Georg Endler, Sandra Rieger, Gotho Geishofer, Bernhard Resch, Christine Mannhalter, Werner Zenz, . (2007) Protein C promoter polymorphisms associate with sepsis in children with systemic meningococcemia. Human Genetics 122:2, 183-190
CrossRef796
Johannes N. Hoffmann, Jan M. Fertmann, Brigitte Vollmar, Matthias W. Laschke, K.-W. Jauch, Michael D. Menger. (2007) IMMUNOGLOBULIN M-ENRICHED HUMAN INTRAVENOUS IMMUNOGLOBULINS REDUCE LEUKOCYTE-ENDOTHELIAL CELL INTERACTIONS AND ATTENUATE MICROVASCULAR PERFUSION FAILURE IN NORMOTENSIVE ENDOTOXEMIA. Shock1
CrossRef797
Michael D. Howell, Michael W. Donnino, Daniel Talmor, Peter Clardy, Long Ngo, Nathan I. Shapiro. (2007) Performance of Severity of Illness Scoring Systems in Emergency Department Patients with Infection. Academic Emergency Medicine 14:8, 709-714
CrossRef798
Ismail Cinel, R Phillip Dellinger. (2007) Advances in pathogenesis and management of sepsis. Current Opinion in Infectious Diseases 20:4, 345-352
CrossRef799
Sundaram Venkataseshan, Sourabh Dutta, Jasmina Ahluwalia, Anil Narang. (2007) Low Plasma Protein C Values Predict Mortality in Low Birth Weight Neonates With Septicemia. The Pediatric Infectious Disease Journal 26:8, 684-688
CrossRef800
Didem Cemile Yesilirmak, Abdullah Kumral, Huseyin Baskin, Bekir Ugur Ergur, Simge Aykan, Sermin Genc, Kursad Genc, Osman Yilmaz, Kazim Tugyan, Ozlem Giray, Nuray Duman, Hasan Ozkan. (2007) Activated protein C reduces endotoxin-induced white matter injury in the developing rat brain. Brain Research 1164, 14-23
CrossRef801
Nigel S Key, Claude Negrier. (2007) Coagulation factor concentrates: past, present, and future. The Lancet 370:9585, 439-448
CrossRef802
Rob Schuster, Kenneth Waxman. (2007) Successful Treatment of Severe Sepsis With Recombinant Human Activated Protein C in a Patient With Traumatic Intracranial Hemorrhage. The Journal of Trauma: Injury, Infection, and Critical Care 63:2, E34-E36
CrossRef803
Masaki Nakamura, Yusuke Shimizu, Yasuko Sato, Yutaka Miyazaki, Tsutomu Satoh, Masashi Mizuno, Yutaka Kato, Yoshitaka Hosaka, Shoji Furusako. (2007) Toll-like receptor 4 signal transduction inhibitor, M62812, suppresses endothelial cell and leukocyte activation and prevents lethal septic shock in mice. European Journal of Pharmacology 569:3, 237-243
CrossRef804
Fredric M Pieracci, Philip S Barie. (2007) Intra-abdominal infections. Current Opinion in Critical Care 13:4, 440-449
CrossRef805
Philip Gierer, Johannes N. Hoffmann, Felix Mahr, Michael D. Menger, Thomas Mittlmeier, Georg Gradl, Brigitte Vollmar. (2007) Activated protein C reduces tissue hypoxia, inflammation, and apoptosis in traumatized skeletal muscle during endotoxemia. Critical Care Medicine 35:8, 1966-1971
CrossRef806
Lorraine B. Ware, Michael A. Matthay, Polly E. Parsons, B Taylor Thompson, James L. Januzzi, Mark D. Eisner. (2007) Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome*. Critical Care Medicine 35:8, 1821-1828
CrossRef807
Djillali Annane, Philippe Vignon, Alain Renault, Pierre-Edouard Bollaert, Claire Charpentier, Claude Martin, Gilles Troché, Jean-Damien Ricard, Gérard Nitenberg, Laurent Papazian, Elie Azoulay, Eric Bellissant. (2007) Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. The Lancet 370:9588, 676-684
CrossRef808
Po-Nien Tsao, Feng-Tsan Chan, Shu-Chen Wei, Wu-Shiun Hsieh, Hung-Chieh Chou, Yi-Ning Su, Chien-Yi Chen, Wen-Ming Hsu, Fon-Jou Hsieh, Su-Ming Hsu. (2007) Soluble vascular endothelial growth factor receptor-1 protects mice in sepsis. Critical Care Medicine 35:8, 1955-1960
CrossRef809
Sonja Bartolome, John G. Wood, Alfred J. Casillan, Steven Q. Simpson, Amy R. O'Brien-Ladner. (2007) ACTIVATED PROTEIN C ATTENUATES MICROVASCULAR INJURY DURING SYSTEMIC HYPOXIA. Shock1
CrossRef810
Oliver Murch, Maha Abdelrahman, Amar Kapoor, Christoph Thiemermann. (2007) MURAMYL DIPEPTIDE ENHANCES THE RESPONSE TO ENDOTOXIN TO CAUSE MULTIPLE ORGAN INJURY IN THE ANESTHETIZED RAT. Shock1
CrossRef811
Timothy D. Girard, E. Wesley Ely. (2007) Bacteremia and Sepsis in Older Adults. Clinics in Geriatric Medicine 23:3, 633-647
CrossRef812
Paul N. Knoebl. (2007) Is there an association between hemostatic abnormalities and the outcome of acute lung injury?*. Critical Care Medicine 35:8, 1980-1982
CrossRef813
A. C. Cheng, D. Limmathurotsakul, W. Chierakul, N. Getchalarat, V. Wuthiekanun, D. P. Stephens, N. P. J. Day, N. J. White, W. Chaowagul, B. J. Currie, S. J. Peacock. (2007) A Randomized Controlled Trial of Granulocyte Colony-Stimulating Factor for the Treatment of Severe Sepsis Due to Melioidosis in Thailand. Clinical Infectious Diseases 45:3, 308-314
CrossRef814
Mark D. Williams, William Macias, Joerg Rustige. (2007) Safety of drotrecogin alfa (activated): a fair comparison requires consistent definitions. Intensive Care Medicine 33:8, 1487-1488
CrossRef815
Maria Plataki, Katerina Vaporidi, Dimitris Georgopoulos. (2007) Is there increasing evidence that the risks of rhAPC may outweigh its benefits?. Intensive Care Medicine 33:8, 1485-1486
CrossRef816
A Martí-Carvajal, G Salanti, AF Cardona, Arturo Martí-Carvajal. 2007. Human recombinant activated protein C for severe sepsis. .
CrossRef817
Franco Scaldaferri, Miquel Sans, Stefania Vetrano, Cristina Graziani, Raimondo De Cristofaro, Bruce Gerlitz, Alessandro Repici, Vincenzo Arena, Alberto Malesci, Julian Panes, Brian W. Grinnell, Silvio Danese. (2007) Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease. Journal of Clinical Investigation 117:7, 1951-1960
CrossRef818
J. C. RAU, L. M. BEAULIEU, J. A. HUNTINGTON, F. C. CHURCH. (2007) Serpins in thrombosis, hemostasis and fibrinolysis. Journal of Thrombosis and Haemostasis 5, 102-115
CrossRef819
Andreas H. Kramer, Thomas P. Bleck. (2007) Neurocritical care of patients with central nervous system infections. Current Infectious Disease Reports 9:4, 308-314
CrossRef820
Dirk J. van der Windt, Rita Bottino, Anna Casu, Nathalie Campanile, David K.C. Cooper. (2007) Rapid loss of intraportally transplanted islets: an overview of pathophysiology and preventive strategies. Xenotransplantation 14:4, 288-297
CrossRef821
Frank Brunkhorst, Yasser Sakr, Stefan Hagel, Konrad Reinhart. (2007) Protein C Concentrations Correlate with Organ Dysfunction and Predict Outcome Independent of the Presence of Sepsis. Anesthesiology 107:1, 15-23
CrossRef822
X. ZHENG, W. LI, Y. SONG, Y. HU, G. L. FERRELL, N. L. ESMON, C. T. ESMON. (2007) Non-hematopoietic EPCR regulates the coagulation and inflammatory responses during endotoxemia. Journal of Thrombosis and Haemostasis 5:7, 1394-1400
CrossRef823
Lingtak-Neander Chan. (2007) Selenium supplementation in septic patients: The method of delivery matters. Critical Care Medicine 35:7, 1802-1803
CrossRef824
Ritesh AGARWAL, Alok NATH, Ashutosh N. AGGARWAL, Dheeraj GUPTA. (2007) Do glucocorticoids decrease mortality in acute respiratory distress syndrome? A meta-analysis. Respirology 12:4, 585-590
CrossRef825
François Haddad, Gerald Berry, Ramona L. Doyle, Pierre Martineau, Tack-Ki Leung, Normand Racine. (2007) Active Bacterial Myocarditis: A Case Report and Review of the Literature. The Journal of Heart and Lung Transplantation 26:7, 745-749
CrossRef826
Roy Ilan, Robert A. Fowler, Ryan Geerts, Ruxandra Pinto, William J. Sibbald, Claudio M. Martin. (2007) Knowledge translation in critical care: Factors associated with prescription of commonly recommended best practices for critically ill patients*. Critical Care Medicine 35:7, 1696-1702
CrossRef827
James L. Wynn, Philip O. Scumpia, Matthew J. Delano, Kerri A. O'Malley, Ricardo Ungaro, Amer Abouhamze, Lyle L. Moldawer. (2007) INCREASED MORTALITY AND ALTERED IMMUNITY IN NEONATAL SEPSIS PRODUCED BY GENERALIZED PERITONITIS. Shock1
CrossRef828
Michael A. Gropper. (2007) Multisystem Organ Failure. Anesthesiology 107:1, 6-7
CrossRef829
J. H. GRIFFIN, J. A. FERNÁNDEZ, A. J. GALE, L. O. MOSNIER. (2007) Activated protein C. Journal of Thrombosis and Haemostasis 5, 73-80
CrossRef830
Sean M. Berenholtz, Peter J. Pronovost. (2007) Monitoring Patient Safety. Critical Care Clinics 23:3, 659-673
CrossRef831
James M. O???Brien. (2007) Recombinant human activated protein C sentenced to the death of a thousand cuts?*. Critical Care Medicine 35:6, 1609-1610
CrossRef832
Clemens Feistritzer, Christian J Wiedermann. (2007) Effects of anticoagulant strategies on activation of inflammation and coagulation. Expert Opinion on Biological Therapy 7:6, 855-870
CrossRef833
I. A. Scott, R. S. Lodge, D. M. Russell. (2007) Evidence-based guide to perioperative medicine. Internal Medicine Journal 37:6, 389-401
CrossRef834
Pierre-Francois Laterre, David R. Nelson, William Macias, Edward Abraham, Andreas Sashegyi, Mark D. Williams, Mitchell Levy, Marcel Levi, Barbara Utterback, Jean-Louis Vincent. (2007) International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety. Journal of Critical Care 22:2, 142-152
CrossRef835
Douglas Schlichting, Jill Shwed McCollam. (2007) Recognizing and Managing Severe Sepsis: A Common and Deadly Threat. Southern Medical Journal 100:6, 594-600
CrossRef836
H. Bryant Nguyen, Dustin Smith. (2007) Sepsis in the 21st century: recent definitions and therapeutic advances. The American Journal of Emergency Medicine 25:5, 564-571
CrossRef837
Robert MacLaren, Kathleen A Stringer. (2007) Emerging Role of Anticoagulants and Fibrinolytics in the Treatment of Acute Respiratory Distress Syndrome. Pharmacotherapy 27:6, 860-873
CrossRef838
Kai-Chien Yang, Jung-Yien Chien, Wei-Kung Tseng, Po-Ren Hsueh, Chong-Jen Yu, Chau-Chung Wu. (2007) Statins do not improve short-term survival in an oriental population with sepsis. The American Journal of Emergency Medicine 25:5, 494-501
CrossRef839
Christian Lehmann, Ricardo Scheibe, Michael Schade, T. I. Usichenko, K. Meissner, M. Gründling, M. Wendt, D. Pavlovic. (2007) Effects of activated protein c in the rat mesenteric microcirculation. Canadian Journal of Anesthesia/Journal canadien d'anesthésie 54:S1, 44448-44448
CrossRef840
Sanjay Manocha, James A. Russell, Ainsley M. Sutherland, Anan Wattanathum, Keith R. Walley. (2007) Fibrinogen-beta gene haplotype is associated with mortality in sepsis. Journal of Infection 54:6, 572-577
CrossRef841
G. Tom Shires, Orna Fisher, Patrick Murphy, Shelley Williams, Annabel Barber, Gayle Johnson, Brett Davis, Stacey Pahulu. (2007) Recombinant Activated Protein C Induces Dose-Dependent Changes in Inflammatory Mediators, Tissue Damage, and Apoptosis in in Vivo Rat Model of Sepsis. Surgical Infections 8:3, 377-386
CrossRef842
Anne-Cornélie J.M. de Pont, Roel Bakx, Marja A. Boermeester, Marcus J. Schultz. (2007) Analysis of efficacy and safety of drotrecogin alfa (activated) in surgical patients, using an international integrated database. Surgery 141:6, 828-829
CrossRef843
Mihae Yu, Alyssa Chapital, Hao Chih Ho, John Wang, Danny Takanishi. (2007) A PROSPECTIVE RANDOMIZED TRIAL COMPARING OXYGEN DELIVERY VERSUS TRANSCUTANEOUS PRESSURE OF OXYGEN VALUES AS RESUSCITATIVE GOALS. Shock 27:6, 615-622
CrossRef844
Pierre-Francois Laterre, Edward Abraham, Jonathan M. Janes, Benjamin L. Trzaskoma, Nancy L. Correll, Frank V. Booth. (2007) ADDRESS (ADministration of DRotrecogin alfa [activated] in Early stage Severe Sepsis) long-term follow-up: One-year safety and efficacy evaluation*. Critical Care Medicine 35:6, 1457-1463
CrossRef845
Craig I. Coleman, Effie L. Kuti, Joseph L. Kuti. 2007. The Principles of Pharmacoeconomics. , 487-504.
CrossRef846
Jeppe Sylvest Nielsen, Anders Larsson, Thomas Rix, Rasmus Nyboe, Jakob Gjedsted, Jan Krog, Thomas Ledet, Else Tønnesen. (2007) The effect of activated protein C on plasma cytokine levels in a porcine model of acute endotoxemia. Intensive Care Medicine 33:6, 1085-1093
CrossRef847
M. J. Llewelyn, J. Cohen. (2007) Tracking the Microbes in Sepsis: Advancements in Treatment Bring Challenges for Microbial Epidemiology. Clinical Infectious Diseases 44:10, 1343-1348
CrossRef848
M. Emonts, F. C. G. J. Sweep, N. Grebenchtchikov, A. Geurts-Moespot, M. Knaup, A. L. Chanson, V. Erard, P. Renner, P. W. M. Hermans, J. A. Hazelzet, T. Calandra. (2007) Association between High Levels of Blood Macrophage Migration Inhibitory Factor, Inappropriate Adrenal Response, and Early Death in Patients with Severe Sepsis. Clinical Infectious Diseases 44:10, 1321-1328
CrossRef849
Matthew E. Lissauer, Steven B. Johnson, Gary Siuzdak, Grant Bochicchio, Craig Whiteford, Bill Nussbaumer, Richard Moore, Thomas M. Scalea. (2007) Coagulation and Complement Protein Differences Between Septic and Uninfected Systemic Inflammatory Response Syndrome Patients. The Journal of Trauma: Injury, Infection, and Critical Care 62:5, 1082-1094
CrossRef850
Andrew F. Shorr, Scott T. Micek, William L. Jackson, Marin H. Kollef. (2007) Economic implications of an evidence-based sepsis protocol: Can we improve outcomes and lower costs?*. Critical Care Medicine 35:5, 1257-1262
CrossRef851
P HAUSFATER. (2007) Le dosage de la procalcitonine en pratique clinique chez l'adulte. La Revue de Médecine Interne 28:5, 296-305
CrossRef852
C. J. Wiedermann. (2007) Gerinnungsaktive Substanzen als Sepsistherapeutika. Der Internist 48:5, 537-544
CrossRef853
Marius Terblanche, Yaniv Almog, Robert S Rosenson, Terry S Smith, Daniel G Hackam. (2007) Statins and sepsis: multiple modifications at multiple levels. The Lancet Infectious Diseases 7:5, 358-368
CrossRef854
Goda Choi, Jorrit-Jan H. Hofstra, Joris J. T. H. Roelofs, Sandrine Florquin, Paul Bresser, Marcel Levi, Tom van der Poll, Marcus J. Schultz. (2007) Recombinant human activated protein C inhibits local and systemic activation of coagulation without influencing inflammation during Pseudomonas aeruginosa pneumonia in rats. Critical Care Medicine 35:5, 1362-1368
CrossRef855
H. Rensing. (2007) Stammzellen und Sepsis. Der Anaesthesist 56:5, 421-422
CrossRef856
Peter A. Ward. (2007) New therapeutic approaches for influenza A H5N1 infected humans*. Critical Care Medicine 35:5, 1437-1438
CrossRef857
Susannah K. Leaver, Simon J. Finney, Anne Burke-Gaffney, Timothy W. Evans. (2007) Sepsis since the discovery of Toll-like receptors: Disease concepts and therapeutic opportunities. Critical Care Medicine 35:5, 1404-1410
CrossRef858
Viktor Y. Dombrovskiy, Andrew A. Martin, Jagadeeshan Sunderram, Harold L. Paz. (2007) Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: A trend analysis from 1993 to 2003*. Critical Care Medicine 35:5, 1244-1250
CrossRef859
Thomas A. Russo, Janet M. Beanan, Ruth Olson, Stacy A. Genagon, Ulrike MacDonald, John J. Cope, Bruce A. Davidson, Brian Johnston, James R. Johnson. (2007) A killed, genetically engineered derivative of a wild-type extraintestinal pathogenic E. coli strain is a vaccine candidate. Vaccine 25:19, 3859-3870
CrossRef860
G. LISSALDE-LAVIGNE, C. COMBESCURE, E. DORANGEON, J.-Y. LEFRANT, J.-C. GRIS. (2007) Simple coagulation tests improve early mortality prediction for patients in intensive care units who have proven or suspected septic shock. Journal of Thrombosis and Haemostasis 5:5, 1081-1083
CrossRef861
Lisa Pleyer, Philip Went, Gudrun Russ, Erika Prinz, Viktoria Faber, Hans-Joachim Röwert, Renate Karlbauer, Richard Greil. (2007) Massive infiltration of bone marrow in colon carcinoma after treatment with activated protein C. Wiener klinische Wochenschrift 119:7-8, 254-258
CrossRef862
Daniel G. Remick. (2007) Pathophysiology of Sepsis. The American Journal of Pathology 170:5, 1435-1444
CrossRef863
Allen C Cheng, Dianne P Stephens, Bart J Currie, Allen C Cheng. 2007. Granulocyte-Colony Stimulating Factor (G-CSF) as an adjunct to antibiotics in the treatment of pneumonia in adults. .
CrossRef864
Steven G. Coca, Paul Bauling, Tracy Schifftner, Clancy S. Howard, Isaac Teitelbaum, Chirag R. Parikh. (2007) Contribution of Acute Kidney Injury Toward Morbidity and Mortality in Burns: A Contemporary Analysis. American Journal of Kidney Diseases 49:4, 517-523
CrossRef865
Karen L. Johnson. (2007) Neuromuscular Complications in the Intensive Care Unit. AACN Advanced Critical Care 18:2, 167-180
CrossRef866
Aima Ahonkai, Noah Lechtzin. (2007) A Case for Vaccination. The American Journal of Medicine 120:4, 319-321
CrossRef867
Lilibeth Pineda, Ali A El Solh. (2007) Severe community-acquired pneumonia: approach to therapy. Expert Opinion on Pharmacotherapy 8:5, 593-606
CrossRef868
Ermanna Rovida, Giuliana Merati, Pasqualina D'Ursi, Sara Zanardelli, Francesca Marino, Gessica Fontana, Giancarlo Castaman, Elena M. Faioni. (2007) Identification and computationally-based structural interpretation of naturally occurring variants of human protein C. Human Mutation 28:4, 345-355
CrossRef869
Didier Payen, Armin Sablotzki, Philip S. Barie, Graham Ramsay, Stephen Lowry, Mark Williams, Samiha Sarwat, Justin Northrup, Patricia Toland, Frank V. McL. Booth. (2007) International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: Analysis of efficacy and safety data in a large surgical cohort. Surgery 141:4, 548-561
CrossRef870
Scott T. Micek, Poorvi Shah, James M. Hollands, Rina A. Shah, William D. Shannon, Marin H. Kollef. (2007) Addition of Vasopressin to Norepinephrine as Independent Predictor of Mortality in Patients with Refractory Septic Shock: An Observational Study. Surgical Infections 8:2, 189-200
CrossRef871
H Bryant Nguyen, Stephen W. Corbett, Robert Steele, Jim Banta, Robin T. Clark, Sean R. Hayes, Jeremy Edwards, Thomas W. Cho, William A. Wittlake. (2007) Implementation of a bundle of quality indicators for the early management of severe sepsis and septic shock is associated with decreased mortality*. Critical Care Medicine 35:4, 1105-1112
CrossRef872
Aaron Joffe, Ken Wood. (2007) Obesity in critical care. Current Opinion in Anaesthesiology 20:2, 113-118
CrossRef873
Derek C. Angus, LiHong Yang, Lan Kong, John A. Kellum, Russell L. Delude, Kevin J. Tracey, Lisa Weissfeld. (2007) Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis*. Critical Care Medicine 35:4, 1061-1067
CrossRef874
Jonathan E. McDunn, R. Reid Townsend, J. Perren Cobb. (2007) The murine plasma protein response to polymicrobial intra-abdominal sepsis. PROTEOMICS – Clinical Applications 1:4, 373-386
CrossRef875
Christoph Engel, Frank M. Brunkhorst, Hans-Georg Bone, Reinhard Brunkhorst, Herwig Gerlach, Stefan Grond, Matthias Gruendling, Guenter Huhle, Ulrich Jaschinski, Stefan John, Konstantin Mayer, Michael Oppert, Derk Olthoff, Michael Quintel, Max Ragaller, Rolf Rossaint, Frank Stuber, Norbert Weiler, Tobias Welte, Holger Bogatsch, Christiane Hartog, Markus Loeffler, Konrad Reinhart. (2007) Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Medicine 33:4, 606-618
CrossRef876
(2007) Management of Sepsis. New England Journal of Medicine 356:11, 1178-1182
Full Text877
L MILONOVICH. (2007) Meningococcemia: Epidemiology, Pathophysiology, and Management. Journal of Pediatric Health Care 21:2, 75-80
CrossRef878
L. A. Mandell, R. G. Wunderink, A. Anzueto, J. G. Bartlett, G. D. Campbell, N. C. Dean, S. F. Dowell, T. M. File, D. M. Musher, M. S. Niederman, A. Torres, C. G. Whitney. (2007) Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clinical Infectious Diseases 44:Supplement 2, S27-S72
CrossRef879
S. Shrivastava, J. H. McVey, A. Dorling. (2007) The Interface Between Coagulation and Immunity. American Journal of Transplantation 7:3, 499-506
CrossRef880
Jeffrey I Weitz, Lori-Ann Linkins. (2007) Beyond heparin and warfarin: the new generation of anticoagulants. Expert Opinion on Investigational Drugs 16:3, 271-282
CrossRef881
E. Browne, D. M. Cressey, K. Agarwal, J. F. Cosgrove. (2007) The use of drotrecogin alfa (activated) in a patient with recent orthotopic liver transplant. Anaesthesia 62:3, 282-285
CrossRef882
F. Pappalardo, E. Cristallo, A. Franco, G. Antonioli, A. Zangrillo. (2007) Drotrecogin alpha and anticoagulants in septic patients after cardiac surgery. European Journal of Anaesthesiology 24:3, 294-295
CrossRef883
Simon Nadel, Brahm Goldstein, Mark D Williams, Heidi Dalton, Mark Peters, William L Macias, Shamel A Abd-Allah, Howard Levy, Robinette Angle, Dazhe Wang, David P Sundin, Brett Giroir. (2007) Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. The Lancet 369:9564, 836-843
CrossRef884
Louis D. Saravolatz. (2007) The Role of Medical Semiology in Clinical Infectious Diseases. Infectious Diseases in Clinical Practice 15:2, 79-80
CrossRef885
Steven M Opal. (2007) Can we RESOLVE the treatment of sepsis?. The Lancet 369:9564, 803-804
CrossRef886
Sandra Peake, Steve Webb, Anthony Delaney. (2007) Early goal-directed therapy of septic shock: We honestly remain skeptical. Critical Care Medicine 35:3, 994-995
CrossRef887
Guido Bertolini, Carlotta Rossi, Abramo Anghileri, Sergio Livigni, Antonio Addis, Daniele Poole. (2007) Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey. Intensive Care Medicine 33:3, 426-434
CrossRef888
Sari Karlsson, Marjut Varpula, Esko Ruokonen, Ville Pettilä, Ilkka Parviainen, Tero I. Ala-Kokko, Elina Kolho, Esa M. Rintala. (2007) Incidence, treatment, and outcome of severe sepsis in ICU-treated adults in Finland: the Finnsepsis study. Intensive Care Medicine 33:3, 435-443
CrossRef889
Peter Q. Eichacker, Charles Natanson. (2007) Increasing evidence that the risks of rhAPC may outweigh its benefits. Intensive Care Medicine 33:3, 396-399
CrossRef890
Salmaan Kanji, Marc M. Perreault, Clarence Chant, David Williamson, Lisa Burry. (2007) Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study. Intensive Care Medicine 33:3, 517-523
CrossRef891
K TANAKA, J LEVY. (2007) Regulation of Thrombin Activity—Pharmacologic and Structural Aspects. Hematology/Oncology Clinics of North America 21:1, 33-50
CrossRef892
Bonnie Greenwood, Paul M Szumita, Howard Levy, Craig M Lilly. (2007) Error Rates Among Clinical Pharmacists in Calculating the APACHE II Score. Pharmacotherapy 27:2, 285-289
CrossRef893
Lea M. Beaulieu, Frank C. Church. (2007) Activated protein C promotes breast cancer cell migration through interactions with EPCR and PAR-1. Experimental Cell Research 313:4, 677-687
CrossRef894
Vicente H. Gracias, Annamarie D. Horan, Patrick K. Kim, Neil K. Puri, Rajan Gupta, John J. Gallagher, Corinna P. Sicoutris, Mario Grasso, C. William Hanson, C. William Schwab. (2007) Digital Output Volumetric Pulmonary Artery Catheters Eliminate Interoperator Interpretation Variability and Improve Consistency of Treatment Decisions. Journal of the American College of Surgeons 204:2, 209-215.e4
CrossRef895
Todd Dorman, Ronald Pauldine. (2007) Economic stress and misaligned incentives in critical care medicine in the United States. Critical Care Medicine 35:Suppl, S36-S43
CrossRef896
Yuanlin Song, Jeanine P. Wiener-Kronish, Judith Flanagan, Susan V. Lynch. (2007) Alveolar hemostasis in patients with species-specific bacterial-mediated ventilator-associated pneumonia*. Critical Care Medicine 35:2, 652-653
CrossRef897
B. Vangerow, M. A. Mignini. (2007) Activated protein C (Xigris
CrossRef898
PR Criado, IM Bernardelli, EA Rivitti, MN Sotto, MAC Vilella, NYS Valente, JEC Martins. (2007) Childhood-onset skin necrosis resulting from protein C deficiency. Journal of the European Academy of Dermatology and Venereology 0:0, 070209222700073-???
CrossRef899
Herwig Gerlach. (2007) Mini-series: basic research-related reviews in intensive care medicine. Intensive Care Medicine 33:1, 1-2
CrossRef900
C CIMENTI, M KOESTENBERGER, B LESCHNIK, H HAIDL, W MUNTEAN. (2007) The respective and combined anticoagulant effects of recombinant human activated protein C, melagatran and heparins using CAT. Thrombosis Research 119:3, 361-367
CrossRef901
Michael R. Pinsky. (2007) Genetics of individualizing patient care*. Critical Care Medicine 35:1, 287-280
CrossRef902
S ZANOTTICAVAZZONI. (2007) Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatmentVincent J-L, for the ENHANCE Study Group (Univ of Brussels, Belgium; et al) Crit Care Med 33:2266–2277, 2005§. Yearbook of Critical Care Medicine 2007, 196-197
CrossRef903
Matthias W. A. Angstwurm, Lothar Engelmann, Thomas Zimmermann, Christian Lehmann, Christoph H. Spes, Peter Abel, Richard Strau, Andreas Meier-Hellmann, Rudolf Insel, Joachim Radke, J??rgen Sch??ttler, Roland G??rtner. (2007) Selenium in Intensive Care (SIC): Results of a prospective randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock*. Critical Care Medicine 35:1, 118-126
CrossRef904
Katharina L. Lohmann, Michelle Henry Barton. 2007. Endotoxemia. , 317-331.
CrossRef905
Nathan I. Shapiro, Michael D. Howell, Daniel Talmor, Michael Donnino, Long Ngo, David W. Bates. (2007) Mortality in Emergency Department Sepsis (MEDS) score predicts 1-year mortality*. Critical Care Medicine 35:1, 192-198
CrossRef906
Pascal Bilbault, Thomas Lavaux, Anne Launoy, Marie P. Gaub, Nicolas Meyer, Pierre Oudet, Thierry Pottecher, Albert Jaeger, Francis Schneider. (2007) Influence of drotrecogin alpha (activated) infusion on the variation of Bax/Bcl-2 and Bax/Bcl-xl ratios in circulating mononuclear cells: A cohort study in septic shock patients. Critical Care Medicine 35:1, 69-75
CrossRef907
Frank M.P. van Haren, Norbert Foudraine, Michael Gillham. 2007. Infection and Sepsis. , 510-536.
CrossRef908
D LAMBERT, S TRZECIAK. (2007) Implementation of an evidence-based “standard operating procedure” and outcome in septic shockKortgen A, Niederprüm P, Bauer M (Friéedrich-Schiller Univ, Jena, Germany; Univ of Saarland, Homburg/Saar, Germany) Crit Care Med 34:943–949, 2006§. Yearbook of Critical Care Medicine 2007, 193-194
CrossRef909
Keith R. Walley, James A. Russell. (2007) Protein C ???1641 AA is associated with decreased survival and more organ dysfunction in severe sepsis*. Critical Care Medicine 35:1, 12-17
CrossRef910
Mercedes Palomar, Rafael Canton, Juan de Dios Colmenero, Emili Díaz, Pilar Marco, Pedro Olaechea, Miguel Sánchez, Jordi Vila, Rafael Zaragoza, Francisco Gudiol. (2007) Update: sepsis and septic shock. Enfermedades Infecciosas y Microbiología Clínica 25, 58-66
CrossRef911
Richard Moreau, Didier Lebrec. (2007) Diagnosis and treatment of acute renal failure in patients with cirrhosis. Best Practice & Research Clinical Gastroenterology 21:1, 111-123
CrossRef912
Daniel De Backer. (2007) Benefit-Risk Assessment of Drotrecogin Alfa (Activated) in the Treatment of Sepsis. Drug Safety 30:11, 995-1010
CrossRef913
Alexandra Westerholt, Stefan Maier, Tobias Traeger, Matthias Gründling, Claus-Dieter Heidecke. (2007) Management bei abdomineller Sepsis. Chirurgische Gastroenterologie 23:1, 64-74
CrossRef914
R NANDA, S ZANOTTICAVAZZONI. (2007) Early changes in organ function predict eventual survival in severe sepsisLevy MM, Macias WL, Vincent J-L, et al (Brown Univ, Providence, RI; Eli Lilly & Co, Indianapolis, Ind; Erasme Univ, Brussels, Belgium; et al) Crit Care Med 33:2194–2201, 2005§. Yearbook of Critical Care Medicine 2007, 207-209
CrossRef915
(2007) Nihon Kyukyu Igakukai Zasshi 18:6, 237-272
CrossRef916
Jae Yeol Kim. (2007) Sepsis. Tuberculosis and Respiratory Diseases 63:1, 13
CrossRef917
T. ITO, K. KAWAHARA, T. NAKAMURA, S. YAMADA, T. NAKAMURA, K. ABEYAMA, T. HASHIGUCHI, I. MARUYAMA. (2007) High-mobility group box 1 protein promotes development of microvascular thrombosis in rats. Journal of Thrombosis and Haemostasis 5:1, 109-116
CrossRef918
Rajesh Aneja, Mitchell P. Fink. (2007) Promising therapeutic agents for sepsis. Trends in Microbiology 15:1, 31-37
CrossRef919
F. R. Ernst, J. A. Johnston, S. Pulgar, J. He, D. E. Ball, J. K. Young, L. M. Cooper. (2007) Timing of drotrecogin alfa (activated) initiation in treatment of severe sepsis: a database cohort study of hospital mortality, length of stay, and costs*. Current Medical Research and Opinion 23:1, 235-244
CrossRef920
S ZANOTTICAVAZZONI. (2007) Rapid and beneficial hemodynamic effects of activated protein C in septic shock patientsMonnet X, Lamia B, Anguel N, et al (Universite Paris XI; Universite de Rouen, France) Intensive Care Med 31:1573–1576, 2005§. Yearbook of Critical Care Medicine 2007, 197-198
CrossRef921
R TANEJA. 2007. Stress, Inflammation, and Shock. , 28-32.
CrossRef922
Zbigniew Rybicki, Andrzej Truszczyński, Marcin Skibiński. (2007) Recombinant Human Activated Protein C Administered Twice to The Same Patient with Shock Caused by the Acute Pancreatitis and With Septic Shock As Iatrogenic Complication. Polish Journal of Surgery 79:1, 47-51
CrossRef923
P MORRIS. (2007) Moving Our Critically Ill Patients: Mobility Barriers and Benefits. Critical Care Clinics 23:1, 1-20
CrossRef924
H. SAITO, I. MARUYAMA, S. SHIMAZAKI, Y. YAMAMOTO, N. AIKAWA, R. OHNO, A. HIRAYAMA, T. MATSUDA, H. ASAKURA, M. NAKASHIMA, N. AOKI. (2007) Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. Journal of Thrombosis and Haemostasis 5:1, 31-41
CrossRef925
Peter Raivio, Jose A. Fernández, Anne Kuitunen, John H. Griffin, Riitta Lassila, Jari Petäjä. (2007) Activation of protein C and hemodynamic recovery after coronary artery bypass surgery. The Journal of Thoracic and Cardiovascular Surgery 133:1, 44-51
CrossRef926
Benjamin Trzaskoma, Andreas Sashegyi. (2007) Predictive Probability of Success and the Assessment of Futility in Large Outcomes Trials. Journal of Biopharmaceutical Statistics 17:1, 45-63
CrossRef927
Dietmar Schranz. 2007. Schock/Schockbekämpfung. , 425-436.
CrossRef928
William C. Aird. 2007. Endothelium. , 35-42.
CrossRef929
Carrie LaBelle, Craig S. Kitchens. 2007. Disseminated Intravascular Coagulation. , 183-198.
CrossRef930
Eefje Jong, Eric C.M. van Gorp, Marcel Levi, Hugo ten Cate. 2007. The Cross-Talk of Inflammation and Coagulation in Infectious Disease and Their Roles in Disseminated Intravascular Coagulation. , 199-209.
CrossRef931
Rainer Seitz, Herbert K
CrossRef932
Christine CC Chiou, Victor L Yu. (2006) Severe pneumococcal pneumonia: new strategies for management. Current Opinion in Internal Medicine 5:6, 559-565
CrossRef933
Mary A. Short, Douglas Schlichting, Rebecca L. Qualy. (2006) From bench to bedside: a review of the clinical trial development plan of drotrecogin alfa (activated). Current Medical Research and Opinion 22:12, 2525-2540
CrossRef934
Christy Chuang-Stein. (2006) A Cautionary Note on Design Implications when the Primary Analysis is a Stratified Analysis of a Binary Endpoint. Biometrical Journal 48:6, 978-983
CrossRef935
Shunji Tajima, Masashi Bando, Hideaki Yamasawa, Shoji Ohno, Hiroshi Moriyama, Toshinori Takada, Eiichi Suzuki, Fumitake Gejyo, Yukihiko Sugiyama. (2006) Preventive Effect of Hochu-ekki-to on Lipopolysaccharide-Induced Acute Lung Injury in BALB/c Mice. Lung 184:6, 318-323
CrossRef936
James S. Krinsley. (2006) Glycemic Control, Diabetic Status, and Mortality in a Heterogeneous Population of Critically Ill Patients Before and During the Era of Intensive Glycemic Management: Six and One-Half Years Experience at a University-Affiliated Community Hospital. Seminars in Thoracic and Cardiovascular Surgery 18:4, 317-325
CrossRef937
Catherine Lee Hough. (2006) Neuromuscular Sequelae in Survivors of Acute Lung Injury. Clinics in Chest Medicine 27:4, 691-703
CrossRef938
Tomoyoshi Mohri, Hiroshi Tanaka, Goro Tajima, Kentaro Kajino, Hideaki Sonoi, Hideo Hosotsubo, Hiroshi Ogura, Yasuyuki Kuwagata, Takeshi Shimazu, Hisashi Sugimoto. (2006) SYNERGISTIC EFFECTS OF RECOMBINANT HUMAN SOLUBLE THROMBOMODULIN AND FLUID-VOLUME RESUSCITATION IN A RAT LETHAL CRUSH INJURY MODEL. Shock 26:6, 581-586
CrossRef939
Shigehiko Uchino. (2006) The epidemiology of acute renal failure in the world. Current Opinion in Critical Care 12:6, 538-543
CrossRef940
Alex P. Betrosian, Tom Berlet, Banwari Agarwal. (2006) Purpura Fulminans in Sepsis. The American Journal of the Medical Sciences 332:6, 339-345
CrossRef941
Kristen C. Sihler, Avery B. Nathens. (2006) Management of Severe Sepsis in the Surgical Patient. Surgical Clinics of North America 86:6, 1457-1481
CrossRef942
HENG JOO NG, MARK CROWTHER. (2006) New anticoagulants and the management of their bleeding complications. Transfusion Alternatives in Transfusion Medicine 8, 12-19
CrossRef943
Ravi Taneja, Davy CH Cheng. (2006) Con: Heparin-Bonded Cardiopulmonary Bypass Circuits Should Be Routine for All Cardiac Surgical Procedures. Anesthesia & Analgesia 103:6, 1370-1372
CrossRef944
Shu-Min Lin, Chien-Da Huang, Horng-Chyuan Lin, Chien-Ying Liu, Chun-Hua Wang, Han-Pin Kuo. (2006) A MODIFIED GOAL-DIRECTED PROTOCOL IMPROVES CLINICAL OUTCOMES IN INTENSIVE CARE UNIT PATIENTS WITH SEPTIC SHOCK. Shock 26:6, 551-557
CrossRef945
Jean-Louis Vincent, Massimo Zambon. (2006) Why Do Patients Who Have Acute Lung Injury/Acute Respiratory Distress Syndrome Die from Multiple Organ Dysfunction Syndrome? Implications for Management. Clinics in Chest Medicine 27:4, 725-731
CrossRef946
Naoko Shiga, Kayo Nemoto, Yasushi Shimada, Yuichi Nakanowatari, Norifumi Ninomiya, Yasuhiro Yamamoto. (2006) Elimination of 2-Arachidonoylglycerol Action by Direct Hemoperfusion Through Immobilized Polymyxin B Fibers: An Experimental Study in Conscious Guinea Pigs. Therapeutic Apheresis and Dialysis 10:6, 504-509
CrossRef947
Gina Howell, Samuel A. Tisherman. (2006) Management of Sepsis. Surgical Clinics of North America 86:6, 1523-1539
CrossRef948
Xiangshao Fang, Wanchun Tang, Shijie Sun, Lei Huang, Yun-Te Chang, Carlos Castillo, Max Harry Weil. (2006) Comparison of buccal microcirculation between septic and hemorrhagic shock. Critical Care Medicine 34:Suppl, S447-S453
CrossRef949
Rui Moreno, Susana Afonso. (2006) Ethical, legal and organizational issues in the ICU: prediction of outcome. Current Opinion in Critical Care 12:6, 619-623
CrossRef950
J.-T. Gräsner, J. Bahr, B. W. Böttiger, E. Cavus, V. Dörges, A. Gries, H. Krieter, V. Wenzel, J. Scholz. (2006) Notfallmedizin in Ausbildung, Lehre, Qualitätsmanagement, Grundlagenforschung und in klinischen Studien. Notfall + Rettungsmedizin 9:8, 702-710
CrossRef951
Isabel Spriet, Wouter Meersseman, Alexander Wilmer, Geert Meyfroidt, Minne Casteels, Ludo Willems. (2006) Evaluation of drotrecogin alpha use in a Belgian university hospital. Pharmacy World & Science 28:5, 290-295
CrossRef952
S. LOUBELE, H. TEN CATE. (2006) Local administration of recombinant human antithrombin in a mouse model of peritoneal sepsis. Journal of Thrombosis and Haemostasis 4:11, 2340-2342
CrossRef953
Abele Donati, Jean-Charles Preiser. (2006) Methylene blue: An old-timer or a compound ready for revival?*. Critical Care Medicine 34:11, 2862-2863
CrossRef954
Suzanne Q. van Veen, Marcel Levi, Arl??ne K. van Vliet, Sandrine Florquin, Thomas M. van Gulik, Marja A. Boermeester. (2006) Peritoneal lavage with activated protein C alters compartmentalized coagulation and fibrinolysis and improves survival in polymicrobial peritonitis. Critical Care Medicine 34:11, 2799-2805
CrossRef955
Peter G. Brindley, Nancy Zhu, Wendy Sligl. (2006) Best evidence in critical care medicine Early antibiotics and survival from septic shock: it’s about time. Canadian Journal of Anesthesia/Journal canadien d'anesthésie 53:11, 1157-1160
CrossRef956
Sandra Crikis, Peter J. Cowan, Anthony J. F. d??Apice. (2006) Intravascular Thrombosis in Discordant Xenotransplantation. Transplantation 82:9, 1119-1123
CrossRef957
Dafer W. Haddadin, Imran Q. Samnani, Jonathan P. Moorman. (2006) Drotrecogin Alfa (Activated) for Nonmenstrual Toxic Shock Syndrome Associated with Methicillin Resistant Staphylococcus aureus Infection. Southern Medical Journal 99:11, 1295-1296
CrossRef958
Yi Li, Bin Du, Jia-qi Pan, De-chang Chen, Da-wei Liu. (2006) Up-regulation interleukin-6 and interleukin-8 by activated protein C in lipopolysaccharide-treated human umbilical vein endothelial cells. Journal of Zhejiang University SCIENCE B 7:11, 899-905
CrossRef959
Scott T. Micek, Nareg Roubinian, Tim Heuring, Meghan Bode, Jennifer Williams, Courtney Harrison, Theresa Murphy, Donna Prentice, Brent E. Ruoff, Marin H. Kollef. (2006) Before???after study of a standardized hospital order set for the management of septic shock*. Critical Care Medicine 34:11, 2707-2713
CrossRef960
Robert W. Schrier. (2006) Urinary Indices and Microscopy in Sepsis-Related Acute Renal Failure. American Journal of Kidney Diseases 48:5, 838-841
CrossRef961
Tong Cheng, Anthony L Petraglia, Zhang Li, Meenakshisundaram Thiyagarajan, Zhihui Zhong, Zhenhua Wu, Dong Liu, Sanjay B Maggirwar, Rashid Deane, José A Fernández, Barbra LaRue, John H Griffin, Michael Chopp, Berislav V Zlokovic. (2006) Activated protein C inhibits tissue plasminogen activator–induced brain hemorrhage. Nature Medicine 12:11, 1278-1285
CrossRef962
José A. Páramo. (2006) Coagulación intravascular diseminada. Medicina Clínica 127:20, 785-789
CrossRef963
Didier Payen, Armin Sablotzki, Philip S. Barie, Graham Ramsay, Stephen Lowry, Mark Williams, Samiha Sarwat, Justin Northrup, Patricia Toland, Frank V. McL. Booth. (2006) International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: Analysis of efficacy and safety data in a large surgical cohort. Surgery 140:5, 726-739
CrossRef964
S H Slofstra, A P Groot, N A Maris, P H Reitsma, H ten Cate, C A Spek. (2006) Inhalation of activated protein C inhibits endotoxin-induced pulmonary inflammation in mice independent of neutrophil recruitment. British Journal of Pharmacology 149:6, 740-746
CrossRef965
Carmelle Cooper, Edward Tredget, Corilee Watters. 2006. Nutrition and Wound Healing in Burns, Trauma, and Sepsis. , 219-260.
CrossRef966
Russell, James A., . (2006) Management of Sepsis. New England Journal of Medicine 355:16, 1699-1713
Full Text967
Denise P. Veelo, Peter E. Spronk, Michael A. Kuiper, Johanna C. Korevaar, Peter H. J. Voort, Marcus J. Schultz. (2006) A change in the Dutch Directive on Medical Research Involving Human Subjects strongly increases the number of eligible intensive care patients: an observational study. Intensive Care Medicine 32:11, 1845-1850
CrossRef968
Christy Chuang-Stein. (2006) Discussion. Statistics in Medicine 25:19, 3297-3301
CrossRef969
Goda Choi, Esther K. Wolthuis, Paul Bresser, Marcel Levi, Tom van der Poll, Misa Dzoljic, Margreeth B. Vroom, Marcus J. Schultz. (2006) Mechanical Ventilation with Lower Tidal Volumes and Positive End-expiratory Pressure Prevents Alveolar Coagulation in Patients without Lung Injury. Anesthesiology 105:4, 689-695
CrossRef970
Bekele Afessa. (2006) Benchmark for intensive care unit length of stay: One step forward, several more to go*. Critical Care Medicine 34:10, 2674-2676
CrossRef971
M. D. Menger, B. Vollmar. (2006) Perspektiven in der Schockforschung. Notfall + Rettungsmedizin 9:6, 542-546
CrossRef972
G Russo, M La Spina, N Disma, M Astuto. (2006) Drotrecogin alfa activated as a treatment for severe sepsis in pediatric cancer. Bone Marrow Transplantation 38:8, 575-576
CrossRef973
Tom Ahrens. (2006) Hemodynamics in Sepsis. AACN Advanced Critical Care 17:4, 435-445
CrossRef974
Robert M. Hardaway. (2006) A Brief Overview of Acute Respiratory Distress Syndrome. World Journal of Surgery 30:10, 1829-1834
CrossRef975
Jean-Louis Vincent. (2006) Management of sepsis in the critically ill patient: key aspects. Expert Opinion on Pharmacotherapy 7:15, 2037-2045
CrossRef976
Jan Powers, Judith Jacobi. (2006) Pharmacologic Treatment Related to Severe Sepsis. AACN Advanced Critical Care 17:4, 423-432
CrossRef977
Annette M. Esper, Marc Moss, Charmaine A. Lewis, Rachel Nisbet, David M. Mannino, Greg S. Martin. (2006) The role of infection and comorbidity: Factors that influence disparities in sepsis. Critical Care Medicine 34:10, 2576-2582
CrossRef978
Jennifer A Quinn, Stacy L Snyder, Jennifer L Berghoff, Claudia S Colombo, Judith Jacobi. (2006) A Practical Approach to Hyperglycemia Management in the Intensive Care Unit: Evaluation of an Intensive Insulin Infusion Protocol. Pharmacotherapy 26:10, 1410-1420
CrossRef979
T WHITE, B PETRISOR, M BHANDARI. (2006) Prevention of fat embolism syndrome
CrossRef980
R. P. Tracy. (2006) The Five Cardinal Signs of Inflammation: Calor, Dolor, Rubor, Tumor ... and Penuria (Apologies to Aulus Cornelius Celsus, De medicina, c. A.D. 25). The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 61:10, 1051-1052
CrossRef981
R STEVENS, P NYQUIST. (2006) Coma, Delirium, and Cognitive Dysfunction in Critical Illness. Critical Care Clinics 22:4, 787-804
CrossRef982
David Gaieski, Munish Goyal. (2006) The Implementation of New Therapies for Severe Sepsis: Some Questions Raised by "Early Goal-directed Therapy, Corticosteroid, and Recombinant Human Activated Protein C for the Treatment of Severe Sepsis and Septic Shock in the Emergency Department". Academic Emergency Medicine 13:9, 997-999
CrossRef983
Kyros Ipaktchi, Saman Arbabi. (2006) Advances in burn critical care. Critical Care Medicine 34:Suppl, S239-S244
CrossRef984
Xiaomei Feng, Wei Yan, Xiaoming Liu, Manlin Duan, Xinhua Zhang, Jianguo Xu. (2006) Effects of Hydroxyethyl Starch 130/0.4 on Pulmonary Capillary Leakage and Cytokines Production and NF-κB Activation in CLP-Induced Sepsis in Rats. Journal of Surgical Research 135:1, 129-136
CrossRef985
Franz Thaller, Karl Stickler, Viktor Lenhart, Christoph Wenisch. (2006) Sepsis. Wiener klinische Wochenschrift Education 1:2, 93-108
CrossRef986
John C. Marshall. (2006) Biomarkers of sepsis. Current Infectious Disease Reports 8:5, 351-357
CrossRef987
Kathy Triantafilou, Martha Triantafilou. (2006) Innate recognition of bacteria: potential therapeutic targets for bacterial sepsis. Expert Review of Clinical Immunology 2:5, 787-799
CrossRef988
H. Bryant Nguyen, Stephen W. Corbett. (2006) In reply. Academic Emergency Medicine 13:9, 999-1000
CrossRef989
B. Gårdlund. (2006) Activated protein C (Xigris
CrossRef990
Ismail Cinel, R. Phillip Dellinger. (2006) Current treatment of severe sepsis. Current Infectious Disease Reports 8:5, 358-365
CrossRef991
Diederik van de Beek, Martijn Weisfelt, Jan de Gans, Allan R Tunkel, Eelco FM Wijdicks. (2006) Drug Insight: adjunctive therapies in adults with bacterial meningitis. Nature Clinical Practice Neurology 2:9, 504-516
CrossRef992
Johannes Hadem, Frank Schröder, Thomas Winkler, Bernhard Gohrbandt, Dieter Fischer, Thomas Korte, Helmut Drexler. (2006) One day from dyspnea to death. Clinical Research in Cardiology 95:9, 477-481
CrossRef993
Germaine Escames, Darío Acuña-Castroviejo, Luis Carlos López, Dun-xian Tan, Maria Dolores Maldonado, Marina Sánchez-Hidalgo, Josefa León, Russel J. Reiter. (2006) Pharmacological utility of melatonin in the treatment of septic shock: experimental and clinical evidence. Journal of Pharmacy and Pharmacology 58:9, 1153-1165
CrossRef994
Michael W. Donnino, Jonathan Fischer. (2006) Determining disease severity in severe sepsis and septic shock. Internal and Emergency Medicine 1:3, 219-220
CrossRef995
B. J. L. Kendrick, A. G. Gray, A. Pickworth, M. P. R. Watters. (2006) Drotrecogin alfa (activated) in severe falciparum malaria. Anaesthesia 61:9, 899-902
CrossRef996
Angela Reynolds, Jonathan Rubin, Gilles Clermont, Judy Day, Yoram Vodovotz, G. Bard Ermentrout. (2006) A reduced mathematical model of the acute inflammatory response: I. Derivation of model and analysis of anti-inflammation. Journal of Theoretical Biology 242:1, 220-236
CrossRef997
Alessandro Pontes-Arruda, Afra Maria Albuquerque Arag??o, Juliana Deusdar?? Albuquerque. (2006) Effects of enteral feeding with eicosapentaenoic acid, ??-linolenic acid, and antioxidants in mechanically ventilated patients with severe sepsis and septic shock*. Critical Care Medicine 34:9, 2325-2333
CrossRef998
Ian Jenkins. (2006) Evidence-based sepsis therapy: A hospitalist perspective. Journal of Hospital Medicine 1:5, 285-295
CrossRef999
Stephanie R. Martin, Michael R. Foley. (2006) Intensive care in obstetrics: An evidence-based review. American Journal of Obstetrics and Gynecology 195:3, 673-689
CrossRef1000
Jean-Louis Vincent. (2006) Combining the old with the new to improve therapeutics. Current Infectious Disease Reports 8:5, 344-345
CrossRef1001
Greg S. Martin. (2006) Sepsis: The future is bright*. Critical Care Medicine 34:9, 2484-2485
CrossRef1002
Marc O. Maybauer, Dirk M. Maybauer, John F. Fraser, Lillian D. Traber, Martin Westphal, Perenlei Enkhbaatar, Robert A. Cox, Ruksana Huda, Hal K. Hawkins, Naoki Morita, Kazunori Murakami, Akio Mizutani, David N. Herndon, Daniel L. Traber. (2006) Recombinant human activated protein C improves pulmonary function in ovine acute lung injury resulting from smoke inhalation and sepsis. Critical Care Medicine 34:9, 2432-2438
CrossRef1003
Rui Moreno, Susana Afonso, Teresa Fevereiro. (2006) Incidence of sepsis in hospitalized patients. Current Infectious Disease Reports 8:5, 346-350
CrossRef1004
Claudia Voves, Walter A Wuillemin, Sacha Zeerleder. (2006) International Society on Thrombosis and Haemostasis score for overt disseminated intravascular coagulation predicts organ dysfunction and fatality in sepsis patients. Blood Coagulation & Fibrinolysis 17:6, 445-451
CrossRef1005
J WEINTRAUB, T SATTERWHITE, M ALLO. (2006) The use of drotrecogin alfa recombinant activated protein C for severe sepsis in the critically burned patient: A new treatment approach. Burns 32:6, 783-787
CrossRef1006
Guillaume Monneret, Alain Lepape, Nicolas Voirin, Julien Bohé, Fabienne Venet, Anne-Lise Debard, Hélène Thizy, Jacques Bienvenu, François Gueyffier, Philippe Vanhems. (2006) Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Medicine 32:8, 1175-1183
CrossRef1007
M. Bauer, F. Brunkhorst, T. Welte, H. Gerlach, K. Reinhart. (2006) Sepsis. Der Anaesthesist 55:8, 835-845
CrossRef1008
K. Reinhart, F. M. Brunkhorst, H.-G. Bone, H. Gerlach, M. Gründling, G. Kreymann, P. Kujath, G. Marggraf, K. Mayer, A. Meier-Hellmann, C. Peckelsen, C. Putensen, F. Stüber, M. Quintel, M. Ragaller, R. Rossaint, N. Weiler, T. Welte, K. Werdan. (2006) Diagnose und Therapie der Sepsis. Clinical Research in Cardiology 95:8, 429-454
CrossRef1009
Marc W Merx, Christian Weber. (2006) Statins in the intensive care unit. Current Opinion in Critical Care 12:4, 309-314
CrossRef1010
Jean-Louis Vincent. (2006) Drotrecogin alfa (activated) in the treatment of severe sepsis. Expert Review of Anti-infective Therapy 4:4, 537-547
CrossRef1011
Farhad Kapadia, Charudatt Shirwadkar. (2006) Drotrecogin alfa in tropical infections and refractory multi-organ failure. Intensive Care Medicine 32:8, 1281-1282
CrossRef1012
Deborah J. Stearns-Kurosawa, Florea Lupu, Fletcher B. Taylor, Gary Kinasewitz, Shinichiro Kurosawa. (2006) Sepsis and Pathophysiology of Anthrax in a Nonhuman Primate Model. The American Journal of Pathology 169:2, 433-444
CrossRef1013
Martin Hughes. (2006) Recombinant human activated protein C. International Journal of Antimicrobial Agents 28:2, 90-94
CrossRef1014
Anastasia Kotanidou, Heleni Loutrari, Evangelos Papadomichelakis, Constantinos Glynos, Christina Magkou, Apostolos Armaganidis, Andreas Papapetropoulos, Charis Roussos, Stylianos E. Orfanos. (2006) Inhaled activated protein C attenuates lung injury induced by aerosolized endotoxin in mice. Vascular Pharmacology 45:2, 134-140
CrossRef1015
Lois W. Br??ggemann, Saskia H. H. F. Schoenmakers, Angelique P. Groot, Pieter H. Reitsma, C Arnold Spek. (2006) Role of the factor V Leiden mutation in septic peritonitis assessed in factor V Leiden transgenic mice*. Critical Care Medicine 34:8, 2201-2206
CrossRef1016
Simon V. Baudouin. (2006) Natural anticoagulants in sepsis???Too much of a good thing?*. Critical Care Medicine 34:8, 2256-2257
CrossRef1017
Sjoukje H. Slofstra, Hugo ten Cate, C. Arnold Spek. (2006) Signal transduction induced by activated protein C: no role in protection against sepsis?. Trends in Molecular Medicine 12:8, 374-381
CrossRef1018
Leslie Hoover, Grant V. Bochicchio, Lena M. Napolitano, Manjari Joshi, Kelly Bochicchio, Walter Meyer, Thomas M. Scalea. (2006) Systemic Inflammatory Response Syndrome and Nosocomial Infection in Trauma. The Journal of Trauma: Injury, Infection, and Critical Care 61:2, 310-317
CrossRef1019
Matthias Turina, Ashley Dickinson, Sarah Gardner, Hiram C. Polk. (2006) Monocyte HLA-DR and Interferon-Gamma Treatment in Severely Injured Patients—A Critical Reappraisal More Than a Decade Later. Journal of the American College of Surgeons 203:1, 73-81
CrossRef1020
Jean-Jacques Quioc, Khalid A. Tazi, Didier Lebrec, Richard Moreau. (2006) The quest for new therapies in patients with cirrhosis and sepsis. Gastroentérologie Clinique et Biologique 30:6-7, 819-822
CrossRef1021
Anne-Cornelie J. M. de Pont, Kamran Bakhtiari, Barbara A. Hutten, Evert de Jonge, George P. Vlasuk, William E. Rote, Marcel Levi, Harry R. Buller, Joost C. M. Meijers. (2006) Endotoxaemia induces resistance to activated protein C in healthy humans. British Journal of Haematology 134:2, 213-219
CrossRef1022
Chin-Ming Chen, Ching-Cheng Hou, Kuo-Chen Cheng, Ru-Ling Tian, Ching-Ping Chang, Mao-Tsun Lin. (2006) Activated protein C therapy in a rat heat stroke model*. Critical Care Medicine 34:7, 1960-1966
CrossRef1023
Keisuke Maeda, Masahiko Hirota, Hideo Baba. (2006) Discussion on Applicability of Disseminated Intravascular Coagulation Parameters in the Assessment of the Severity of Acute Pancreatitis. Pancreas 33:1, 107-108
CrossRef1024
Philip S. Barie, Lynn J. Hydo, Jian Shou, Soumitra R. Eachempati. (2006) Efficacy and Safety of Drotrecogin Alfa (Activated) for the Therapy of Surgical Patients with Severe Sepsis. Surgical Infections 7:supplement 2, s-77-s-80
CrossRef1025
Kenichi A. Tanaka, Fania Szlam, Jerrold H. Levy. (2006) The effect of aprotinin on activated protein C-mediated downregulation of endogenous thrombin generation. British Journal of Haematology 134:1, 77-82
CrossRef1026
Zacharyx A. Rubin, Michael K. Leonard, Greg S. Martin. (2006) Brief Report: Tuberculosis Sepsis and Activated Protein C. The American Journal of the Medical Sciences 332:1, 48-50
CrossRef1027
Dejan V. Radenkovic, Djordje D. Bajec, Aleksandar R. Karamarkovic. (2006) Discussion on Applicability of Disseminated Intravascular Coagulation Parameters in the Assessment of the Severity of Acute Pancreatitis. Pancreas 33:1, 106-107
CrossRef1028
Graham Ramsay. (2006) Progress in the Management of Sepsis: The Surviving Sepsis Campaign. Surgical Infections 7:supplement 2, s-73-s-75
CrossRef1029
Sukhjeewan Basran, Robert J. Frumento, Allison Cohen, Samuel Lee, Yuling Du, Ervant Nishanian, Harold S. Kaplan, Mark Stafford-Smith, Elliott Bennett-Guerrero. (2006) The Association Between Duration of Storage of Transfused Red Blood Cells and Morbidity and Mortality After Reoperative Cardiac Surgery. Anesthesia & Analgesia 103:1, 15-20
CrossRef1030
Olaf Penack, Thomas Beinert, Dieter Buchheidt, Hermann Einsele, Holger Hebart, Michael G. Kiehl, Gero Massenkeil, Xaver Schiel, Jan Schleicher, Philipp B. Staber, Stefan Wilhelm, Hans Wolf, Helmut Ostermann. (2006) Management of sepsis in neutropenia: guidelines of the infectious diseases working party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Annals of Hematology 85:7, 424-433
CrossRef1031
Daniel De Backer, Colin Verdant, Marialuisa Chierego, Marc Koch, Antonino Gullo, Jean-Louis Vincent. (2006) Effects of drotrecogin alfa activated on microcirculatory alterations in patients with severe sepsis. Critical Care Medicine 34:7, 1918-1924
CrossRef1032
Martina Brueckmann, Ursula Hoffmann, Martin Borggrefe. (2006) Beyond sepsis: Activated protein C and heat stroke*. Critical Care Medicine 34:7, 2020-2021
CrossRef1033
KA Brown, SD Brain, JD Pearson, JD Edgeworth, SM Lewis, DF Treacher. (2006) Neutrophils in development of multiple organ failure in sepsis. The Lancet 368:9530, 157-169
CrossRef1034
Shannon M. Bates, Jeffrey I. Weitz. (2006) The status of new anticoagulants. British Journal of Haematology 134:1, 3-19
CrossRef1035
Philip Hunter. (2006) Sepsis under siege: A new understanding of sepsis might lead to the development of therapies to treat septic shock. EMBO reports 7:7, 667-669
CrossRef1036
K REINHART. (2006) Markers for Sepsis Diagnosis: What is Useful?. Critical Care Clinics 22:3, 503-519
CrossRef1037
A GULLO. (2006) Management of Severe Sepsis and Septic Shock: Challenges and Recommendations. Critical Care Clinics 22:3, 489-501
CrossRef1038
F HURTADO. (2006) The Role of Bundles in Sepsis Care. Critical Care Clinics 22:3, 521-529
CrossRef1039
E. G. Seferian, B. Afessa. (2006) Adult Intensive Care Unit Use at the End of Life: A Population-Based Study. Mayo Clinic Proceedings 81:7, 896-901
CrossRef1040
M K Holly, J W Dear, X Hu, A N Schechter, M T Gladwin, S M Hewitt, P S T Yuen, R A Star. (2006) Biomarker and drug-target discovery using proteomics in a new rat model of sepsis-induced acute renal failure. Kidney International
CrossRef1041
Titus L. Daniels, J Stephen Dummer, Gordon R. Bernard, Aaron P. Milstone. (2006) A Case Series of Drotrecogin Alfa (Activated) in Lung Transplant Recipients. Transplantation 81:12, 1739-1742
CrossRef1042
Bharath Wootla, Suryasarathi Dasgupta, Vincent Mallet, Michel D Kazatchkine, Valakunja Nagaraja, Alain Friboulet, Srinivas V Kaveri, Sébastien Lacroix-Desmazes. (2006) Physiopathology of catalytic antibodies: the case for factor VIII-hydrolyzing immunoglobulin G. Blood Coagulation & Fibrinolysis 17:4, 229-234
CrossRef1043
Jonas Sunden-Cullberg, Anna Norrby-Teglund, Carl Johan Treutiger. (2006) The role of high mobility group box-1 protein in severe sepsis. Current Opinion in Infectious Diseases 19:3, 231-236
CrossRef1044
Raphael Favory, Steve Lancel, Xavier Maréchal, Stéphanie Tissier, Remi Neviere. (2006) Cardiovascular protective role for activated protein C during endotoxemia in rats. Intensive Care Medicine 32:6, 899-905
CrossRef1045
Elliot Melendez, Richard Bachur. (2006) Advances in the emergency management of pediatric sepsis. Current Opinion in Pediatrics 18:3, 245-253
CrossRef1046
Fredric M. Pieracci, Philip S. Barie, Alfons Pomp. (2006) Critical care of the bariatric patient. Critical Care Medicine 34:6, 1796-1804
CrossRef1047
Karl Thomas. (2006) Transmitting and absorbing new information on the early identification of sepsis patients: The partial thromboplastin time biphasic waveform*. Critical Care Medicine 34:6, 1829-1831
CrossRef1048
K. Reinhart, F. M. Brunkhorst, H.-G. Bone, H. Gerlach, M. Gründling, G. Kreymann, P. Kujath, G. Marggraf, K. Mayer, A. Meier-Hellmann, C. Peckelsen, C. Putensen, F. Stüber, M. Quintel, M. Ragaller, R. Rossaint, N. Weiler, T. Welte, K. Werdan. (2006) Diagnose und Therapie der Sepsis. Intensivmedizin und Notfallmedizin 43:5, 369-384
CrossRef1049
Richard N. Pierson. (2006) Lung Transplantation: Current Status and Challenges. Transplantation 81:12, 1609-1615
CrossRef1050
Heather L. Cox, Kevin B. Laupland, Braden J. Manns. (2006) Economic evaluation in critical care medicine. Journal of Critical Care 21:2, 117-124
CrossRef1051
Vinay K Sharma, R Phillip Dellinger. (2006) Treatment options for severe sepsis and septic shock. Expert Review of Anti-infective Therapy 4:3, 395-403
CrossRef1052
Dominique Lasne, Brigitte Jude, Sophie Susen. (2006) From normal to pathological hemostasis. Canadian Journal of Anesthesia/Journal canadien d'anesthésie 53:S2, S2-S11
CrossRef1053
Yaniv Almog, Victor Novack, Rinat Megralishvili, Sergio Kobal, Leonid Barski, Daniel King, Doron Zahger. (2006) Plasma Level of N Terminal Pro-Brain Natriuretic Peptide as a Prognostic Marker in Critically Ill Patients. Anesthesia & Analgesia 102:6, 1809-1815
CrossRef1054
C. Bauer. (2006) Aktiviertes Protein C auch bei niedrigem Mortalitätsrisiko?. Der Anaesthesist 55:6, 711-712
CrossRef1055
Jan J De Waele, Eric Hoste. (2006) Current pharmacotherapeutic recommendations for acute pancreatitis. Expert Opinion on Pharmacotherapy 7:8, 1017-1025
CrossRef1056
Martina Brueckmann, Adriane Schulze Nahrup, Siegfried Lang, Thomas Bertsch, Kenji Fukudome, Volker Liebe, Jens J. Kaden, Ursula Hoffmann, Martin Borggrefe, Guenter Huhle. (2006) Recombinant human activated protein C upregulates the release of soluble fractalkine from human endothelial cells. British Journal of Haematology 133:5, 550-557
CrossRef1057
Mitchell P. Fink, Peter M. Suter. (2006) The future of our specialty: Critical care medicine a decade from now. Critical Care Medicine 34:6, 1811-1816
CrossRef1058
Vanaporn Wuthiekanun, Sharon J Peacock. (2006) Management of melioidosis. Expert Review of Anti-infective Therapy 4:3, 445-455
CrossRef1059
H Yasuda, P S T Yuen, X Hu, H Zhou, R A Star. (2006) Simvastatin improves sepsis-induced mortality and acute kidney injury via renal vascular effects. Kidney International 69:9, 1535-1542
CrossRef1060
M. Brueckmann, G. Huhle, M. Max. (2006) Wirkungsweise von rekombinantem humanem aktiviertem Protein C. Der Anaesthesist 55:S1, 5-15
CrossRef1061
O. Moerer, H. Burchardi. (2006) Kosten der Sepsis. Der Anaesthesist 55:S1, 36-42
CrossRef1062
Brahm Goldstein, Simon Nadel, Mark Peters, Roger Barton, Flavia Machado, Howard Levy, Douglas J. Haney, Barbara Utterback, Mark D. Williams, Brett P. Giroir. (2006) ENHANCE: Results of a global open-label trial of drotrecogin alfa (activated) in children with severe sepsis*. Pediatric Critical Care Medicine 7:3, 200-211
CrossRef1063
Brahm Goldstein, Simon Nadel, Mark Peters, Roger Barton, Flavia Machado, Brett Giroir. (2006) The authors reply: Academic and industry partnerships*. Pediatric Critical Care Medicine 7:3, 278-279
CrossRef1064
L. Engelmann, S. Petros. (2006) Identifikation internistischer Patienten für die Therapie mit aktiviertem Protein C. Der Anaesthesist 55:S1, 24-29
CrossRef1065
Jan A. Hazelzet. (2006) How to ENHANCE our knowledge of activated protein C during pediatric sepsis trials: Pediatric versus adult trials*. Pediatric Critical Care Medicine 7:3, 277-278
CrossRef1066
Peter Schellongowski, Edith Bauer, Ulrike Holzinger, Thomas Staudinger, Michael Frass, Klaus Laczika, Gottfried J. Locker, Peter Quehenberger, Werner Rabitsch, Peter Schenk, Paul Knobl. (2006) Treatment of adult patients with sepsis-induced coagulopathy and purpura fulminans using a plasma-derived protein C concentrate (CeprotinR). Vox Sanguinis 90:4, 294-301
CrossRef1067
Andreas Sashegyi, Benjamin L. Trzaskoma, David R. Nelson, Mark D. Williams, William Macias. (2006) International INtegrated Database for the Evaluation of severe sePsis and drotrecogin alfa (activated) THerapy: component trials and statistical methods for INDEPTH. Current Medical Research and Opinion 22:5, 1001-1012
CrossRef1068
John P. Kepros, Jeff M. Gauvin, Donald N. Reed, Janet Osuch. (2006) Acute Lung Injury: An Indicator of Serious Systemic Illness. Current Surgery 63:3, 197-201
CrossRef1069
M. Cobas Meyer, H. Langenfeld, R. Rossaint, A. Sablotzki. (2006) PROWESS, ENHANCE und ADDRESS. Der Anaesthesist 55:S1, 16-23
CrossRef1070
Bruce R. Bistrian, Karen C. McCowen. (2006) Nutritional and metabolic support in the adult intensive care unit: Key controversies. Critical Care Medicine 34:5, 1525-1531
CrossRef1071
S. Utzolino, P. Baier, U. T. Hopt. (2006) Identifikation chirurgischer Patienten für die Therapie mit aktiviertem Drotrecogin alfa. Der Anaesthesist 55:S1, 30-35
CrossRef1072
R. Rossaint, H. Gerlach. (2006) Forschen als Selbstzweck oder Forschen zum Wohle des Patienten?. Der Anaesthesist 55:S1, 3-4
CrossRef1073
Marcus Hentrich, Karl Fehnle, Helmut Ostermann, Joachim Kienast, Oliver Cornely, Christoph Salat, Ralf ??belacker, Dieter Buchheidt, Gerhard Behre, Wolfgang Hiddemann, Xaver Schiel. (2006) IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: A randomized, controlled, multiple-center trial*. Critical Care Medicine 34:5, 1319-1325
CrossRef1074
The National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. (2006) Efficacy and Safety of Corticosteroids for Persistent Acute Respiratory Distress Syndrome. New England Journal of Medicine 354:16, 1671-1684
Full Text1075
Ranjit I Kylat, Arne Ohlsson, Ranjit I Kylat. 2006. Recombinant human activated protein C for severe sepsis in neonates. .
CrossRef1076
L. Keith Scott, Steven A. Conrad. 2006. Sepsis. .
CrossRef1077
José A. Fernández, Antti E. Vento, Mikko Jormalainen, John H. Griffin, Ero Pesonen, Martti Syrjälä, Heikki Repo, Sten-Erik Jansson, O. Juhan Rämö, Jari Petäjä. (2006) Activated Protein C in the Cardioplegic Solution on a Porcine Model of Coronary Ischemia-Reperfusion has Deleterious Hemodynamic Effects. Cardiovascular Drugs and Therapy 20:2, 113-121
CrossRef1078
M. J. Nyirenda, T. Sandeep, I. Grant, G. Price, J. A. McKnight. (2006) Severe acidosis in patients taking metformin-rapid reversal and survival despite high APACHE score. Diabetic Medicine 23:4, 432-435
CrossRef1079
Jean-Louis Vincent. (2006) Sepsis in the ICU: who needs progress?. Intensive Care Medicine 32:4, 609-609
CrossRef1080
K. Reinhart, F. M. Brunkhorst, H. G. Bone, H. Gerlach, M. Gründling, G. Kreymann, P. Kujath, G. Marggraf, K. Mayer, A. Meier-Hellmann, C. Peckelsen, C. Putensen, M. Quintel, M. Ragaller, R. Rossaint, F. Stüber, N. Weiler, T. Welte, K. Werdan. (2006) Diagnose und Therapie der Sepsis. Der Internist 47:4, 356-373
CrossRef1081
Alexei Iakhiaev, Steven Idell. (2006) Activation and Degradation of Protein C by Primary Rabbit Pleural Mesothelial Cells. Lung 184:2, 81-88
CrossRef1082
William L. Macias. (2006) Activated protein C: do more survive?. Intensive Care Medicine 32:4, 605-607
CrossRef1083
Andreas Kortgen, Petra Niederpr??m, Michael Bauer. (2006) Implementation of an evidence-based ???standard operating procedure??? and outcome in septic shock*. Critical Care Medicine 34:4, 943-949
CrossRef1084
Bradford Winters, Todd Dorman. (2006) Patient-safety and quality initiatives in the intensive-care unit. Current Opinion in Anaesthesiology 19:2, 140-145
CrossRef1085
A. P. Meert, J. P. Sculier. (2006) Activated protein C in daily practice. Intensive Care Medicine 32:4, 617-617
CrossRef1086
Marcus J. Schultz, Peter E. Spronk, Hazra S. Moeniralam. (2006) Tight glycaemic control: a survey of intensive care practice in the Netherlands. Intensive Care Medicine 32:4, 618-619
CrossRef1087
Mark D. Siegel. (2006) Applying the evidence: Multiple urgent therapies for patients with sepsis*. Critical Care Medicine 34:4, 1264-1265
CrossRef1088
Marcus J. Schultz, Marcel Levi. (2006) Prescription of rh-APC differs substantially among western European countries. Intensive Care Medicine 32:4, 630-631
CrossRef1089
Sherri L Alexander, Frank R Ernst. (2006) Use of Drotrecogin alfa (activated) in Older Patients with Severe Sepsis. Pharmacotherapy 26:4, 533-538
CrossRef1090
Marius Terblanche, Yaniv Almog, Robert S Rosenson, Terry S Smith, Daniel G Hackam. (2006) Statins: panacea for sepsis?. The Lancet Infectious Diseases 6:4, 242-248
CrossRef1091
Nathan I. Shapiro, Michael D. Howell, Daniel Talmor, Dermot Lahey, Long Ngo, Jon Buras, Richard E. Wolfe, J Woodrow Weiss, Alan Lisbon. (2006) Implementation and outcomes of the Multiple Urgent Sepsis Therapies (MUST) protocol*. Critical Care Medicine 34:4, 1025-1032
CrossRef1092
S. Kluge, G. Kreymann. (2006) Zielgerichtete Kreislauftherapie. Der Internist 47:4, 389-401
CrossRef1093
O. Moerer, H. Burchardi. (2006) Kosten der Sepsis. Der Anaesthesist
CrossRef1094
(2006) Eficacia de la drotrecogina alfa (activada) en el tratamiento de la sepsis grave con baja probabilidad de muerte. Medicina Intensiva 30:2, 84-86
CrossRef1095
Charles L. Sprung, Yasser Sakr, Jean-Louis Vincent, Jean-Roger Gall, Konrad Reinhart, V. Marco Ranieri, Herwig Gerlach, Jonathan Fielden, C. B. Groba, Didier Payen. (2006) An evaluation of systemic inflammatory response syndrome signs in the Sepsis Occurrence in Acutely ill Patients (SOAP) study. Intensive Care Medicine 32:3, 421-427
CrossRef1096
H. A. Adams, G. Baumann, I. Cascorbi, C. Ebener, M. Emmel, S. Geiger, U. Janssens, U. Klima, H. J. Klippe, W. T. Knoefel, G. Marx, U. Müller-Werdan, H. C. Pape, J. Piek, H. Prange, D. Roesner, B. Roth, T. Schürholz, T. Standl, W. Teske, P. M. Vogt, G. S. Werner, J. Windolf, R. Zander, H. R. Zerkowski. (2006) Empfehlungen zur Diagnostik und Therapie der Schockformen der IAG Schock der DIVI. Intensivmedizin und Notfallmedizin 43:2, 156-172
CrossRef1097
M. Furebring, L. Hakansson, P. Venge, J. Sjolin. (2006) C5a, Interleukin-8 and Tumour Necrosis factor-alpha-Induced Changes in Granulocyte and Monocyte Expression of Complement Receptors in Whole Blood and on Isolated Leukocytes. Scandinavian Journal of Immunology 63:3, 208-216
CrossRef1098
Suveer Singh, Timothy W. Evans. (2006) Organ dysfunction during sepsis. Intensive Care Medicine 32:3, 349-360
CrossRef1099
Bekele Afessa. (2006) Intensive care unit physician staffing: Seven days a week, 24 hours a day*. Critical Care Medicine 34:3, 894-895
CrossRef1100
Arthur J. Chu. (2006) Tissue factor upregulation drives a thrombosis–inflammation circuit in relation to cardiovascular complications. Cell Biochemistry and Function 24:2, 173-192
CrossRef1101
John H. Griffin, José A. Fernández, Laurent O. Mosnier, Dong Liu, Tong Cheng, Huang Guo, Berislav V. Zlokovic. (2006) The promise of protein C. Blood Cells, Molecules, and Diseases 36:2, 211-216
CrossRef1102
R DELLINGER, E ABRAHAM, G BERNARD, J MARSHALL, J VINCENT. (2006) Controversies in sepsis clinical trials: proceedings of a meeting of the International Sepsis Forum, Lausanne, Switzerland, September 29, 2001. Journal of Critical Care 21:1, 38-47
CrossRef1103
Neil A. Goldenberg, Marilyn J. Manco-Johnson. (2006) Pediatric hemostasis and use of plasma components. Best Practice & Research Clinical Haematology 19:1, 143-155
CrossRef1104
Marcel Levi, Evert de Jonge, Tom van der Poll. (2006) Plasma and plasma components in the management of disseminated intravascular coagulation. Best Practice & Research Clinical Haematology 19:1, 127-142
CrossRef1105
George J Rubeiz, Christopher M Marrone, Jacques R Leclerc. (2006) Treatment of Heparin-Induced Thrombocytopenia with Drotrecogin Alfa (activated). Pharmacotherapy 26:3, 428-434
CrossRef1106
Chin-Wei Chiao, Shoei-Sheng Lee, Chin-Chen Wu, Ming-Jai Su. (2006) N-Allylsecoboldine as a novel agent prevents acute renal failure during endotoxemia. European Journal of Pharmacology 535:1-3, 291-300
CrossRef1107
Mario Menschikowski, Albert Hagelgans, Gabriele Siegert. (2006) Secretory phospholipase A2 of group IIA: Is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases?. Prostaglandins & Other Lipid Mediators 79:1-2, 1-33
CrossRef1108
Yasser Sakr, Konrad Reinhart, Jean-Louis Vincent, Charles L. Sprung, Rui Moreno, V Marco Ranieri, Daniel De Backer, Didier Payen. (2006) Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study*. Critical Care Medicine 34:3, 589-597
CrossRef1109
Jérome Aboab, Olivier Nardi, Diane Lipiner, Tarek Sharshar, Djillali Annane. (2006) Emerging drugs for the treatment of sepsis. Expert Opinion on Emerging Drugs 11:1, 7-22
CrossRef1110
James S. Krinsley. (2006) A simple intervention that saves lives and money*. Critical Care Medicine 34:3, 896-897
CrossRef1111
William H Fissell. (2006) Developments towards an artificial kidney. Expert Review of Medical Devices 3:2, 155-165
CrossRef1112
Bruce B. Feinberg. (2006) Preeclampsia: the Death of Goliath. American Journal of Reproductive Immunology 55:2, 84-98
CrossRef1113
R Phillip Dellinger. (2006) Recombinant activated protein C: Decisions for administration. Critical Care Medicine 34:2, 530-531
CrossRef1114
Krista M King, Ginger D Langley, Kenneth VI Rolston, Gregory F Pratt, Todd W Canada, Gregory H Botz. (2006) Economic evaluation in critical care: a focus on severe sepsis in oncology. Expert Review of Pharmacoeconomics & Outcomes Research 6:1, 49-58
CrossRef1115
David T Huang, Derek C Angus. (2006) Designing clinical trials in acute lung injury/acute respiratory distress syndrome. Current Opinion in Critical Care 12:1, 32-36
CrossRef1116
Joan T Merrill, Ronald A Asherson. (2006) Catastrophic antiphospholipid syndrome. Nature Clinical Practice Rheumatology 2:2, 81-89
CrossRef1117
R Phillip Dellinger, Steven M. Hollenberg. (2006) Is It Over Yet? Time for Reassessment of the Determination of Septic Shock Resolution. Critical Care Medicine 34:2, 576-577
CrossRef1118
Matthias W. A. Angstwurm, Carl-Erik Dempfle, Michael Spannagl. (2006) New disseminated intravascular coagulation score: A useful tool to predict mortality in comparison with Acute Physiology and Chronic Health Evaluation II and Logistic Organ Dysfunction scores. Critical Care Medicine 34:2, 314-320
CrossRef1119
A. GRUBER, J. A. FERNANDEZ, L. BUSH, U. MARZEC, J. H. GRIFFIN, S. R. HANSON, E. DI CERA. (2006) Limited generation of activated protein C during infusion of the protein C activator thrombin analog W215A/E217A in primates. Journal of Thrombosis and Haemostasis 4:2, 392-397
CrossRef1120
Greg S. Martin. (2006) Albumin. Critical Care Medicine 34:2, 579
CrossRef1121
Kevin E Anger, Paul M Szumita. (2006) Barriers to Glucose Control in the Intensive Care Unit. Pharmacotherapy 26:2, 214-228
CrossRef1122
Peter C. Minneci, Katherine J. Deans, Xizhong Cui, Steven M. Banks, Charles Natanson, Peter Q. Eichacker. (2006) Antithrombotic therapies for sepsis: A need for more studies*. Critical Care Medicine 34:2, 538-541
CrossRef1123
Michael H Young, N Cary Engleberg, Zuber D Mulla, David M Aronoff. (2006) Therapies for necrotising fasciitis. Expert Opinion on Biological Therapy 6:2, 155-165
CrossRef1124
M Michele Mariscalco. (2006) Unlocking (perhaps unblocking) the microcirculation in sepsis*. Critical Care Medicine 34:2, 561-562
CrossRef1125
B. Poulton. (2006) Advances in the management of sepsis: the randomised controlled trials behind the Surviving Sepsis Campaign recommendations. International Journal of Antimicrobial Agents 27:2, 97-101
CrossRef1126
Jonathan E. McDunn, T. Philip Chung, Jason M. Laramie, R. Reid Townsend, J. Perren Cobb. (2006) Physiologic genomics. Surgery 139:2, 133-139
CrossRef1127
Thomas A Russo, James R Johnson. (2006) Extraintestinal isolates of Escherichia coli : identification and prospects for vaccine development. Expert Review of Vaccines 5:1, 45-54
CrossRef1128
Jean-Louis Vincent, Yasser Sakr, Charles L. Sprung, V Marco Ranieri, Konrad Reinhart, Herwig Gerlach, Rui Moreno, Jean Carlet, Jean-Roger Le Gall, Didier Payen. (2006) Sepsis in European intensive care units: Results of the SOAP study*. Critical Care Medicine 34:2, 344-353
CrossRef1129
Jason Paragas, Thomas W Geisbert. (2006) Development of treatment strategies to combat Ebola and Marburg viruses. Expert Review of Anti-infective Therapy 4:1, 67-76
CrossRef1130
J Carlet. (2006) Prescribing indications based on successful clinical trials in sepsis: A difficult exercise. Critical Care Medicine 34:2, 525-529
CrossRef1131
Minna Ilmakunnas, Eero J. Pesonen, Krister H??ckerstedt, Heikki M??kisalo, Jose A. Fernandez, John H. Griffin, Heikki Repo, Sanna Siitonen, Jari Pet??j??. (2006) Graft protein C entrapment is associated with reduced phagocyte activation during reperfusion in human liver transplantation. Critical Care Medicine 34:2, 426-432
CrossRef1132
Christian Schumann, Kathy Triantafilou, Joachim Kamenz, Hartmut Hanke, Martha Triantafilou, Silke Wittemann, Thomas Joos, Vinzenz Hombach, E. Marion Schneider, Philipp Lepper. (2006) Septic shock caused by Streptococcus pneumoniae in a post-splenectomy patient successfully treated with recombinant human activated protein C. Scandinavian Journal of Infectious Diseases 38:2, 139-142
CrossRef1133
O. Len Abad. (2006) Sepsis y shock séptico. Medicine - Programa de Formación Médica Continuada Acreditado 9:49, 3211-3218
CrossRef1134
R. Jain, A. DalNogare. (2006) Pharmacological Therapy for Acute Respiratory Distress Syndrome. Mayo Clinic Proceedings 81:2, 205-212
CrossRef1135
(2006) Drotrecogin Alfa (Activated) in Severe Sepsis. New England Journal of Medicine 354:1, 94-96
Full Text1136
Christophe Clec???h, Jean-Philippe Fosse, Philippe Karoubi, Francois Vincent, Imad Chouahi, Lilia Hamza, Michel Cupa, Yves Cohen. (2006) Differential diagnostic value of procalcitonin in surgical and medical patients with septic shock. Critical Care Medicine 34:1, 102-107
CrossRef1137
2006. Anticoagulant proteins. , 266-267.
CrossRef1138
N Naeem, M D Reed, R J Creger, S J Youngner, H M Lazarus. (2006) Transfer of the hematopoietic stem cell transplant patient to the intensive care unit: does it really matter?. Bone Marrow Transplantation 37:2, 119-133
CrossRef1139
Kenji Okajima. (2006) Journal of Microwave Surgery 24, 19-26
CrossRef1140
(2006) The editorial board, pediatric anesthesia. Pediatric Anesthesia 16:1, 1-2
CrossRef1141
Thomas L. Petty. (2006) The acute respiratory distress syndrome: Evolution of concepts and progress. Journal of Organ Dysfunction 2:1, 5-14
CrossRef1142
Patrick J. Neligan. 2006. Infectious Diseases and Bioterrorism. , 377-411.
CrossRef1143
Pasquale Piccinni, Maurizio Dan, Stefano Barbacini, Rizzieri Carraro, Emanuela Lieta, Silvio Marafon, Nereo Zamperetti, Alessandra Brendolan, Vincenzo D’Intini, Ciro Tetta, Rinaldo Bellomo, Claudio Ronco. (2006) Early isovolaemic haemofiltration in oliguric patients with septic shock. Intensive Care Medicine 32:1, 80-86
CrossRef1144
Yoshinobu SEKI. (2006) Guideline for unfractionated heparin therapy in DIC. Japanese Journal of Thrombosis and Hemostasis 17:3, 298-300
CrossRef1145
Todd W Rice. (2006) Treatment of severe sepsis: where next? Current and future treatment approaches after the introduction of drotrecogin alfa. Vascular Health and Risk Management 2:1, 3-18
CrossRef1146
H. Bryant Nguyen, Stephen W. Corbett, Kevin Menes, Thomas Cho, Jennifer Daugharthy, Walter Klein, William A. Wittlake. (2006) Early Goal-directed Therapy, Corticosteroid, and Recombinant Human Activated Protein C for the Treatment of Severe Sepsis and Septic Shock in the Emergency Department. Academic Emergency Medicine 13:1, 109-113
CrossRef1147
Greg S. Martin, David M. Mannino, Marc Moss. (2006) The effect of age on the development and outcome of adult sepsis*. Critical Care Medicine 34:1, 15-21
CrossRef1148
Kees H. Polderman, Armand R. J. Girbes. (2006) Intensive insulin therapy: Of harm and health, of hypes and hypoglycemia*. Critical Care Medicine 34:1, 246-248
CrossRef1149
Alan E. Jones. (2006) Evidence-based Therapies for Sepsis Care in the Emergency Department: Striking a Balance between Feasibility and Necessity. Academic Emergency Medicine 13:1, 82-83
CrossRef1150
Ziad Dahabreh, Rozalia Dimitriou, Byron Chalidis, Peter V Giannoudis. (2006) Coagulopathy and the role of recombinant human activated protein C in sepsis and following polytrauma. Expert Opinion on Drug Safety 5:1, 67-82
CrossRef1151
G Umberto Meduri, George P. Chrousos. (2006) Effectiveness of prolonged glucocorticoid treatment in acute respiratory distress syndrome: The right drug, the right way?*. Critical Care Medicine 34:1, 236-238
CrossRef1152
Lionel Riou França, Robert Launois, Katell Le Lay, Philippe Aegerter, Myriam Bouhassira, Patrick Meshaka, Bertrand Guidet. (2006) Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure. International Journal of Technology Assessment in Health Care 22:01,
CrossRef1153
Delphine Borgel, Sylvain Clauser, Caroline Bornstain, Ivan Bi??che, Alvine Bissery, V??ronique Remones, Jean-Yves Fagon, Martine Aiach, Jean-Luc Diehl. (2006) Elevated growth-arrest-specific protein 6 plasma levels in patients with severe sepsis. Critical Care Medicine 34:1, 219-222
CrossRef1154
Grażyna Michalska-Krzanowska, Maria Czupryńska. (2006) Recombinant Factor VII (Activated) for Haemorrhagic Complications of Severe Sepsis Treated with Recombinant Protein C (Activated). Acta Haematologica 116:2, 126-130
CrossRef1155
Harold L. Paz, Andrew A. Martin. (2006) Sepsis in an aging population*. Critical Care Medicine 34:1, 234-235
CrossRef1156
Colin Green, Jacqueline Dinnes, Andrea L. Takeda, Brian H. Cuthbertson. (2006) Evaluation of the cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom. International Journal of Technology Assessment in Health Care 22:01,
CrossRef1157
Michihiko Yamaguchi, Esteban C Gabazza, Osamu Taguchi, Yutaka Yano, Jiro Ikoma, Masahiko Kaito, Yuji Kojima, Ichiro Imoto, Akitoshi Satomi, Corina N. D'Alessandro-Gabazza, Tatsuya Hayashi, Hisataka Moriwaki, Koji Suzuki, Yukihiko Adachi. (2006) Decreased protein C activation in patients with fulminant hepatic failure. Scandinavian Journal of Gastroenterology 41:3, 331-337
CrossRef1158
Kenichi A. Tanaka, Jose A. Fernandez, Ulla M. Marzec, Andrew B. Kelly, Mitsunobu Mohri, John H. Griffin, Stephen R. Hanson, Andras Gruber. (2006) Soluble thrombomodulin is antithrombotic in the presence of neutralising antibodies to protein C and reduces circulating activated protein C levels in primates. British Journal of Haematology 132:2, 197-203
CrossRef1159
Thomas K. Day, Shane Bateman. 2006. Shock Syndromes. , 540-564.
CrossRef1160
Heng Joo Ng, Mark A. Crowther. (2006) New Anti-thrombotic Agents: Emphasis on Hemorrhagic Complications and Their Management. Seminars in Hematology 43, S77-S83
CrossRef1161
Caroline Riddell, Bronagh Blackwood. (2006) Severe sepsis: patient management focusing on administration of drotrecogin alpha (activated) infusion. Nursing in Critical Care 11:1, 7-15
CrossRef1162
Frederic Chagnon, M???hamed Bentourkia, Roger Lecomte, Michel Lessard, Olivier Lesur. (2006) Endotoxin-induced heart dysfunction in rats: Assessment of myocardial perfusion and permeability and the role of fluid resuscitation*. Critical Care Medicine 34:1, 127-133
CrossRef1163
Masami Yamada, Takashi Ichikawa, Toru Yamano, Fumio Kikumoto, Yuji Nishikimi, Norikazu Tamura, Tomoyuki Kitazaki. (2006) Optically Active Cyclohexene Derivative as a New Antisepsis Agent: An Efficient Synthesis of Ethyl (6R)-6-[N-(2-Chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242). CHEMICAL & PHARMACEUTICAL BULLETIN 54:1, 58-62
CrossRef1164
Martin H. Bluth, Emad Kandil, Catherine M. Mueller, Vishal Shah, Yin-Yao Lin, Hong Zhang, Lisa Dresner, Leonid Lempert, Maja Nowakowski, Richard Gross, Robert Schulze, Michael E. Zenilman. (2006) Sophorolipids block lethal effects of septic shock in rats in a cecal ligation and puncture model of experimental sepsis*. Critical Care Medicine 34:1, E188
CrossRef1165
Marcus J. Schultz, Jack J. Haitsma, Haibo Zhang, Arthur S. Slutsky. (2006) Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia???A review. Critical Care Medicine PAP,
CrossRef1166
S LAROSA, S OPAL, B UTTERBACK, S YAN, J HELTERBRAND, A SIMPSON, W CHAOWAGUL, N WHITE, C FISHERJR. (2006) Decreased protein C, protein S, and antithrombin levels are predictive of poor outcome in Gram-negative sepsis caused by Burkholderia pseudomallei
CrossRef1167
William R. Clark, Jeffrey J. Letteri, Shigehiko Uchino, Rinaldo Bellomo, Claudio Ronco. (2006) Recent Clinical Advances in the Management of Critically Ill Patients with Acute Renal Failure. Blood Purification 24:5-6, 487-498
CrossRef1168
Ware, Lorraine B., Matthay, Michael A., . (2005) Acute Pulmonary Edema. New England Journal of Medicine 353:26, 2788-2796
Full Text1169
M. Bodi, A. Rodriguez, J. Sole-Violan, M. C. Gilavert, J. Garnacho, J. Blanquer, J. Jimenez, M. V. de la Torre, J. M. Sirvent, J. Almirall, A. Doblas, J. R. Badia, F. Garcia, A. Mendia, R. Jorda, F. Bobillo, J. Valles, M. J. Broch, N. Carrasco, M. A. Herranz, J. Rello, . (2005) Antibiotic Prescription for Community-Acquired Pneumonia in the Intensive Care Unit: Impact of Adherence to Infectious Diseases Society of America Guidelines on Survival. Clinical Infectious Diseases 41:12, 1709-1716
CrossRef1170
Alasdair F. Mackenzie. (2005) Activated protein C: do more survive?. Intensive Care Medicine 31:12, 1624-1626
CrossRef1171
S. H. H. F. SCHOENMAKERS, L. W. BRUGGEMANN, A. P. GROOT, S. MAIJS, P. H. REITSMA, C. A. SPEK. (2005) Role of coagulation FVIII in septic peritonitis assessed in hemophilic mice. Journal of Thrombosis and Haemostasis 3:12, 2738-2744
CrossRef1172
Elliott Bennett-Guerrero, Thomas F. Slaughter, William D. White, Ian J. Welsby, Charles S. Greenberg, Habib El-Moalem, Thomas L. Ortel. (2005) Preoperative anti-PF4/heparin antibody level predicts adverse outcome after cardiac surgery. The Journal of Thoracic and Cardiovascular Surgery 130:6, 1567-1572
CrossRef1173
M. NAKAMURA, E. C. GABAZZA, I. IMOTO, Y. YANO, O. TAGUCHI, N. HORIKI, K. FUKUDOME, K. SUZUKI, Y. ADACHI. (2005) Anti-inflammatory effect of activated protein C in gastric epithelial cells. Journal of Thrombosis and Haemostasis 3:12, 2721-2729
CrossRef1174
Daniel G Remick, Peter A Ward. (2005) EVALUATION OF ENDOTOXIN MODELS FOR THE STUDY OF SEPSIS. Shock 24:Supplement 1, 7-11
CrossRef1175
A. Bauer, D. Bruegger, F. Christ. (2005) Mikrozirkulatorisches Monitoring der Sepsis. Der Anaesthesist 54:12, 1163-1175
CrossRef1176
Deborah J. Cook, Mark A. Crowther, Maureen O. Meade, Jim Douketis. (2005) Prevalence, incidence, and risk factors for venous thromboembolism in medical-surgical intensive care unit patients. Journal of Critical Care 20:4, 309-313
CrossRef1177
Alexandra A. MacLean, Zoyla Almeida, Peter Lopez. (2005) Complications of acute fatty liver of pregnancy treated with activated protein C. Archives of Gynecology and Obstetrics 273:2, 119-121
CrossRef1178
Gerhard Cvirn, Martin Koestenberger, Bettina Leschnik, Christoph Male, Joerg Kutschera, Ulrika Ferstl, Wolfgang Muntean, Guenther Juergens, Siegfried Gallistl. (2005) Protein S modulates the anticoagulant action of recombinant human activated protein C: a comparison between neonates and adults. British Journal of Pharmacology 146:8, 1082-1086
CrossRef1179
Hye-Eun Han, Seong-Hwan Rho, Yong Jae Lee, Woo Jin Park. (2005) Engineering of Kex2 variants exhibiting altered substrate specificity. Biochemical and Biophysical Research Communications 337:4, 1102-1106
CrossRef1180
J L Diehl, D Borgel. (2005) Sepsis and coagulation. Current Opinion in Internal Medicine 4:6, 619-625
CrossRef1181
Kevin J. Sullivan, Salvatore R. Goodwin, Eric Sandler, Michael Joyce. (2005) Critical care of the pediatric hematopoietic stem cell recipient in 2005. Pediatric Transplantation 9, 12-24
CrossRef1182
Jos?? A Lorente, John C Marshall. (2005) NEUTRALIZATION OF TUMOR NECROSIS FACTOR IN PRECLINICAL MODELS OF SEPSIS. Shock 24:Supplement 1, 107-119
CrossRef1183
Jie-Jen Lee, Mao-Tsun Lin, Nien-Lu Wang, Chia-Li Lin, Cheng-Kuei Chang. (2005) PLATONIN, A CYANINE PHOTOSENSITIZING DYE, CAUSES ATTENUATION OF CIRCULATORY SHOCK, HYPERCOAGULABLE STATE, AND TISSUE ISCHEMIA DURING HEAT STROKE. Shock 24:6, 577-582
CrossRef1184
Rinaldo Bellomo, Joseph Bonventre, William Macias, Michael Pinsky. (2005) Management of early acute renal failure: focus on post-injury prevention. Current Opinion in Critical Care 11:6, 542-547
CrossRef1185
Derek C. Angus, Mitchell P. Fink. (2005) Molecular biology for today???s practicing intensivist. Critical Care Medicine 33:Suppl, S399
CrossRef1186
Andrew F. Shorr, William L. Jackson. (2005) Deep vein thrombosis in the intensive care unit: underappreciated, understudied, and undertreated. Journal of Critical Care 20:4, 301-303
CrossRef1187
Alan E Jones, Patrick A Craddock, Vivek S Tayal, Jeffrey A Kline. (2005) DIAGNOSTIC ACCURACY OF LEFT VENTRICULAR FUNCTION FOR IDENTIFYING SEPSIS AMONG EMERGENCY DEPARTMENT PATIENTS WITH NONTRAUMATIC SYMPTOMATIC UNDIFFERENTIATED HYPOTENSION. Shock 24:6, 513-517
CrossRef1188
Elke G. Czeslick, Frank Nestler, Andreas Simm, Anja Struppert, Armin Sablotzki. (2005) Drotrecogin Alfa (Activated) Does Not Affect Intracellular Production of Interleukin-6 and Tumor Necrosis Factor-?? in Endotoxin-Stimulated Human Monocytes. Anesthesia & Analgesia1805-1808
CrossRef1189
Steven M Opal, Alan S Cross. (2005) THE USE OF IMMUNOCOMPROMISED ANIMALS AS MODELS FOR HUMAN SEPTIC SHOCK. Shock 24:Supplement 1, 64-70
CrossRef1190
P. W. M. Hermans, J. A. Hazelzet. (2005) Plasminogen Activator Inhibitor Type 1 Gene Polymorphism and Sepsis. Clinical Infectious Diseases 41:Supplement 7, S453-S458
CrossRef1191
R. J. Feezor, A. Cheng, H. N. Paddock, H. V. Baker, L. L. Moldawer. (2005) Functional Genomics and Gene Expression Profiling in Sepsis: Beyond Class Prediction. Clinical Infectious Diseases 41:Supplement 7, S427-S435
CrossRef1192
Charles T. Esmon. (2005) The interactions between inflammation and coagulation. British Journal of Haematology 131:4, 417-430
CrossRef1193
Michael Darmon, Guillaume Thiery, Magali Ciroldi, Sandra de Miranda, Lionel Galicier, Emmanuel Raffoux, Jean-Roger Le Gall, Beno??t Schlemmer, ??lie Azoulay. (2005) Intensive care in patients with newly diagnosed malignancies and a need for cancer chemotherapy*. Critical Care Medicine 33:11, 2488-2493
CrossRef1194
Marcus J. Schultz, Esther K. Wolthuis, Peter E. Spronk. (2005) Need for Critical Appraisal of Implementation of Use of Lower Tidal Volumes. Critical Care Medicine 33:11, 2718
CrossRef1195
Nathan I. Shapiro, Michael W. Donnino. (2005) Sepsis: The changing times*. Critical Care Medicine 33:11, 2700-2701
CrossRef1196
Shui Q. Ye, Li Q. Zhang, Djanybek Adyshev, Peter V. Usatyuk, Alexander N. Garcia, Tera L. Lavoie, Alexander D. Verin, Viswanathan Natarajan, Joe G.N. Garcia. (2005) Pre-B-cell-colony-enhancing factor is critically involved in thrombin-induced lung endothelial cell barrier dysregulation. Microvascular Research 70:3, 142-151
CrossRef1197
Cheng-Hock Toh, Colin Downey. (2005) Back to the future: testing in disseminated intravascular coagulation. Blood Coagulation & Fibrinolysis 16:8, 535-542
CrossRef1198
Vinod V. Balasa. (2005) New anticoagulants: A pediatric perspective. Pediatric Blood & Cancer 45:6, 741-752
CrossRef1199
J. P. Dillon, A. J. Laing, R. A. Cahill, G. C. O'Brien, J. T. Street, J. H. Wang, A. Mc Guinness, H. P. Redmond. (2005) Activated protein C attenuates acute ischaemia reperfusion injury in skeletal muscle. Journal of Orthopaedic Research 23:6, 1454-1459
CrossRef1200
X. Monnet, B. Lamia, N. Anguel, C. Richard, G. Bonmarchand, J. L. Teboul. (2005) Rapid and beneficial hemodynamic effects of activated protein C in septic shock patients. Intensive Care Medicine 31:11, 1573-1576
CrossRef1201
Viktor Y. Dombrovskiy, Andrew A. Martin, Jagadeeshan Sunderram, Harold L. Paz. (2005) Facing the challenge: Decreasing case fatality rates in severe sepsis despite increasing hospitalizations*. Critical Care Medicine 33:11, 2555-2562
CrossRef1202
M RANGELFRAUSTO. (2005) Sepsis: Still Going Strong. Archives of Medical Research 36:6, 672-681
CrossRef1203
DAVID EPSTEIN, JUDITH E. BRILL. (2005) A History of Pediatric Critical Care Medicine. Pediatric Research 58:5, 987-996
CrossRef1204
Peter Q. Eichacker, Robert L. Danner, Anthony F. Suffredini, Xizhong Cui, Charles Natanson. (2005) Reassessing recombinant human activated protein C for sepsis: Time for a new randomized controlled trial*. Critical Care Medicine 33:10, 2426-2428
CrossRef1205
Marc Maegele, Edmund Neugebauer. (2005) Multifactorial aspects to explain variations of control group mortality rates of randomized controlled trials*. Critical Care Medicine 33:10, 2410-2411
CrossRef1206
Mitchell M. Levy, William L. Macias, Jean-Louis Vincent, James A. Russell, Eliezer Silva, Benjamin Trzaskoma, Mark D. Williams. (2005) Early changes in organ function predict eventual survival in severe sepsis*. Critical Care Medicine 33:10, 2194-2201
CrossRef1207
Michael Meisner. (2005) Biomarkers of sepsis: clinically useful?. Current Opinion in Critical Care 11:5, 473-480
CrossRef1208
J??rgen Graf, Uwe Janssens. (2005) The early bird catches the worm*. Critical Care Medicine 33:10, 2412-2414
CrossRef1209
Linda Peelen, Nicolette F. de Keizer, Niels Peek, Robert J. Bosman, Gert Jan Scheffer, Evert de Jonge. (2005) Influence of entry criteria on mortality risk and number of eligible patients in recent studies on severe sepsis*. Critical Care Medicine 33:10, 2178-2183
CrossRef1210
Bruno Levy, Benjamin Dusang, Djillali Annane, Sebastien Gibot, Pierre-Edouard Bollaert. (2005) Cardiovascular response to dopamine and early prediction of outcome in septic shock: A prospective multiple-center study*. Critical Care Medicine 33:10, 2172-2177
CrossRef1211
Kamal Patel. (2005) More to the paper on ‘Homeopathy in Sepsis in ICU’ than meets the eye. Homeopathy 94:4, 213-214
CrossRef1212
Jean-Louis Vincent, Gordon R. Bernard, Richard Beale, Christopher Doig, Christian Putensen, Jean-Francois Dhainaut, Antonio Artigas, Roberto Fumagalli, William Macias, Theressa Wright, Kar Wong, David P. Sundin, Mary Ann Turlo, Jonathan Janes. (2005) Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*. Critical Care Medicine 33:10, 2266-2277
CrossRef1213
J Christopher Farmer. (2005) Drotrecogin alfa (activated) treatment in severe sepsis: A ???journal club??? review of the global ENHANCE trial*. Critical Care Medicine 33:10, 2428-2431
CrossRef1214
Evans R. Fern??ndez-P??rez, Salam Salman, Shanthan Pendem, J Christopher Farmer. (2005) Sepsis during pregnancy. Critical Care Medicine 33:Supplement, S286-S293
CrossRef1215
Jon A. Buras, Bernhard Holzmann, Michail Sitkovsky. (2005) Model organisms: Animal Models of sepsis: setting the stage. Nature Reviews Drug Discovery 4:10, 854-865
CrossRef1216
John Arcaroli, Michael B Fessler, Edward Abraham. (2005) GENETIC POLYMORPHISMS AND SEPSIS. Shock 24:4, 300-312
CrossRef1217
S M Pastores, A Shaw, M D Williams, E Mongan, M Alicea, N A Halpern. (2005) A safety evaluation of drotrecogin alfa (activated) in hematopoietic stem cell transplant patients with severe sepsis: lessons in clinical research. Bone Marrow Transplantation 36:8, 721-724
CrossRef1218
Gary T. Kinasewitz, Joe G. Zein, Gregory L. Lee, Shoab A. Nazir, Fletcher B. Taylor. (2005) Prognostic value of a simple evolving disseminated intravascular coagulation score in patients with severe sepsis*. Critical Care Medicine 33:10, 2214-2221
CrossRef1219
J. F. Aduen, W. C. Hellinger, D. J. Kramer, W. H. Stapelfeldt, H. Bonatti, J. E. Crook, J. L. Steers, C. D. Burger. (2005) Spectrum of Pneumonia in the Current Era of Liver Transplantation and Its Effect on Survival. Mayo Clinic Proceedings 80:10, 1303-1306
CrossRef1220
Parrillo, Joseph E., . (2005) Severe Sepsis and Therapy with Activated Protein C. New England Journal of Medicine 353:13, 1398-1400
Full Text1221
Abraham, Edward, Laterre, Pierre-François, Garg, Rekha, Levy, Howard, Talwar, Deepak, Trzaskoma, Benjamin L., François, Bruno, Guy, Jeffrey S., Brückmann, Martina, Rea-Neto, Álvaro, Rossaint, Rolf, Perrotin, Dominique, Sablotzki, Armin, Arkins, Nancy, Utterback, Barbara G., Macias, William L., . (2005) Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of Death. New England Journal of Medicine 353:13, 1332-1341
Full Text1222
Jolanda G. Keulen, Reinoud J. B. J. Gemke, Kees H. Polderman. (2005) Effect of training and strict guidelines on the reliability of risk adjustment systems in paediatric intensive care. Intensive Care Medicine 31:9, 1229-1234
CrossRef1223
Dale M. Needham, David W. Dowdy, Pedro A. Mendez-Tellez, Margaret S. Herridge, Peter J. Pronovost. (2005) Studying outcomes of intensive care unit survivors: measuring exposures and outcomes. Intensive Care Medicine 31:9, 1153-1160
CrossRef1224
M SCHULTZ, E WOLTHUIS, H MOENIRALAM, M LEVI. (2005) Struggle for implementation of new strategies in intensive care medicine: anticoagulation, insulin, and lower tidal volumes. Journal of Critical Care 20:3, 199-204
CrossRef1225
H. A. Adams, G. Baumann, I. Cascorbi, C. Ebener, M. Emmel, S. Geiger, U. Janssens, U. Klima, H. J. Klippe, W. T. Knoefel, G. Marx, U. Müller-Werdan, H. C. Pape, J. Piek, H. Prange, D. Roesner, B. Roth, T. Schürholz, T. Standl, W. Teske, P. M. Vogt, G. S. Werner, J. Windolf, R. Zander, H. R. Zerkowski. (2005) Empfehlungen zur Diagnostik und Therapie der Schockformen der IAG Schock der DIVI. Intensivmedizin und Notfallmedizin 42:6, 531-543
CrossRef1226
Marcus J. Schultz. (2005) Still Puzzled by Additional Data from the PROWESS Study. Critical Care Medicine 33:9, 2146
CrossRef1227
Pajman Danai, Greg S. Martin. (2005) Epidemiology of sepsis: Recent advances. Current Infectious Disease Reports 7:5, 329-334
CrossRef1228
Jordan L. Geller, Dani Hackner. (2005) Diffuse venous thromboemboli associated with IVIg therapy in the treatment of streptococcal toxic shock syndrome: case report and review. Annals of Hematology 84:9, 601-604
CrossRef1229
Meaghan M. Taylor. (2005) ARDS Diagnosis and Management. Dimensions of Critical Care Nursing 24:5, 197-207
CrossRef1230
Navneet Singh, Ritesh Agarwal. (2005) It Is Time to "SALVAGE" Patients with Severe Sepsis. Academic Emergency Medicine 12:9, 912-912
CrossRef1231
C. J. Crnich, D. G. Maki. (2005) Are Antimicrobial-Impregnated Catheters Effective? When Does Repetition Reach the Point of Exhaustion?. Clinical Infectious Diseases 41:5, 681-685
CrossRef1232
Arto J. Turunen, Jose A. Fernandez, Leena Lindgren, Kaija T. Salmela, Lauri E. Kyllonen, Heikki Makisalo, John H. Griffin, Sanna M. Siitonen, Jari Petaja, Eero J. Pesonen. (2005) Activated Protein C Reduces Graft Neutrophil Activation in Clinical Renal Transplantation. American Journal of Transplantation 5:9, 2204-2212
CrossRef1233
Steven A. Earle, Kenneth G. Proctor, Mayur B. Patel, Matthias Majetschak. (2005) Ubiquitin reduces fluid shifts after traumatic brain injury. Surgery 138:3, 431-438
CrossRef1234
David Bracco, Marc-Jacques Dubois. (2005) Hemodynamic support in septic shock: Is restoring a normal blood pressure the right target?*. Critical Care Medicine 33:9, 2113-2115
CrossRef1235
Jonas Hjelmgren, Ulf Persson, Gunnel Ragnarson Tennvall. (2005) Local Treatment Pattern Versus Trial-based Data: A Cost-effectiveness Analysis of Drotrecogin Alfa (Activated) in the Treatment of Severe Sepsis in Sweden. American Journal of Therapeutics 12:5, 425-430
CrossRef1236
Brian P. Kavanagh, L. Joanne Meyer. (2005) Normalizing physiological variables in acute illness: five reasons for caution. Intensive Care Medicine 31:9, 1161-1167
CrossRef1237
Ritesh Agarwal, Dheeraj Gupta. (2005) Anticoagulation in sepsis: Is low-dose heparin as effective as activated protein C?. Intensive Care Medicine 31:9, 1297-1298
CrossRef1238
S SHAFAZAND, G COLICE. (2005) Putting the cart before the horse: a cautious look at the role of IgM-enriched polyclonal immunoglobulin in sepsis therapy. Journal of Critical Care 20:3, 249-250
CrossRef1239
A NEILSON, H BURCHARDI, H SCHNEIDER. (2005) Cost-effectiveness of immunoglobulin M–enriched immunoglobulin (Pentaglobin) in the treatment of severe sepsis and septic shock. Journal of Critical Care 20:3, 239-249
CrossRef1240
Berislav V. Zlokovic, Chunling Zhang, Dong Liu, Jose Fernandez, John H. Griffin, Michael Chopp. (2005) Functional recovery after embolic stroke in rodents by activated protein C. Annals of Neurology 58:3, 474-477
CrossRef1241
László Medve, István Kis Csitári, Zsolt Molnár, Ádám László. (2005) Recombinant human activated protein C treatment of septic shock syndrome in a patient at 18th week of gestation: A case report. American Journal of Obstetrics and Gynecology 193:3, 864-865
CrossRef1242
W. RUF. (2005) Is APC activation of endothelial cell PAR1 important in severe sepsis?: Yes. Journal of Thrombosis and Haemostasis 3:9, 1912-1914
CrossRef1243
C.M. Luna, A. Monteverde, A. Rodríguez, C. Apezteguia, G. Zabert, S. Ilutovich, G. Menga, W. Vasen, A.R. Díez, J. Mera. (2005) Neumonía intrahospitalaria: guía clínica aplicable a Latinoamérica preparada en común por diferentes especialistas. Archivos de Bronconeumología 41:8, 439-456
CrossRef1244
James W. Suliburk, Kenneth S. Helmer, Ernest A. Gonzalez, Emily K. Robinson, David W. Mercer. (2005) Ketamine attenuates liver injury attributed to endotoxemia: Role of cyclooxygenase-2. Surgery 138:2, 134-140
CrossRef1245
Claudio M. Martin, Gordon Guyatt, Victor M. Montori. (2005) The sirens are singing: The perils of trusting trials stopped early and subgroup analyses*. Critical Care Medicine 33:8, 1870-1871
CrossRef1246
John C. Marshall, Jean-Louis Vincent, Gordon Guyatt, Derek C. Angus, Edward Abraham, Gordon Bernard, Claire Bombardier, Thierry Calandra, Henrik Stig J??rgensen, Richard Sylvester, Maarten Boers. (2005) Outcome measures for clinical research in sepsis: A report of the 2nd Cambridge Colloquium of the International Sepsis Forum. Critical Care Medicine 33:8, 1708-1716
CrossRef1247
Jung-Yien Chien, Jih-Shuin Jerng, Chong-Jen Yu, Pan-Chyr Yang. (2005) Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis*. Critical Care Medicine 33:8, 1688-1693
CrossRef1248
Emily E. Castelli, Colleen M. Culley, Mitchell P. Fink. (2005) Challenge and Rechallenge: Drotrecogin alfa (activated)–Induced Prolongation of Activated Partial Thromboplastin Time in a Patient with Severe Sepsis. Pharmacotherapy 25:8, 1147-1150
CrossRef1249
Steven Doherty. (2005) History of evidence-based medicine. Oranges, chloride of lime and leeches: Barriers to teaching old dogs new tricks. Emergency Medicine Australasia 17:4, 314-321
CrossRef1250
Gotho Geishofer, Alexander Binder, Martin Müller, Bettina Zöhrer, Bernhard Resch, Wilhelm Müller, Jörg Faber, Adam Finn, Georg Endler, Christine Mannhalter, Werner Zenz, . (2005) 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene in children with systemic meningococcaemia. European Journal of Pediatrics 164:8, 486-490
CrossRef1251
R. K. WINN, J. M. HARLAN. (2005) The role of endothelial cell apoptosis in inflammatory and immune diseases. Journal of Thrombosis and Haemostasis 3:8, 1815-1824
CrossRef1252
Toshiaki Iba, Akio Kidokoro, Masaki Fukunaga, Kunihiko Nagakari, Masaru Suda, Seiichiro Yoshikawa, Yukiko Ida. (2005) Antithrombin ameliorates endotoxin-induced organ dysfunction more efficiently when combined with danaparoid sodium than with unfractionated heparin. Intensive Care Medicine 31:8, 1101-1108
CrossRef1253
J. I. WEITZ, S. M. BATES. (2005) New anticoagulants. Journal of Thrombosis and Haemostasis 3:8, 1843-1853
CrossRef1254
M JIAN, T KOIZUMI, K TSUSHIMA, K FUJIMOTO, K KUBO. (2005) Activated protein C attenuates acid-aspiration lung injury in rats. Pulmonary Pharmacology & Therapeutics 18:4, 291-296
CrossRef1255
Donald E Low, Tony Mazzulli, Tom Marrie. (2005) Progressive and nonresolving pneumonia. Current Opinion in Internal Medicine 4:4, 410-415
CrossRef1256
A Afshari, AM Møller, J Wetterslev, Arash Afshari. 2005. Antithrombin III for critically ill patients. .
CrossRef1257
RI Kylat, A Ohlsson, Ranjit Kylat. 2005. Human recombinant activated protein C for severe sepsis in neonates. .
CrossRef1258
Howard L. Corwin. 2005. Critical Care. .
CrossRef1259
David W. Dowdy, Dale M. Needham, Pedro A. Mendez-Tellez, Margaret S. Herridge, Peter J. Pronovost. (2005) Studying outcomes of intensive care unit survivors: the role of the cohort study. Intensive Care Medicine 31:7, 914-921
CrossRef1260
Christophe Adrie, Mehran Monchi, Ivan Laurent, Suzan Um, S. Betty Yan, Marie Thuong, Alain Cariou, Julien Charpentier, Jean François Dhainaut. (2005) Coagulopathy After Successful Cardiopulmonary Resuscitation Following Cardiac Arrest. Journal of the American College of Cardiology 46:1, 21-28
CrossRef1261
Martin Koestenberger, Gerhard Cvirn, Siegfried Gallistl, Joerg Kutschera, Wolfgang Muntean. (2005) Recombinant human activated protein C, heparin and melagatran in umbilical cord versus adult plasma. Acta Paediatrica 94:7, 884-889
CrossRef1262
John E. Mazuski. (2005) Clinical Challenges and Unmet Needs in the Management of Complicated Intra-abdominal Infections. Surgical Infections 6:s2, s-49-s-69
CrossRef1263
Glenn Hernandez, Alejandro Bruhn, Carlos Romero, Francisco Javier Larrondo, Rene De La Fuente, Luis Castillo, Guillermo Bugedo. (2005) Management of septic shock with a norepinephrine-based haemodynamic algorithm. Resuscitation 66:1, 63-69
CrossRef1264
D. Hasper, D. Schrage, K.-D. Schaser, I. Melcher, D. Barckow, U. Frei, M. Oppert. (2005) 60-jähriger Patient mit Weichteilinfektion des rechten Beines. Der Internist 46:7, 783-788
CrossRef1265
Dominique D. Benoit, Pieter O. Depuydt, Jan J. De Waele, Eric A. Hoste, Kirsten E. Colpaert, Vanessa D. Van Hende, Johan M. Decruyenaere. (2005) Would Patients with More Subtle Signs of Coagulopathy Have Benefited from Treatment with Activated Protein C?. Critical Care Medicine 33:7, 1670
CrossRef1266
W. LI, X. ZHENG, J. GU, J. HUNTER, G. L. FERRELL, F. LUPU, N. L. ESMON, C. T. ESMON. (2005) Overexpressing endothelial cell protein C receptor alters the hemostatic balance and protects mice from endotoxin. Journal of Thrombosis and Haemostasis 3:7, 1351-1359
CrossRef1267
Reza Askari, Robert G. Sawyer. (2005) New Antibacterial Administration Treatment Strategies. Surgical Infections 6:s2, s-83-s-95
CrossRef1268
Carson C Chow, Gilles Clermont, Rukmini Kumar, Claudio Lagoa, Zacharia Tawadrous, David Gallo, Binnie Betten, John Bartels, Gregory Constantine, Mitchell P Fink, Timothy R Billiar, Yoram Vodovotz. (2005) THE ACUTE INFLAMMATORY RESPONSE IN DIVERSE SHOCK STATES. Shock 24:1, 74-84
CrossRef1269
Stephen E. Lapinsky. (2005) Cardiopulmonary complications of pregnancy. Critical Care Medicine 33:7, 1616-1622
CrossRef1270
T. J. RAIFE, S. R. LENTZ. (2005) The benefits of excess EPCR. Journal of Thrombosis and Haemostasis 3:7, 1349-1350
CrossRef1271
J VINCENT, D DEBACKER. (2005) Does Disseminated Intravascular Coagulation Lead to Multiple Organ Failure?. Critical Care Clinics 21:3, 469-477
CrossRef1272
M LEVI. (2005) Disseminated Intravascular Coagulation: What's New?. Critical Care Clinics 21:3, 449-467
CrossRef1273
E WIEL, B VALLET, H TENCATE. (2005) The Endothelium in Intensive Care. Critical Care Clinics 21:3, 403-416
CrossRef1274
W AIRD. (2005) Sepsis and Coagulation. Critical Care Clinics 21:3, 417-431
CrossRef1275
Angelina J. Lay, Zhong Liang, Elliot D. Rosen, Francis J. Castellino. (2005) Mice with a severe deficiency in protein C display prothrombotic and proinflammatory phenotypes and compromised maternal reproductive capabilities. Journal of Clinical Investigation 115:6, 1552-1561
CrossRef1276
Arne Slungaard. (2005) Platelet factor 4: a chemokine enigma. The International Journal of Biochemistry & Cell Biology 37:6, 1162-1167
CrossRef1277
Eleanor M. Summerhill, Michael Baram. (2005) Principles of Pulmonary Artery Catheterization in the Critically Ill. Lung 183:3, 209-219
CrossRef1278
Colin Verdant, Daniel De Backer. (2005) How monitoring of the microcirculation may help us at the bedside. Current Opinion in Critical Care 11:3, 240-244
CrossRef1279
Christian Lehmann, Taras I. Usichenko, Dragan Pavlovic. (2005) Heparins in sepsis-induced disseminated intravascular coagulation: Low weight???high impact?*. Critical Care Medicine 33:6, 1455-1457
CrossRef1280
Hugh O??Brodovich. (2005) Pulmonary edema in infants and children. Current Opinion in Pediatrics 17:3, 381-384
CrossRef1281
Scott K. Aberegg. (2005) Forums for Expressing Concerns. Critical Care Medicine 33:6, 1467
CrossRef1282
Marius Keel, Otmar Trentz. (2005) Pathophysiology of polytrauma. Injury 36:6, 691-709
CrossRef1283
Aleksandar Karamarkovic, Dejan Radenkovic, Natasa Milic, Vesna Bumbasirevic, Branislav Stefanovic. (2005) Protein C as an Early Marker of Severe Septic Complications in Diffuse Secondary Peritonitis. World Journal of Surgery 29:6, 759-765
CrossRef1284
Peter Q. Eichacker, Charles Natanson. (2005) Forums for Expressing Concerns. Critical Care Medicine 33:6, 1467-1468
CrossRef1285
Susan Scollan-Boring. (2005) Cardiovascular Surgery, the Systemic Inflammatory Response, and Corticosteroids. Progress in Cardiovascular Nursing 20:3, 127-128
CrossRef1286
Sjoukje H. Slofstra, Cornelis van ???t Veer, Wim A. Buurman, Pieter H. Reitsma, Hugo ten Cate, C Arnold Spek. (2005) Low molecular weight heparin attenuates multiple organ failure in a murine model of disseminated intravascular coagulation*. Critical Care Medicine 33:6, 1365-1370
CrossRef1287
Kazuhiro Abeyama, David M. Stern, Yuji Ito, Ko-ichi Kawahara, Yasushi Yoshimoto, Motoyuki Tanaka, Tomonori Uchimura, Nobuo Ida, Yoshiaki Yamazaki, Shingo Yamada, Yasuhiko Yamamoto, Hiroshi Yamamoto, Satoshi Iino, Noboru Taniguchi, Ikuro Maruyama. (2005) The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. Journal of Clinical Investigation 115:5, 1267-1274
CrossRef1288
Taketoshi Furugohri, Yoko Shiozaki, Sumie Muramatsu, Yuko Honda, Chikako Matsumoto, Koji Isobe, Nobutoshi Sugiyama. (2005) Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models. European Journal of Pharmacology 514:1, 35-42
CrossRef1289
Pierre-Francois Laterre, Gary Garber, Howard Levy, Richard Wunderink, Gary T. Kinasewitz, Jean-Pierre Sollet, Dennis G. Maki, Becky Bates, Sau Chi Betty Yan, Jean-Francois Dhainaut. (2005) Severe community-acquired pneumonia as a cause of severe sepsis: Data from the PROWESS study*. Critical Care Medicine 33:5, 952-961
CrossRef1290
Charles Esmon. (2005) Do-all receptor takes on coagulation, inflammation. Nature Medicine 11:5, 475-477
CrossRef1291
Joseph A. Carcillo. (2005) Reducing the global burden of sepsis in infants and children: A clinical practice research agenda. Pediatric Critical Care Medicine 6:Supplement, S157-S164
CrossRef1292
M TORRES, A DEMAIO. (2005) An Exaggerated Inflammatory Response after CLP Correlates with a Negative Outcome. Journal of Surgical Research 125:1, 88-93
CrossRef1293
Annette M Esper, Greg S Martin. (2005) Evolution of treatments for patients with acute lung injury. Expert Opinion on Investigational Drugs 14:5, 633-645
CrossRef1294
Steven M. Opal. (2005) Concept of PIRO as a new conceptual framework to understand sepsis. Pediatric Critical Care Medicine 6:Supplement, S55-S60
CrossRef1295
Gregory P. Priebe. (2005) Editorial: Sepsis in the immunocompromised child: The least studied with the most to gain. Pediatric Critical Care Medicine 6:Supplement, S78-S79
CrossRef1296
J. N. Hoffmann. (2005) Immunmodulierende Therapien bei der Sepsis: Irrwege der Vergangenheit?. Intensivmedizin + Notfallmedizin 42:4, 371-377
CrossRef1297
E. Ruokonen, V. Pettila. (2005) Surviving Sepsis campaign - outcome of severe sepsis can be improved by revising procedural standards. Acta Anaesthesiologica Scandinavica 49:5, 597-598
CrossRef1298
Ruth M. Kleinpell. (2005) Working Out the Complexities of Severe Sepsis. The Nurse Practitioner 30:4, 43-48
CrossRef1299
Henry F. Chambers. (2005) Editorial Commentary: Staphylococcal Purpura Fulminans: A Toxin‐Mediated Disease?. Clinical Infectious Diseases 40:7, 948-950
CrossRef1300
Daren Heyland, Rupinder Dhaliwal. (2005) Immunonutrition in the critically ill: from old approaches to new paradigms. Intensive Care Medicine 31:4, 501-503
CrossRef1301
Katherine J. Deans, Michael Haley, Charles Natanson, Peter Q. Eichacker, Peter C. Minneci. (2005) Novel Therapies for Sepsis: A Review. The Journal of Trauma: Injury, Infection, and Critical Care 58:4, 867-874
CrossRef1302
Javier Corral, José Yélamos, David Hernández-Espinosa, Yolanda Monreal, Ruben Mota, Isabel Arcas, Antonia Miñano, Pascual Parrilla, Vicente Vicente. (2005) Role of Lipopolysaccharide and Cecal Ligation and Puncture on Blood Coagulation and Inflammation in Sensitive and Resistant Mice Models. The American Journal of Pathology 166:4, 1089-1098
CrossRef1303
Michael H Young, David M Aronoff, N Cary Engleberg. (2005) Necrotizing fasciitis: pathogenesis and treatment. Expert Review of Anti-infective Therapy 3:2, 279-294
CrossRef1304
J COHEN. (2005) Sepsis. Medicine 33:4, 52-54
CrossRef1305
Nathan I. Shapiro, Michael Howell, Daniel Talmor. (2005) A Blueprint for a Sepsis Protocol. Academic Emergency Medicine 12:4, 352-359
CrossRef1306
M Frass, M Linkesch, S Banyai, G Resch, C Dielacher, T Löbl, C Endler, M Haidvogl, I Muchitsch, E Schuster. (2005) Adjunctive homeopathic treatment in patients with severe sepsis: a randomized, double-blind, placebo-controlled trial in an intensive care unit. Homeopathy 94:2, 75-80
CrossRef1307
David Zygun. (2005) Non-neurological organ dysfunction in neurocritical care: impact on outcome and etiological considerations. Current Opinion in Critical Care 11:2, 139-143
CrossRef1308
Pierre Lain??e, Philip Efron, Sven K. Tschoeke, Laetitia Elies, Hilde De Winter, Katrien Lorr??, Lyle L. Moldawer. (2005) Delayed neutralization of interferon-?? prevents lethality in primate Gram-negative bacteremic shock. Critical Care Medicine 33:4, 797-805
CrossRef1309
Gilman B Allen, Polly Parsons. (2005) Acute lung injury: significance, treatment and outcome. Current Opinion in Anaesthesiology 18:2, 209-215
CrossRef1310
Shannon M Bates, Jeffrey I Weitz. (2005) New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin. British Journal of Pharmacology 144:8, 1017-1028
CrossRef1311
Brendon Smith. (2005) Drotrecogin alfa: Too early to give it early. Emergency Medicine Australasia 17:2, 179-180
CrossRef1312
J. Gandjour, J. Oehler, A. Mohr, P. D. Schellinger. (2005) Hitzschlag mit Alpha-Koma. Der Nervenarzt 76:4, 467-470
CrossRef1313
K. H. Staubach. (2005) Pilzsepsis - Therapeutische Strategie. Fungal sepsis - therapeutical strategy. Mycoses 48:s1, 72-77
CrossRef1314
Jennifer Klenzak, Jonathan Himmelfarb. (2005) Sepsis and the Kidney. Critical Care Clinics 21:2, 211-222
CrossRef1315
E. A. J. Hoste. (2005) Assessment of renal function in recently admitted critically ill patients with normal serum creatinine. Nephrology Dialysis Transplantation 20:4, 747-753
CrossRef1316
S. Reith, K. Werdan. (2005) Therapie des Organversagens bei prim
CrossRef1317
A. Sablotzki, F. Nestler, E. Czeslick. (2005) Adjunktive Sepsistherapie?Gerinnungsinhibitoren und anti-inflammatorische Effekte. Intensivmedizin + Notfallmedizin 42:2, 146-155
CrossRef1318
Grant W. Waterer, Richard G. Wunderink. (2005) Genetic Susceptibility to Pneumonia. Clinics in Chest Medicine 26:1, 29-38
CrossRef1319
Michelle A. Beutz, Edward Abraham. (2005) Community-Acquired Pneumonia and Sepsis. Clinics in Chest Medicine 26:1, 19-28
CrossRef1320
Timothy D. Girard, Steven M. Opal, E. Wesley Ely. (2005) Insights into Severe Sepsis in Older Patients: From Epidemiology to Evidence‐Based Management. Clinical Infectious Diseases 40:5, 719-727
CrossRef1321
U. Janssens, J. Graf. (2005) Einsch
CrossRef1322
Martin A. Schreiber, Jerome Differding, Per Thorborg, John C. Mayberry, Richard J. Mullins. (2005) Hypercoagulability Is Most Prevalent Early after Injury and in Female Patients. The Journal of Trauma: Injury, Infection, and Critical Care 58:3, 475-481
CrossRef1323
John C. Marshall. (2005) Measuring organ dysfunction in the intensive care unit: why and how?. Canadian Journal of Anesthesia/Journal canadien d'anesthésie 52:3, 224-230
CrossRef1324
Bruce H Davis. (2005) Improved diagnostic approaches to infection/sepsis detection. Expert Review of Molecular Diagnostics 5:2, 193-207
CrossRef1325
David A. Zygun, Kevin B. Laupland, Gordon H. Fick, James Dean Sandham, Christopher J. Doig. (2005) Neuroanesthesia and Intensive Care Limited ability of SOFA and MOD scores to discriminate outcome: a prospective evaluation in 1,436 patients. Canadian Journal of Anesthesia/Journal canadien d'anesthésie 52:3, 302-308
CrossRef1326
J??rgen Graf, J??rg Wagner, Carmen Graf, Karl-Christian Koch, Uwe Janssens. (2005) Five-year survival, quality of life, and individual costs of 303 consecutive medical intensive care patients???A cost-utility analysis. Critical Care Medicine 33:3, 547-555
CrossRef1327
Jonas Sund??n-Cullberg, Anna Norrby-Teglund, Ari Rouhiainen, Heikki Rauvala, Gunilla Herman, Kevin J. Tracey, Martin L. Lee, Jan Andersson, Leif Tokics, Carl Johan Treutiger. (2005) Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock*. Critical Care Medicine 33:3, 564-573
CrossRef1328
Mark Oltermann. 2005. Systemic Inflammatory Response and Sepsis. , 565-577.
CrossRef1329
A. Davies, S. Ridley, J. Hutton, C. Chinn, B. Barber, D. C. Angus. (2005) Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom*. Anaesthesia 60:2, 155-162
CrossRef1330
Jes
CrossRef1331
Arzu Topeli, Franco Laghi, Martin J. Tobin. (2005) Effect of closed unit policy and appointing an intensivist in a developing country*. Critical Care Medicine 33:2, 299-306
CrossRef1332
Jean-Francois Dhainaut, Andrew F. Shorr, William L. Macias, Marin J. Kollef, Marcel Levi, Konrad Reinhart, David R. Nelson. (2005) Dynamic evolution of coagulopathy in the first day of severe sepsis: Relationship with mortality and organ failure*. Critical Care Medicine 33:2, 341-348
CrossRef1333
Marino Viviani, Luciano Silvestri, Hendrick K. F. van Saene, Antonino Gullo. (2005) Surviving Sepsis Campaign Guidelines: Selective Decontamination of the Digestive Tract Still Neglected. Critical Care Medicine 33:2, 462-463
CrossRef1334
Marc Fischer, Joseph Hilinski, David S. Stephens. (2005) Adjuvant Therapy for Meningococcal Sepsis. The Pediatric Infectious Disease Journal 24:2, 177-178
CrossRef1335
U. Koca, C. Olguner, S. Ozkardesler, A. Karci, C. Coker, P. Tuncel, A. Tasdogen, S. Duru, C. Ulukus, Z. Elar. (2005) Antithrombin III pretreatment reduces neutrophil recruitment into the lung in a rat model of abdominal sepsis. Acta Anaesthesiologica Scandinavica 49:2, 203-208
CrossRef1336
Paul Kn??bl. (2005) Predicting the course of sepsis: The next step?*. Critical Care Medicine 33:2, 450-452
CrossRef1337
Todd W. Rice, Gordon R. Bernard. (2005) Therapeutic Intervention and Targets for Sepsis*. Annual Review of Medicine 56:1, 225-248
CrossRef1338
F FROST, M ROACH, I KUSHNER, P SCHREIBER. (2005) Inflammatory C-reactive protein and cytokine levels in asymptomatic people with chronic spinal cord injury. Archives of Physical Medicine and Rehabilitation 86:2, 312-317
CrossRef1339
Toshiaki Iba, Akio Kidokoro, Masaki Fukunaga, Kunihiko Nagakari, Akihiko Shirahama, Yukiko Ida. (2005) Activated protein C improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat lipopolysaccharide model. Critical Care Medicine 33:2, 368-372
CrossRef1340
Lori-Ann Linkins, Jeffrey I. Weitz. (2005) New Anticoagulant Therapy. Annual Review of Medicine 56:1, 63-77
CrossRef1341
Luis Ulloa, Kevin J. Tracey. (2005) The ‘cytokine profile’: a code for sepsis. Trends in Molecular Medicine 11:2, 56-63
CrossRef1342
B. Afessa, M. T. Keegan, R. D. Hubmayr, J. M. Naessens, O. Gajic, K. H. Long, S. G. Peters. (2005) Evaluating the Performance of an Institution Using an Intensive Care Unit Benchmark. Mayo Clinic Proceedings 80:2, 174-180
CrossRef1343
Djillali Annane, Eric Bellissant, Jean-Marc Cavaillon. (2005) Septic shock. The Lancet 365:9453, 63-78
CrossRef1344
Hideo IWASAKA. (2005) Lung Repairing and Remodeling by Tissue Regenerative Factor —Analysis by a New Tissue Damaging Factor and Fibrosing Factor—. THE JOURNAL OF JAPAN SOCIETY FOR CLINICAL ANESTHESIA 25:3, 301-309
CrossRef1345
Jean-Louis Vincent. (2005) Organ dysfunction scores in critical illness. Journal of Organ Dysfunction 1:1, 18-23
CrossRef1346
Chin-Wei Chiao, Shoei-Sheng Lee, Chin-Chen Wu, Ming-Jai Su. (2005) Thaliporphine increases survival rate and attenuates multiple organ injury in LPS-induced endotoxaemia. Naunyn-Schmiedeberg's Archives of Pharmacology 371:1, 34-43
CrossRef1347
Francisco Garcia Soriano. (2005) Quality of life: Late sequela in sepsis*. Critical Care Medicine 33:1, 262
CrossRef1348
Vijaya Sundararajan, Christopher M. MacIsaac, Jeffrey J. Presneill, John F. Cade, Kumar Visvanathan. (2005) Epidemiology of sepsis in Victoria, Australia. Critical Care Medicine 33:1, 71-80
CrossRef1349
A HAYNESIII, K RUMBAUGH, P PARK, A HAMOOD, J GRISWOLD. (2005) Protamine sulfate reduces the susceptibility of thermally injured mice to infection. Journal of Surgical Research 123:1, 109-117
CrossRef1350
Claudio Ronco, Ranistha Ratanarat, Rihaloo Bellomo, Gabriella Salvatori, Dimitri Petras, Massimo De Cal, Federico Nalasso, Monica Bonello, Alessandra Brendolan. (2005) Multiple organ support therapy for the critically ill patient in intensive care. Journal of Organ Dysfunction 1:1, 57-68
CrossRef1351
Lorraine B. Ware, Julie A. Bastarache, Ling Wang. (2005) Coagulation and fibrinolysis in human acute lung injury-New therapeutic targets?. The Keio Journal of Medicine 54:3, 142-149
CrossRef1352
BW SYKES, MO FURR. (2005) Equine endotoxaemia - A state-of-the-art review of therapy. Australian Veterinary Journal 83:1-2, 45-50
CrossRef1353
Marc Moss. (2005) Epidemiology of Sepsis: Race, Sex, and Chronic Alcohol Abuse. Clinical Infectious Diseases 41:s7, S490
CrossRef1354
G. Umberto Meduri, Muthiah P. Muthiah, Pierluigi Carratu, Mahmoud Eltorky, George P. Chrousos. (2005) Nuclear Factor-κB- and Glucocorticoid Receptor α- Mediated Mechanisms in the Regulation of Systemic and Pulmonary Inflammation during Sepsis and Acute Respiratory Distress Syndrome. Neuroimmunomodulation 12:6, 321-338
CrossRef1355
Toshiaki Iba, Akio Kidokoro, Masaki Fukunaga, Kazuyoshi Sugiyama, Tomohiro Sawada, Hisaaki Kato. (2005) ASSOCIATION BETWEEN THE SEVERITY OF SEPSIS AND THE CHANGES IN HEMOSTATIC MOLECULAR MARKERS AND VASCULAR ENDOTHELIAL DAMAGE MARKERS. Shock 23:1, 25-29
CrossRef1356
Gunnar Nilsson, Jan Astermark, Stefan Lethagen, Einar Vernersson, Erik Berntorp. (2005) Protein C levels can be forecasted by global haemostatic tests in critically ill patients and predict long-term survival. Thrombosis Research 116:1, 15-24
CrossRef1357
Syed Hashmi, Selwyn O. Rogers. (2005) Current concepts in critical care. Journal of the American College of Surgeons 200:1, 88-95
CrossRef1358
Scott T. Micek, Warren Isakow, William Shannon, Marin H. Kollef. (2005) Predictors of Hospital Mortality for Patients with Severe Sepsis Treated with Drotrecogin alfa (activated). Pharmacotherapy 25:1, 26-34
CrossRef1359
Tom Ahrens. (2005) Evidenced–based Practice. AACN Clinical Issues: Advanced Practice in Acute and Critical Care 16:1, 36-42
CrossRef1360
Martin Koestenberger, Gerhard Cvirn, Siegfried Gallistl, Joerg Kutschera, Wolfgang Muntean. (2005) Recombinant human activated protein C, heparin and melagatran in umbilical cord versus adult plasma. Acta Paediatrica 94:7, 884
CrossRef1361
Afsaneh Vazin ., Mojtaba Mojtahedzadeh ., Ebrahim Salehifar ., Noushin Rastkari ., Siavash Khalaj ., Ali Rezaie ., Mohammad Abdollahi .. (2005) Future Drugs for Treatment of Acute Respiratory Distress Syndrome. International Journal of Pharmacology 1:1, 9-16
CrossRef1362
Hongyan Xiao, Daniel G. Remick. (2005) Correction of perioperative hypothermia decreases experimental sepsis mortality by modulating the inflammatory response. Critical Care Medicine 33:1, 161-167
CrossRef1363
Derek C. Angus. (2005) The future of critical care. Critical Care Clinics 21:1, 163-169
CrossRef1364
Maja Surbatovic, Sonja Radakovic, Krsta Jovanovic, Predrag Romic. (2005) New strategies in multiple organ dysfunction syndrometherapy for sepsis. Srpski arhiv za celokupno lekarstvo 133:7-8, 379-383
CrossRef1365
Nancy F. Crum, Harold L. Groff, John S. Parrish, William Ring. (2004) A Novel Use for Drotrecogin Alfa (Activated): Successful Treatment of Septic Shock Associated with Coccidioidomycosis. Clinical Infectious Diseases 39:11, e122-e123
CrossRef1366
Didier Dreyfuss. (2004) Beyond randomized, controlled trials. Current Opinion in Critical Care 10:4, 574-578
CrossRef1367
R WUNDERINK, G WATERER. (2004) Community-acquired pneumonia: pathophysiology and host factors with focus on possible new approaches to management of lower respiratory tract infections. Infectious Disease Clinics of North America 18:4, 743-759
CrossRef1368
Kamran Bakhtiari, Joost C.M. Meijers, Evert de Jonge, Marcel Levi. (2004) Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation*. Critical Care Medicine 32:12, 2416-2421
CrossRef1369
Lars Heslet. (2004) Clinical implications of a validated scoring system for disseminated intravascular coagulation*. Critical Care Medicine 32:12, 2548-2549
CrossRef1370
William L. Macias, Benoit Vallet, Gordon R. Bernard, Jean-Louis Vincent, Pierre-Francois Laterre, David R. Nelson, P Alexander Derchak, Jean-Francois Dhainaut. (2004) Sources of variability on the estimate of treatment effect in the PROWESS trial: Implications for the design and conduct of future studies in severe sepsis*. Critical Care Medicine 32:12, 2385-2391
CrossRef1371
Avery B. Nathens, J Randall Curtis, Richard J. Beale, Deborah J. Cook, Rui P. Moreno, Jacques-Andre Romand, Shawn J. Skerrett, Renee D. Stapleton, Lorraine B. Ware, Carl S. Waldmann. (2004) Management of the critically ill patient with severe acute pancreatitis. Critical Care Medicine 32:12, 2524-2536
CrossRef1372
Leonidas G. Koniaris, David Kaufman, Teresa A. Zimmers, Nathan Wang, Patrice F. Spitalnik, Lindsey Henson, Carol Miller-Graziano, James V. Sitzmann. (2004) Two Third-Year Medical Student–Level Laboratory Shock Exercises without Large Animals. Surgical Infections 5:4, 343-348
CrossRef1373
S. S. Wong, N. N. Sun, J. D. Hyde, L. Ruiz, E. Meigs, B. R. Herrin, C. D. Fastje, S. J. Macdonald, M. L. Witten. (2004) Drotrecogin Alfa (activated) Prevents Smoke-Induced Increases in Pulmonary Microvascular Permeability and Proinflammatory Cytokine IL-1β in Rats. Lung 182:6, 319-330
CrossRef1374
Martin Koestenberger, Gerhard Cvirn, Siegfried Gallistl, Wolfgang Muntean. (2004) Drotrecogin alfa activated (recombinant human activated protein C) in combination with heparin or melagatran. Blood Coagulation & Fibrinolysis 15:8, 693-697
CrossRef1375
Katherine J. Deans, Peter C. Minneci, Steven M. Banks, Charles Natanson, Peter Q. Eichacker. (2004) Substantiating the concerns about recombinant human activated protein C use in sepsis*. Critical Care Medicine 32:12, 2542-2543
CrossRef1376
Toshiaki Iba, Akio Kidokoro. (2004) WHAT CAN WE LEARN FROM THE THREE MEGATRIALS USING ANTICOAGULANTS IN SEVERE SEPSIS?. Shock 22:6, 508-512
CrossRef1377
Philip S. Barie, Lynn J. Hydo, Soumitra R. Eachempati. (2004) Longitudinal Outcomes of Intra-abdominal Infection Complicated by Critical Illness. Surgical Infections 5:4, 365-373
CrossRef1378
Jon A. Buras, Lauren Rice, Daniel Orlow, Stavros Pavlides, Wende R. Reenstra, Kathleen Ceonzo, Gregory L. Stahl. (2004) Inhibition of C5 or absence of C6 protects from sepsis mortality. Immunobiology 209:8, 629-635
CrossRef1379
Eng H Lo. (2004) Combination stroke therapy: easy as APC?. Nature Medicine 10:12, 1295-1296
CrossRef1380
CrossRef1381
Fran??ois Fourrier. (2004) Recombinant human activated protein C in the treatment of severe sepsis: An evidence-based review. Critical Care Medicine 32:Supplement, S534-S541
CrossRef1382
Mitchell M. Levy, Peter J. Pronovost, R Phillip Dellinger, Sean Townsend, Roger K. Resar, Terry P. Clemmer, Graham Ramsay. (2004) Sepsis change bundles: Converting guidelines into meaningful change in behavior and clinical outcome. Critical Care Medicine 32:Supplement, S595-S597
CrossRef1383
Stephen Laver, Catherine Farrow, Duncan Turner, Jerry Nolan. (2004) Mode of death after admission to an intensive care unit following cardiac arrest. Intensive Care Medicine 30:11, 2126-2128
CrossRef1384
J.-F. Dhainaut, S. B. Yan, D. E. Joyce, V. Pettila, B. Basson, J. T. Brandt, D. P. Sundin, M. Levi. (2004) Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation1. Journal of Thrombosis and Haemostasis 2:11, 1924-1933
CrossRef1385
Greet Van den Berghe. (2004) How does blood glucose control with insulin save lives in intensive care?. Journal of Clinical Investigation 114:9, 1187-1195
CrossRef1386
Alison J Ruffell. (2004) Sepsis strategies: an ICU package?. Nursing in Critical Care 9:6, 257-263
CrossRef1387
Juan C. Gea-Banacloche, Steven M. Opal, James Jorgensen, Joseph A. Carcillo, Kent A. Sepkowitz, Catherine Cordonnier. (2004) Sepsis associated with immunosuppressive medications: An evidence-based review. Critical Care Medicine 32:Supplement, S578-S590
CrossRef1388
Jeffrey E. Schmidt, Jim I. Morgan, Carlos Rodriguez-Galindo, David L. Webb, Hua Liang, Robert F. Tamburro. (2004) Heme oxygenase-1 messenger RNA expression is induced in peripheral blood mononuclear cells of pediatric cancer patients with systemic inflammatory response syndrome. Pediatric Critical Care Medicine 5:6, 554-560
CrossRef1389
E. Schmutzhard, R. Helbok. (2004) Parasit
CrossRef1390
Wisam Khoury, Joseph M. Klausner, Ron Ben-Abraham, Oded Szold. (2004) Glucose Control by Insulin for Critically Ill Surgical Patients. The Journal of Trauma: Injury, Infection, and Critical Care 57:5, 1132-1138
CrossRef1391
M.L. Lozano Almela, J. Rivera Pozo, V. Vicente García. (2004) Alteraciones de las plaquetas. Etiopatogenia, clasificación, manifestaciones clínicas, diagnóstico y actitudes terapéuticas. Medicine - Programa de Formación Médica Continuada Acreditado 9:22, 1379-1392
CrossRef1392
Christopher McCoy. (2004) Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis. Expert Opinion on Drug Safety 3:6, 625-637
CrossRef1393
Michael A Matthay, Lorraine B Ware. (2004) Can nicotine treat sepsis?. Nature Medicine 10:11, 1161-1162
CrossRef1394
Ralph L. Nachman, Eric A. Jaffe. (2004) Endothelial cell culture: beginnings of modern vascular biology. Journal of Clinical Investigation 114:8, 1037-1040
CrossRef1395
Todd W. Rice, Gordon R. Bernard. (2004) Drotrecogin Alfa (Activated) for the Treatment of Severe Sepsis and Septic Shock. The American Journal of the Medical Sciences 328:4, 205-214
CrossRef1396
Gary An. (2004) In silico experiments of existing and hypothetical cytokine-directed clinical trials using agent-based modeling*. Critical Care Medicine 32:10, 2050-2060
CrossRef1397
Charles T. Esmon. (2004) Interactions between the innate immune and blood coagulation systems. Trends in Immunology 25:10, 536-542
CrossRef1398
M. Bauer, K. Reinhart. (2004)
CrossRef1399
Gilles Clermont, John Bartels, Rukmini Kumar, Greg Constantine, Yoram Vodovotz, Carson Chow. (2004) In silico design of clinical trials: A method coming of age. Critical Care Medicine 32:10, 2061-2070
CrossRef1400
Jasjit Singh, Antonio C. Arrieta. (2004) Management of Meningococcemia. The Indian Journal of Pediatrics 71:10, 909-913
CrossRef1401
Warren R. Summer. (2004) Severe Sepsis: New Concepts in Pathogenesis and Management. The American Journal of the Medical Sciences 328:4, 193-195
CrossRef1402
Kyle I. Happel, Steve Nelson, Warren Summer. (2004) The Lung in Sepsis: Fueling the Fire. The American Journal of the Medical Sciences 328:4, 230-237
CrossRef1403
Tonya Jagneaux, David E. Taylor, Stephen P. Kantrow. (2004) Coagulation in Sepsis. The American Journal of the Medical Sciences 328:4, 196-204
CrossRef1404
Curtis N Sessler, John C Perry, Kimberly L Varney. (2004) Management of severe sepsis and septic shock. Current Opinion in Critical Care 10:5, 354-363
CrossRef1405
Jorge G. Ganopolsky, Francis J. Castellino. (2004) A Protein C Deficiency Exacerbates Inflammatory and Hypotensive Responses in Mice During Polymicrobial Sepsis in a Cecal Ligation and Puncture Model. The American Journal of Pathology 165:4, 1433-1446
CrossRef1406
J. Graf, U. Janssens. (2004) Scoring-Systeme in der Diagnostik und Verlaufsbeurteilung der Sepsis?diagnostische und therapeutische Implikationen. Intensivmedizin und Notfallmedizin 41:7, 476-487
CrossRef1407
L. Engelmann, H.-P. Schuster. (2004) Sepsis? Sepsis!. Intensivmedizin und Notfallmedizin 41:7, 449-450
CrossRef1408
Scott D Imahara, Grant E O’Keefe. (2004) Genetic determinants of the inflammatory response. Current Opinion in Critical Care 10:5, 318-324
CrossRef1409
Alexander Geppert, Kurt Huber. (2004) Inflammation and cardiovascular diseases: lessons that can be learned for the patient with cardiogenic shock in the intensive care unit. Current Opinion in Critical Care 10:5, 347-353
CrossRef1410
A. R. T. Ven, A. C. M. Vliet, B. Maraha, H. H. Ponssen. (2004) Fibrinolytic therapy in Capnocytophaga canimorsus sepsis after dog bite. Intensive Care Medicine 30:10, 1980-1980
CrossRef1411
Michael R. Pinsky. (2004) Dysregulation of the Immune Response in Severe Sepsis. The American Journal of the Medical Sciences 328:4, 220-229
CrossRef1412
Hidesaku Asakura, Yoko Sano, Tomotaka Yoshida, Mika Omote, Yasuo Ontachi, Tomoe Mizutani, Masahide Yamazaki, Eriko Morishita, Akiyoshi Takami, Ken-ichi Miyamoto, Shinji Nakao. (2004) Beneficial effect of low-molecular-weight heparin against lipopolysaccharide-induced disseminated intravascular coagulation in rats is abolished by coadministration of tranexamic acid. Intensive Care Medicine 30:10, 1950-1955
CrossRef1413
Michael Haley, Xizhong Cui, Peter C. Minneci, Katherine J. Deans, Charles Natanson, Peter Q. Eichacker. (2004) Recombinant Human Activated Protein C in Sepsis: Assessing Its Clinical Use. The American Journal of the Medical Sciences 328:4, 215-219
CrossRef1414
J SHEFFIELD. (2004) Sepsis and septic shock in pregnancy. Critical Care Clinics 20:4, 651-660
CrossRef1415
J STEINGRUB. (2004) Pregnancy-associated severe liver dysfunction. Critical Care Clinics 20:4, 763-776
CrossRef1416
Donald E. Fry, Gregory Beilman, Steven Johnson, Dr. Williams, George Rodman, Frank V. Booth, Becky M. Bates, Jill Shwed McCollam, Stephen F. Lowry. (2004) Safety of Drotrecogin Alfa (Activated) in Surgical Patients with Severe Sepsis. Surgical Infections 5:3, 253-259
CrossRef1417
Stephen F. Lowry, Samir Awad, Henri Ford, William Cheadle, Mark D. Williams, Rebecca L. Qualy, Jill Shwed McCollam, Becky M. Bates, Donald E. Fry. (2004) Static and Dynamic Assessment of Biomarkers in Surgical Patients with Severe Sepsis. Surgical Infections 5:3, 261-268
CrossRef1418
Steven M. Hollenberg, Tom S. Ahrens, Djillali Annane, Mark E. Astiz, Donald B. Chalfin, Joseph F. Dasta, Stephen O. Heard, Claude Martin, Lena M. Napolitano, Gregory M. Susla, Richard Totaro, Jean-Louis Vincent, Sergio Zanotti-Cavazzoni. (2004) Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Critical Care Medicine 32:9, 1928-1948
CrossRef1419
Johannes N. Hoffmann, Dieter Mühlbayer, Marianne Jochum, Dietrich Inthorn. (2004) Effect of long-term and high-dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis*. Critical Care Medicine 32:9, 1851-1859
CrossRef1420
Stefan P. Maar. (2004) Emergency Care in Pediatric Septic Shock. Pediatric Emergency Care 20:9, 617-624
CrossRef1421
Alpesh Amin, Joel Diamant, Lorenzo Di Francesco, David Feinbloom, Thomas J. Ferro, Paul Holtom, Joseph Li, Mary Pak, Daniel Rauch, Michael Rovzar, Gregory B. Seymann. (2004) Management of Community-Acquired Pneumonia. Infectious Diseases in Clinical Practice 12:Supplement 2, S10-S16
CrossRef1422
Joseph John, Steven Idell. (2004) Strategies for Optimizing Oxygenation in Acute Respiratory Distress Syndrome. Clinical Pulmonary Medicine 11:5, 318-327
CrossRef1423
Peter J. Pronovost, Michael L. Rinke, Katherine Emery, Cheryl Dennison, Charles Blackledge, Sean M. Berenholtz. (2004) Interventions to reduce mortality among patients treated in Intensive Care Units. Journal of Critical Care 19:3, 158-164
CrossRef1424
Michael Haley, Xizhong Cui, Peter C Minneci, Katherine J Deans, Charles Natanson, Peter Q Eichacker. (2004) Recombinant human activated protein C in sepsis: previous concerns and current usage. Therapy 1:1, 123-129
CrossRef1425
Dieter Buchheidt, Margit Hummel, Georg Engelich, Rüdiger Hehlmann. (2004) Management of infections in critically ill neutropenic cancer patients. Journal of Critical Care 19:3, 165-173
CrossRef1426
Wolfram Ruf. (2004) Emerging roles of tissue factor in viral hemorrhagic fever. Trends in Immunology 25:9, 461-464
CrossRef1427
Todd W. Rice, Gordon R. Bernard. (2004) Advances in sepsis treatment. Current Infectious Disease Reports 6:5, 354-360
CrossRef1428
Greg J. Beilman. (2004) New Strategies to Improve Outcomes in the Surgical Intensive Care Unit. Surgical Infections 5:3, 289-300
CrossRef1429
P BARIE. (2004) Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis. The American Journal of Surgery 188:3, 212-220
CrossRef1430
S. Jacobson, G. Johansson, O. Winso. (2004) Primary sepsis in a university hospital in northern Sweden: A retrospective study. Acta Anaesthesiologica Scandinavica 48:8, 960-967
CrossRef1431
Rukmini Kumar, Gilles Clermont, Yoram Vodovotz, Carson C. Chow. (2004) The dynamics of acute inflammation. Journal of Theoretical Biology 230:2, 145-155
CrossRef1432
Yasser Sakr, Marc-Jacques Dubois, Daniel De Backer, Jacques Creteur, Jean-Louis Vincent. (2004) Persistent microcirculatory alterations are associated with organ failure and death in patients with septic shock*. Critical Care Medicine 32:9, 1825-1831
CrossRef1433
Robert L. Smith, Tae W. Chong, Micheal G. Hughes, Traci L. Hedrick, Heather L. Evans, Shannon T. McElearney, Alison R. Saalwachter, Daniel P. Raymond, Kangping Du, Christine K. Rudy, Timothy L. Pruett, Robert G. Sawyer. (2004) Impact of immunomodulatory oligodeoxynucleotides on cytokine production in the lipopolysaccharide-stimulated human whole blood model. Surgery 136:2, 464-472
CrossRef1434
H Bryant Nguyen, Emanuel P. Rivers, Bernhard P. Knoblich, Gordon Jacobsen, Alexandria Muzzin, Julie A. Ressler, Michael C. Tomlanovich. (2004) Early lactate clearance is associated with improved outcome in severe sepsis and septic shock*. Critical Care Medicine 32:8, 1637-1642
CrossRef1435
Adam M McLeay. (2004) Drotrecogin alfa: A role in emergency department treatment of severe sepsis?. Emergency Medicine Australasia 16:4, 324-335
CrossRef1436
Artur Bauhofer, Alexander Torossian, Wilfried Lorenz, Martin Middeke, Ulrike Plaul, Philipp Sch
CrossRef1437
Hiroshi Morimatsu, Kulgit Singh, Shigehiko Uchino, Rinaldo Bellomo, Graeme Hart. (2004) Early and exclusive use of norepinephrine in septic shock. Resuscitation 62:2, 249-254
CrossRef1438
Djillali Annane, Bernard Clair, Jérôme Salomon. (2004) Managing toxic shock syndrome with antibiotics. Expert Opinion on Pharmacotherapy 5:8, 1701-1710
CrossRef1439
Elisheva Simchen, Charles L. Sprung, Noya Galai, Yana Zitser-Gurevich, Yaron Bar-Lavi, Gabriel Gurman, Moti Klein, Amiram Lev, Leon Levi, Fabio Zveibil, Micha Mandel, George Mnatzaganian. (2004) Survival of critically ill patients hospitalized in and out of intensive care units under paucity of intensive care unit beds*. Critical Care Medicine 32:8, 1654-1661
CrossRef1440
Andrew E. Sama, Jason D'Amore, Mary F. Ward, Guoqian Chen, Haichao Wang. (2004) Bench to Bedside: HMGB1—A Novel Proinflammatory Cytokine and Potential Therapeutic Target for Septic Patients in the Emergency Department. Academic Emergency Medicine 11:8, 867-873
CrossRef1441
Paul Baines, Enitan D. Carrol. (2004) Recombinant tissue plasminogen activator in children with meningococcal purpura fulminans—Role uncertain*. Critical Care Medicine 32:8, 1806-1807
CrossRef1442
Malcolm Fisher. (2004) Ethical issues in the intensive care unit. Current Opinion in Critical Care 10:4, 292-298
CrossRef1443
Konrad Reinhart, Andreas Meier-Hellmann, Richard Beale, Helmuth Forst, Dieter Boehm, Sheila Willatts, Karl F. Rothe, Michael Adolph, Joerg E. Hoffmann, Marc Boehme, Donald L. Bredle. (2004) Open randomized phase II trial of an extracorporeal endotoxin adsorber in suspected Gram-negative sepsis*. Critical Care Medicine 32:8, 1662-1668
CrossRef1444
Willem Ronald Verweij, Hafida Bentala, Ali Huizinga van der Vlag, Anne Miek van Loenen-Weemaes, Kor Kooi, Dirk Klaas Fokke Meijer, Klaas Poelstra. (2004) PROTECTION AGAINST AN ESCHERICHIA COLI-INDUCED SEPSIS BY ALKALINE PHOSPHATASE IN MICE. Shock 22:2, 174-179
CrossRef1445
John C Marshall. (2004) Sepsis: current status, future prospects. Current Opinion in Critical Care 10:4, 250-264
CrossRef1446
Guido Grass, Edmund Alwin Martin Neugebauer. (2004) Extracorporeal endotoxin adsorption in septic patients—Does it work?*. Critical Care Medicine 32:8, 1792-1793
CrossRef1447
John J Marini. (2004) Advances in the understanding of acute respiratory distress syndrome: summarizing a decade of progress. Current Opinion in Critical Care 10:4, 265-271
CrossRef1448
Douglas J. Minnich, Lyle L. Moldawer. (2004) Anti-cytokine and anti-inflammatory therapies for the treatment of severe sepsis: progress and pitfalls. Proceedings of the Nutrition Society 63:03, 437-441
CrossRef1449
Michael A. Gropper. (2004) Evidence-Based Management of Critically Ill Patients: Analysis and Implementation. Anesthesia & Analgesia566-572
CrossRef1450
G. Van den Berghe. (2004) Tight Blood Glucose Control With Insulin in "Real-Life" Intensive Care. Mayo Clinic Proceedings 79:8, 977-978
CrossRef1451
J. S. Krinsley. (2004) Effect of an Intensive Glucose Management Protocol on the Mortality of Critically Ill Adult Patients. Mayo Clinic Proceedings 79:8, 992-1000
CrossRef1452
AC Cheng, DP Stephens, BJ Currie, Allen C Cheng. 2004. Granulocyte-Colony Stimulating Factor (G-CSF) as an adjunct to antibiotics in the treatment of pneumonia in adults. .
CrossRef1453
Kenneth V. I. Rolston. (2004) The Infectious Diseases Society of America 2002 Guidelines for the Use of Antimicrobial Agents in Patients with Cancer and Neutropenia: Salient Features and Comments. Clinical Infectious Diseases 39:s1, S44-S48
CrossRef1454
Schrier, Robert W., Wang, Wei, . (2004) Acute Renal Failure and Sepsis. New England Journal of Medicine 351:2, 159-169
Full Text1455
Bruce Beutler. (2004) Inferences, questions and possibilities in Toll-like receptor signalling. Nature 430:6996, 257-263
CrossRef1456
Edward M. Manno, J. Christopher Farmer. (2004) Acute brain injury: If hypothermia is good, then is hyperthermia bad?*. Critical Care Medicine 32:7, 1611-1612
CrossRef1457
Josef G. Heuer, Ganesh R. Sharma, Bruce Gerlitz, Tonghai Zhang, Dianna L. Bailey, Chunjin Ding, David T. Berg, Douglas Perkins, Eddie J. Stephens, Kimberly C. Holmes, Renee L. Grubbs, Kelly A. Fynboe, Yun-Fei Chen, Brian Grinnell, Joseph A. Jakubowski. (2004) Evaluation of protein C and other biomarkers as predictors of mortality in a rat cecal ligation and puncture model of sepsis*. Critical Care Medicine 32:7, 1570-1578
CrossRef1458
John N. Stallone. (2004) Predicting mortality from sepsis: Is protein C a true crystal ball?*. Critical Care Medicine 32:7, 1620-1621
CrossRef1459
Michael A. Matthay, John A. Clements. (2004) Coagulation-dependent mechanisms and asthma. Journal of Clinical Investigation 114:1, 20-23
CrossRef1460
Hau C Kwaan, Meyer M Samama. (2004) Anticoagulant drugs: an update. Expert Review of Cardiovascular Therapy 2:4, 511-522
CrossRef1461
Kazuhiro Okabayashi, Hideo Wada, Syunsuke Ohta, Hirosi Shiku, Tsutomu Nobori, Kazuo Maruyama. (2004) Hemostatic markers and the sepsis-related organ failure assessment score in patients with disseminated intravascular coagulation in an intensive care unit. American Journal of Hematology 76:3, 225-229
CrossRef1462
Jonathan Cohen, Pat Cristofaro, Jean Carlet, Steven Opal. (2004) New method of classifying infections in critically ill patients*. Critical Care Medicine 32:7, 1510-1526
CrossRef1463
Alexander Vogetseder, Caroline Ospelt, Markus Reindl, Maria Schober, Erich Schmutzhard. (2004) Time course of coagulation parameters, cytokines and adhesion molecules in Plasmodium falciparum malaria. Tropical Medicine and International Health 9:7, 767-773
CrossRef1464
Barry W. Festoff, Syed Ameenuddin, Karen Santacruz, John Morser, Zhiming Suo, Paul M. Arnold, Kristie E. Stricker, Bruce A. Citron. (2004) Neuroprotective Effects of Recombinant Thrombomodulin in Controlled Contusion Spinal Cord Injury Implicates Thrombin Signaling. Journal of Neurotrauma 21:7, 907-922
CrossRef1465
Jean-François Timsit. (2004) Sepsis: Let’s go back to the infectious process*. Critical Care Medicine 32:7, 1616-1617
CrossRef1466
T. Hayashi, J. Nishioka, H. Kamada, K. Asanuma, H. Kondo, E. C. Gabazza, M. Ido, K. Suzuki. (2004) Characterization of a novel human protein C inhibitor (PCI) gene transgenic mouse useful for studying the role of PCI in physiological and pathological conditions. Journal of Thrombosis and Haemostasis 2:6, 949-961
CrossRef1467
Cynthia M. Otto. (2004) Writing for publication in veterinary critical care literature: What does authorship mean?. Journal of Veterinary Emergency and Critical Care 14:2, 81-83
CrossRef1468
J Perren Cobb, Grant E O'Keefe. (2004) Injury research in the genomic era. The Lancet 363:9426, 2076-2083
CrossRef1469
Athena F Zuppa, Vinay M Nadkarni. (2004) Recent developments in the pharmacologic approach to pediatric critical care. Current Opinion in Anaesthesiology 17:3, 223-228
CrossRef1470
Michael Haley, Xizhong Cui, Peter C Minneci, Katherine J Deans, Charles Natanson, Peter Q Eichacker. (2004) Activated protein C in sepsis: emerging insights regarding its mechanism of action and clinical effectiveness. Current Opinion in Infectious Diseases 17:3, 205-211
CrossRef1471
Brian S. Donahue. (2004) Factor V Leiden and Perioperative Risk. Anesthesia & Analgesia1623-1634
CrossRef1472
Hideo Wada. (2004) Disseminated intravascular coagulation. Clinica Chimica Acta 344:1-2, 13-21
CrossRef1473
W.P Robson. (2004) From A&E to ICU: how nurses can support the Surviving Sepsis Campaign. Intensive and Critical Care Nursing 20:3, 113-115
CrossRef1474
K LAUPLAND, P BOUCHER, C ROTSTEIN, D COOK, C DOIG. (2004) Intravenous immunoglobulin for severe infections: a survey of Canadian specialists
CrossRef1475
Todd C. Duffy, Rebecca Kirby, Elke Rudloff. (2004) Critical role of the vascular endothelial cell in health and disease: a review article. Journal of Veterinary Emergency and Critical Care 14:2, 84-99
CrossRef1476
Marcel Levi, Goda Choi, Ivo Schoots, Marcus Schultz, Tom van der Poll. (2004) Beyond sepsis: Activated protein C and ischemia–reperfusion injury. Critical Care Medicine 32:Supplement, S309-S312
CrossRef1477
Toshio Toyosawa, Mamoru Suzuki, Kohtarou Kodama, Seiichi Araki. (2004) Effects of intravenous infusion of highly purified vitamin B2 on lipopolysaccharide-induced shock and bacterial infection in mice. European Journal of Pharmacology 492:2-3, 273-280
CrossRef1478
Martin Hauer-Jensen, Louis M. Fink, Junru Wang. (2004) Radiation injury and the protein C pathway. Critical Care Medicine 32:Supplement, S325-S330
CrossRef1479
Jean-François Dhainaut, S. Betty Yan, Yann-Erick Claessens. (2004) Protein C/activated protein C pathway: Overview of clinical trial results in severe sepsis. Critical Care Medicine 32:Supplement, S194-S201
CrossRef1480
Kees H Polderman, Armand RJ Girbes. (2004) Drug intervention trials in sepsis: divergent results. The Lancet 363:9422, 1721-1723
CrossRef1481
F. B. Taylor, G. Kinasewitz. (2004) Activated protein C in sepsis. Journal of Thrombosis and Haemostasis 2:5, 708-717
CrossRef1482
S. Betty Yan, David R. Nelson. (2004) Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C. Critical Care Medicine 32:Supplement, S239-S246
CrossRef1483
Patricia C. Y. Liaw. (2004) Endogenous protein C activation in patients with severe sepsis. Critical Care Medicine 32:Supplement, S214-S218
CrossRef1484
Marlies Van de Wouwer, Edward M. Conway. (2004) Novel functions of thrombomodulin in inflammation. Critical Care Medicine 32:Supplement, S254-S261
CrossRef1485
Martina Brueckmann, Ursula Hoffmann, Lothar de Rossi, Hans Martin Weiler, Volker Liebe, Siegfried Lang, Jens J Kaden, Martin Borggrefe, Karl K Haase, Guenter Huhle. (2004) Activated protein C inhibits the release of macrophage inflammatory protein-1-alpha from THP-1 cells and from human monocytes. Cytokine 26:3, 106-113
CrossRef1486
Michael A. Matthay, Lorraine B. Ware. (2004) Plasma protein C levels in patients with acute lung injury: Prognostic significance. Critical Care Medicine 32:Supplement, S229-S232
CrossRef1487
Richard G. Wunderink, Grant W. Waterer. (2004) Genetic Effects on Sepsis and Pneumonia. Clinical Pulmonary Medicine 11:3, 143-153
CrossRef1488
Charles T. Esmon. (2004) Why do animal models (sometimes) fail to mimic human sepsis?. Critical Care Medicine 32:Supplement, S219-S222
CrossRef1489
James M. O’Brien, Edward Abraham. (2004) Human models of endotoxemia and recombinant human activated protein C. Critical Care Medicine 32:Supplement, S202-S208
CrossRef1490
Song Hui Jia, Yue Li, Jean Parodo, Andras Kapus, Lingzhi Fan, Ori D. Rotstein, John C. Marshall. (2004) Pre–B cell colony–enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. Journal of Clinical Investigation 113:9, 1318-1327
CrossRef1491
Mark N Smithies, Christine B Weaver. (2004) Role of the tissue factor pathway in the pathogenesis and management of multiple organ failure. Blood Coagulation & Fibrinolysis 15:Supplement 1, S11-S20
CrossRef1492
A. G. Tsiotou, G. H. Sakorafas. (2004) Management of septic shock: current concepts, with a particular emphasis on the role of source control, and future perspectives. European Journal of Anaesthesiology 21:5, 337-360
CrossRef1493
Hartmut Weiler, Bryce Kerlin, Mary C. Lytle. (2004) Factor V Leiden polymorphism modifies sepsis outcome: Evidence from animal studies. Critical Care Medicine 32:Supplement, S233-S238
CrossRef1494
Laszlo Bajzar, Nidhi Jain, Ping Wang, John B. Walker. (2004) Thrombin activatable fibrinolysis inhibitor: Not just an inhibitor of fibrinolysis. Critical Care Medicine 32:Supplement, S320-S324
CrossRef1495
William L. Macias, David R. Nelson. (2004) Severe protein C deficiency predicts early death in severe sepsis. Critical Care Medicine 32:Supplement, S223-S228
CrossRef1496
William C. Aird. (2004) Endothelium as an organ system. Critical Care Medicine 32:Supplement, S271-S279
CrossRef1497
Wei Zeng, William F. Matter, S. Betty Yan, Suzane L. Um, Chris J. Vlahos, Ling Liu. (2004) Effect of drotrecogin alfa (activated) on human endothelial cell permeability and Rho kinase signaling. Critical Care Medicine 32:Supplement, S302-S308
CrossRef1498
Joelle Texereau, Frédéric Pene, Jean-Daniel Chiche, Christophe Rousseau, Jean-Paul Mira. (2004) Importance of hemostatic gene polymorphisms for susceptibility to and outcome of severe sepsis. Critical Care Medicine 32:Supplement, S313-S319
CrossRef1499
Rafal Pawlinski, Nigel Mackman. (2004) Tissue factor, coagulation proteases, and protease-activated receptors in endotoxemia and sepsis. Critical Care Medicine 32:Supplement, S293-S297
CrossRef1500
David E. Joyce, David R. Nelson, Brian W. Grinnell. (2004) Leukocyte and endothelial cell interactions in sepsis: Relevance of the protein C pathway. Critical Care Medicine 32:Supplement, S280-S286
CrossRef1501
Jean-Louis Vincent. (2004) Endpoints in sepsis trials: More than just 28-day mortality?. Critical Care Medicine 32:Supplement, S209-S213
CrossRef1502
D. G. Maki. (2004) Pneumococcal Bacteremia: Lessons Learned, Yet More to Learn. Mayo Clinic Proceedings 79:5, 599-603
CrossRef1503
Carl-Erik Dempfle. (2004) Disseminated intravascular coagulation and coagulation disorders. Current Opinion in Anaesthesiology 17:2, 125-129
CrossRef1504
Gavin G Lavery, Ken G Lowry. (2004) Management of blast injuries and shock lung. Current Opinion in Anaesthesiology 17:2, 151-157
CrossRef1505
Alberto Corona, Ferdinando Raimondi, Mervyn Singer. (2004) Severe bloodstream infections from the community: Risk factors and outcomes *. Critical Care Medicine 32:4, 1083-1084
CrossRef1506
Richard G. Wunderink. (2004) A long and winding road *. Critical Care Medicine 32:4, 1077-1079
CrossRef1507
L. IyilikCi, S. Erbayraktar, N. Gokmen, H. Ellidokuz, H. C. Kara, A. Gunerli. (2004) Practices of anaesthesiologists with regard to withholding and withdrawal of life support from the critically ill in Turkey. Acta Anaesthesiologica Scandinavica 48:4, 457-462
CrossRef1508
Bhanu Paladugu, Anand Kumar, Joseph E Parrillo, Sandy Der, Jailan Osman, Joel Mensing, Lisa Falvo, Xiulong Xu, Aseem Kumar. (2004) BACTERIAL DNA AND RNA INDUCE RAT CARDIAC MYOCYTE CONTRACTION DEPRESSION IN VITRO. Shock 21:4, 364-369
CrossRef1509
Vibeke Brix-Christensen, Søren Kæseler Andersen, René Andersen, Annette Mengel, Thomas Dyhr, Niels Trolle Andersen, Anders Larsson, Ole Schmitz, Hans Ørskov, Else Tønnesen. (2004) Acute Hyperinsulinemia Restrains Endotoxin-induced Systemic Inflammatory Response. Anesthesiology 100:4, 861-870
CrossRef1510
Konrad Reinhart, Thomas Uhlig. (2004) Differential gene expression: a (new) topic in the intensive care unit. Current Opinion in Anaesthesiology 17:2, 93-95
CrossRef1511
Charles T. Esmon. (2004) Crosstalk between inflammation and thrombosis. Maturitas 47:4, 305-314
CrossRef1512
Johannes N. Hoffmann, Brigitte Vollmar, Matthias W. Laschke, Dietrich Inthorn, Jan Fertmann, Friedrich W. Schildberg, Michael D. Menger. (2004) Microhemodynamic and cellular mechanisms of activated protein C action during endotoxemia*. Critical Care Medicine 32:4, 1011-1017
CrossRef1513
Annie Sparrow, Frank Willis. (2004) Management of septic shock in childhood. Emergency Medicine Australasia 16:2, 125-134
CrossRef1514
Helen Lee, Christopher James Doig, William A. Ghali, Cam Donaldson, David Johnson, Braden Manns. (2004) Detailed cost analysis of care for survivors of severe sepsis. Critical Care Medicine 32:4, 981-985
CrossRef1515
Kevin B. Laupland, Daniel B. Gregson, David A. Zygun, Christopher J. Doig, Garth Mortis, Deirdre L. Church. (2004) Severe bloodstream infections: A population-based assessment*. Critical Care Medicine 32:4, 992-997
CrossRef1516
Tom van der Poll, Marcel Levi. (2004) Mechanisms of action of activated protein C: An evolving story *. Critical Care Medicine 32:4, 1086-1087
CrossRef1517
ALAN LEVITON, OLAF DAMMANN. (2004) Coagulation, Inflammation, and the Risk of Neonatal White Matter Damage. Pediatric Research 55:4, 541-545
CrossRef1518
Aihua Wu, Charles J. Hinds, Christoph Thiemermann. (2004) High-Density Lipoproteins in Sepsis and Septic Shock: Metabolism, Actions, and Therapeutic Applications. Shock 21:3, 210-221
CrossRef1519
John A. Kellum, Mingchen Song, Ramesh Venkataraman. (2004) Hemoadsorption removes tumor necrosis factor, interleukin-6, and interleukin-10, reduces nuclear factor-κB DNA binding, and improves short-term survival in lethal endotoxemia*. Critical Care Medicine 32:3, 801-805
CrossRef1520
Steven M. Opal. (2004) Unintended bias, clinical trial results, and the heparin post hoc crossover fallacy. Critical Care Medicine 32:3, 874-875
CrossRef1521
Peter J Pronovost, Thomas Nolan, Scott Zeger, Marlene Miller, Haya Rubin. (2004) How can clinicians measure safety and quality in acute care?. The Lancet 363:9414, 1061-1067
CrossRef1522
R. Phillip Dellinger, Jean M. Carlet, Henry Masur, Herwig Gerlach, Thierry Calandra, Jonathan Cohen, Juan Gea-Banacloche, Didier Keh, John C. Marshall, Margaret M. Parker, Graham Ramsay, Janice L. Zimmerman, Jean-Louis Vincent, Mitchell M. Levy. (2004) Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Critical Care Medicine 32:3, 858-873
CrossRef1523
Victor J Marder, Michael H Rosove, Dena M Minning. (2004) Foundation and sites of action of antithrombotic agents. Best Practice & Research Clinical Haematology 17:1, 3-22
CrossRef1524
Andre C. Kalil, Susette M. Coyle, John Y. Um, Steven P. LaRosa, Mary Ann Turlo, Steve E. Calvano, David P. Sundin, David R. Nelson, Stephen F. Lowry. (2004) Effects of Drotrecogin Alfa (Activated) in Human Endotoxemia. Shock 21:3, 222-229
CrossRef1525
William C Aird. (2004) Natural anticoagulant inhibitors: activated Protein C. Best Practice & Research Clinical Haematology 17:1, 161-182
CrossRef1526
Marcel Levi. (2004) Current understanding of disseminated intravascular coagulation. British Journal of Haematology 124:5, 567-576
CrossRef1527
W. Macias, S. B. Yan. (2004) Antithrombin and heparin may limit the activation of Protein C. Acta Anaesthesiologica Scandinavica 48:3, 385-385
CrossRef1528
Milo Engoren, Robert H Habib. (2004) Effects of intraaortic balloon augmentation in a porcine model of endotoxemic shock. Resuscitation 60:3, 319-326
CrossRef1529
Sherman C. Stein, David I. Graham, Xiao-Han Chen, Douglas H. Smith. (2004) Association between Intravascular Microthrombosis and Cerebral Ischemia in Traumatic Brain Injury. Neurosurgery 54:3, 687-691
CrossRef1530
Andrew J. Gale, John H. Griffin. (2004) Characterization of a thrombomodulin binding site on protein C and its comparison to an activated protein C binding site for factor Va. Proteins: Structure, Function, and Bioinformatics 54:3, 433-441
CrossRef1531
Sean P. Keenan, Peter Dodek, Keith Chan, Mathieu Simon, Robert S. Hogg, Aslam H. Anis, John J. Spinelli, Jessica Tilley, Monica Norena, Hubert Wong. (2004) Intensive care unit survivors have fewer hospital readmissions and readmission days than other hospitalized patients in British Columbia. Critical Care Medicine 32:2, 391-398
CrossRef1532
Christopher J. Doig, David A. Zygun, Gordon H. Fick, Kevin B. Laupland, Paul J. E. Boiteau, Reza Shahpori, Tom Rosenal, J. Dean Sandham. (2004) Study of clinical course of organ dysfunction in intensive care. Critical Care Medicine 32:2, 384-390
CrossRef1533
Christopher James Doig, David A Zygun, Anthony Delaney, Braden J Manns. (2004) Drotrecogin alfa (activated; Xigris®): an effective and cost-efficient treatment for severe sepsis. Expert Review of Pharmacoeconomics & Outcomes Research 4:1, 15-26
CrossRef1534
Björn Dahlbäck. (2004) Progress in the Understanding of the Protein C Anticoagulant Pathway. International Journal of Hematology 79:2, 109-116
CrossRef1535
Huang Guo, Dong Liu, Harris Gelbard, Tong Cheng, Rae Insalaco, José A Fernández, John H Griffin, Berislav V Zlokovic. (2004) Activated Protein C Prevents Neuronal Apoptosis via Protease Activated Receptors 1 and 3. Neuron 41:4, 563-572
CrossRef1536
S. B. Yan, W. L. Macias. (2004) Activated protein C levels in patients with severe sepsis: rebuttal. Journal of Thrombosis and Haemostasis 2:2, 366-366
CrossRef1537
Kenji Okajima. (2004) Regulation of inflammatory responses by activated protein C: the molecular mechanism(s) and therapeutic implications. Clinical Chemistry and Laboratory Medicine 42:2, 132-141
CrossRef1538
Robert L Sheridan, Ronald G Tompkins. (2004) What's new in burns and metabolism. Journal of the American College of Surgeons 198:2, 243-263
CrossRef1539
Mark T. Lin, Timothy E. Albertson. (2004) Genomic polymorphisms in sepsis. Critical Care Medicine 32:2, 569-579
CrossRef1540
Peter A. Ward. (2004) The dark side of C5a in sepsis. Nature Reviews Immunology 4:2, 133-142
CrossRef1541
Peter C. Minneci, Katherine J. Deans, Steven M. Banks, Peter Q. Eichacker, Charles Natanson. (2004) Should we continue to target the platelet-activating factor pathway in septic patients? *. Critical Care Medicine 32:2, 585-588
CrossRef1542
S. Betty Yan, Jean-Francois Dhainaut. (2004) Only Activated Protein C Treatment and Not Protein C Has Demonstrated an Improvement in Survival in Severe Sepsis. Critical Care Medicine 32:2, 618
CrossRef1543
H. Isobe, K. Okajima, N. Harada, W. Liu, H. Okabe. (2004) Activated protein C reduces stress-induced gastric mucosal injury in rats by inhibiting the endothelial cell injury. Journal of Thrombosis and Haemostasis 2:2, 313-320
CrossRef1544
Isaiah R. Turnbull, Pardis Javadi, Timothy G. Buchman, Richard S. Hotchkiss, Irene E. Karl, Craig M. Coopersmith. (2004) Antibiotics Improve Survival in Sepsis Independent of Injury Severity but do not Change Mortality in Mice with Markedly Elevated Interleukin 6 Levels. Shock 21:2, 121-125
CrossRef1545
S. Playfor. (2004) Management of the critically ill child with sepsis. Continuing Education in Anaesthesia, Critical Care & Pain 4:1, 12-15
CrossRef1546
Michael A Fischer, Craig M Lilly, William W Churchill, Lindsey R Baden, Jerry Avorn. (2004) An Algorithmic Computerised Order Entry Approach to Assist in the Prescribing of New Therapeutic Agents. Drug Safety 27:15, 1253-1261
CrossRef1547
Thomas Gl??ck, Steven M Opal. (2004) Advances in Sepsis Therapy. Drugs 64:8, 837-859
CrossRef1548
Olivier Joannes-Boyau, Stephane Rapaport, Romain Bazin, Catherine Fleureau, Gerard Janvier. (2004) Impact of High Volume Hemofiltration on Hemodynamic Disturbance and Outcome during Septic Shock. ASAIO Journal 50:1, 102-109
CrossRef1549
Marilyn J. Manco-Johnson, Rhonda Knapp-Clevenger. (2004) Activated Protein C Concentrate Reverses Purpura Fulminans in Severe Genetic Protein C Deficiency. Journal of Pediatric Hematology/Oncology 26:1, 25-27
CrossRef1550
Hilmar Burchardi, Heinz Schneider. (2004) Economic Aspects of Severe Sepsis. PharmacoEconomics 22:12, 793-813
CrossRef1551
(2004) BACCN News. Nursing in Critical Care 9:1, 34-38
CrossRef1552
H. Muth, U. Maus, M. Wygrecka, J. Lohmeyer, F. Grimminger, W. Seeger, A. Günther. (2004) Pro- and antifibrinolytic properties of human pulmonary microvascular versus artery endothelial cells: Impact of endotoxin and tumor necrosis factor-α. Critical Care Medicine 32:1, 217-226
CrossRef1553
Daren Purnell, Tod Hazlett, Sherri L. Alexander. (2004) A New Weapon Against Severe Sepsis Related to Necrotizing Fasciitis. Dimensions of Critical Care Nursing 23:1, 18-23
CrossRef1554
Kristen H. Goodell, Michael R. Jordan, Roger Graham, Charles Cassidy, Stanley A. Nasraway. (2004) Rapidly advancing necrotizing fasciitis caused by Photobacterium (Vibrio) damsela: A hyperaggressive variant. Critical Care Medicine 32:1, 278-281
CrossRef1555
M ANGSTWURM. (2004) -Dimer as marker for microcirculatory failure: correlation with LOD and APACHE II scores. Thrombosis Research 113:6, 353-359
CrossRef1556
A OHLIN. (2004) Genetic variation in the human thrombomodulin promoter locus and prognosis after acute coronary syndrome. Thrombosis Research 113:5, 319-326
CrossRef1557
C. Holm, F. Hörbrand, M. Mayr, G. Henckel von Donnersmarck, W. Mühlbauer. (2004) Acute hyperglycaemia following thermal injury: friend or foe?. Resuscitation 60:1, 71-77
CrossRef1558
H KAMADA, K HATTORI, T HAYASHI, K SUZUKI. (2004) In vitro evaluation of blood coagulation activation and microthrombus formation by a microchannel array flow analyzer. Thrombosis Research 114:3, 195-203
CrossRef1559
R. Phillip Dellinger, Joseph E. Parrillo. (2004) Mediator modulation therapy of severe sepsis and septic shock: Does it work? *. Critical Care Medicine 32:1, 282-286
CrossRef1560
Aleksandar Karamarkovic, Darko Mirkovic, Nebojsa Stankovic, Valentina Nikolic, Vasilije Jeremic, Dejan Radenkovic, Branislav Stefanovic. (2004) Disturbances of protein c activity in abdominal sepsis: Diagnostic and predictive importance. Vojnosanitetski pregled 61:6, 599-606
CrossRef1561
Cabot, Richard C.Harris, Nancy Lee, McNeely, William F., Shepard, Jo-Anne O., Ebeling, Sally H.Ellender, Stacey M.Peters, Christine C., Warren, H. Shaw Jr., Gonzalez, R. Gilberto, Tian, Di, . (2003) Case 38-2003. New England Journal of Medicine 349:24, 2341-2349
Full Text1562
Bradley D. Freeman. (2003) A Meta-Analysis of Controlled Trials of Anticoagulant Therapies in Patients with Sepsis.. Shock 20:6, 583-584
CrossRef1563
Michael Bergmann, Alexander Gornikiewicz, Dietmar Tamandl, Ruth Exner, Erich Roth, Reinhold F??gger, Peter G??tzinger, Thomas Sautner. (2003) Continuous Therapeutic Epinephrine but not Norepinephrine Prolongs Splanchnic IL-6 Production in Porcine Endotoxic Shock. Shock 20:6, 575-581
CrossRef1564
Keyuan Jiang, S.B. Higgins, B.B. Swindell, G.R. Bernard. (2003) CommLog: a communication log system for clinical trials. IEEE Transactions on Information Technology in Biomedicine 7:4, 378-383
CrossRef1565
Paul B. Baines, Enitan D. Carrol. (2003) In meningococcal disease 4G bad, 5G good *. Critical Care Medicine 31:12, 2813-2814
CrossRef1566
Li Wan, Rinaldo Bellomo, David Di Giantomasso, Claudio Ronco. (2003) The pathogenesis of septic acute renal failure. Current Opinion in Critical Care 9:6, 496-502
CrossRef1567
A. R. J. Girbes, K. H. Polderman. (2003) A definite role for treatment with activated protein C in sepsis? Standard use is premature. Journal of Thrombosis and Haemostasis 1:12, 2469-2471
CrossRef1568
Saxon Ridley. (2003) Critical care. Anaesthesia 58:12, 1178-1183
CrossRef1569
Yuval Shilon, Ariella Bar-Gil Shitrit, Bernard Rudensky, Amos M Yinnon, Maya Margalit, Jaqueline Sulkes, David Shitrit. (2003) A rapid quantitative D-dimer assay at admission correlates with the severity of community acquired pneumonia. Blood Coagulation & Fibrinolysis 14:8, 745-748
CrossRef1570
An S. De Vriese, Marc Bourgeois. (2003) Pharmacologic treatment of acute renal failure in sepsis. Current Opinion in Critical Care 9:6, 474-480
CrossRef1571
Aurelie Plessier, Marie-Helene Denninger, Yann Consigny, Fabienne Pessione, Claire Francoz, Francois Durand, Sven Francque, Annie Bezeaud, Laurence Chauvelot-Moachon, Didier Lebrec, Dominique-Charles Valla, Richard Moreau. (2003) Coagulation disorders in patients with cirrhosis and severe sepsis. Liver International 23:6, 440-448
CrossRef1572
Jose Garnacho-Montero, Jose Luis Garcia-Garmendia, Ana Barrero-Almodovar, Francisco J. Jimenez-Jimenez, Carmen Perez-Paredes, Carlos Ortiz-Leyba. (2003) Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis*. Critical Care Medicine 31:12, 2742-2751
CrossRef1573
Daniel A. Anaya, Avery B. Nathens. (2003) Risk Factors for Severe Sepsis in Secondary Peritonitis. Surgical Infections 4:4, 355-362
CrossRef1574
James M. O'Brien, Edward Abraham. (2003) New approaches to the treatment of sepsis. Clinics in Chest Medicine 24:4, 521-548
CrossRef1575
E. Wiel, B. Vallet. (2003) A definite role for treatment with activated protein C in sepsis? Yes. Journal of Thrombosis and Haemostasis 1:12, 2466-2468
CrossRef1576
Cheryl L Holmes, Keith R Walley. (2003) The evaluation and management of shock. Clinics in Chest Medicine 24:4, 775-789
CrossRef1577
Nancy M. Richards. (2003) Breakthroughs beckon new approaches to existing procedures. Nursing Management (Springhouse) 34:12, 18-22
CrossRef1578
E. Mattsson, H. Herwald, A. Egesten. (2003) Superantigens from Staphylococcus aureus induce procoagulant activity and monocyte tissue factor expression in whole blood and mononuclear cells via IL-1beta. Journal of Thrombosis and Haemostasis 1:12, 2569-2576
CrossRef1579
Jordi Rello, Alejandro Rodriguez. (2003) Improving survival for sepsis: On the cutting edge *. Critical Care Medicine 31:12, 2807-2808
CrossRef1580
Elene Haralambous, Martin L. Hibberd, Peter W. M. Hermans, Nelly Ninis, Simon Nadel, Michael Levin. (2003) Role of functional plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism in susceptibility, severity, and outcome of meningococcal disease in Caucasian children*. Critical Care Medicine 31:12, 2788-2793
CrossRef1581
Reed E Drews. (2003) Critical issues in hematology: anemia, thrombocytopenia, coagulopathy, and blood product transfusions in critically ill patients. Clinics in Chest Medicine 24:4, 607-622
CrossRef1582
A Neilson. (2003) Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany. Journal of Critical Care 18:4, 217-227
CrossRef1583
Henri M.H. Spronk, Jos
CrossRef1584
J GAINER, N YOST. (2003) Critical care infectious disease. Obstetrics and Gynecology Clinics of North America 30:4, 695-709
CrossRef1585
S AWAD. (2003) State-of-the-art therapy for severe sepsis and multisystem organ dysfunction. The American Journal of Surgery 186:5, 23-30
CrossRef1586
Johannes Pleiner, Friedrich Mittermayer, Georg Schaller, Claudia Marsik, Raymond J. MacAllister, Michael Wolzt. (2003) Inflammation-induced vasoconstrictorhyporeactivity is caused by oxidative stress. Journal of the American College of Cardiology 42:9, 1656-1662
CrossRef1587
Alan S Cross, Steven M Opal, John E Palardy, Joseph J Drabick, H.Shaw Warren, Christian Huber, Pamela Cook, Apurba K Bhattacharjee. (2003) Phase I study of detoxified Escherichia coli J5 lipopolysaccharide (J5dLPS)/group B meningococcal outer membrane protein (OMP) complex vaccine in human subjects. Vaccine 21:31, 4576-4587
CrossRef1588
Takehiko Miyaji, Xuzhen Hu, Peter S.T. Yuen, Yasunari Muramatsu, Swarnalatha Iyer, Stephen M. Hewitt, Robert A. Star. (2003) Ethyl pyruvate decreases sepsis-induced acute renal failure and multiple organ damage in aged mice. Kidney International 64:5, 1620-1631
CrossRef1589
Philip Efron, Lyle L. Moldawer. (2003) Sepsis and the Dendritic Cell. Shock 20:5, 386-401
CrossRef1590
Scott T. Micek, Rina A. Shah, Marin H. Kollef. (2003) Management of Severe Sepsis: Integration of Multiple Pharmacologic Interventions. Pharmacotherapy 23:11, 1486-1496
CrossRef1591
Michael R. Pinsky. (2003) Antioxidant therapy for severe sepsis: Promise and perspective *. Critical Care Medicine 31:11, 2697-2698
CrossRef1592
Gilles Clermont, Derek C. Angus, Kenneth G. Kalassian, Walter T. Linde-Zwirble, Nagarajan Ramakrishnan, Peter K. Linden, Michael R. Pinsky. (2003) Reassessing the value of short-term mortality in sepsis: Comparing conventional approaches to modeling. Critical Care Medicine 31:11, 2627-2633
CrossRef1593
Christopher James Doig, Kevin B Laupland, David A Zygun, Braden J Manns. (2003) The epidemiology of severe sepsis syndrome and its treatment with recombinant human activated protein C. Expert Opinion on Pharmacotherapy 4:10, 1789-1799
CrossRef1594
Jean-Louis Vincent. (2003) Should Albumin Be Used to Correct Hypoalbuminemia in the Critically Ill? Yes. Transfusion Alternatives in Transfusion Medicine 5:4, 397-400
CrossRef1595
Gourang P. Patel, David P. Gurka, Robert A. Balk. (2003) New treatment strategies for severe sepsis and septic shock. Current Opinion in Critical Care 9:5, 390-396
CrossRef1596
A. Y. Y. Lee, G. P. Vlasuk. (2003) Recombinant nematode anticoagulant protein c2 and other inhibitors targeting blood coagulation factor VIIa/tissue factor. Journal of Internal Medicine 254:4, 313-321
CrossRef1597
Joseph V. DiCarlo, Steven R. Alexander, Rajni Agarwal, Joshua D. Schiffman. (2003) Continuous Veno-Venous Hemofiltration May Improve Survival From Acute Respiratory Distress Syndrome After Bone Marrow Transplantation or Chemotherapy. Journal of Pediatric Hematology/Oncology 25:10, 801-805
CrossRef1598
Rodney M. Durham, J. J. Moran, John E. Mazuski, Marc J. Shapiro, Arthur E. Baue, Lewis M. Flint. (2003) Multiple Organ Failure in Trauma Patients. The Journal of Trauma: Injury, Infection, and Critical Care 55:4, 608-616
CrossRef1599
H. David Humes, Deborah A. Buffington, Liandi Lou, Simin Abrishami, Min Wang, Jun Xia, William H. Fissell. (2003) Cell therapy with a tissue-engineered kidney reduces the multiple-organ consequences of septic shock. Critical Care Medicine 31:10, 2421-2428
CrossRef1600
J. Carlet. (2003) Drotrecogin Alfa (Activated) Administration: Too Many Subgroups. Critical Care Medicine 31:10, 2564
CrossRef1601
Alain P Vasserot, Jeffry D Watkins. (2003) Expanding the clinical utility of therapeutic proteins: activated protein C variants with improved pharmacological properties. Trends in Pharmacological Sciences 24:10, 501-504
CrossRef1602
Steven M. Opal. (2003) Clinical Trial Design and Outcomes in Patients with Severe Sepsis. Shock 20:4, 295-302
CrossRef1603
Mitchell P. Fink. (2003) The Therapeutic Potential of Ethyl Pyruvate for the Management of Ischemia/Reperfusion Syndromes, Sepsis and Sepsis-Related Organ Dysfunction, and Other Conditions Associated With Excessive Inflammation. Transfusion Alternatives in Transfusion Medicine 5:4, 432-436
CrossRef1604
I CHENG, M MATTHAY. (2003) Acute lung injury and the acute respiratory distress syndrome. Critical Care Clinics 19:4, 693-712
CrossRef1605
Glenn M Chertow, Maria T Pascual, Sharon Soroko, Brandon R Savage, Jonathan Himmelfarb, T.Alp Ikizler, Emil P Paganini, Ravindra L Mehta. (2003) Reasons for non-enrollment in a cohort study of ARF: the Program to Improve Care in Acute Renal Disease (PICARD) experience and implications for a clinical trials network. American Journal of Kidney Diseases 42:3, 507-512
CrossRef1606
Robert A Fowler, Marya Hill-Popper, John Stasinos, Constantia Petrou, Gillian D Sanders, Alan M Garber. (2003) Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis. Journal of Critical Care 18:3, 181-191
CrossRef1607
Jumei Shi, Junru Wang, Huaien Zheng, Wen Ling, Jacob Joseph, Dayuan Li, Jawahar L Mehta, Usha Ponnappan, Pei Lin, Louis M Fink, Martin Hauer-Jensen. (2003) Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation. Blood Coagulation & Fibrinolysis 14:6, 575-585
CrossRef1608
Gerald J. Kost, Nam K. Tran, Richard F. Louie, Zuping Tang, Ashley A. Woodruff, Timothy E. Albertson, Robert W. Derlet, Rahman Azari. (2003) Rapid Diagnosis of Sepsis. Point of Care: The Journal of Near-Patient Testing & Technology 2:3, 163-171
CrossRef1609
D. King, D. Higgins. (2003) Subarachnoid haemorrhage following activated protein C for bacterial meningitis. Anaesthesia 58:9, 913-914
CrossRef1610
Armelle M. Laforcade, Lisa M. Freeman, Scott P. Shaw, Marjory B. Brooks, Elizabeth A. Rozanski, John E. Rush. (2003) Hemostatic Changes in Dogs with Naturally Occurring Sepsis. Journal of Veterinary Internal Medicine 17:5, 674-679
CrossRef1611
Jean-François Dhainaut, Pierre-François Laterre, Steven P. LaRosa, Howard Levy, Gary E. Garber, Darell Heiselman, Gary T. Kinasewitz, R. Bruce Light, Peter Morris, Roland Schein, Jean-Pierre Sollet, Becky M. Bates, Barbara G. Utterback, Dennis Maki. (2003) The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): Role, methodology, and results*. Critical Care Medicine 31:9, 2291-2301
CrossRef1612
Hideo Wada, Esteban C. Gabazza, Hidesaku Asakura, Kaoru Koike, Kohji Okamoto, Ikurou Maruyama, Hiroshi Shiku, Tsutomu Nobori. (2003) Comparison of diagnostic criteria for disseminated intravascular coagulation (DIC): diagnostic criteria of the International Society of Thrombosis and Hemostasis (ISTH) and of the Japanese Ministry of Health and Welfare for overt DIC. American Journal of Hematology 74:1, 17-22
CrossRef1613
William R. Clark. (2003) Renal Replacement Therapy in Acute Renal Failure. Artificial Organs 27:9, 753-754
CrossRef1614
A Topp. (2003) Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis. Journal of Critical Care 18:3, 191-194
CrossRef1615
Andrew Padkin, Caroline Goldfrad, Anthony R. Brady, Duncan Young, Nick Black, Kathy Rowan. (2003) Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. Critical Care Medicine 31:9, 2332-2338
CrossRef1616
Richard Teplick. (2003) Clinical evaluation committees: The time is right but is the timing right? *. Critical Care Medicine 31:9, 2403-2405
CrossRef1617
Douglas B. Coursin, Brian Liddy, Kenneth E. Wood. (2003) Corticosteroid Replacement in Critical Illness. Clinical Pulmonary Medicine 10:5, 278-288
CrossRef1618
Niels C. Riedemann, Ren-Feng Guo, Peter A. Ward. (2003) The enigma of sepsis. Journal of Clinical Investigation 112:4, 460-467
CrossRef1619
Heidi J. Dalton. (2003) Recombinant activated protein C in pediatric sepsis. The Pediatric Infectious Disease Journal 22:8, 743-745
CrossRef1620
Sean Berenholtz, Peter J. Pronovost. (2003) Barriers to translating evidence into practice. Current Opinion in Critical Care 9:4, 321-325
CrossRef1621
M Badamchian. (2003) Thymosin β4 reduces lethality and down-regulates inflammatory mediators in endotoxin-induced septic shock. International Immunopharmacology 3:8, 1225-1233
CrossRef1622
Derek C. Angus. (2003) Towards better care: an exploration of some barriers and solutions to research transfer in the intensive care unit. Current Opinion in Critical Care 9:4, 306-307
CrossRef1623
Anaadriana Zakarija, Hau C Kwaan. (2003) Bleeding and thrombosis in the cancer patient. Expert Review of Cardiovascular Therapy 1:2, 271-281
CrossRef1624
A. Lignell, A. Siegbahn, M. Stridsberg, K. Pauksen, R. Gedeborg, J. Sjolin. (2003) Low utilisation of unactivated protein C in a patient with meningococcal septic shock and disseminated intravascular coagulation. Acta Anaesthesiologica Scandinavica 47:7, 897-900
CrossRef1625
Kelly A. Wood, E. Wes Ely. (2003) What does it mean to be critically ill and elderly?. Current Opinion in Critical Care 9:4, 316-320
CrossRef1626
Jean-Louis Vincent, Frédérique Jacobs. (2003) Infection in critically ill patients: clinical impact and management. Current Opinion in Infectious Diseases 16:4, 309-313
CrossRef1627
Shannon S. Carson, Andrew F. Shorr. (2003) Is the implementation of research findings in the critically ill hampered by the lack of universal definitions of illness?. Current Opinion in Critical Care 9:4, 308-315
CrossRef1628
Rhonda S. Fishel, Chandrakanth Are, Adrian Barbul. (2003) Vessel injury and capillary leak. Critical Care Medicine 31:Supplement, S502-S511
CrossRef1629
Trevor Duke, Nigel Curtis, David G Fuller. (2003) The management of bacterial meningitis in children. Expert Opinion on Pharmacotherapy 4:8, 1227-1240
CrossRef1630
Matthias Riewald, Wolfram Ruf. (2003) Proteinase-activated receptor activation by coagulation proteinases. Drug Development Research 59:4, 400-407
CrossRef1631
Simon Eaton. (2003) Impaired energy metabolism during neonatal sepsis: the effects of glutamine. Proceedings of the Nutrition Society 62:03, 745-751
CrossRef1632
E. W. Ely, D. C. Angus, M. D. Williams, B. Bates, R. Qualy, G. R. Bernard. (2003) Drotrecogin Alfa (Activated) Treatment of Older Patients with Severe Sepsis. Clinical Infectious Diseases 37:2, 187-195
CrossRef1633
Bradley D. Freeman, Barbara A. Zehnbauer, Timothy G. Buchman. (2003) A Meta-Analysis of Controlled Trials of Anticoagulant Therapies in Patients With Sepsis. Shock 20:1, 5-9
CrossRef1634
Waheedullah Karzai, Xizhong Cui, Bjoern Mehlhorn, Eberhard Straube, Thomas Hartung, Eric Gerstenberger, Steven M. Banks, Charles Natanson, Konrad Reinhart, Peter Q. Eichacker. (2003) Protection with Antibody to Tumor Necrosis Factor Differs with Similarly Lethal Escherichia coli versus Staphylococcus aureus Pneumonia in Rats. Anesthesiology 99:1, 81-89
CrossRef1635
Vida Foubister. (2003) New mode of intervention in sepsis treatment. Drug Discovery Today 8:14, 610-612
CrossRef1636
Steven M. Opal, Gary E. Garber, Steven P. LaRosa, Dennis G. Maki, Ross C. Freebairn, Gary T. Kinasewitz, Jean‐Francois Dhainaut, S. Betty Yan, Mark D. Williams, Delores E. Graham, David R. Nelson, Howard Levy, Gordon R. Bernard. (2003) Systemic Host Responses in Severe Sepsis Analyzed by Causative Microorganism and Treatment Effects of Drotrecogin Alfa (Activated). Clinical Infectious Diseases 37:1, 50-58
CrossRef1637
Jack Hirsh. (2003) Current anticoagulant therapy—unmet clinical needs. Thrombosis Research 109, S1-S8
CrossRef1638
B. Dahlback, B. O. Villoutreix. (2003) Molecular recognition in the protein C anticoagulant pathway. Journal of Thrombosis and Haemostasis 1:7, 1525-1534
CrossRef1639
Lorraine B. Ware. (2003) Advances in the Pathogenesis and Treatment of the Acute Respiratory Distress Syndrome. Clinical Pulmonary Medicine 10:4, 208-218
CrossRef1640
T SHANLEY, H WONG. (2003) Molecular genetics in the pediatric intensive care unit. Critical Care Clinics 19:3, 577-594
CrossRef1641
J CARCILLO. (2003) Pediatric septic shock and multiple organ failure. Critical Care Clinics 19:3, 413-440
CrossRef1642
M NIMAH, R BRILLI. (2003) Coagulation dysfunction in sepsis and multiple organ system failure. Critical Care Clinics 19:3, 441-458
CrossRef1643
W. C. Aird. (2003) The Hematologic System as a Marker of Organ Dysfunction in Sepsis. Mayo Clinic Proceedings 78:7, 869-881
CrossRef1644
Christopher J. Czura, Huan Yang, Kevin J. Tracey. (2003) High Mobility Group Box–1 as a Therapeutic Target Downstream of Tumor Necrosis Factor. The Journal of Infectious Diseases 187:s2, S391-S396
CrossRef1645
Daniel P. Schuster, Michael Metzler, Steven Opal, Stephen Lowry, Robert Balk, Edward Abraham, Howard Levy, Gus Slotman, Eileen Coyne, Sonia Souza, John Pribble. (2003) Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial*. Critical Care Medicine 31:6, 1612-1619
CrossRef1646
Bulent Cuhaci. (2003) Plasma exchange in multiple organ failure: Changing gears in sepsis and organ failure *. Critical Care Medicine 31:6, 1875-1877
CrossRef1647
Ester D. de Kleijn, Ronald de Groot, C. Erik Hack, Paul G. H. Mulder, Werner Engl, Berta Moritz, Koen F. M. Joosten, Jan A. Hazelzet. (2003) Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: A randomized, double-blinded, placebo-controlled, dose-finding study. Critical Care Medicine 31:6, 1839-1847
CrossRef1648
Djuro Josic, Lutz Hoffer, Andrea Buchacher. (2003) Preparation of vitamin K-dependent proteins, such as clotting factors II, VII, IX and X and clotting inhibitor Protein C. Journal of Chromatography B 790:1-2, 183-197
CrossRef1649
Laura N. Glasscock, Bruce Gerlitz, Scott T. Cooper, Brian W. Grinnell, Frank C. Church. (2003) Basic residues in the 37-loop of activated protein C modulate inhibition by protein C inhibitor but not by α1-antitrypsin. Biochimica et Biophysica Acta (BBA) - Proteins & Proteomics 1649:1, 106-117
CrossRef1650
M. Radosevich, F.-L. Zhou, J.-J. Huart, T. Burnouf. (2003) Chromatographic purification and properties of a therapeutic human protein C concentrate. Journal of Chromatography B 790:1-2, 199-207
CrossRef1651
R. Phillip Dellinger. (2003) Inflammation and Coagulation: Implications for the Septic Patient. Clinical Infectious Diseases 36:10, 1259-1265
CrossRef1652
Sat Sharma, Anand Kumar. (2003) Septic shock, multiple organ failure, and acute respiratory distress syndrome. Current Opinion in Pulmonary Medicine 9:3, 199-209
CrossRef1653
P. M. Warner, R. J. Kagan, K. P. Yakuboff, N. Kemalyan, T. L. Palmieri, D. G. Greenhalgh, R. L. Sheridan, D. W. Mozingo, D. M. Heimbach, N. S. Gibran, L. Engrav, J. R. Saffle, L. S. Edelman, G. D. Warden. (2003) Current Management of Purpura Fulminans: A Multicenter Study. Journal of Burn Care & Rehabilitation 24:3, 119-126
CrossRef1654
LeeAnn Braun, Liesl M. Cooper, William N. Malatestinic, Rebecca M. Huggins. (2003) A Sepsis Review. Dimensions of Critical Care Nursing 22:3, 117-124
CrossRef1655
JAN POWERS, JUDITH JACOBI. (2003) Treatment of Severe Sepsis With Xigris. Clinical Nurse Specialist 17:3, 128-130
CrossRef1656
John C. Marshall, Jean-Louis Vincent, Mitchell P. Fink, Deborah J. Cook, Gordon Rubenfeld, Debra Foster, Charles J. Fisher, Eugen Faist, Konrad Reinhart. (2003) Measures, markers, and mediators: Toward a staging system for clinical sepsis. A Report of the Fifth Toronto Sepsis Roundtable, Toronto, Ontario, Canada, October 25–26, 2000. Critical Care Medicine 31:5, 1560-1567
CrossRef1657
Julie Andrews, Behzad Nadjm, Vanya Gant, Nandini Shetty. (2003) Community-acquired pneumonia. Current Opinion in Pulmonary Medicine 9:3, 175-180
CrossRef1658
Henry Geiter,. (2003) Disseminated Intravascular Coagulopathy. Dimensions of Critical Care Nursing 22:3, 108-114
CrossRef1659
José A Fernández, Xiao Xu, Dong Liu, Berislav V Zlokovic, John H Griffin. (2003) Recombinant murine-activated protein C is neuroprotective in a murine ischemic stroke model. Blood Cells, Molecules, and Diseases 30:3, 271-276
CrossRef1660
Steven Friedman, Christopher Czura, Kevin Tracey. (2003) Current Opinion in Clinical Nutrition & Metabolic Care 6:3, 283-287
CrossRef1661
Craig M. Coopersmith, Daniel M. Amiot, Paul E. Stromberg, W. Michael Dunne, Christopher G. Davis, Dale F. Osborne, Kareem D. Husain, Isaiah R. Turnbull, Irene E. Karl, Richard S. Hotchkiss, Timothy G. Buchman. (2003) Antibiotics Improve Survival and Alter the Inflammatory Profile in a Murine Model of Sepsis From Pseudomonas aeruginosa Pneumonia. Shock 19:5, 408-414
CrossRef1662
Steven G. Friedman, Christopher J. Czura, Kevin J. Tracey. (2003) The gesture life of high mobility group box 1. Current Opinion in Clinical Nutrition and Metabolic Care 6:3, 283-287
CrossRef1663
F Fourrier. (2003) Inhibiteurs de la coagulation et états septiques graves. La Revue de Médecine Interne 24:5, 295-304
CrossRef1664
Martin, Greg S., Mannino, David M., Eaton, Stephanie, Moss, Marc, . (2003) The Epidemiology of Sepsis in the United States from 1979 through 2000. New England Journal of Medicine 348:16, 1546-1554
Full Text1665
Russell M. Petrak, Daniel J. Sexton, Michael L. Butera, Marvin J. Tenenbaum, Mary C. MacGregor, Mary E. Schmidt, W. Patrick Joseph, Sandra A. Kemmerly, Mark J. Dougherty, Johan S. Bakken, Maria F. Curfman, Lawrence P. Martinelli, R. Brooks Gainer. (2003) The Value of an Infectious Diseases Specialist. Clinical Infectious Diseases 36:8, 1013-1017
CrossRef1666
Wolfram Ruf, Matthias Riewald. (2003) Tissue factor-dependent coagulation protease signaling in acute lung injury. Critical Care Medicine 31:Supplement, S231-S237
CrossRef1667
Lucas Liaudet, Mauro Oddo. (2003) Role of poly(adenosine diphosphate???ribose) polymerase 1 in septic peritonitis. Current Opinion in Critical Care 9:2, 152-158
CrossRef1668
M. Levi. (2003) Measuring activated protein C in plasma to assess its role as a critical modulator of coagulation and inflammation. Journal of Thrombosis and Haemostasis 1:4, 643-644
CrossRef1669
Jukka Takala, Michael Booke, Martin Westphal, Frank Hinder, Lillian D. Traber, Daniel L. Traber. (2003) Cerebral Blood Flow Is Not Altered in Sheep with Pseudomonas aeruginosa Sepsis Treated with Norepinephrine or Nitric Oxide Synthase Inhibition. Anesthesia & Analgesia1122-1128
CrossRef1670
Kelly A. Wood, David Huang, Derek C. Angus. (2003) Improving clinical trial design in acute lung injury. Critical Care Medicine 31:Supplement, S305-S311
CrossRef1671
John B. Cone, Thomas J. Ferrer, Bonny H. Wallace, Junru Wang, Martin Hauer-Jensen. (2003) Alterations in Endothelial Thrombomodulin Expression in Zymosan-Induced Lung Injury. The Journal of Trauma: Injury, Infection, and Critical Care 54:4, 731-736
CrossRef1672
Steven Idell. (2003) Coagulation, fibrinolysis, and fibrin deposition in acute lung injury. Critical Care Medicine 31:Supplement, S213-S220
CrossRef1673
James A. Russell. (2003) Genetics of coagulation factors in acute lung injury. Critical Care Medicine 31:Supplement, S243-S247
CrossRef1674
Michael Booke, Martin Westphal. (2003) Treatment of sepsis and septic shock: is there a light at the end of the tunnel?. Current Opinion in Anaesthesiology 16:2, 101-104
CrossRef1675
Pierre-François Laterre, Xavier Wittebole, Jean-François Dhainaut. (2003) Anticoagulant therapy in acute lung injury. Critical Care Medicine 31:Supplement, S329-S336
CrossRef1676
David R. Williamson, Marc Lapointe. (2003) The Hypothalamic-Pituitary-Adrenal Axis and Low-Dose Glucocorticoids in the Treatment of Septic Shock. Pharmacotherapy 23:4, 514-525
CrossRef1677
Ulla Derhaschnig, Thomas Pernerstorfer, Marteen Knechtelsdorfer, Ursula Hollenstein, Simon Panzer, Bernd Jilma. (2003) Evaluation of antiinflammatory and antiadhesive effects of heparins in human endotoxemia. Critical Care Medicine 31:4, 1108-1112
CrossRef1678
Mitchell M. Levy, Mitchell P. Fink, John C. Marshall, Edward Abraham, Derek Angus, Deborah Cook, Jonathan Cohen, Steven M. Opal, Jean-Louis Vincent, Graham Ramsay. (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Critical Care Medicine 31:4, 1250-1256
CrossRef1679
JEFFREY P. BURNS. (2003) Septic shock in the pediatric patient: Pathogenesis and novel treatments. Pediatric Emergency Care 19:2, 112-115
CrossRef1680
Niels C Riedemann, Peter A Ward. (2003) Anti-inflammatory strategies for the treatment of sepsis. Expert Opinion on Biological Therapy 3:2, 339-350
CrossRef1681
P. C. Y. Liaw, G. Ferrell, C. T. Esmon. (2003) A monoclonal antibody against activated protein C allows rapid detection of activated protein C in plasma and reveals a calcium ion dependent epitope involved in factor Va inactivation. Journal of Thrombosis and Haemostasis 1:4, 662-670
CrossRef1682
M WILLIAMS, N PHIL, M WALLACE, B RIEDEL, A SHAW. (2003) Venous thromboembolism in the intensive care unit. Critical Care Clinics 19:2, 185-207
CrossRef1683
(2003) Low-Dose Heparin for Severe Sepsis. New England Journal of Medicine 348:12, 1185-1186
Full Text1684
M Brueckmann. (2003) Clinical and laboratory effects of recombinant human activated protein C in the treatment of a patient with sepsis-induced multiple organ failure. Thrombosis Research 109:5-6, 259-263
CrossRef1685
Sanjay Kulkarni, Edward Naureckas, David C. Cronin. (2003) Solid-organ transplant recipients treated with drotrecogin alfa (activated) for severe sepsis. Transplantation 75:6, 899-901
CrossRef1686
D GATTAS, D COOK. (2003) Procalcitonin as a diagnostic test for sepsis: Health technology assessment in the ICU. Journal of Critical Care 18:1, 52-58
CrossRef1687
Jean-Louis Vincent, Derek C. Angus, Antonio Artigas, Andre Kalil, Bruce R. Basson, Hassan H. Jamal, Gerald Johnson, Gordon R. Bernard. (2003) Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial*. Critical Care Medicine 31:3, 834-840
CrossRef1688
David Kelly, Paul E. Wischmeyer. (2003) Role of L-glutamine in critical illness: new insights. Current Opinion in Clinical Nutrition and Metabolic Care 6:2, 217-222
CrossRef1689
Ruth M Kleinpell. (2003) The role of the critical care nurse in the assessment and management of the patient with severe sepsis. Critical Care Nursing Clinics of North America 15:1, 27-34
CrossRef1690
Marcel Levi. (2003) Disseminated Intravascular Coagulation. Transfusion Alternatives in Transfusion Medicine 4:6, 212-217
CrossRef1691
C. Tetta, R. Bellomo, C. Ronco. (2003) Artificial Organ Treatment for Multiple Organ Failure, Acute Renal Failure, and Sepsis: Recent New Trends. Artificial Organs 27:3, 202-213
CrossRef1692
Nathan I. Shapiro, Richard E. Wolfe, Richard B. Moore, Eric Smith, Elizabeth Burdick, David W. Bates. (2003) Mortality in Emergency Department Sepsis (MEDS) score: A prospectively derived and validated clinical prediction rule*. Critical Care Medicine 31:3, 670-675
CrossRef1693
Paul Scheel, Joseph Eustace, Hamid Rabb. (2003) Continuous dialysis as systemic therapy in the critically ill patient? *. Critical Care Medicine 31:3, 988-989
CrossRef1694
R. Phillip Dellinger. (2003) Cardiovascular management of septic shock. Critical Care Medicine 31:3, 946-955
CrossRef1695
Emanuel P. Rivers, H. Bryant Nguyen, David Amponsah. (2003) Sepsis: A landscape from the emergency department to the intensive care unit *. Critical Care Medicine 31:3, 968-969
CrossRef1696
Benoit Misset, Michael A. Gropper, Jeanine P. Wiener-Kronish. (2003) Predicting mortality in acute respiratory distress syndrome: Circulatory system knows best *. Critical Care Medicine 31:3, 980-981
CrossRef1697
Marilyn Sawyer Sommers. (2003) The cellular basis of septic shock. Critical Care Nursing Clinics of North America 15:1, 13-25
CrossRef1698
Edward Abraham, Chris Naum, Venkata Bandi, Daniel Gervich, Stephen F. Lowry, Richard Wunderink, Roland M. Schein, William Macias, Simona Skerjanec, Alex Dmitrienko, Nagy Farid, S. Thomas Forgue, Frank Jiang. (2003) Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure. Critical Care Medicine 31:3, 718-728
CrossRef1699
Marcel Levi. (2003) Benefit of recombinant human activated protein C beyond 28-day mortality: There is more to life than death *. Critical Care Medicine 31:3, 984-985
CrossRef1700
Minna Ilmakunnas, Jari Pet??j??, Krister H??ckerstedt, Heikki M??kisalo, Jose A. Fernandez, John H. Griffin, Sten-Erik Jansson, Heikki Repo, Eero J. Pesonen. (2003) Activation of protein C during reperfusion in clinical liver transplantation. Transplantation 75:4, 467-472
CrossRef1701
Anna Norrby-Teglund, S. Ragnar Norrby, Donald E. Low. (2003) The treatment of severe group a streptococcal infections. Current Infectious Disease Reports 5:1, 28-37
CrossRef1702
R.S. Heyderman, H.P. Lambert, I. O'Sullivan, J.M. Stuart, B.L. Taylor, R.A. Wall. (2003) Early Management of Suspected Bacterial Meningitis and Meningococcal Septicaemia in Adults. Journal of Infection 46:2, 75-77
CrossRef1703
Vinay K Sharma, R Phillip Dellinger. (2003) Recent developments in the treatment of sepsis. Expert Opinion on Investigational Drugs 12:2, 139-152
CrossRef1704
Michael S. Niederman. (2003) Granulocyte colony-stimulating factor for severe pneumonia: What do we do when the best laid plans for men (and mice and rats…) fail? *. Critical Care Medicine 31:2, 635-637
CrossRef1705
Christopher McCoy, Samuel James Matthews. (2003) Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis. Clinical Therapeutics 25:2, 396-421
CrossRef1706
Neal H. Cohen. (2003) Assessing futility of medical interventions—Is it futile? *. Critical Care Medicine 31:2, 646-648
CrossRef1707
Timothy E. Albertson, Edward A. Panacek, Rodger D. MacArthur, Steven B. Johnson, Ernest Benjamin, George M. Matuschak, Gary Zaloga, Dennis Maki, Jeffrey Silverstein, Jeffrey K. Tobias, Kathy Haenftling, George Black, J. Wayne Cowens. (2003) Multicenter evaluation of a human monoclonal antibody to Entero-bacteriaceae common antigen in patients with Gram-negative sepsis. Critical Care Medicine 31:2, 419-427
CrossRef1708
Rakesh Lodha, Vishal Kapoor. (2003) Peripheral circulatory failure. The Indian Journal of Pediatrics 70:2, 163-168
CrossRef1709
Brett P. Giroir. (2003) Recombinant human activated protein C for the treatment of severe sepsis: is there a role in pediatrics?. Current Opinion in Pediatrics 15:1, 92-96
CrossRef1710
Hotchkiss, Richard S., Karl, Irene E., . (2003) The Pathophysiology and Treatment of Sepsis. New England Journal of Medicine 348:2, 138-150
Full Text1711
Michael T. Coughlin, Derek C. Angus. (2003) Economic evaluation of new therapies in critical illness. Critical Care Medicine 31:Supplement, S7-S16
CrossRef1712
Derek C. Angus, Walter T. Linde-Zwirble, Gilles Clermont, Daniel E. Ball, Bruce R. Basson, E. Wesley Ely, Pierre-Francois Laterre, Jean-Louis Vincent, Gordon Bernard, Ben van Hout. (2003) Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis*. Critical Care Medicine 31:1, 1-11
CrossRef1713
Christine Smith Schulman, Kathy Hare. (2003) New Thoughts on Sepsis. Dimensions of Critical Care Nursing 22:1, 20-30
CrossRef1714
Donald B. Chalfin, Daniel Teres, John Rapoport. (2003) A price for cost-effectiveness: Implications for recombinant human activated protein C (rhAPC). Critical Care Medicine 31:1, 306-308
CrossRef1715
Peter Q. Eichacker, Charles Natanson. (2003) Recombinant human activated protein C in sepsis: Inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials. Critical Care Medicine 31:Supplement, S94-S96
CrossRef1716
Gordon R. Bernard. (2003) Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis. Critical Care Medicine 31:Supplement, S85-S93
CrossRef1717
Thomas Hartung, Sonja von Aulock, Christian Schneider, Eugen Faist. (2003) How to leverage an endogenous immune defense mechanism: The example of granulocyte colony-stimulating factor. Critical Care Medicine 31:Supplement, S65-S75
CrossRef1718
E. Wesley Ely, Pierre-François Laterre, Derek C. Angus, Jeffrey D. Helterbrand, Howard Levy, Jean-François Dhainaut, Jean-Louis Vincent, William L. Macias, Gordon R. Bernard. (2003) Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Critical Care Medicine 31:1, 12-19
CrossRef1719
M. Anand, K. Rajagopal, K. R. Rajagopal. (2003) A Model Incorporating Some of the Mechanical and Biochemical Factors Underlying Clot Formation and Dissolution in Flowing Blood. Journal of Theoretical Medicine 5:3-4, 183-218
CrossRef1720
Madeline Betancourt, Peggy S McKinnon, R Michael Massanari, Salmaan Kanji, David Bach, John W Devlin. (2003) An Evaluation of the Cost Effectiveness of Drotrecogin Alfa (Activated) Relative to the Number of Organ System Failures. PharmacoEconomics 22:18, 1331-1340
CrossRef1721
Steven M. Banks, Eric Gerstenberger, Peter Q. Eichacker, Charles Natanson. (2003) Long-term cost effectiveness of drotrecogin alfa (activated): An unanswered question *. Critical Care Medicine 31:1, 308-309
CrossRef1722
Guenther Mathiak, Lewis F. Neville, Guido Grass. (2003) Targeting the coagulation cascade in sepsis: Did we find the “magic bullet”? *. Critical Care Medicine 31:1, 310-311
CrossRef1723
Hideo Wada, Yoshitaka Mori, Kazuhiro Okabayashi, Esteban C Gabazza, Fumihiko Kushiya, Masato Watanabe, Masakatsu Nishikawa, Hiroshi Shiku, Tsutomu Nobori. (2003) High plasma fibrinogen level is associated with poor clinical outcome in DIC patients. American Journal of Hematology 72:1, 1-7
CrossRef1724
Jeffrey I Weitz, Mark A Crowther. (2003) New Anticoagulants. American Journal of Cardiovascular Drugs 3:3, 201-209
CrossRef1725
Aleksandar Karamarkovic, Vladimir Djukic, Branislav Stefanovic, Mirka Ilic, Nada Popovic, Dragana Vukosavljevic, Tatjana Vodnik. (2003) Protein C as diagnostic and predictive biomarker of sepsis during severe intra-abdominal infections. Jugoslovenska medicinska biohemija 22:3, 229-236
CrossRef1726
Vladimir Bumbasirevic, Miroslav Milicevic, V. Bukumirovic, Vitomir Rankovic, A. Pavlovic, Vladimir Djukic, Dejan Radenkovic, Z. Lausevic, Ana Sijacki. (2003) Prevention and treatment of progressive multiple organ disfunction in acute pancreatitis. Acta chirurgica iugoslavica 50:2, 115-125
CrossRef1727
Jonathan Cohen. (2002) The immunopathogenesis of sepsis. Nature 420:6917, 885-891
CrossRef1728
P MORRIS. (2002) Identifying patients with severe sepsis who should not be treated with drotrecogin alfa (activated). The American Journal of Surgery 184:6, S19-S24
CrossRef1729
Pierre-François Laterre, Darell Heiselman. (2002) Management of patients with severe sepsis, treated by drotrecogin alfa (activated). The American Journal of Surgery 184:6, S39-S46
CrossRef1730
Shaolong Yang, Mian Zhou, Dale E. Fowler, Ping Wang. (2002) Mechanisms of the beneficial effect of adrenomedullin and adrenomedullin-binding protein-1 in sepsis: Down-regulation of proinflammatory cytokines. Critical Care Medicine 30:12, 2729-2735
CrossRef1731
Eduardo R. C. Schiffer, Guido Reber, Philippe de Moerloose, Denis R. Morel. (2002) Evaluation of unfractionated heparin and recombinant hirudin on survival in a sustained ovine endotoxin shock model. Critical Care Medicine 30:12, 2689-2699
CrossRef1732
J Roemisch, E Gray, J N Hoffmann, C J Wiedermann. (2002) Antithrombin. Blood Coagulation& Fibrinolysis 13:8, 657-670
CrossRef1733
R SCHEIN. (2002) Risk-benefit analysis for drotrecogin alfa (activated). The American Journal of Surgery 184:6, S25-S38
CrossRef1734
Bradley A. Boucher, Keith M. Olsen. (2002) Introduction. Pharmacotherapy 22:12 Part 2, 167S-168S
CrossRef1735
S KEENAN, J CARLET, R CURTIS, M PINSKY, G RUBENFELD, J VINCENT. (2002) Patient-centered outcomes. Journal of Critical Care 17:4, 221-234
CrossRef1736
Marcel Levi, Evert de Jonge, Joost Meijers. (2002) The diagnosis of disseminated intravascular coagulation. Blood Reviews 16:4, 217-223
CrossRef1737
J RODRIGUEZ. (2002) Editorial. The American Journal of Surgery 184:6, S1-S2
CrossRef1738
Derek Strassheim, Jong Sung Park, Edward Abraham. (2002) Sepsis: current concepts in intracellular signaling. The International Journal of Biochemistry & Cell Biology 34:12, 1527-1533
CrossRef1739
Joseph F. Dasta, Liesl M. Cooper. (2002) Impact of Drotrecogin alfa (activated) on Resource Use and Implications for Reimbursement. Pharmacotherapy 22:12 Part 2, 216S-222S
CrossRef1740
Gordon Bernard. (2002) Foreword: severe sepsis. The American Journal of Surgery 184:6, S3-S4
CrossRef1741
Jean-François Dhainaut. (2002) Introduction: rationale for using drotrecogin alfa (activated) in patients with severe sepsis. The American Journal of Surgery 184:6, S5-S10
CrossRef1742
Dennis G. Maki. (2002) Conclusions: drotrecogin alfa (activated)—from bench to practical use at the bedside. The American Journal of Surgery 184:6, S47-S50
CrossRef1743
Keith M. Olsen, Steven J. Martin. (2002) Pharmacokinetics and Clinical Use of Drotrecogin alfa (activated) in Patients with Severe Sepsis. Pharmacotherapy 22:12 Part 2, 196S-205S
CrossRef1744
Judith Jacobi. (2002) Sepsis: A Frequent, Life-Threatening Syndrome. Pharmacotherapy 22:12 Part 2, 169S-181S
CrossRef1745
Erkan Hassan, Henry J. Mann. (2002) Current Issues Regarding the Use of Drotrecogin alfa (activated). Pharmacotherapy 22:12 Part 2, 206S-215S
CrossRef1746
Jean-Pierre Sollet, Gary E Garber. (2002) Selecting patients with severe sepsis for drotrecogin alfa (activated) therapy. The American Journal of Surgery 184:6, S11-S18
CrossRef1747
Maria I. Rudis, Douglas N. Fish. (2002) Pharmacology, Clinical Efficacy, and Safety of Drotrecogin alfa (activated). Pharmacotherapy 22:12 Part 2, 182S-195S
CrossRef1748
C. H. Toh, A. R. Giles. (2002) Waveform analysis of clotting test optical profiles in the diagnosis and management of disseminated intravascular coagulation (DIC). Clinical and Laboratory Haematology 24:6, 321-327
CrossRef1749
Henry Cohen, Lynda S. Welage. (2002) Strategies to Optimize Drotrecogin alfa (activated) Use: Guidelines and Therapeutic Controversies. Pharmacotherapy 22:12 Part 2, 223S-235S
CrossRef1750
Hafida Bentala, Willem R. Verweij, Ali Huizinga-Van der Vlag, Annemiek M. van Loenen-Weemaes, Dirk K. F. Meijer, Klaas Poelstra. (2002) Removal of Phosphate from Lipid A as a Strategy to Detoxify Lipopolysaccharide. Shock 18:6, 561-566
CrossRef1751
H Kanehara. (2002) Thrombomodulin expression by THP-1 but not by vascular endothelial cells is upregulated by pioglitazone. Thrombosis Research 108:4, 227-234
CrossRef1752
Gerald A. Maccioli. (2002) Sepsis and trials: Are we studying the right patients in the correct fashion? *. Critical Care Medicine 30:11, 2594-2595
CrossRef1753
Susan D. Roseff, Naomi L.C. Luban, Catherine S. Manno. (2002) Guidelines for assessing appropriateness of pediatric transfusion. Transfusion 42:11, 1398-1413
CrossRef1754
Daniel Teres, John Rapoport, Stanley Lemeshow, Sunny Kim, Kasem Akhras. (2002) Effects of severity of illness on resource use by survivors and nonsurvivors of severe sepsis at intensive care unit admission*. Critical Care Medicine 30:11, 2413-2419
CrossRef1755
Curtis N. Sessler, Wes Shepherd. (2002) New concepts in sepsis. Current Opinion in Critical Care 8:5, 465-472
CrossRef1756
Markus M Mueller, Barbara Bomke, Erhard Seifried. (2002) Fresh frozen plasma in patients with disseminated intravascular coagulation or in patients with liver diseases. Thrombosis Research 107, S9-S17
CrossRef1757
&NA;. (2002) High-Dose Antithrombin III in Severe Sepsis: A Randomized Controlled Trial. Survey of Anesthesiology 46:5, 258-259
CrossRef1758
L Brochard. (2002) Points forts en réanimation. La Revue de Médecine Interne 23:10, 847-852
CrossRef1759
Manns, Braden J., Lee, Helen, Doig, Christopher James, Johnson, David, Donaldson, Cam, . (2002) An Economic Evaluation of Activated Protein C Treatment for Severe Sepsis. New England Journal of Medicine 347:13, 993-1000
Full Text1760
Siegel, Jay P., . (2002) Assessing the Use of Activated Protein C in the Treatment of Severe Sepsis. New England Journal of Medicine 347:13, 1030-1034
Full Text1761
Ely, E. Wesley, Bernard, Gordon R., , Vincent, Jean-Louis, . (2002) Activated Protein C for Severe Sepsis. New England Journal of Medicine 347:13, 1035-1036
Full Text1762
Davidson, Bruce L., , Geerts, William H., , Lensing, Anthonie W.A., . (2002) Low-Dose Heparin for Severe Sepsis. New England Journal of Medicine 347:13, 1036-1037
Full Text1763
Warren, H. Shaw, , Suffredini, Anthony F., Eichacker, Peter Q., , Munford, Robert S., . (2002) Risks and Benefits of Activated Protein C Treatment for Severe Sepsis. New England Journal of Medicine 347:13, 1027-1030
Full Text1764
Arthur S. Slutsky. (2002) Hot new therapy for sepsis and the acute respiratory distress syndrome. Journal of Clinical Investigation 110:6, 737-739
CrossRef1765
(2002) Haemostasis: from bench to bedside. Haemophilia 8:5, 685-693
CrossRef1766
J.B. Schnog, M.R. Mac Gillavry, R.A. Rojer, J.C.M. Meijers, R. Fijnheer, H. ten Cate, D.P.M. Brandjes, A.J. Duits. (2002) No effect of acenocoumarol therapy on levels of endothelial activation markers in sickle cell disease. American Journal of Hematology 71:1, 53-55
CrossRef1767
Andrew J. Gale, Xiao Xu, Jean-Luc Pellequer, Elizabeth D. Getzoff, John H. Griffin. (2002) Interdomain engineered disulfide bond permitting elucidation of mechanisms of inactivation of coagulation factor Va by activated protein C. Protein Science 11:9, 2091-2101
CrossRef1768
Nigel S. Key, E. Wesley Ely. (2002) Coagulation inhibition for sepsis. Current Opinion in Hematology 9:5, 416-421
CrossRef1769
Robert MacLaren, Rose Jung. (2002) Stress-Dose Corticosteroid Therapy for Sepsis and Acute Lung Injury or Acute Respiratory Distress Syndrome in Critically Ill Adults. Pharmacotherapy 22:9, 1140-1156
CrossRef1770
David S. Stephens, Shanta M. Zimmer. (2002) Pathogenesis, therapy, and prevention of meningococcal sepsis. Current Infectious Disease Reports 4:5, 377-386
CrossRef1771
Brad Spellberg, John E. Edwards. (2002) The pathophysiology and treatment of Candida sepsis. Current Infectious Disease Reports 4:5, 387-399
CrossRef1772
Andrew Specht, Daniel Chan, Therese O'Toole, Marc Kent, John Benson, Elizabeth A. Rozanski, John E. Rush. (2002) Acute staphylococcal peritonitis following cystocentesis in a dog. Journal of Veterinary Emergency and Critical Care 12:3, 183-187
CrossRef1773
Peter von Dadelszen, Laura A. Magee, Shoo K. Lee, Shawn D. Stewart, Carmine Simone, Gideon Koren, Keith R. Walley, James A. Russell. (2002) Activated protein C in normal human pregnancy and pregnancies complicated by severe preeclampsia: A therapeutic opportunity?*. Critical Care Medicine 30:8, 1883-1892
CrossRef1774
Charlene E. Hafer-Macko, Frederick M. Ivey, Kymberly A. Gyure, John D. Sorkin, Richard F. Macko. (2002) Reduced thrombomodulin in human peripheral nerve microvasculature. Muscle & Nerve 26:2, 218-224
CrossRef1775
Grant V. Bochicchio, Lena M. Napolitano, Manjari Joshi, Kelly Knorr, J. Kathleen Tracy, Obeid Ilahi, Thomas M. Scalea. (2002) Persistent Systemic Inflammatory Response Syndrome Is Predictive of Nosocomial Infection in Trauma. The Journal of Trauma: Injury, Infection, and Critical Care 53:2, 245-251
CrossRef1776
Christoph Caliezi, Sacha Zeerleder, Maurice Redondo, Bruno Regli, Hans-Ulrich Rothen, Regula Zürcher-Zenklusen, Robert Rieben, Jan Devay, C. Erik Hack, Bernhard Lämmle, Walter A. Wuillemin. (2002) C1-inhibitor in patients with severe sepsis and septic shock: Beneficial effect on renal dysfunction. Critical Care Medicine 30:8, 1722-1728
CrossRef1777
Sergio Zanotti, Anand Kumar, Aseem Kumar. (2002) Cytokine modulation in sepsis and septic shock. Expert Opinion on Investigational Drugs 11:8, 1061-1075
CrossRef1778
Susan Hadley, Winnie W. Lee, Robin Ruthazer, Stanley A. Nasraway. (2002) Candidemia as a cause of septic shock and multiple organ failure in nonimmunocompromised patients. Critical Care Medicine 30:8, 1808-1814
CrossRef1779
Marcel Levi. (2002) The imbalance between tissue factor and tissue factor pathway inhibitor in sepsis*. Critical Care Medicine 30:8, 1914-1915
CrossRef1780
Stephen E. Lapinsky, Sangeeta Mehta. (2002) Activated protein C for preeclampsia: Tailoring the disease to the therapy*. Critical Care Medicine 30:8, 1929-1930
CrossRef1781
Martin Westphal, Henning Stubbe, Hans-Georg Bone, Fritz Daudel, Sebastian Vocke, Hugo Van Aken, Michael Booke. (2002) Hemodynamic effects of exogenous adrenomedullin in healthy and endotoxemic sheep. Biochemical and Biophysical Research Communications 296:1, 134-138
CrossRef1782
Andrew L. Rosenberg. (2002) Recent innovations in intensive care unit risk-prediction models. Current Opinion in Critical Care 8:4, 321-330
CrossRef1783
Jean-Louis Vincent. (2002) Drotrecogin alfa: a new approach in the treatment of severe sepsis. Expert Opinion on Biological Therapy 2:6, 659-664
CrossRef1784
Ch. Pechlaner, Nicole C. Kaneider, Angela Djanani, A. Sandhofer, P. Schratzberger, J. R. Patsch. (2002) Antithrombin and Near-Fatal Exertional Heat Stroke. Acta Medica Austriaca 29:3, 107-111
CrossRef1785
Deborah J. Cook, Maureen O. Meade, Lori E. Hand, Joseph P. McMullin. (2002) Toward understanding evidence uptake: Semirecumbency for pneumonia prevention. Critical Care Medicine 30:7, 1472-1477
CrossRef1786
Neal H. Cohen. (2002) How should patients feel about prolonged mechanical ventilation? Can we predict their choices, and if so, should we? *. Critical Care Medicine 30:7, 1656-1658
CrossRef1787
Ch. Pechlaner. (2002) Plasminogen Activators in Inflammation and Sepsis. Acta Medica Austriaca 29:3, 80-88
CrossRef1788
John H Griffin, Berislav Zlokovic, José A Fernández. (2002) Activated protein C: Potential therapy for severe sepsis, thrombosis, and stroke. Seminars in Hematology 39:3, 197-205
CrossRef1789
Stephan Moll, Harold R Roberts. (2002) Overview of anticoagulant drugs for the future. Seminars in Hematology 39:3, 145-157
CrossRef1790
Marc-Jacques Dubois, A Jean-Louis Vincent. (2002) Use of Albumin in the Intensive Care Unit. Transfusion Alternatives in Transfusion Medicine 4:3, 80-84
CrossRef1791
T KALB, S LORIN. (2002) Infection in the chronically critically ill: unique risk profile in a newly defined population. Critical Care Clinics 18:3, 529-552
CrossRef1792
Bouchama, Abderrezak, Knochel, James P., . (2002) Heat Stroke. New England Journal of Medicine 346:25, 1978-1988
Full Text1793
Chad K Oh, Barbara Ariue, Rodrigo F Alban, Bryan Shaw, Seong H Cho. (2002) PAI-1 promotes extracellular matrix deposition in the airways of a murine asthma model. Biochemical and Biophysical Research Communications 294:5, 1155-1160
CrossRef1794
Christian R. H. Raetz, Chris Whitfield. (2002) L
IPOPOLYSACCHARIDE ENDOTOXINS . Annual Review of Biochemistry 71:1, 635-700
CrossRef1795
C. James Carrico, John B. Holcomb, Irshad H. Chaudry. (2002) Scientific Priorities and Strategic Planning for Resuscitation Research and Life Saving Therapy Following Traumatic Injury: Report of the PULSE Trauma Work Group. Academic Emergency Medicine 9:6, 621-626
CrossRef1796
Arieh Eden. (2002) Multiple Organ Dysfunction Syndrome: A Narrative Review. Survey of Anesthesiology 46:3, 128-129
CrossRef1797
KARL TAMUSSINO. (2002) Postoperative Infection. Clinical Obstetrics and Gynecology 45:2, 562-573
CrossRef1798
Junru Wang, Huaien Zheng, Xuemei Ou, Louis M. Fink, Martin Hauer-Jensen. (2002) Deficiency of Microvascular Thrombomodulin and Up-Regulation of Protease-Activated Receptor-1 in Irradiated Rat Intestine. The American Journal of Pathology 160:6, 2063-2072
CrossRef1799
Nobuo Aoki, Tamotsu Matsuda, Hidehiko Saito, Kiyoshi Takatsuki, Kenji Okajima, Hoyu Takahashi, Junki Takamatsu, Hidesaku Asakura, Nobuya Ogawa. (2002) A Comparative Double-Blind Randomized Trial of Activated Protein C and Unfractionated Heparin in the Treatment of Disseminated Intravascular Coagulation. International Journal of Hematology 75:5, 540-547
CrossRef1800
Maeve Sheehan, Hector R. Wong. (2002) Yet another potential role for nitric oxide in the pathophysiology of septic shock *. Critical Care Medicine 30:6, 1393-1394
CrossRef1801
William Geerts, Deborah Cook, Rita Selby, Edward Etchells. (2002) Venous thromboembolism and its prevention in critical care. Journal of Critical Care 17:2, 95-104
CrossRef1802
Petter Brandtzaeg, Marcel van Deuren. (2002) Current concepts in the role of the host response in Neisseria meningitidis septic shock. Current Opinion in Infectious Diseases 15:3, 247-252
CrossRef1803
C. Morris. (2002) Activated protein C in the treatment of sepsis. Anaesthesia 57:5, 501-521
CrossRef1804
Steven M. Opal, Craig M. Kessler, Juergen Roemisch, Sigurd Knaub. (2002) Antithrombin, heparin, and heparan sulfate. Critical Care Medicine 30:Supplement, S325-S331
CrossRef1805
Mir H. Ali, Paul T. Schumacker. (2002) Endothelial responses to mechanical stress: Where is the mechanosensor?. Critical Care Medicine 30:Supplement, S198-S206
CrossRef1806
Yoanna Skrobik, Brian Kavanagh, David Mazer, Deborah Cook. (2002) Special Article Toronto critical care medicine symposium report. Canadian Journal of Anesthesia/Journal canadien d'anesthésie 49:5, 513-516
CrossRef1807
David E. Joyce, Brian W. Grinnell. (2002) Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-κB. Critical Care Medicine 30:Supplement, S288-S293
CrossRef1808
Steven Idell. (2002) Endothelium and disordered fibrin turnover in the injured lung: Newly recognized pathways. Critical Care Medicine 30:Supplement, S274-S280
CrossRef1809
Sadatomo Tasaka, Naoki Hasegawa, Akitoshi Ishizaka. (2002) Pharmacology of Acute Lung Injury. Pulmonary Pharmacology & Therapeutics 15:2, 83-95
CrossRef1810
Konrad Reinhart, Ole Bayer, Frank Brunkhorst, Michael Meisner. (2002) Markers of endothelial damage in organ dysfunction and sepsis. Critical Care Medicine 30:Supplement, S302-S312
CrossRef1811
William C. Aird. (2002) Endothelial cell dynamics and complexity theory. Critical Care Medicine 30:Supplement, S180-S185
CrossRef1812
Marcel Levi, Hugo ten Cate, Tom van der Poll. (2002) Endothelium: Interface between coagulation and inflammation. Critical Care Medicine 30:Supplement, S220-S224
CrossRef1813
Jean-François Dhainaut, S. Betty Yan, Alain Cariou, Jean-Paul Mira. (2002) Soluble thrombomodulin, plasma-derived unactivated protein C, and recombinant human activated protein C in sepsis. Critical Care Medicine 30:Supplement, S318-S324
CrossRef1814
Hazar Shadid, Salim Aziz, Sarfraz Ahmad, Jawed Fareed, Debra Hoppensteadt, Harry Messmore, William Wehrmacher, Mahmut Tobu, Omer Iqbal. (2002) Antithrombotic agents in the treatment of severe sepsis. Expert Opinion on Emerging Drugs 7:1, 111-139
CrossRef1815
Ines J. Laudes, Jeffrey C. Chu, Sujata Sikranth, Markus Huber-Lang, Ren-Feng Guo, Niels Riedemann, J. Vidya Sarma, Alvin H. Schmaier, Peter A. Ward. (2002) Anti-C5a Ameliorates Coagulation/Fibrinolytic Protein Changes in a Rat Model of Sepsis. The American Journal of Pathology 160:5, 1867-1875
CrossRef1816
Bruce R. Gordon. (2002) Fish oil and endotoxemia *. Critical Care Medicine 30:5, 1173-1174
CrossRef1817
David B. Safran, William G. Sullivan. (2002) Necrotizing soft tissue infection of the chest wall: reply. The Annals of Thoracic Surgery 73:5, 1695
CrossRef1818
Tihomir Štefanec. (2002) The Effects of Statins on Mortality Rates among Bacteremic Patients. Clinical Infectious Diseases 34:8, 1158-1158
CrossRef1819
Jean‐Louis Vincent, Qinghua Sun, Marc‐Jacques Dubois. (2002) Clinical Trials of Immunomodulatory Therapies in Severe Sepsis and Septic Shock. Clinical Infectious Diseases 34:8, 1084-1093
CrossRef1820
Serdar Akca, Philip Haji-Michael, Arnaldo de Mendonça, Peter Suter, Marcel Levi, Jean- Louis Vincent. (2002) Time course of platelet counts in critically ill patients. Critical Care Medicine 30:4, 753-756
CrossRef1821
Clifford S. Deutschman. (2002) Ghosts of studies past, present, and future: A cautionary tale *. Critical Care Medicine 30:4, 942-944
CrossRef1822
Mats Eriksson, Kjeld Christensen, Tomas L Lindahl, Anders Larsson. (2002) Pharmaceutical thrombosis prevention in cardiovascular disease. Expert Opinion on Investigational Drugs 11:4, 553-563
CrossRef1823
Michael A. Matthay, Tokujiro Uchida, Xiaohui Fang. (2002) Clinical acute lung injury and acute respiratory distress syndrome. Current Treatment Options in Cardiovascular Medicine 4:2, 139-149
CrossRef1824
(2002) Goal-Directed Therapy for Severe Sepsis. New England Journal of Medicine 346:13, 1025-1026
Full Text1825
Jean-Louis Vincent. (2002) Sepsis definitions. The Lancet Infectious Diseases 2:3, 135
CrossRef1826
Melpo Christofidou-Solomidou, Stephen Kennel, Arnaud Scherpereel, Rainer Wiewrodt, Charalambos C. Solomides, Giuseppe G. Pietra, Juan-Carlos Murciano, Sayed A. Shah, Harry Ischiropoulos, Steven M. Albelda, Vladimir R. Muzykantov. (2002) Vascular Immunotargeting of Glucose Oxidase to the Endothelial Antigens Induces Distinct Forms of Oxidant Acute Lung Injury. The American Journal of Pathology 160:3, 1155-1169
CrossRef1827
C Raeburn. (2002) Cytokines for surgeons. The American Journal of Surgery 183:3, 268-273
CrossRef1828
C. James Carrico, John B. Holcomb, Irshad H. Chaudry. (2002) Scientific Priorities and Strategic Planning for Resuscitation Research and Life Saving Therapy Following Traumatic Injury: Report of the PULSE Trauma Work Group. Shock 17:3, 165-168
CrossRef1829
David B Hoyt. (2002) What’s new in general surgery: trauma and critical care. Journal of the American College of Surgeons 194:3, 335-351
CrossRef1830
J LETARTE, C LONGO, J PELLETIER, B NABONNE, H FISHER. (2002) Patient characteristics and costs of severe sepsis and septic shock in Quebec. Journal of Critical Care 17:1, 39-49
CrossRef1831
L. Joseph, L. M. Fink, M. Hauer-Jensen. (2002) Cytokines in coagulation and thrombosis: a preclinical and clinical review. Blood Coagulation & Fibrinolysis 13:2, 105-116
CrossRef1832
Clifford S. Deutschman. (2002) Understanding sepsis: Promise, caution, and accolades to a mentor’s mentor*. Critical Care Medicine 30:3, 717-718
CrossRef1833
Andy Hodgson, Tom Ryan, Jan Moriarty, George Mellotte, Ciaran Murphy, Owen P. Smith. (2002) Plasma exchange as a source of protein C for acute onset protein C pathway failure. British Journal of Haematology 116:4, 905-908
CrossRef1834
Sandra L. Kane, Joseph F. Dasta. (2002) Clinical Outcomes of Critical Illness Polyneuropathy. Pharmacotherapy 22:3, 373-379
CrossRef1835
Nicholas J. Kenyon, Timothy E. Albertson. (2002) Steroids and Sepsis: Time for Another Reevaluation. Journal of Intensive Care Medicine 17:2, 68-74
CrossRef1836
Paul E. Marik. (2002) Definition of sepsis: Not quite time to dump SIRS?*. Critical Care Medicine 30:3, 706-708
CrossRef1837
H Hassouna. (2002) Proteolysis of protein C in pooled normal plasma and purified protein C by activated protein C (APC). Biophysical Chemistry 95:2, 109-124
CrossRef1838
Brian Laufer, Ron Butler. (2002) Best evidence in anesthetic practice Prevention: recombinant human activated protein C reduces mortality in severe sepsis. Canadian Journal of Anesthesia/Journal canadien d'anesthésie 49:2, 207-209
CrossRef1839
Deborah T Hung, Lindsey R Baden. (2002) A new era for sepsis treatment? Understanding sepsis as a consequence of host immune response. Expert Opinion on Therapeutic Patents 12:2, 181-192
CrossRef1840
George R. Saade, Claire McLintock. (2002) Inherited thrombophilia and stillbirth. Seminars in Perinatology 26:1, 51-69
CrossRef1841
Juan J. Ronco. (2002) Tissue dysoxia in sepsis: Getting to know the mitochondrion. Critical Care Medicine 30:2, 483-484
CrossRef1842
David Bar-Or, Leonard T. Rael, James V. Winkler, Richard L. Yukl, Gregory W. Thomas, Richard P. Shimonkevitz. (2002) Copper Inhibits Activated Protein C: Protective Effect of Human Albumin and an Analogue of Its High-Affinity Copper-Binding Site, d-DAHK. Biochemical and Biophysical Research Communications 290:5, 1388-1392
CrossRef1843
M Heinzelmann. (2002) Factors predisposing to bacterial invasion and infection. The American Journal of Surgery 183:2, 179-190
CrossRef1844
Hiroshi Ikeguchi, Shoichi Maruyama, Yoshiki Morita, Yutaka Fujita, Tomomi Kato, Yasuhiro Natori, Hiroyasu Akatsu, William Campbell, Noriko Okada, Hidechika Okada, Yukio Yuzawa, Seiichi Matsuo. (2002) Effects of human soluble thrombomodulin on experimental glomerulonephritis. Kidney International 61:2, 490-501
CrossRef1845
William S. Lyons. (2002) Uncontrolled Resuscitation and ???Sepsis???. The Journal of Trauma: Injury, Infection, and Critical Care 52:2, 412
CrossRef1846
Edward R. Sherwood. (2002) Current Concepts of the Inflammatory Response. ASA Refresher Courses in Anesthesiology 30:1, 169-184
CrossRef1847
U. Suchner, D. K. Heyland, K. Peter. (2002) Immune-modulatory actions of arginine in the critically ill. British Journal of Nutrition 87:S1, S121
CrossRef1848
Paolo Gresele, Giancarlo Agnelli. (2002) Novel approaches to the treatment of thrombosis. Trends in Pharmacological Sciences 23:1, 25-32
CrossRef1849
Timothy G Buchman, Bradley D Freeman. (2002) Coagulation inhibitors in the treatment of sepsis. Expert Opinion on Investigational Drugs 11:1, 69-74
CrossRef1850
Greg Martin, Stephanie Eaton. (2002) Clinical developments for treating ARDS. Expert Opinion on Investigational Drugs 11:1, 37-48
CrossRef1851
Steven Idell. (2002) The Fibrinolytic Defect in Adult Respiratory Distress Syndrome: A New Therapeutic Opportunity?. Clinical Pulmonary Medicine 9:1, 13-19
CrossRef1852
Peter E. Morris, R. Duncan Hite, Christopher Ohl. (2002) Relationship Between the Inflammation and Coagulation Pathways in Patients with Severe Sepsis. BioDrugs 16:6, 403-417
CrossRef1853
R KHADAROO. (2002) ARDS and the multiple organ dysfunction syndrome Common mechanisms of a common systemic process. Critical Care Clinics 18:1, 127-141
CrossRef1854
J VINCENT. (2002) New management strategies in ARDS: Immunomodulation. Critical Care Clinics 18:1, 69-78
CrossRef1855
(2001) Endothelial Protein C Activation in Meningococcal Sepsis. New England Journal of Medicine 345:24, 1776-1777
Full Text1856
Stephen R Ash, Janusz Steczko, Howard Levy, Donald E Blake, David J Carr. (2001) Treatment of Systemic Inflammatory Response Syndrome by Push-Pull Powdered Sorbent Pheresis: A Phase 1 Clinical Trial. Therapeutic Apheresis and Dialysis 5:6, 497-505
CrossRef1857
Matthew J. Kuehnert, Virginia R. Roth, N. Rebecca Haley, Kay R. Gregory, Kathy V. Elder, George B. Schreiber, Matthew J. Arduino, Stacey C. Holt, Loretta A. Carson, Shailen N. Banerjee, William R. Jarvis. (2001) Transfusion-transmitted bacterial infectionin the United States, 1998 through 2000. Transfusion 41:12, 1493-1499
CrossRef1858
M LEVI. (2001) Pathogenesis and treatment of disseminated intravascular coagulation in the septic patient. Journal of Critical Care 16:4, 167-177
CrossRef1859
Marcos I. Restrepo, James H. Jorgensen, Eric M. Mortensen, Antonio Anzueto. (2001) Severe community-acquired pneumonia: current outcomes, epidemiology, etiology, and therapy. Current Opinion in Infectious Diseases 14:6, 703-709
CrossRef1860
C. M. Albertson, K. K. Richter, B. J. Kudryk, L. M. Fink, M. Hauer-Jensen. (2001) Association between decreased pulmonary endothelial cell thrombomodulin and local fibrin deposition in pneumonia. Blood Coagulation & Fibrinolysis 12:8, 729-733
CrossRef1861
Tariq Hoth, Timothy W. Evans. (2001) Activated protein C: the cure for sepsis - again?. Anaesthesia 56:12, 1133-1135
CrossRef1862
Van den Berghe, Greet, Wouters, Pieter, Weekers, Frank, Verwaest, Charles, Bruyninckx, Frans, Schetz, Miet, Vlasselaers, Dirk, Ferdinande, Patrick, Lauwers, Peter, Bouillon, Roger, . (2001) Intensive Insulin Therapy in Critically Ill Patients. New England Journal of Medicine 345:19, 1359-1367
Full Text1863
Evans, Timothy W., . (2001) Hemodynamic and Metabolic Therapy in Critically Ill Patients. New England Journal of Medicine 345:19, 1417-1418
Full Text1864
Arthur M. Friedlander. (2001) Microbiology: Tackling anthrax. Nature 414:6860, 160-161
CrossRef1865
Anders Oldner, David Konrad, Eddie Weitzberg, Anders Rudehill, Patrik Rossi, Michael Wanecek. (2001) Effects of levosimendan, a novel inotropic calcium-sensitizing drug, in experimental septic shock. Critical Care Medicine 29:11, 2185-2193
CrossRef1866
Debra A Hoppensteadt, Brigitte Kaiser, Jawed Fareed. (2001) Tissue factor pathway inhibitor: an update of potential implications in the treatment of cardiovascular disorders. Expert Opinion on Investigational Drugs 10:11, 1925-1935
CrossRef1867
Leeona Galligan, Wendy Livingstone, Yuri Volkov, Karsten Hokamp, Ciaran Murphy, Mark Lawler, Kenji Fukudome, Owen Smith. (2001) Characterization of protein C receptor expression in monocytes. British Journal of Haematology 115:2, 408-414
CrossRef1868
Salmaan Kanji, John W. Devlin, Krista A. Piekos, Eric Racine. (2001) Recombinant Human Activated Protein C, Drotrecogin Alfa (activated): A Novel Therapy for Severe Sepsis. Pharmacotherapy 21:11, 1389-1402
CrossRef1869
Edward Abraham, Konrad Reinhart, Petr Svoboda, Allan Seibert, Derk Olthoff, Anthony Dal Nogare, Russell Postier, Gunter Hempelmann, Thomas Butler, Eike Martin, Christian Zwingelstein, Sandra Percell, Vincent Shu, Anton Leighton, Abla A. Creasey. (2001) Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Critical Care Medicine 29:11, 2081-2089
CrossRef1870
Stephen R. Ash. (2001) Powdered Sorbent Liver Dialysis and Pheresis in Treatment of Hepatic Failure. Therapeutic Apheresis and Dialysis 5:5, 404-416
CrossRef1871
Mark R. Looney, Michael A. Matthay. (2001) The role of protein C in sepsis. Current Infectious Disease Reports 3:5, 413-418
CrossRef1872
Tom van der Poll. (2001) Immunotherapy of sepsis. The Lancet Infectious Diseases 1:3, 165-174
CrossRef1873
Jonathan Cohen. (2001) Practical implications of the availability of effective drugs to treat sepsis. Current Opinion in Critical Care 7:5, 345-346
CrossRef1874
Derek S. Wheeler, Hector R. Wong. (2001) The impact of molecular biology on the practice of pediatric critical care medicine. Pediatric Critical Care Medicine 2:4, 299-310
CrossRef1875
Steven M. Opal. (2001) Clinical impact of novel anticoagulation strategies in sepsis. Current Opinion in Critical Care 7:5, 347-353
CrossRef1876
Paul E Marik, Joseph Varon. (2001) Sepsis: State of the art. Disease-a-Month 47:10, 462-532
CrossRef1877
Karen E Welty-Wolf, Martha S Carraway, Steve Idell, Thomas L Ortel, Mirella Ezban, Claude A Piantadosi. (2001) Tissue factor in experimental acute lung injury. Seminars in Hematology 38, 35-38
CrossRef1878
Gloria Lee Wilder. (2001) Pharmacological Update on New Infusion Drugs. Journal of Infusion Nursing 24:5, 319-325
CrossRef1879
Juan J. Ronco. (2001) Anti-inflammatory effects of inotropic drugs in the treatment of septic shock: Another piece to the puzzle. Critical Care Medicine 29:9, 1837-1838
CrossRef1880
Elihu H. Estey. (2001) Therapeutic options for acute myelogenous leukemia. Cancer 92:5, 1059-1073
CrossRef1881
A.-M. B. Münster, J. Ingemann Jensen, B. Bech, J. Gram. (2001) Activation of blood coagulation in pigs following lower limb gunshot trauma. Blood Coagulation and Fibrinolysis 12:6, 477-485
CrossRef1882
Thomas Raife, Robert Montgomery. (2001) NEW ASPECTS IN THE PATHOGENESIS AND TREATMENT OF THROMBOTIC THROMBOCYTOPENIC PURPURA AND HEMOLYTIC UREMIC SYNDROME. Reviews in Clinical and Experimental Hematology 5:3, 236-261
CrossRef1883
Berend Isermann, Sara B. Hendrickson, Mark Zogg, Mark Wing, Marjorie Cummiskey, Yaz Y. Kisanuki, Masashi Yanagisawa, Hartmut Weiler. (2001) Endothelium-specific loss of murine thrombomodulin disrupts the protein C anticoagulant pathway and causes juvenile-onset thrombosis. Journal of Clinical Investigation 108:4, 537-546
CrossRef1884
Faust, Saul N., Levin, Michael, Harrison, Odile B., Goldin, Robert D., Lockhart, Marion S., Kondaveeti, Sheila, Laszik, Zoltan, Esmon, Charles T., Heyderman, Robert S., . (2001) Dysfunction of Endothelial Protein C Activation in Severe Meningococcal Sepsis. New England Journal of Medicine 345:6, 408-416
Full Text1885
Enitan D Carrol, Alistair PJ Thomson, C Anthony Hart. (2001) New therapies and vaccines for meningococcal disease. Expert Opinion on Investigational Drugs 10:8, 1487-1500
CrossRef1886
Gilbert R. Park. (2001) New drugs for old. Current Opinion in Critical Care 7:4, 219-220
CrossRef1887
Malcolm C. Mathew, Julia A. Wendon. (2001) Perioperative management of liver transplantation patients. Current Opinion in Critical Care 7:4, 275-280
CrossRef1888
(2001) Current Awareness. Pharmacoepidemiology and Drug Safety 10:5, 467-482
CrossRef1889
(2001) Clinical Trials. Biotechnology Law Report 20:4, 555-570
CrossRef1890
Ramon L Añel, Anand Kumar. (2001) Experimental and emerging therapies for sepsis and septic shock. Expert Opinion on Investigational Drugs 10:8, 1471-1485
CrossRef1891
Ari Robin Joffe. (2001) Critical Care Medicine: Major Changes in Dogma of the Past Decade. Journal of Intensive Care Medicine 16:4, 177-192
CrossRef1892
(2001) Recombinant Human Activated Protein C for Severe Sepsis. New England Journal of Medicine 345:3, 219-221
Full Text1893
Hugo ten Cate, Saskia H. H. F. Schoenmakers, Rendrik Franco, Janneke J. Timmerman, Angelique P. Groot, C. Arnold Spek, Pieter H. Reitsma. (2001) Microvascular coagulopathy and disseminated intravascular coagulation. Critical Care Medicine 29, S95-S97
CrossRef1894
Jean-Louis Vincent, Derek Angus, Djillali Annane, Gordon Bernard, Eugen Faist, Brett Giroir, Konrad Reinhart. (2001) Clinical expert round table discussion (session 5) at the Margaux Conference on Critical Illness: Outcomes of clinical trials in sepsis: Lessons learned. Critical Care Medicine 29, S136-S137
CrossRef1895
S. Betty Yan, Jean-François Dhainaut. (2001) Activated protein C versus protein C in severe sepsis. Critical Care Medicine 29, S69-S74
CrossRef1896
Jan A. Hazelzet. (2001) Microvascular thrombosis: What is the importance?. Pediatric Critical Care Medicine 2:3, 284-285
CrossRef1897
Richard P. Wenzel, Michael B. Edmond. (2001) Severe sepsis—National estimates. Critical Care Medicine 29:7, 1472-1473
CrossRef1898
Lena M. Napolitano. (2001) Hemofiltration in sepsis: Additional supportive evidence. Critical Care Medicine 29:7, 1485-1486
CrossRef1899
Marcel Levi, Evert de Jonge, Tom van der Poll. (2001) Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation. Critical Care Medicine 29, S90-S94
CrossRef1900
Brian W. Grinnell, David Joyce. (2001) Recombinant human activated protein C: A system modulator of vascular function for treatment of severe sepsis. Critical Care Medicine 29, S53-S60
CrossRef1901
Gordon Bernard, Antonio Artigas, Philip Dellinger, Charles Esmon, Eugen Faist, Saul N. Faust, Charles J. Fisher, Roberto Fumagalli, Brian W. Grinnell, Charles Sprung. (2001) Clinical expert round table discussion (session 3) at the Margaux Conference on Critical Illness: The role of activated protein C in severe sepsis. Critical Care Medicine 29, S75-S77
CrossRef1902
Trung Nguyen, Mark Hall, Yong Han, Melinda Fiedor, Andrea Hasset, Ileana Lopez-Plaza, Scott Watson, Lucy Lum, Joseph A. Carcillo. (2001) Microvascular thrombosis in pediatric multiple organ failure: Is it a therapeutic target?. Pediatric Critical Care Medicine 2:3, 187-196
CrossRef1903
John C. Marshall. (2001) Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Critical Care Medicine 29, S99-S106
CrossRef1904
A SAFDAR, D ARMSTRONG. (2001) INFECTIOUS MORBIDITY IN CRITICALLY ILL PATIENTS WITH CANCER. Critical Care Clinics 17:3, 531-570
CrossRef1905
Dennis L. Stevens. (2001) Bacterial shock: clinical definitions, clinical trials and the dynamics of the host response. Current Opinion in Infectious Diseases 14:3, 247-249
CrossRef1906
Robert I. Parker. (2001) IIb/IIIa or not IIb/IIIa, that is adhesion. Critical Care Medicine 29:6, 1286-1287
CrossRef1907
J. Perren Cobb. (2001) Nitric Oxide Synthase Inhibition as Therapy for Sepsis: A Decade of Promise. Surgical Infections 2:2, 93-101
CrossRef1908
Omer Iqbal, Salim Aziz, Debra A Hoppensteadt, Sarfraz Ahmad, Jeanine M Walenga, Mamdouh Bakhos, Jawed Fareed. (2001) Emerging anticoagulant and thrombolytic drugs. Expert Opinion on Emerging Drugs 6:1, 111-135
CrossRef1909
Matthay, Michael A., . (2001) Severe Sepsis — A New Treatment with Both Anticoagulant and Antiinflammatory Properties. New England Journal of Medicine 344:10, 759-762
Full Text1910
Sreenandh Krishnagopalan, R. Phillip Dellinger. (2001) Innovative Therapies for Sepsis. BioDrugs 15:10, 645-654
CrossRef1911
Tariq Hoth, Timothy W. Evans. (2001) Activated protein C: the cure for sepsis - again?. Anaesthesia 56:12, 1133
CrossRef
- Letters
